

# Vanderbilt University Medical Center

**Consolidated Financial Statements and  
Supplementary Information, Including  
Uniform Guidance Reports and Schedule  
Years Ended June 30, 2021 and 2020**

Ernst & Young LLP



**Vanderbilt University Medical Center  
Index to Consolidated Financial Statements  
June 30, 2021 and 2020**

---

	<b>Page</b>
<b>Report of Independent Auditors</b> .....	1
<b>Consolidated Financial Statements</b>	
Consolidated Balance Sheets .....	3
Consolidated Statements of Operations .....	4
Consolidated Statements of Changes in Net Assets .....	5
Consolidated Statements of Cash Flows .....	6
Notes to Consolidated Financial Statements .....	7
<b>Supplementary Information</b>	
Schedule of Expenditures of Federal Awards .....	44
Notes to the Schedule of Expenditures of Federal Awards .....	91
<b>Uniform Guidance Reports and Schedule</b>	
Report of Independent Auditors on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance With <i>Government Auditing Standards</i> .....	92
Report of Independent Auditors on Compliance With Requirements for Each Major Federal Program and Report on Internal Control Over Compliance Required by the Uniform Guidance .....	94
Schedule of Findings and Questioned Costs .....	98



Ernst & Young LLP  
Suite 2100  
222 2nd Avenue South  
Nashville, TN 37201

Tel: +1 615 252 2000  
ey.com

## Report of Independent Auditors

Senior Management and the Board of Directors  
Vanderbilt University Medical Center

### **Report on the Financial Statements**

We have audited the accompanying consolidated financial statements of Vanderbilt University Medical Center, which comprise the consolidated balance sheets as of June 30, 2021 and 2020, and the related consolidated statements of operations and changes in net assets, and cash flows for the years then ended, and the related notes to the consolidated financial statements.

### ***Management's Responsibility for the Financial Statements***

Management is responsible for the preparation and fair presentation of these financial statements in conformity with U.S. generally accepted accounting principles; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free of material misstatement, whether due to fraud or error.

### ***Auditor's Responsibility***

Our responsibility is to express an opinion on these financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

### ***Opinion***


In our opinion, the financial statements referred to above present fairly, in all material respects, the consolidated balance sheets of Vanderbilt University Medical Center as of June 30, 2021 and 2020, and the consolidated results of its operations and its cash flows for the years then ended in conformity with U.S. generally accepted accounting principles.

### ***Supplementary Information***

Our audit was conducted for the purpose of forming an opinion on the consolidated financial statements as a whole. We have not performed any procedures with respect to the audited consolidated financial statements subsequent to October 1, 2021. The Schedule of Expenditures of Federal Awards as required by Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* is presented for purposes of additional analysis and is not a required part of the consolidated financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The information has been subjected to the auditing procedures applied in the audit of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States. In our opinion, the information is fairly stated, in all material respects, in relation to the consolidated financial statements as a whole.

### ***Other Reporting Required by Government Auditing Standards***

In accordance with *Government Auditing Standards*, we also have issued our report dated October 1, 2021 on our consideration of Vanderbilt University Medical Center's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements and other matters. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on the effectiveness of Vanderbilt University Medical Center's internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering Vanderbilt University Medical Center's internal control over financial reporting and compliance.



October 1, 2021, except for our report on the Schedule of Expenditures of Federal Awards for which the date is September 29, 2022

**Vanderbilt University Medical Center**  
**Consolidated Balance Sheets**  
**June 30, 2021 and 2020**

<i>(\$ in thousands)</i>	<u>2021</u>	<u>2020</u>
<b>Assets</b>		
Current assets:		
Cash and cash equivalents	\$ 837,312	\$ 1,170,526
Current investments	215,484	232,178
Patient accounts receivable	553,874	470,550
Grants and contracts receivable	77,365	60,031
Inventories	140,281	104,603
Other current assets	118,259	118,439
Total current assets	<u>1,942,575</u>	<u>2,156,327</u>
Restricted cash	27,404	11,806
Noncurrent investments	779,389	539,173
Noncurrent investments limited as to use	127,414	113,526
Property, plant, and equipment, net	1,630,325	1,525,103
Operating lease assets	839,850	846,695
Other noncurrent assets	96,351	53,347
Total assets	<u>\$ 5,443,308</u>	<u>\$ 5,245,977</u>
<b>Liabilities and Net Assets</b>		
Current liabilities:		
Current portion of long-term debt	\$ 14,704	\$ 14,321
Short-term borrowings	300,000	100,000
Accounts payable and other accrued expenses	356,171	309,162
Medicare accelerated payments	189,427	222,445
Estimated payables under third-party programs	37,669	45,957
Accrued compensation and benefits	316,531	238,039
Current portion of operating lease liabilities	67,343	70,062
Current portion of deferred revenue	4,240	4,827
Current portion of medical malpractice self-insurance reserves	15,820	12,577
Total current liabilities	<u>1,301,905</u>	<u>1,017,390</u>
Long-term debt, net of current portion	1,432,150	1,841,290
Noncurrent portion of operating lease liabilities	795,330	797,811
Fair value of interest rate exchange agreements	76,864	100,342
Noncurrent portion of medical malpractice self-insurance reserves	56,770	47,682
Noncurrent portion of deferred revenue	2,923	4,027
Other noncurrent liabilities	46,986	35,449
Total liabilities	<u>3,712,928</u>	<u>3,843,991</u>
Net assets		
Net assets without donor restrictions controlled by Vanderbilt University Medical Center	1,497,483	1,208,796
Net assets without donor restrictions related to noncontrolling interests	8,339	6,635
Total net assets without donor restrictions	<u>1,505,822</u>	<u>1,215,431</u>
Net assets with donor restrictions	224,558	186,555
Total net assets	<u>1,730,380</u>	<u>1,401,986</u>
Total liabilities and net assets	<u>\$ 5,443,308</u>	<u>\$ 5,245,977</u>

The accompanying notes are an integral part of these consolidated financial statements.

**Vanderbilt University Medical Center**  
**Consolidated Statements of Operations**  
**Years Ended June 30, 2021 and 2020**

<i>(\$ in thousands)</i>	<u>2021</u>	<u>2020</u>
<b>Operating revenues</b>		
Patient service revenue	\$ 4,691,814	\$ 4,031,720
Academic and research revenue	614,611	552,822
Other operating revenue	228,204	301,143
Total operating revenues	<u>5,534,629</u>	<u>4,885,685</u>
<b>Operating expenses</b>		
Salaries, wages, and benefits	2,836,544	2,495,795
Supplies and drugs	1,216,203	1,046,398
Facilities and equipment	296,748	273,405
Services and other	795,287	740,255
Depreciation and amortization	151,454	126,654
Interest	60,530	60,771
Total operating expenses	<u>5,356,766</u>	<u>4,743,278</u>
Income from operations	<u>177,863</u>	<u>142,407</u>
<b>Nonoperating revenues and expenses</b>		
Income from investments	68,201	27,224
Gift income	19,104	20,702
Earnings of unconsolidated organizations	8,100	4,865
Unrealized gain (loss) on interest rate exchange agreements, net of cash settlements	17,372	(37,152)
Total nonoperating revenues and expenses	<u>112,777</u>	<u>15,639</u>
Excess of revenues over expenses	290,640	158,046
Excess of revenues over expenses attributable to noncontrolling interests	(6,295)	(4,074)
Excess of revenues over expenses attributable to VUMC	<u>284,345</u>	<u>153,972</u>
<b>Other changes in net assets without donor restrictions</b>		
Change in noncontrolling interests' net assets	1,704	(1,141)
Net assets released from restriction for capital	474	4,773
Other changes	3,868	(458)
Total changes in net assets without donor restrictions	<u>\$ 290,391</u>	<u>\$ 157,146</u>

The accompanying notes are an integral part of these consolidated financial statements.

**Vanderbilt University Medical Center**  
**Consolidated Statements of Changes in Net Assets**  
**Years Ended June 30, 2021 and 2020**

<i>(\$ in thousands)</i>	<u>2021</u>	<u>2020</u>
<b>Net assets without donor restrictions</b>		
Net assets without donor restrictions at the beginning of the period	\$ 1,215,431	\$ 1,058,285
Excess of revenues over expenses	284,345	153,972
Change in noncontrolling interests' net assets	1,704	(1,141)
Net assets released from restriction for capital	474	4,773
Other changes	3,868	(458)
Change in net assets without donor restrictions	<u>290,391</u>	<u>157,146</u>
Net assets without donor restrictions at the end of the period	<u>\$ 1,505,822</u>	<u>\$ 1,215,431</u>
<b>Net assets with donor restrictions</b>		
Net assets with donor restrictions at the beginning of the period	\$ 186,555	\$ 155,897
Contributions	46,824	45,079
Restricted investment income	11,169	1,727
Net assets released from restrictions for operations	(15,647)	(13,788)
Net assets released from restriction for capital	(474)	(4,773)
Other changes	(3,869)	2,413
Change in net assets with donor restrictions	<u>38,003</u>	<u>30,658</u>
Net assets with donor restrictions at the end of the period	<u>\$ 224,558</u>	<u>\$ 186,555</u>
<b>Total net assets</b>		
Beginning of the period	\$ 1,401,986	\$ 1,214,182
Change in total net assets	<u>328,394</u>	<u>187,804</u>
End of the period	<u>\$ 1,730,380</u>	<u>\$ 1,401,986</u>

The accompanying notes are an integral part of these consolidated financial statements.

**Vanderbilt University Medical Center**  
**Consolidated Statements of Cash Flows**  
**Years Ended June 30, 2021 and 2020**

<i>(\$ in thousands)</i>	<b>2021</b>	<b>2020</b>
<b>Cash flows from operating activities</b>		
Change in total net assets	\$ 328,394	\$ 187,804
Adjustments to reconcile change in total net assets to net cash provided by operating activities:		
Depreciation and amortization	151,454	126,654
Amortization of debt issuance costs, and original issue premium and discount	953	709
Loss on disposal of assets	524	1,116
Undistributed equity in earnings of equity method affiliates	(2,949)	(1,754)
Investment gains and losses	(64,917)	(8,662)
Purchases of trading securities	(391,959)	(392,111)
Sales of trading securities	363,454	242,191
Change in split-interest trusts	(2,380)	260
Unrealized (gain) loss on interest rate exchange agreements	(23,478)	32,441
Restricted contributions for endowments and property, plant, and equipment	(21,755)	(14,073)
Increase (decrease) in cash due to changes in:		
Patient accounts receivable	(83,324)	11,935
Accounts payable and other accrued expenses	44,666	21,141
Medicare accelerated payments	(33,018)	222,445
Other assets and other liabilities, net	46,411	6,755
Net cash provided by operating activities	<u>312,076</u>	<u>436,851</u>
<b>Cash flows from investing activities</b>		
Purchase of property, plant, and equipment	(236,244)	(238,291)
Acquisition of hospitals	(15,600)	(19,252)
Acquisition of equity method investment	(36,927)	-
Purchases of long-term securities	(437,281)	(255,581)
Sales and maturities of long-term securities	295,673	239,623
Proceeds on sale of property, plant, and equipment	15	5
Net cash used in investing activities	<u>(430,364)</u>	<u>(273,496)</u>
<b>Cash flows from financing activities</b>		
Proceeds from issuance of debt	200,000	463,600
Draws on lines of credit	100,000	100,000
Debt issuance costs	(459)	(1,645)
Repayment of debt and lines of credit	(510,267)	(133,070)
Principal payments under finance lease obligations	(5,766)	(4,334)
Restricted contributions for endowments and property, plant, and equipment	21,755	14,073
Distributions to noncontrolling interests	(4,591)	(6,333)
Net cash (used in) provided by financing activities	<u>(199,328)</u>	<u>432,291</u>
Net change in cash, cash equivalents, and restricted cash	(317,616)	595,646
<b>Cash, cash equivalents, and restricted cash</b>		
Beginning of the period	1,182,332	586,686
End of the period	<u>\$ 864,716</u>	<u>\$ 1,182,332</u>

The accompanying notes are an integral part of these consolidated financial statements.



# Vanderbilt University Medical Center

## Notes to Consolidated Financial Statements

### June 30, 2021 and 2020

---

#### 1. Description of Organization

Vanderbilt University Medical Center (“VUMC”) is a Tennessee not-for-profit corporation incorporated in March 2015 to operate an academic medical center, including a comprehensive research, teaching, and patient care health system (the “Medical Center”). Until April 29, 2016, the Medical Center operated as a unit within Vanderbilt University (“the University” or “VU”), as a part of the University’s administrative structure, with the same governing board, legal, financial, and other shared services.

VUMC began operations effective April 30, 2016, following the closing of the sale of the Medical Center by the University (the “Acquisition”). VUMC owns and operates three hospitals located on the main campus of the University in Nashville, Tennessee: Vanderbilt University Hospital (“VUH”), Monroe Carell Junior Children’s Hospital at Vanderbilt (“MCJCHV”), and Vanderbilt Psychiatric Hospital (“VPH”). In addition, VUMC partially owns Vanderbilt Stallworth Rehabilitation Hospital (“VSRH”), also located on the main campus of the University, through a joint venture with Encompass Health Corp. in which VUMC holds a 50% interest, which includes a 1% interest held by Vanderbilt Health Services, LLC, (“VHS”), a VUMC wholly owned subsidiary. Effective August 1, 2019, VUMC acquired a hospital from Community Health Systems, Inc. (“CHS”): Tennova Healthcare – Lebanon, now known as Vanderbilt Wilson County Hospital (“VWCH”). Effective January 1, 2021, VUMC acquired from CHS: Tennova Healthcare – Shelbyville and Tennova Healthcare – Harton, now known as Vanderbilt Bedford Hospital (“VBCH”) and Vanderbilt Tullahoma-Harton Hospital (“VTHH”). At the same time as the acquisition of VBCH and VTHH, VUMC acquired a noncontrolling ownership interest of 20% in CHS’s affiliated Tennova Healthcare – Clarksville (“VMH”). VUH, MCJCHV, VPH, VWCH, VBCH, and VTHH are licensed for 1,664 beds, and VSRH is licensed for 80 beds.

VUMC consists of two major operating divisions and an administrative overhead division. The operating divisions include the Clinical Enterprise and Academic Enterprise divisions. The administrative overhead division is referred to as Medical Center Administration (“MCA”).

The Clinical Enterprise division includes the professional clinical practice revenues and related expenses of Vanderbilt Medical Group (“VMG”), and technical revenues and associated expenses for the operation of VUMC’s hospitals and clinic facilities, including VUH, MCJCHV, VPH, VWCH, VBCH, and VTHH. The Clinical Enterprise also includes VHS.

- VUH is a quaternary care teaching hospital licensed for 726 acute care and specialty beds. VUH, a Level I trauma center, provides advanced patient care and serves as a key site for medical education and clinical research conducted by physician faculty. VUH includes a comprehensive burn center, the Vanderbilt Transplant Center, the Vanderbilt Heart and Vascular Institute, and the Vanderbilt Ingram Cancer Center. As of June 30, 2021, VUMC held a temporary license provided under the Board for Licensing Health Care Facilities (“BLHCF”) Policy 82 to license 49 additional beds in response to COVID-19. This licensure increase is comprised of 34 observation beds and 15 double occupancy beds. The beds associated with this temporary license are not included in the above VUH bed count.
- MCJCHV is a pediatric quaternary care teaching hospital licensed for 343 beds (159 acute and specialty, 65 pediatric intensive care, and 119 neonatal intensive care). MCJCHV is the region’s only full-service pediatric hospital, with over 30 pediatric specialties. MCJCHV serves as a site for medical education and clinical research conducted by pediatric physician faculty, houses the only Level IV neonatal intensive care center and the only Level 1 pediatric trauma center within the region, and is a regional referral center for extracorporeal membrane oxygenation (heart and lung failure).

# Vanderbilt University Medical Center

## Notes to Consolidated Financial Statements

### June 30, 2021 and 2020

---

- VPH is a psychiatric hospital licensed for 106 beds and provides inpatient care to pediatric, adolescent, adult, and geriatric patients. Also, VPH provides partial hospitalization programs to both adult and adolescent patients, psychiatric assessment services, adult intensive outpatient programs, pediatric and adult ambulatory outpatient treatment, and neuromodulation procedures through electroconvulsive therapy and transcranial magnetic stimulation.
- VWCH is a two-campus facility licensed for 245 beds and is a substantial provider of both inpatient and outpatient medical services in Lebanon, Tennessee. Services offered include an accredited chest pain center, a stroke center, and a comprehensive total joint program for orthopedics. In addition, Vanderbilt Ingram Cancer Center extended services to this campus in 2020, and it includes a state-of-the-art linear accelerator.
- VBCH is a 60-bed, Joint Commission-accredited hospital, which offers a range of inpatient and outpatient medical and surgical services, along with urgent care services.
- VTHH is a 135-bed Joint Commission-accredited hospital, which offers a full range of inpatient and outpatient surgical and specialty services including a sleep center, cardiac rehabilitation, and physical rehabilitation. The hospital features an accredited Chest Pain Center.
- VMG is the practice group of physicians and advanced practice nurses employed by VUMC, most of whom have faculty appointments from the University, who perform billable professional medical services. VMG is not a separate legal entity. VMG has a board which consists of the VUMC clinical service chiefs, who also serve as clinical department chairs. Under the oversight of VUMC executive leadership, VMG sets professional practice standards, bylaws, policies, and procedures. VUMC bills for services rendered by VMG clinicians in both inpatient and outpatient locations. VMG includes nationally recognized physicians whose expertise spans the spectrum from primary care to the most specialized quaternary discipline. The entire clinical faculty is “board certified” or eligible for board certification. All staff members are re-credentialed every two years by the National Committee for Quality Assurance standards. All specialties and subspecialties currently recognized by the various national specialty boards are represented on the clinical faculty.
- VHS serves as a holding company for 16 first-tier health care related subsidiaries and joint ventures owned with various entities, including, but not limited to, VSRH and the Vanderbilt Health Affiliated Network (“VHAN”). VHS operations primarily consist of community physician practices, walk-in and retail health clinics, imaging services, outpatient surgery centers, radiation oncology centers, a home health care agency, a home infusion and respiratory service, an affiliated health network, accountable care organizations, and a rehabilitation hospital. These subsidiaries include clinics managed in multiple outpatient locations throughout middle Tennessee and southwestern Kentucky.
- Health Professional Solutions, LLC (“HPS”) is a holding company that holds interest in five VUMC subsidiaries that engage in or support various health care activities in order to improve the quality and availability of health care services in the community. These subsidiaries include businesses focused on pharmacy, supply chain, and clinically integrated support services.
- Nashville Biosciences, LLC (“NashBio”) operates exclusively in support of VUMC’s non-academic medical research activities. NashBio deploys the biospecimens and genomic data and de-identified medical records of VUMC known as “BioVU”, along with other information, to provide commercial services and products to life science industry customers in connection with pharmaceutical, biotechnology, and medical research and development activities.

# Vanderbilt University Medical Center

## Notes to Consolidated Financial Statements

### June 30, 2021 and 2020

---

The Academic Enterprise division includes all clinically related research, research-support activities, and faculty endeavors supporting post-graduate training programs. A significant funding source for VUMC's research is the federal government. Federal funding is received from the Department of Health and Human Services, the Department of Defense, the National Science Foundation, and other federal agencies. Sponsored research awards, including multiple year grants and contracts from government sources, foundations, associations, and corporations signify future research commitments. Also, core activities supporting research, including advanced computing and grant administration, are included in this division.

The terms "Company," "VUMC," "we," "our", or "us" as used herein and unless otherwise stated or indicated by context refer to Vanderbilt University Medical Center and its affiliates. The terms "facilities" or "hospitals" refer to entities owned and operated by VUMC and its affiliates, and the term "employees" refers to employees of VUMC and its affiliates.

VUMC operates on a fiscal year which ends on June 30. The term "Fiscal" preceding a year refers to a particular VUMC fiscal year.

## 2. Summary of Significant Accounting Policies

### Basis of Presentation

The accompanying consolidated financial statements have been prepared on the accrual basis in accordance with accounting principles generally accepted in the U.S. ("GAAP"). Based on the existence or absence of donor-imposed restrictions, VUMC classifies resources into two categories: net assets without donor restrictions and net assets with donor restrictions.

### Principles of Consolidation

The consolidated financial statements include the accounts of VUMC and its wholly owned, majority-owned, and controlled organizations. Noncontrolling interests in less-than-wholly owned consolidated subsidiaries of VUMC are presented as a component of net assets to distinguish between the interests of VUMC and the interests of the noncontrolling owners. All material intercompany transactions and account balances among the various entities have been eliminated.

VUMC uses the equity method to account for its interests in unconsolidated partnerships, joint ventures, and limited liability entities over which it exercises significant influence. Investment carrying amounts are adjusted for VUMC's share of investee earnings or losses based on percentage of ownership. Distributions received from unconsolidated entities that represent returns on VUMC's investment (i.e., dividends) are reported as cash flows from operating activities in VUMC's statement of cash flows.

### Use of Estimates

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect amounts reported in the consolidated financial statements and accompanying notes. These estimates affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated balance sheets and the reported amounts of revenues and expenses during the reporting periods. Actual results ultimately could differ from those estimates.

### Cash and Cash Equivalents

Cash and cash equivalents are liquid assets with minimal interest rate risk and maturities of three months or less when purchased. VUMC invests operating assets in a diversified manner. At times, VUMC may have cash and cash equivalents at a financial institution in excess of federally insured limits, and therefore, bears a risk of loss.

# Vanderbilt University Medical Center

## Notes to Consolidated Financial Statements

### June 30, 2021 and 2020

---

#### **Liquidity and Availability**

As of June 30, 2021, VUMC has \$2,386.1 million of financial assets available within one year of the balance sheet date to meet cash needs for general expenditures consisting of cash and cash equivalents of \$837.3 million, patient accounts receivable of \$553.9 million, and unrestricted investments of \$994.9 million. As of June 30, 2020, VUMC had \$2,412.5 million of financial assets available within one year of the balance sheet date to meet cash needs for general expenditures consisting of cash and cash equivalents of \$1,170.5 million, patient accounts receivable of \$470.6 million, and unrestricted investments of \$771.4 million. None of these financial assets are subject to donor or other contractual restrictions that make them unavailable for general expenditure within one year of the balance sheet date.

VUMC has a policy to structure its financial assets to be available as its general expenditures, liabilities, and other obligations come due. In addition, as part of its liquidity management, VUMC invests cash in excess of daily requirements in various short-term investments, including certificates of deposit and short-term treasury instruments.

As more fully described in Note 11 Long-Term Debt, VUMC also has committed lines of credit in the amount of \$200.0 million, which it could draw upon in the event of an unanticipated liquidity need, with \$100.0 million drawn as of June 30, 2021 and 2020.

#### **Revenue Recognition – Patient Services**

VUMC recognizes revenue from patient services at the amount that reflects the consideration to which VUMC expects to be paid for providing such services. These amounts, representing transaction price, are due from patients, third-party payors (including health insurers and government programs), and others and include variable consideration for retroactive revenue adjustments due to settlements of audits, reviews, and investigations. Patient service revenue is recognized as performance obligations based on the nature of the services provided by VUMC are satisfied.

Performance obligations satisfied over time relate to admitted patients in VUMC hospitals receiving inpatient acute care services from admission to the point when services are no longer required, which is generally at the time of discharge. Revenue for performance obligations satisfied over time is recognized based on actual charges incurred in relation to total expected or actual charges. Outpatient services are performance obligations satisfied at a point in time with the related revenue being recognized when goods or services are provided.

VUMC has elected to apply the optional exemption provided in FASB (ASC) 606-10-50-14 as substantially all of its performance obligations relate to contracts with a duration of less than one year. Therefore, VUMC is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially satisfied at the end of the reporting period. Unsatisfied or partially satisfied performance obligations are primarily related to in-house patients at the end of the reporting period. The performance obligations for these contracts are generally completed when the patients are discharged, which is typically within a week.

VUMC uses a portfolio approach consisting of major payor classes to account for categories of patient contracts as a collective group rather than recognizing revenue on an individual contract basis. Based on historical collection trends and other analysis, VUMC believes that revenue recognized by utilizing the portfolio approach approximates the revenue that would have been recognized if an individual contract approach were used.

VUMC determines the transaction price, which involves estimates and judgment, based on standard charges for goods and services provided, reduced by explicit and implicit price concessions, including contractual adjustments provided to third-party payors, discounts provided

# **Vanderbilt University Medical Center**

## **Notes to Consolidated Financial Statements**

### **June 30, 2021 and 2020**

---

to uninsured and underinsured patients in accordance with VUMC policy, and historical collection experience. VUMC analyzes its history and identifies trends for each of its major revenue categories to estimate the appropriate price concessions. Management regularly reviews data for these major revenue categories in evaluating the reasonableness of the transaction price, taking into consideration recent experience by payor category, payor agreement rate changes, and other factors.

In addition to patient payments, VUMC earns revenue and reimbursements from certain services provided under federal healthcare programs and other contracts with third-party payors. These compensation arrangements are complex programs which extend over multiple accounting periods and are subject to the interpretation of federal and state-specific reimbursement rates, new or changing legislation, and final cost report settlements. Estimated settlements under these programs are recorded in the period the related services are performed and are subsequently adjusted, as needed, based on new information.

VUMC provides care to patients who meet the criteria for charity care under its financial assistance policy for no payment or at payment amounts less than its established charge rates. VUMC does not recognize the charges that qualify as charity care as revenue because VUMC does not pursue collection of these amounts.

#### **Revenue Recognition – Non-Patient Services**

Revenue for non-patient services is recognized at an amount that reflects the consideration VUMC expects to be entitled in exchange for providing goods or services. The amounts recognized reflect considerations due from customers, the U.S. government, and others, and is recognized as performance obligations are satisfied. Primary categories of non-patient revenue include academic and research revenue as well as other miscellaneous activities as further described in Note 8 Other Relevant Financial Information.

VUMC receives funding through grants and contracts issued by departments and agencies of the U.S. government, industry, and other foundation sponsors who restrict the use of such funds to academic and research purposes. VUMC recognizes revenue from these grants and contracts in accordance with contract terms, as defined in the agreements governing that funding. VUMC recognizes facilities and administrative (“F&A”) costs recovery as revenue when the allowable expenditure is incurred on the associated grant or contract. This activity represents reimbursement, primarily from the federal government, of F&A costs on sponsored activities.

Grants and contracts receivable include amounts due from these sponsors of externally funded research. These amounts have been billed or are billable to the sponsor and are recorded at the amount that reflects the consideration VUMC expects to receive.

#### **Deferred Revenue**

Deferred revenue is recorded for funds received in advance. The related revenue is recognized when the performance obligations have been met.

#### **Gift Income and Pledges**

VUMC recognizes unconditional promises to give cash and other assets, referred to as pledges, as gift income at fair value when the pledge is received. Conditional promises to give are recognized as pledges once the conditions are substantially met. Pledges are recognized as net assets with donor restrictions. Gifts received with donor stipulations limiting the use of the donated assets are reported as net assets with donor restrictions. Donor-restricted contributions whose restrictions are met within the same year as received are reported as gift income in the consolidated statements of operations. Gift income is recognized when a donor restriction expires, that is, when a stipulated

# Vanderbilt University Medical Center

## Notes to Consolidated Financial Statements

### June 30, 2021 and 2020

---

time restriction ends or purpose restriction is accomplished. Gifts of cash or other assets that must be used to acquire long-lived assets are reported as net assets with donor restrictions until the assets are placed in service, at which point they are reclassified to net assets without donor restrictions.

Pledges receivable are reported net of allowances for uncollectible amounts based on an analysis of past collection experience and other judgmental factors. Pledges receivable are included in other current or other noncurrent assets in the consolidated balance sheets based on the expected timing of cash flows. VUMC discounts the noncurrent portion of pledges receivables at a rate commensurate with the scheduled timing of receipt. VUMC applied annual discount rates ranging from 0.5% to 1.5% to amounts outstanding as of June 30, 2021 and 2020.

#### **Concentrations of Credit Risk**

VUMC grants unsecured credit to its patients, primarily residing in Nashville, Tennessee and the surrounding areas of middle Tennessee, most of whom are insured under commercial, Medicare (both traditional fee-for-service and Managed Medicare), or TennCare agreements. Medicare, Blue Cross Blue Shield (“BCBS”), and TennCare (which includes BCBS of Tennessee, United, and Amerigroup) represent VUMC’s significant concentrations of credit risk from payors.

#### **Inventories**

VUMC reports inventories at the lower of cost or market, with cost being determined on the first-in, first-out method. Inventories consist primarily of medical supplies, surgical implants, and pharmaceuticals.

#### **Restricted Cash**

VUMC reports cash whose use is restricted at cost, which approximates fair value. The cash is primarily restricted for use in purchasing and constructing property, plant, and equipment.

#### **Investments**

VUMC reports investments held at fair value in the consolidated balance sheets. Private equity investments are reported using the equity method of accounting based on net asset value (NAV) provided by the respective fund manager. VUMC records purchases and sales of securities on the trade dates, and realized gains and losses are determined based on the average historical cost of the securities sold. VUMC reports net receivables and payables arising from unsettled trades as a component of investments.

#### **Property, Plant, and Equipment, Net**

VUMC records purchases of property, plant, and equipment at cost and expenses repairs and maintenance costs as incurred. VUMC capitalizes interest cost incurred on borrowed funds during the period of construction of capital assets as a component of the cost of acquiring those assets. VUMC capitalizes donated assets at fair value on the date of donation.

Capitalized software for internal use is recorded during the application development stage. These costs include fees paid to third parties for direct costs of materials and services consumed in developing or obtaining the software; payroll related costs and capitalized interest costs. Costs for training and application maintenance in the post-implementation operation stage are expensed as incurred.

VUMC computes depreciation using the straight-line method over the estimated useful life of land improvements (5 to 18 years), buildings and leasehold improvements (2 to 40 years), and equipment (2 to 20 years). Equipment costs also include capitalized internal use software costs, which are expensed over the expected useful life, which is generally 3 to 12 years.

# Vanderbilt University Medical Center

## Notes to Consolidated Financial Statements

### June 30, 2021 and 2020

---

Software for internal use is amortized on a straight-line basis over its estimated useful life. In determining the estimated useful life, management considers the effects of obsolescence, technology, competition, other economic factors, and rapid changes that may be occurring in the development of software products, operating systems, and computer hardware. Amortization begins once the software is ready for its intended use.

#### **Impairment of Long-Lived Assets**

VUMC reviews long-lived assets, such as property, plant, and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. VUMC measures the recoverability of assets to be held and used by comparing the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, VUMC recognizes an impairment charge to the extent the carrying amount of the asset exceeds its fair value.

#### **Conditional Asset Retirement Costs and Obligations**

VUMC recognizes the estimated fair value of liabilities for existing legal obligations to perform certain activities, primarily asbestos removal, in connection with the retirement, disposal, or abandonment of assets. These liabilities are included in other noncurrent liabilities on the consolidated balance sheets and total \$6.7 million and \$6.5 million as of June 30, 2021 and 2020, respectively. VUMC measures these liabilities using estimated cash flows with an inflation rate applied of 3.0% as of June 30, 2021 and 2020. VUMC discounts those cash flow estimates at a credit-adjusted, risk-free rate, which ranged from 2.9% to 4.2% as of June 30, 2021 and 2020, and adjusts these liabilities for accretion costs and revisions in estimated cash flows.

#### **Long-Term Debt**

The carrying value of VUMC's debt is the par amount adjusted for the net unamortized amount of debt issuance costs, bond premiums and discounts.

#### **Interest Rate Exchange Agreements**

VUMC reports interest rate exchange agreements at fair value, which is determined to be the present value of future net cash settlements that reflect market yields as of the measurement date and estimated amounts that VUMC would pay, or receive, to terminate the contracts as of the report date. VUMC considers current interest rates and creditworthiness of the interest rate exchange counterparties when estimating termination settlements.

#### **Self-Insurance Reserves**

VUMC elects to self-insure a portion of its medical malpractice, professional, and general liability coverage via an irrevocable self-insurance trust. For Fiscal 2021 and 2020, the maximum annual self-insurance retention was \$6.0 million per occurrence, up to \$46.0 million in the aggregate. Actuarial firms assist management in estimating expected losses on an annual basis, at which time VUMC records medical malpractice, professional, and general liability expense within the limits of the program. These liabilities are classified as current or noncurrent based on the expected timing of cash flows and are measured at the net present value of those cash flows using a discount rate of 2.5% as of June 30, 2021 and 2020. For both Fiscal 2021 and 2020, VUMC obtained excess medical malpractice, professional, and general liability coverage from commercial insurance carriers for claims exceeding the retention limits, up to \$175.0 million. These policies would also provide coverage up to \$175.0 million if any claims in the aggregate exceeded the retention limits.

# Vanderbilt University Medical Center

## Notes to Consolidated Financial Statements

### June 30, 2021 and 2020

---

VUMC also elects to self-insure for employee health and workers' compensation expenses. Actuarial firms assist management in estimating expected losses on an annual basis. The maximum retention for workers' compensation was \$0.8 million per occurrence for both Fiscal 2021 and 2020. There is no stop loss insurance on health plan claims.

#### **Income Taxes**

VUMC is a tax-exempt organization as described in Section 501(c)(3) of the Internal Revenue Code (the "Code") and is generally exempt from federal income taxes under Section 501(a) of the Code.

#### **Excess of Revenues Over Expenses**

The consolidated statements of operations include excess of revenues over expenses as a performance indicator. Excess of revenues over expenses includes all changes in net assets without donor restrictions, except for changes in noncontrolling interest holders' share of consolidated entities, net assets released from restrictions used for capital, and certain other items.

#### **Statement of Cash Flows**

For VUMC's consolidated statements of cash flows, cash, cash equivalents, and restricted cash is defined as those amounts included in the cash and cash equivalents caption and restricted cash caption on the consolidated balance sheets.

#### **Recent Accounting Pronouncements**

Periodically, the FASB issues Accounting Standards Updates ("ASUs") that may impact the recognition, measurement, and presentation of balances and activity in VUMC's consolidated financial statements or the disclosures contained within those statements. As part of preparing consolidated financial statements, VUMC evaluates the effects of the ASUs and applies the updated guidance within the required effective dates.

#### *Adopted*

- Effective July 1, 2020, VUMC adopted FASB ASU 2018-13, Fair Value Measurement. This ASU improves the effectiveness of the notes to the financial statements through changes in the disclosure requirements for fair value measurement. The adoption of this ASU did not materially impact the consolidated financial statements.

#### *Not Yet Adopted*

- In August 2018, the FASB issued ASU 2018-15, Intangibles – Goodwill and Other, Internal-Use Software (Subtopic 350-40), Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That is a Service Contract. The primary effect of adopting this ASU will be capitalization of implementation costs incurred in hosting arrangements that are service contracts and subsequent amortization expenses in the consolidated statements of operations. The ASU is effective for fiscal years beginning after December 15, 2020 and will be applied using a prospective approach. VUMC is currently assessing the impact of this ASU on the consolidated financial statements.
- In September 2020, the FASB issued ASU 2020-07, Presentation and Disclosures by Not-for-Profit Entities for Contributed Nonfinancial Assets (Topic 958). This ASU requires presentation of nonfinancial assets as a separate line in the consolidated statement of operations, apart from contributions of cash or other financial assets. The ASU is effective for fiscal years beginning after June 15, 2021 and will be applied on a retrospective basis. VUMC is currently assessing the impact of this ASU on the consolidated financial statements.



# Vanderbilt University Medical Center

## Notes to Consolidated Financial Statements

### June 30, 2021 and 2020

---

### 3. Related Parties

On April 29, 2016, VUMC acquired the assets, liabilities, rights, and obligations of the clinical enterprise, postgraduate medical training programs, and clinically related research of the University's owned and operated Medical Center, "the Acquisition".

The assets acquired and liabilities assumed from the Acquisition were detailed in a Master Transfer and Separation Agreement ("MTSA"). The MTSA contains the framework for the ongoing economic relationship between VUMC and the University. The relationship is memorialized in the form of an Academic Affiliation Agreement ("AAA"), a Trademark License Agreement ("TMLA"), a Ground Lease, and a Reciprocal Master Services Agreement ("MSA"). The agreements are described below.

- The AAA outlines the ongoing academic, research, and clinical affiliation between the University and VUMC for all the University's degree-granting, certificate, and research programs. The AAA allocates responsibility between the University and VUMC for jointly administered research and academic programs and is an exclusive agreement between VUMC and VU requiring VUMC to be organized, governed, and operated in a manner that supports VU's academic and research mission. The agreement provides that VU will be the exclusive academic affiliate of VUMC, and VUMC will be the exclusive clinical affiliate of VU.

The AAA requires VUMC to pay VU an annual fee in equal monthly payments adjusted annually for inflation based upon the Biomedical Research and Development Price Index ("BRDPI") in perpetuity under certain mutually agreed-upon termination or default clauses. During Fiscal 2021 and 2020, VUMC recorded operating expense totaling \$78.5 million and \$76.9 million, respectively, in connection with fees due under the AAA.

- Under the TMLA, VU grants, subject to certain consents and approvals, a perpetual license to use various VU-owned licensed marks in connection with VUMC's fundamental activities after the Acquisition date. The licensed marks, which VUMC continues to use as its primary brands, include virtually all those previously in use by VUMC. This agreement requires VUMC to pay VU royalties consisting of a monthly payment equal to 1.0% of all operating revenue of VUMC and 15% of income from operations. During Fiscal 2021 and 2020, VUMC recorded operating expense totaling \$83.7 million and \$70.4 million, respectively, in connection with the 1.0% of operating revenue and percentage of operating income payments due under the TMLA. Also, VUMC is required to pay in equal monthly installments an annual TMLA base fee royalty, which increases 3% annually, but is also reduced by the amount of principal payments made under a subordinate note discussed in Note 11 Long-Term Debt (the "Fixed TMLA Royalty Payment"). During Fiscal 2021 and 2020, VUMC recorded operating expense totaling \$64.6 million and \$62.5 million, respectively, in connection with this base fee royalty. In Fiscal 2018, VU sold its rights to future base fee royalty payments to a third party. In Fiscal 2019, VU sold its rights to future 1.0% of operating revenue payments to a third party. The TMLA is in force in perpetuity under certain mutually agreed-upon termination or default clauses.
- The Ground Lease is an agreement between VU and VUMC that allows VUMC to use the land on which VUMC's campus and related buildings are located. The initial term of the Ground Lease ends June 30, 2114, with the option to extend the lease for two additional terms of up to 50 to 99 years each with agreement between VU and VUMC. The lease covers 1.7 million square feet or 38.75 acres of space, payable monthly and CPI adjusted annually. During Fiscal 2021 and 2020, VUMC recorded operating expense totaling \$19.6 million and \$19.4 million, respectively, in connection with fees due under the Ground Lease.

**Vanderbilt University Medical Center**  
**Notes to Consolidated Financial Statements**  
**June 30, 2021 and 2020**

---

- The University and VUMC provide services to one another for agreed-upon consideration as outlined in the MSA. VU provides services to VUMC, such as information technology infrastructure support, utilities, and law enforcement staffing. VUMC provides various operational services for the University, such as a student health clinic and animal care. Additionally, the MSA encompasses an Employee Matters Agreement (“EMA”) and specific Employee Service Agreements (“ESAs”). The EMA and ESAs govern employee transactions and ongoing sharing between VU and VUMC in various capacities, such as research, teaching, clinical, and other administrative services. Services under the MSA can be terminated by either party subject to predetermined cancellation notification periods. In connection with the MSA, during Fiscal 2021 and 2020, VUMC recognized revenue totaling \$43.4 million and \$44.2 million, respectively, and recorded operating expense totaling \$119.5 million and \$123.4 million, respectively.
- Also, as part of the Acquisition, VUMC issued to VU a \$100.0 million subordinate promissory note payable, which is further described in Note 11 Long-Term Debt, with a balance of \$74.6 million as of June 30, 2021, and \$79.6 million as of June 30, 2020. VU sold its rights to future principal and interest payments on this note to a third party.

The impact of these agreements in the consolidated statements of operations during Fiscal 2021 and 2020 is as follows:

<i>(\$ in thousands)</i>	<u>2021</u>	<u>2020</u>
Academic and research revenue	\$ 15,816	\$ 13,055
Other operating revenue	27,565	31,192
Total operating revenues	<u>\$ 43,381</u>	<u>\$ 44,247</u>
Operating expenses		
Salaries, wages, and benefits	\$ 8,223	\$ 9,086
Facilities and equipment	56,910	59,516
Services and other	300,656	284,040
Interest	2,498	2,661
Total operating expenses	<u>\$ 368,287</u>	<u>\$ 355,303</u>

Other current assets include amounts receivable from VU, which totaled \$8.0 million as of June 30, 2021, and \$6.7 million as of June 30, 2020. Accounts payable and other accrued expenses include amounts payable to related parties, which totaled \$58.5 million as of June 30, 2021, and \$51.1 million as of June 30, 2020.

In the normal course of business, members of VUMC’s Board of Directors or VUMC employees may be directly or indirectly associated with companies engaged in business activities with VUMC. VUMC has a written conflict of interest policy that requires, among other things, that members of the VUMC community (including trustees) may not review, approve, or administratively control contracts or business relationships when (i) the contract or business relationship is between VUMC and a business in which the individual or a family member has a material financial interest, or (ii) the individual or a family member is an employee of the business and is directly involved with activities pertaining to VUMC.

**Vanderbilt University Medical Center**  
**Notes to Consolidated Financial Statements**  
**June 30, 2021 and 2020**

---

Furthermore, VUMC's conflict of interest policy extends beyond the foregoing business activities in that disclosure is required for any situation in which an applicable individual's financial, professional, or other personal activities may directly or indirectly affect, or have the appearance of affecting, an individual's professional judgment in exercising any VUMC duty or responsibility, including the conduct or reporting of research.

The policy extends to all individual members of the VUMC community (including Board of Directors, VUMC officials, full-time, part-time, temporary faculty and staff). Each applicable person is required to certify compliance with the conflict of interest policy on an annual basis. This certification includes specifically disclosing whether VUMC conducts business with an entity in which he or she (or an immediate family member) has a material financial interest, as well as any other situation that could appear to present a conflict with VUMC's best interests.

When situations exist relative to the conflict of interest policy, VUMC takes active measures to appropriately manage the actual or perceived conflict in the best interests of VUMC, including periodic reporting of measures taken to the Audit and Compliance Committee of the Board of Directors.

**4. Patient Service Revenue, Patient Accounts Receivable, and Estimated Third-Party Settlements**

Management has determined that the nature, amount, timing, and uncertainty of revenue and cash flows are affected by the major classes of payors. The sources of patient service revenue by payor for Fiscal 2021 and 2020 are as follows:

<i>(\$ in thousands)</i>	<u>2021</u>	<u>2020</u>
Other third-party payors, primarily commercial carriers	\$ 2,961,480	\$ 2,553,307
Medicare/Managed Medicare	1,084,216	924,241
TennCare/Medicaid	608,791	522,606
Uninsured (self-pay)	37,327	31,566
	<u>\$ 4,691,814</u>	<u>\$ 4,031,720</u>

Patient accounts receivable comprise amounts due from the following sources as of June 30, 2021 and 2020:

<i>(\$ in thousands)</i>	<u>2021</u>	<u>2020</u>
Medicare	\$ 95,382	\$ 77,696
TennCare/Medicaid	70,487	57,741
Blue Cross	115,028	99,861
Other third-party payors, primarily commercial carriers	219,643	192,258
Patient responsibility <sup>(1)</sup>	53,334	42,994
Patient accounts receivable	<u>\$ 553,874</u>	<u>\$ 470,550</u>

<sup>(1)</sup> Includes self-pay after insurance.

**Vanderbilt University Medical Center**  
**Notes to Consolidated Financial Statements**  
**June 30, 2021 and 2020**

Estimated third-party settlements by major payor category as of June 30, 2021 and 2020, are as follows:

<i>(\$ in thousands)</i>	<u>2021</u>	<u>2020</u>
Receivables under third-party programs		
Tricare/Champus <sup>(1)</sup>	\$ 4,635	\$ 4,484
Total receivables under third-party programs	<u>\$ 4,635</u>	<u>\$ 4,484</u>
Payables under third-party programs		
TennCare/Medicaid	\$ 33,781	\$ 37,781
Medicare <sup>(1)</sup>	8,170	9,752
Other	353	2,908
Total payables under third-party programs	<u>\$ 42,304</u>	<u>\$ 50,441</u>

<sup>(1)</sup> These two federal healthcare programs are combined for presentation purposes on the face of the consolidated balance sheets and are reflected as an obligation in Fiscal 2021 and Fiscal 2020.

Certain contracts require pay for performance or episode of care settlements whereby VUMC receives additional payment or pays a penalty based on its ability to achieve certain clinical measures or manage the cost of care for patients within various thresholds. VUMC estimates and accrues these adjustments in the period the related services are rendered and adjusts these estimates in future periods as settlements are finalized. The aggregate liability associated with pay for performance and episode of care settlements at June 30, 2021 and 2020, was \$1.1 million and \$2.5 million, respectively, with the ultimate resolution of such financial arrangements not expected to have a material impact on the operating results of VUMC.

*Medicare*

Amounts received under Medicare are subject to review and final determination by program intermediaries or their agents. Final settlements have been reached for program periods ended June 30, 2015. Final settlements have not been reached for subsequent years due to audit delays experienced with the Medicare Administrative Contractor, and thus, those periods remain subject to audit by program representatives.

*TennCare*

TennCare is a Medicaid managed care program implemented by the state of Tennessee to provide healthcare coverage to those patients eligible for Medicaid through the Federal 1115 Waiver Program. VUMC contracts with each of the three TennCare managed care organizations (“MCOs”), which offer health maintenance organization (“HMO”) and Medicare Special Needs Products for Dual Eligible Enrollees. VUMC receives inpatient reimbursement through payments that are primarily based on the Medicare severity diagnostic related group system (“MS-DRG”) for these plans. VUMC receives outpatient payments generally based on an ambulatory payment classification system (“APC”), and/or a payor-developed fee schedule.

In accordance with the Tennessee Hospital Assessment Act, VUMC receives a payment of a portion of its unreimbursed TennCare costs based upon VUMC’s share of uninsured TennCare costs for all of the covered hospitals.

There is no assurance that this program will be continued in its current structure or will not be materially modified in the future, however, we anticipate funding will remain relatively stable over the coming year.

**Vanderbilt University Medical Center**  
**Notes to Consolidated Financial Statements**  
**June 30, 2021 and 2020**

---

In Fiscal 2021 and 2020, patient service revenue includes the following supplemental amounts received in each respective period from TennCare.

<i>(\$ in thousands)</i>	<u>2021</u>	<u>2020</u>
Charity pool	\$ 26,659	\$ 24,696
Graduate medical education	14,618	14,592
Trauma fund	1,560	1,685
Virtual disproportionate share	6,400	960
Changes in prior year virtual disproportionate share reserve estimate	<u>20,411</u>	<u>-</u>
Total supplemental TennCare revenue, net of audit provision	<u>\$ 69,648</u>	<u>\$ 41,933</u>

**5. Charity Care Assistance, Community Benefits, and Other Unrecovered Costs**

VUMC maintains a policy which sets forth the criteria under which health care services are provided to patients who have minimal financial resources to pay for medical care. Additionally, VUMC provides other services that benefit the economically disadvantaged for which little or no payment is expected.

Charity care is determined by examining patient and family income relative to the federal poverty guidelines. VUMC provides additional discounts based on the income level of the patient household using a sliding scale for those patients with a major catastrophic medical event not qualifying for full charity assistance. Tennessee law mandates that all uninsured patients receive a discount from billed charges for medically necessary services. These amounts are classified as charity care if the patient meets charity care criteria, for which no revenue is recorded, or is included as a part of price concessions.

VUMC maintains records to identify and monitor the level of charity care provided, and these records include gross charges and patient deductibles, coinsurance and copayments foregone for services furnished under its charity care policy, and the estimated cost of those services. VUMC calculates a ratio of total costs to gross charges and then multiplies the ratio by foregone charity care charges in determining the estimated cost of charity care. The gross amount of foregone charity care revenue in Fiscal 2021 and 2020 totals \$474.1 million and \$422.7 million, respectively. The estimated cost of providing care to charity patients in Fiscal 2021 and 2020 totals \$123.6 million and \$110.1 million, respectively.

In addition to the charity care services described above, TennCare/Medicaid and state indigent programs do not cover the full cost of providing care to beneficiaries of those programs. As a result, in addition to direct charity care costs, VUMC provided services related to TennCare/Medicaid and state indigent programs and was reimbursed substantially below the cost of rendering such services. VUMC also provides public health education and training for new health professionals and provides, without charge, services to the community at large for many patients with special needs.

**Vanderbilt University Medical Center**  
**Notes to Consolidated Financial Statements**  
**June 30, 2021 and 2020**

**6. Academic and Research Revenue, and Grants and Contracts Receivable**

Academic and research revenue comprises the following for Fiscal 2021 and 2020:

<i>(\$ in thousands)</i>	<u>2021</u>	<u>2020</u>
Grants and contracts revenue		
Federally funded	\$ 345,745	\$ 297,651
Non-federally funded	124,690	132,557
	<u>470,435</u>	<u>430,208</u>
Facilities and administrative costs recovery	144,176	122,614
Academic and research revenue	<u>\$ 614,611</u>	<u>\$ 552,822</u>

Grants and contracts receivable comprise the following as of June 30, 2021 and 2020:

<i>(\$ in thousands)</i>	<u>2021</u>	<u>2020</u>
Federally funded	\$ 38,472	\$ 28,077
Non-federally funded	38,893	31,954
Total grants and contracts receivable	<u>\$ 77,365</u>	<u>\$ 60,031</u>

**7. Pledges Receivable, Net**

Pledges receivable, net of applied discounts and allowance for uncollectible pledges, as of June 30, 2021 and 2020, were as follows:

<i>(\$ in thousands)</i>	<u>2021</u>	<u>2020</u>
Amounts due		
Within one year	\$ 10,660	\$ 11,347
In one to five years	26,257	24,809
Total pledges receivable	<u>36,917</u>	<u>36,156</u>
Unamortized discount	(1,225)	(1,112)
	<u>35,692</u>	<u>35,044</u>
Allowance for uncollectible pledges	(4,806)	(6,126)
Net pledges receivable	<u>\$ 30,886</u>	<u>\$ 28,918</u>
Net pledges receivable classified as		
Current	\$ 6,615	\$ 7,552
Noncurrent	24,271	21,366
	<u>\$ 30,886</u>	<u>\$ 28,918</u>

In addition to pledges reported as pledges receivable, VUMC had cumulative bequest intentions and conditional promises to give totaling \$79.5 million as of June 30, 2021, and \$66.9 million as of June 30, 2020. Due to their conditional nature, VUMC does not recognize intentions to give as assets.

**Vanderbilt University Medical Center**  
**Notes to Consolidated Financial Statements**  
**June 30, 2021 and 2020**

---

**8. Other Relevant Financial Information**

Other current assets comprise the following as of June 30, 2021 and 2020:

<i>(\$ in thousands)</i>	<u>2021</u>	<u>2020</u>
Prepaid expenses	\$ 44,552	\$ 42,115
Other receivables	55,295	59,436
Amounts due from VU (see Note 3 Related Parties)	7,977	6,684
Current pledges receivable, net (see Note 7 Pledges Receivable, Net)	6,615	7,552
Expected recoveries from commercial insurance excess coverage	3,820	2,652
Total other current assets	<u>\$ 118,259</u>	<u>\$ 118,439</u>

Other noncurrent assets comprise the following as of June 30, 2021 and 2020:

<i>(\$ in thousands)</i>	<u>2021</u>	<u>2020</u>
Equity in unconsolidated organizations	\$ 63,109	\$ 23,234
Noncurrent pledges receivable (see Note 7 Pledges Receivable, Net)	24,271	21,366
Other	8,971	8,747
Total other noncurrent assets	<u>\$ 96,351</u>	<u>\$ 53,347</u>

Other operating revenues comprise the following for Fiscal 2021 and 2020

<i>(\$ in thousands)</i>	<u>2021</u>	<u>2020</u>
CARES funding	\$ 63,045	\$ 130,399
Clinical contracts	49,701	46,886
Amounts recognized under MSA with VU (see Note 3 Related Parties)	27,565	31,192
VHS other revenue	21,556	28,176
Nonclinical contracts	16,846	11,898
Resident and house staff rotations	10,151	10,557
Other	39,340	42,035
Total other operating revenue	<u>\$ 228,204</u>	<u>\$ 301,143</u>

**Vanderbilt University Medical Center**  
**Notes to Consolidated Financial Statements**  
**June 30, 2021 and 2020**

---

**9. Investments**

VUMC investments are made up of current investments, restricted cash, noncurrent investments, and noncurrent investments limited as to use on the face of the consolidated balance sheets. VUMC investments include assets limited as to use related to the following specified purposes as of June 30, 2021 and 2020:

<i>(\$ in thousands)</i>	<u>2021</u>	<u>2020</u>
Self-insured malpractice program	\$ 46,991	\$ 46,223
Donor endowments	65,083	52,590
Split-interest trusts	9,503	7,124
Supplemental employee retirement program assets	<u>5,837</u>	<u>7,589</u>
	<u>\$ 127,414</u>	<u>\$ 113,526</u>

VUMC's endowment does not include gift annuities, interests in trusts held by others, contributions pending donor designation, or contributions receivable.

The Board of Directors' interpretation of its fiduciary responsibilities for donor-restricted endowments under the Uniform Prudent Management of Institutional Funds Act ("UPMIFA") requirements is to preserve intergenerational equity, barring the existence of any donor-specific provisions. Under this broad guideline, future endowment beneficiaries should receive at least the same level of real economic support as the current generation. The overarching objective is to preserve and enhance the real (inflation-adjusted) purchasing power of the endowment in perpetuity. VUMC invests assets to provide a relatively predictable and stable stream of earnings to meet spending needs and attain long-term return objectives without the assumption of undue risks.

Self-insured malpractice program – VUMC elects to self-insure a portion of its medical malpractice, professional, and general liability via an irrevocable self-insurance trust.

Donor endowments – Donor-restricted gifts where the principal amount is to be held in perpetuity. Distributions of earnings are restricted for use according to the donor's intent, as specified in a gift agreement. Donor endowments typically benefit specific programs in clinical departments of the Medical Center, for either, research, directorships, or general program support.

Split-interest trusts – Trusts established by donors where VUMC is named as beneficiary. Depending on the terms of the trust, VUMC may receive periodic distributions, and potentially a principal amount at some point in the future. Like donor endowments, split-interest trusts typically benefit specific programs as defined in the terms of the trust.

Supplemental executive retirement program assets – Assets set aside to fulfill obligations as they come due according to the terms of the retirement program.



**Vanderbilt University Medical Center**  
**Notes to Consolidated Financial Statements**  
**June 30, 2021 and 2020**

Investments were as follows as of June 30, 2021 and 2020:

<i>(\$ in thousands)</i>	<u>2021</u>	<u>2020</u>
Corporate bonds	\$ 336,905	\$ 235,249
Equity mutual funds	151,200	128,569
Cash and cash equivalents	27,681	13,147
Split-interest trusts	9,503	7,124
Hedged equity mutual funds	107,548	64,986
Fixed income mutual funds	217,762	190,054
Certificates of deposit	21,162	16,338
Asset-backed securities	28,971	26,448
Mortgage-backed securities	6,503	-
Real estate mutual funds	-	20,680
Commercial paper	37,040	22,218
Government bonds	53,133	80,145
Hedged debt mutual funds	114,474	70,958
Commodities and managed futures mutual funds	19,802	15,902
Target date mutual funds	5,168	4,865
Total investments reported at fair value	<u>\$ 1,136,852</u>	<u>\$ 896,683</u>
Private equity investments recorded at net asset value	12,839	-
Total investments	<u><u>\$ 1,149,691</u></u>	<u><u>\$ 896,683</u></u>

Investment returns comprise the following elements for Fiscal 2021 and 2020:

<i>(\$ in thousands)</i>	<u>2021</u>	<u>2020</u>
Interest and dividend income	\$ 14,910	\$ 20,740
Net realized gains on sales of securities	14,922	5,025
Realized investment gains	29,832	25,765
Unrealized investment gains (losses), net	49,995	3,637
Total investment returns	79,827	29,402
Investment manager, trustee and other fees	(457)	(451)
Restricted investment income	(11,169)	(1,727)
Total income from investments, net	<u><u>\$ 68,201</u></u>	<u><u>\$ 27,224</u></u>

VUMC has exposure to risks, including liquidity, interest rate, counterparty, basis, regulatory, market, and credit risks, for marketable securities. Due to the level of risk exposure, it is possible that material near-term valuation changes for investment securities may occur.

VUMC manages all investments, including endowments, in various investment pools.

**Vanderbilt University Medical Center**  
**Notes to Consolidated Financial Statements**  
**June 30, 2021 and 2020**

---

**10. Property, Plant, and Equipment, Net**

Property, plant, and equipment comprise the following as of June 30, 2021 and 2020:

<i>(\$ in thousands)</i>	<u>2021</u>	<u>2020</u>
Land and land improvements	\$ 40,800	\$ 40,800
Buildings and improvements	1,249,125	1,189,614
Equipment and software	683,108	562,360
Leasehold improvements	141,358	86,869
Construction in progress	94,027	77,739
Property, plant, and equipment at cost	<u>2,208,418</u>	<u>1,957,382</u>
Accumulated depreciation and amortization	<u>(578,093)</u>	<u>(432,279)</u>
Property, plant, and equipment, net	<u>\$ 1,630,325</u>	<u>\$ 1,525,103</u>

As part of the MTSA, VUMC acquired land and land improvements and buildings and improvements which are not allowed to be repurposed without the express consent of VU.

In Fiscal 2021 and 2020, VUMC capitalized interest of \$2.3 million and \$2.9 million, respectively, related to long-term capital projects, primarily the MCJCHV expansion and the VUH bed expansion.

Property, plant, and equipment balances above include the following amounts related to capitalized internal use software:

<i>(\$ in thousands)</i>	<u>2021</u>	<u>2020</u>
Equipment and software	\$ 188,334	\$ 167,897
Construction in progress	7,095	11,063
	195,429	178,960
Accumulated amortization	<u>(58,662)</u>	<u>(40,823)</u>
Internal use software, carrying value	<u>\$ 136,767</u>	<u>\$ 138,137</u>

Depreciation and amortization comprise the following amounts in Fiscal 2021 and 2020:

<i>(\$ in thousands)</i>	<u>2021</u>	<u>2020</u>
Depreciation of tangible assets	\$ 117,183	\$ 97,976
Amortization of finance leases, leasehold improvements, and internal use software	34,271	28,678
Total depreciation and amortization	<u>\$ 151,454</u>	<u>\$ 126,654</u>

**Vanderbilt University Medical Center**  
**Notes to Consolidated Financial Statements**  
**June 30, 2021 and 2020**

**11. Long-Term Debt**

Long-term debt comprises the following as of June 30, 2021 and 2020:

<i>(\$ in thousands)</i>	<u>2021</u> <b>Carrying Amount</b>	<u>2020</u> <b>Carrying Amount</b>	<b>Effective Interest Rate <sup>(2)</sup></b>	<b>Fiscal Year of Maturity</b>
<b>Series debt</b>				
Fixed-rate debt				
Series 2016A	\$ 476,930	\$ 476,930	4.1%	2047
Series 2016B	300,000	300,000	4.1%	2027
Series 2017A	121,270	121,270	4.1%	2049
Series 2017	100,000	100,000	4.2%	2038
Series 2019B	128,600	128,600	3.9%	2055
Series 2020A	-	300,000	2.2%	2022
Total fixed-rate debt	<u>1,126,800</u>	<u>1,426,800</u>	3.8%	
Variable-rate debt				
Series 2016D	-	100,000	2.8%	2047
Series 2016F	21,900	21,900	1.3%	2025
Series 2017B	50,000	50,000	1.3%	2047
Series 2018	53,385	53,385	0.7%	2050
Series 2019A	35,000	35,000	0.6%	2050
Series 2021A	200,000	-	0.5%	2022
Total variable-rate debt	<u>360,285</u>	<u>260,285</u>	1.2%	
Total series debt	<u>1,487,085</u>	<u>1,687,085</u>		
<b>Other long-term debt</b>				
Lines of credit	100,000	100,000	0.7%	2022
Subordinated note payable	74,583	79,583	3.2%	2036
Product financing arrangement	25,121	29,236	4.2%	2027
Finance leases	16,997	15,980	2.5%	Various
Subtotal <sup>(1)</sup>	<u>1,703,786</u>	<u>1,911,884</u>	3.3%	
Net unamortized premiums	53,986	56,244		
Net unamortized issuance costs	<u>(10,918)</u>	<u>(12,517)</u>		
Total long-term debt	1,746,854	1,955,611		
Short-term borrowings	(300,000)	(100,000)		
Current portion of long-term debt	<u>(14,704)</u>	<u>(14,321)</u>		
Long-term debt, net	<u>\$ 1,432,150</u>	<u>\$ 1,841,290</u>		

(1) The effective interest rate of 3.3% as of June 30, 2021, is presented exclusive of interest rate exchange agreements discussed in Note 12 Interest Rate Exchange Agreements. Inclusive of these agreements, the overall portfolio effective interest rate was 3.6%.

(2) The effective interest rate for each debt instrument is calculated by dividing each instrument's interest expense by the weighted average debt outstanding, and where applicable, interest expense is reduced by premium amortization and increased by original issue discount amortization. Interest rates per the agreements are detailed in the accompanying notes.

# Vanderbilt University Medical Center

## Notes to Consolidated Financial Statements

### June 30, 2021 and 2020

---

On April 29, 2016, VUMC issued the Series 2016 A, B, D, E, and F bonds (“2016 Series Debt”) and notes aggregating \$1.3 billion of proceeds for the purpose of financing the Medical Center Acquisition and paying a portion of the costs of issuance associated with the 2016 Series Debt.

The bonds and notes comprising the 2016 Series Debt were issued by the Health and Educational Facilities Board of The Metropolitan Government of Nashville and Davidson County, Tennessee (“HEFB”). As a conduit issuer, the HEFB loaned the debt proceeds to VUMC. VUMC’s debt service requirements under these loan agreements coincide with required debt service of the actual HEFB bonds.

- The Series 2016A tax-exempt fixed-rate revenue bonds were issued in the par amount of \$476.9 million and include an original issue premium of \$59.6 million. The Series 2016A bonds have a final maturity date of July 1, 2046, and can be optionally redeemed at par on or after July 1, 2026. The 2016A bonds were structured as serial bonds with maturities from Fiscal 2030 through 2032, as well as three term bonds maturing Fiscal 2036 through 2047, which are subject to mandatory sinking fund redemption in lots. The Series 2016A bonds bear interest at 5% per annum and pay interest semiannually on July 1 and January 1.
- The Series 2016B taxable fixed-rate revenue bonds were issued in the par amount of \$300.0 million, bearing interest at 4.1% per annum. Interest is paid semiannually on July 1 and January 1, and has a bullet maturity of July 1, 2026. VUMC is entitled, at its option, to redeem all or a portion of the Series 2016B bonds before April 1, 2026, at a make-whole redemption price, which equals the greater of (i) 100% of the remaining outstanding principal and (ii) the net present value of the remaining scheduled principal and interest payments to the original maturity date, using a discount rate of 35 basis points above rates for U.S. Treasury securities with comparable maturities.
- The Series 2016D taxable variable-rate revenue notes (“floating rate notes”) were issued in the par amount of \$100.0 million and bear interest initially at a fixed spread to one-month LIBOR of 2.5% through the initial mandatory tender date of July 1, 2021, and a final maturity of July 1, 2046. Beginning six months prior to the mandatory tender date of July 1, 2021, the bonds have an optional redemption feature. If the Series 2016D bonds are successfully remarketed at the mandatory tender date, they are subject to mandatory redemption in lots commencing on July 1, 2021, and each July thereafter until final maturity. During Fiscal 2021, the Series 2016D floating rate notes were extinguished using cash on hand.
- The Series 2016E taxable term loan revenue notes were issued in the par amount of \$128.1 million and were placed privately with a bank. The notes bear interest in a variable-rate mode at a fixed spread to one-month LIBOR of 2.4% through the initial mandatory tender date of July 1, 2022, and a final maturity of July 1, 2046. During Fiscal 2018, VUMC renegotiated the interest to a variable-rate mode at a fixed spread to one-month LIBOR of 1.8%. In addition to optional redemption of all or a portion of the notes at any time, subject to notice, the Series 2016E notes are subject to principal amortization commencing on July 1, 2022, as defined in the Series 2016E loan agreement between VUMC and the lender. During Fiscal 2020, the Series 2016E bonds were extinguished using proceeds from the 2019B taxable fixed private placement notes, discussed further below.
- The Series 2016F taxable variable-rate revenue bonds were issued in the par amount of \$75.0 million and were placed privately with a bank. The bonds bear interest in a variable-rate mode at a fixed spread to one-month LIBOR of 2.5% through the initial mandatory tender date of July 1, 2022. During Fiscal 2018, \$53.1 million of the Series 2016F bonds were extinguished using proceeds from the 2018 tax-exempt fixed-rate revenue bonds, discussed further below.

# Vanderbilt University Medical Center

## Notes to Consolidated Financial Statements

### June 30, 2021 and 2020

---

The renegotiated interest rate on the remaining \$21.9 million of principal outstanding is a variable-rate mode at a fixed spread to one-month LIBOR of 1.2%. The remaining principal has a mandatory tender date of July 1, 2024. Prior to that, VUMC must pay \$2.1 million of principal on July 1, 2022, and \$2.2 million of principal on July 1, 2023. The remaining \$17.6 million of principal is due on July 1, 2024.

On July 26, 2017, the Series 2017A Tax-Exempt and Series 2017 Taxable Corporate Bonds were issued, and on August 1, 2017, the Series 2017B Taxable Revenue Bonds were issued ("2017 Series Debt"), aggregating \$271.3 million of proceeds for the purpose of refinancing existing debt, funding capital projects related to the MCJCHV expansion and the VUH bed expansion/clinical relocation, which is a phased project, and paying a portion of the costs of issuance associated with the 2017 Series Debt.

The Series 2017A Tax-Exempt Revenue Bonds and the Series 2017B Taxable Term Loan Revenue Note were issued by the HEFB. The Series 2017 Taxable Bonds were a corporate issue with VUMC as the issuer.

- The Series 2017A tax-exempt fixed-rate revenue bonds were issued in the par amount of \$121.3 million and include an original issue premium of \$5.1 million. The final maturity date is July 1, 2048, and optional redemption at par can occur on or after July 1, 2027. The Series 2017A bonds bear interest at 4.4% per annum and pay interest semiannually on July 1 and January 1.
- The Series 2017 taxable fixed-rate corporate bonds were issued in the par amount of \$100.0 million, bearing interest at 4.2% per annum. Interest is paid semiannually on July 1 and January 1, and the bonds have a final maturity date of July 1, 2037. There is a bullet payable beginning July 1, 2026, that allows VUMC to call the debt.
- The Series 2017B taxable variable-rate term loan notes were issued in the par amount of \$50 million and placed privately with a bank. The notes bear interest initially at a fixed-spread to one-month LIBOR of 1.2%. The notes have a final maturity date of July 1, 2046, a tender date of August 1, 2024, and may be redeemed at any time. Proceeds from the issuance of the Series 2017B notes were used to extinguish the Series 2016C R-FLOATs, initially issued on April 29, 2016.

On April 20, 2018, the Series 2018 Tax-Exempt Revenue Bonds ("2018 Series Debt") aggregating \$53.4 million of proceeds were issued for the purpose of refinancing existing debt and paying a portion of the costs of issuance associated with the 2018 Series Debt. The Series 2018 Tax-Exempt Revenue Bonds were issued by the HEFB, were placed privately with a bank, and bear interest at a fixed spread to 81% of one-month LIBOR of 0.6%. The bonds have a final maturity date of July 1, 2049 and can be optionally redeemed on or after July 1, 2025. Proceeds from the issuance of the Series 2018 bonds were used to extinguish a portion of the Series 2016F taxable variable-rate bonds.

On July 30, 2019, VUMC entered into a term loan agreement (2019A Term Loan) with a lender for \$35 million to pay for the acquisition of Tennova – Lebanon (now VWCH) hospital facilities, near term capital expenditures, and costs of issuance. The term loan bears interest at a variable rate plus a fixed spread to one-month LIBOR of 0.50% through the maturity date of August 1, 2029. VUMC has the option to redeem prepay all or a portion of the loan at any time, subject to notice. The 2019 loan is subject to principal amortization commencing on July 1, 2024 and ending July 1, 2049, as defined in the 2019 loan agreement between VUMC and the lender.

# **Vanderbilt University Medical Center**

## **Notes to Consolidated Financial Statements**

### **June 30, 2021 and 2020**

---

On October 22, 2019, the Series 2019B Taxable Fixed Private Placement Notes (“Series 2019B Notes”) aggregating \$128.6 million of proceeds were issued for the purpose of refinancing existing debt and paying a portion of the costs of issuance associated with the Series 2019B Notes. The Series 2019B Notes were placed privately with a bank, and bear interest at a fixed rate of 3.9% per annum. The notes have a final maturity date of July 1, 2054. Proceeds from the issuance of the Series 2019B Notes were used to extinguish the Series 2016E Taxable Term Loan Revenue Notes.

On April 9, 2020, the Series 2020A Taxable Fixed Term Loan (“Series 2020A Loan”) aggregating \$300 million was issued to provide additional liquidity during the COVID-19 pandemic. The lender for the Series 2020A Loan was JPMorgan Chase Bank. The debt bears interest at a fixed rate of 2.1% per annum, has an optional redemption after one year, and has a final maturity date of April 1, 2022. During Fiscal 2021, the Series 2020A Loan was extinguished using proceeds from the Series 2021A Short-Term Loan discussed further below, and draws on available lines of credit.

On April 9, 2021, the Series 2021A Short-Term Loan was issued in the par amount of \$200.0 million for the purpose of refinancing the Series 2020A Loan. The lender for the Series 2021A Short-Term Loan was Royal Bank of Canada. The debt bears interest at a fixed spread to LIBOR of 0.4% and has a maturity of April 8, 2022.

Each of the bonds and notes comprising the 2016, 2017, 2018, 2019, 2020, and 2021 Series Debt represent separate obligations under a Master Trust Indenture (“MTI”) structure. The MTI provides the flexibility for multiple parties to participate in debt issuances as part of an obligated group; presently, VUMC has no other third-party members participating in the obligated group. All debt issued under the MTI is a general obligation of the obligated group. Under the provisions of the Leasehold Deed of Trust, Security Agreement, Assignment of Rents and Leases, and Fixture Filing (the “Security Agreement”) within the MTI, gross receivables of the obligated group are pledged as collateral. Additionally, the Security Agreement established a mortgage lien on (i) the leasehold interest of the land subject to the Ground Lease; (ii) the buildings, structures, improvements, and fixtures now or hereafter located on the land subject to the Ground Lease; and (iii) certain other collateral.

Trust indentures for certain bond issues contain covenants and restrictions, the most material of which include limitations on the issuance of additional debt, maintenance of a specified debt service coverage ratio, and a minimum amount of days cash on hand. VUMC complied with such covenants and restrictions as of June 30, 2021 and 2020.

On April 29, 2016, VUMC delivered a secured subordinated promissory note in the amount of \$100.0 million to VU to finance the Acquisition (the “subordinated note”). In July of 2018, VU sold its rights to future principal and interest payments on this note to a third party. The note was issued at a fixed rate of 3.25% with monthly principal payments totaling \$5.0 million annually commencing on May 31, 2016, for a period of 20 years ending on April 30, 2036. VUMC may, at any time and from time to time, without premium or penalty, prepay all or any portion of the unpaid principal amount of the subordinated note. This note is secured by the gross receivables and mortgaged property described in the Security Agreement subject to the requirements of the 2016 Series Debt and the MTI.

As part of the Acquisition, VUMC assumed a 10-year, unsecured, noninterest-bearing product financing arrangement with a vendor for the purchase and implementation of internal use software. The annual payment of \$5.3 million is payable in monthly installments, is considered principal and imputed interest, and continues through Fiscal 2027. The balance due under the Product Financing Arrangement is \$25.1 million and \$29.2 million as of June 30, 2021 and 2020, respectively.

# Vanderbilt University Medical Center

## Notes to Consolidated Financial Statements

### June 30, 2021 and 2020

---

At June 30, 2021 and 2020, \$4.3 million and \$4.1 million was included in the current portion of long-term debt caption, with the remaining balance in long-term debt, net of current portion.

In Fiscal 2021 and 2020, noncash investing and financing activities totaled \$6.8 million and \$19.1 million, respectively, related to finance leases.

VUMC has an agreement with a bank to provide a general use line of credit with a maximum available commitment totaling \$100.0 million. On March 18, 2020, VUMC drew down the available \$100 million, which bears interest at a fixed spread to one-month LIBOR of 0.65% and has no maturity date if the line of credit is renewed annually. The outstanding balance on the line of credit is \$59.5 million and \$100.0 million as of June 30, 2021 and 2020, respectively. The line of credit accrues a commitment fee of 0.15% per annum on any unused portion of the line of credit.

VUMC established one additional line of credit with a bank in Fiscal 2021. A \$50 million line of credit with Royal Bank of Canada, bearing interest at a fixed spread to one-month LIBOR of 0.45%, maturing in Fiscal 2022 with a commitment fee of 0.2% on any unused portion of the line of credit. As of June 30, 2021, this line of credit had an outstanding balance of \$40.5 million.

VUMC established three additional lines of credit with banks in Fiscal 2020:

- \$50 million line of credit with Truist, bearing interest at a fixed spread to one-month LIBOR of 1.0%, maturing in Fiscal 2022 with a commitment fee of 0.25% on any unused portion of the line of credit. As of June 30, 2021 and 2020, this line of credit had no outstanding balance.
- \$50 million line of credit with Truist, bearing interest at a fixed spread to one-month LIBOR of 0.85%, maturing in Fiscal 2021 with a commitment fee of 0.25% on any unused portion of the line of credit. As of June 30, 2020, this line of credit had no outstanding balance. This line of credit expired during Fiscal 2021.
- \$50 million line of credit with Bank of New York Mellon, bearing interest at a fixed spread to one-month LIBOR of 1.4%, maturing in Fiscal 2021 with a commitment fee of 0.25% on any unused portion of the line of credit. As of June 30, 2020, this line of credit had no outstanding balance. This line of credit expired during Fiscal 2021.

The total outstanding balance on lines of credit is \$100.0 million as of June 30, 2021 and 2020. Commitment fees for the lines of credit totaled \$0.4 million and \$0.2 million in Fiscal 2021 and Fiscal 2020, respectively.

Interest paid on all obligations, including interest rate swap settlements, net of amounts capitalized, was \$68.4 million and \$62.7 million in Fiscal 2021 and 2020, respectively.

**Vanderbilt University Medical Center**  
**Notes to Consolidated Financial Statements**  
**June 30, 2021 and 2020**

---

Principal retirements and scheduled sinking fund requirements based on nominal maturity schedules for long-term debt due in subsequent fiscal years ending June 30 are as follows:

*(\$ in thousands)*

2022	\$ 314,585
2023	16,094
2024	15,915
2025	80,974
2026	64,785
Thereafter	1,211,433
	<u>\$ 1,703,786</u>

**12. Interest Rate Exchange Agreements**

Key features of VUMC interest rate exchange agreements are summarized below:

<u>Notional Amount</u>	<u>Pay Fixed Rate</u>	<u>Receive Variable Rate</u>	<u>Mandatory Termination Date</u>
\$75.0 million	4.28%	68% of one-month LIBOR	April 29, 2026
\$75.0 million	4.18%	68% of one-month LIBOR	April 29, 2023

VUMC incorporates these interest rate exchange agreements into its debt portfolio management strategy. There are no collateral pledging requirements. The agreements terminate automatically on April 29, 2026 and 2023, if not renegotiated or extended, at which point the exchange agreements will be settled at fair value.

VUMC recorded the following activity related to the interest rate exchange agreements during Fiscal 2021 and 2020:

*(\$ in thousands)*

	<u>2021</u>	<u>2020</u>
Mark-to-market adjustments	\$ 23,478	\$ (32,441)
Cash settlements	<u>(6,106)</u>	<u>(4,711)</u>
Unrealized gain (loss) on interest rate exchange agreements, net of cash settlements	<u>\$ 17,372</u>	<u>\$ (37,152)</u>

**13. Leases**

VUMC has operating and finance leases for real estate, personal property and equipment. VUMC determines if an arrangement is a lease at the inception of a contract. Leases with an initial term of twelve months or less are not recorded on the consolidated balance sheets.

VUMC has lease agreements which require payments for lease and non-lease components and has elected to account for these as a single lease component. For leases that commenced before the effective date of ASU 2016-02, VUMC elected the permitted practical expedients to not reassess the following: (i) whether any expired or existing contracts contain leases; (ii) the lease classification for any expired or existing leases; and (iii) initial direct costs for any existing leases.



**Vanderbilt University Medical Center**  
**Notes to Consolidated Financial Statements**  
**June 30, 2021 and 2020**

Right-of-use assets represent VUMC's right to use an underlying asset during the lease term, and lease liabilities represent VUMC's obligation to make lease payments arising from the lease. Right-of-use assets and liabilities are recognized at the commencement date, based on the net present value of fixed lease payments over the lease term. VUMC's lease terms include options to extend or terminate the lease when it is reasonably certain that the options will be exercised. As most of VUMC's operating leases do not provide an implicit rate, VUMC uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. VUMC considers recent debt issuances, as well as publicly available data for instruments with similar characteristics when calculating its incremental borrowing rates. Finance lease agreements generally include an interest rate that is used to determine the present value of future lease payments. Operating fixed lease expense and finance lease depreciation expense are recognized on a straight-line basis over the lease term. Variable lease costs consist primarily of common area maintenance and other index adjustments.

Operating and finance lease right-of-use assets and lease liabilities as of June 30, 2021 and 2020, are as follows:

<i>(\$ in thousands)</i>	<b>Balance Sheet Classification</b>	<b>2021</b>	<b>2020</b>
<b>Assets:</b>			
Operating leases	Operating leases	\$ 839,850	\$ 846,695
Finance leases	Property, plant, and equipment, net	17,363	16,712
Total lease assets		<u>\$ 857,213</u>	<u>\$ 863,407</u>
<b>Liabilities:</b>			
<b>Current:</b>			
Operating leases	Current portion of operating lease liabilities	\$ 67,343	\$ 70,062
Finance leases	Current portion of long-term debt	5,412	5,206
<b>Noncurrent:</b>			
Operating leases	Noncurrent portion of operating lease liabilities	795,330	797,811
Finance leases	Long-term debt, net of current portion	11,584	10,774
Total lease liabilities		<u>\$ 879,669</u>	<u>\$ 883,853</u>
<b>Weighted-average remaining term:</b>			
Operating leases		57.4 years	57.3 years
Finance leases		3.6 years	3.8 years
<b>Weighted-average discount rate:</b>			
Operating leases		3.7%	3.7%
Finance leases		2.4%	2.4%

Included in the tables above is the Ground Lease with VU expiring in 2114 discussed below. Excluding this lease, the weighted average remaining lease term for VUMC's operating leases is 8.2 years as of June 30, 2021. As of June 30, 2021 and 2020, the land lease comprises \$489.2 million and \$489.7 million, respectively, of the operating lease asset and \$491.9 million and \$492.5 million, respectively, of the operating lease liability detailed above.

**Vanderbilt University Medical Center**  
**Notes to Consolidated Financial Statements**  
**June 30, 2021 and 2020**

Lease expense for finance and operating leases for the years ended June 30, 2021 and 2020, are as follows:

<i>(\$ in thousands)</i>	<u>2021</u>	<u>2020</u>
Finance lease expense:		
Amortization of leased assets	\$ 6,125	\$ 4,433
Interest on lease liabilities	410	273
Operating lease expense <sup>(1)</sup>	109,665	107,358
Short-term lease expense <sup>(1)</sup>	4,578	3,787
Variable lease expense <sup>(1)</sup>	16,181	13,321
	<u>\$ 136,959</u>	<u>\$ 129,172</u>

<sup>(1)</sup> Expense is included in "Facilities and equipment" in the consolidated statements of operations.

The following table presents supplemental cash flow information for the years ended June 30, 2021 and 2020:

<i>(\$ in thousands)</i>	<u>2021</u>	<u>2020</u>
Cash paid for amounts included in the measurement of lease liabilities:		
Operating cash flows for operating leases	\$ 105,136	\$ 103,166
Operating cash flows for finance leases	410	273
Financing cash flows for finance leases	5,766	4,334

The following table reconciles the undiscounted minimum lease payments to the operating and financing lease liabilities recorded on the consolidated balance sheet at June 30, 2021:

<i>(\$ in thousands)</i>	<u>Operating Leases</u>	<u>Finance Leases</u>
2022	\$ 95,338	\$ 5,666
2023	82,660	4,743
2024	74,699	4,176
2025	69,689	2,567
2026	58,694	360
Thereafter	1,848,298	202
Total minimum lease payments	<u>2,229,378</u>	<u>17,714</u>
Less: amount of lease payments representing interest	<u>(1,366,705)</u>	<u>(718)</u>
Present value of future minimum lease payments	862,673	16,996
Less: current lease obligations	<u>(67,343)</u>	<u>(5,412)</u>
Long-term lease obligations	<u>\$ 795,330</u>	<u>\$ 11,584</u>

# Vanderbilt University Medical Center

## Notes to Consolidated Financial Statements

### June 30, 2021 and 2020

---

Essential provisions of leases considered by management to be material are as follows:

- On April 29, 2016, VUMC entered into a Ground Lease with VU for approximately 1.7 million square feet of land for an initial term ending June 30, 2114, and an option to extend for up to two additional terms of 50 to 99 years each upon agreement by VU and VUMC. The annual base rent is payable monthly, and is CPI adjusted annually. VUMC made rental payments totaling \$19.6 million and \$19.4 million in Fiscal 2021 and Fiscal 2020, respectively. The Ground Lease allows VUMC to use the land on which its campus and related buildings are located. Included in the table above are \$1.8 billion in ground lease payments representing future minimum rentals based on the initial annual base rent of \$19.4 million, excluding annual CPI adjustments.
- In July 2007, VU entered into an agreement to lease approximately 50% of the space in the 850,000 square foot One Hundred Oaks shopping center located approximately five miles from the main campus ("100 Oaks Lease"). VU redeveloped this leased space primarily for medical and office uses. In October 2014, VU agreed to an amendment which extends the original lease term to November 30, 2035, with an option to renew the lease further for four additional 10-year periods. As part of the lease agreement, the lessee also has first rights on leasing additional space in the shopping center and first rights on purchasing if the landlord desires to sell. On April 29, 2016, the 100 Oaks Lease was assigned to VUMC. As a condition of the assignment, amendments to the 100 Oaks Lease were added which required VUMC to provide the landlord a \$25.0 million irrevocable standby letter of credit. The amounts related to this standby letter of credit are recorded as facilities and equipment expense and totaled \$0.2 million in both Fiscal 2021 and 2020. The standby letter of credit is no longer required under the lease and has been released as of June 10, 2021. VUMC included minimum property rental payments totaling \$111.6 million related to this space in the above minimum lease payments table.
- On April 29, 2016, VU assigned to VUMC a lease for approximately 231,000 square feet of office space at 2525 West End Avenue with expiration dates ranging from 2026 through 2030, with options to renew for two additional five-year periods. VUMC included minimum lease payments totaling \$59.0 million related to this space in the above minimum lease payments table.
- On April 29, 2016, VUMC and VU entered into certain lease agreements for the use of space in buildings owned by both entities. As of June 30, 2021, VUMC's estimated future minimum lease payments to VU totaled \$33.6 million. Estimated future lease receipts from VU for the fiscal year ended June 30, 2022, are \$7.5 million, subject to annual renewal.

**Vanderbilt University Medical Center**  
**Notes to Consolidated Financial Statements**  
**June 30, 2021 and 2020**

---

**14. Net Assets**

Net asset restrictions relate to the following purposes as of June 30, 2021 and 2020:

<i>(\$ in thousands)</i>	<b>2021</b>	<b>2020</b>
Donor-restricted – time or purpose		
Property, plant, and equipment	\$ 13,044	\$ 10,920
Research and education	115,897	106,167
Operations	15,087	4,661
Total donor-restricted – time or purpose	\$ 144,028	\$ 121,748
Donor restricted – perpetuity		
Research and education	\$ 80,530	\$ 64,807

**Net assets without donor restrictions** are free of donor-imposed restrictions. This classification includes all revenues, gains, and losses not restricted by donors. VUMC reports all expenditures in net assets without donor restrictions since the use of restricted contributions in accordance with donors' stipulations results in the release of the restriction.

**Donor restricted – time or purpose** contain donor-imposed stipulations that expire with the passage of time or that can be satisfied by the action of VUMC. These net assets may include restricted gifts including unconditional pledges, split-interest agreements, interests in trusts held by others, and accumulated appreciation on donor-restricted endowments not yet appropriated by the Board of Directors for distribution. Donor gifts that are restricted for funding capital projects are considered released from restriction once related capital expenditures have been made and the asset is placed in service.

**Donor restricted – perpetuity** contains amounts held in perpetuity as requested by donors. These net assets may include unconditional pledges, donor-restricted endowments, split-interest agreements, and interests in trusts held by others. Generally, the donors of these assets permit VUMC to use a portion of the income earned on related investments for specific purposes.

UPMIFA specifies that unless stated otherwise in a gift instrument, donor-restricted assets in an endowment fund are restricted assets until appropriated for expenditure. Barring the existence of specific instructions in gift agreements for donor-restricted endowments, VUMC reports the historical value of such endowments as donor restricted – perpetuity and the net accumulated appreciation as donor restricted – time or purpose. In this context, the historical value represents the original value of initial contributions restricted as permanent endowments plus the original value of subsequent contributions and, if applicable, the value of accumulations made in accordance with the direction of specific donor gift agreements.

# Vanderbilt University Medical Center

## Notes to Consolidated Financial Statements

### June 30, 2021 and 2020

---

#### 15. Fair Value Measurements

Fair value measurements represent the amount at which the instrument could be exchanged in an orderly transaction between market participants at the measurement date. VUMC utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three levels:

- Level 1      Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets that VUMC has the ability to access.
  
- Level 2      Inputs to the valuation methodology include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in inactive markets, inputs other than quoted prices that are observable for the assets or liabilities, and inputs that are derived principally from or corroborated by observable market data by correlation or other means.
  
- Level 3      Inputs to the valuation methodology are unobservable and significant to the fair value measurement. Unobservable inputs reflect VUMC's assumptions about the inputs market participants would use in pricing the asset or liability, including assumptions about risk. Unobservable inputs are developed based on the best information available in the circumstances and may include VUMC's own data.

VUMC's principal assets and liabilities are cash and cash equivalents, investments, patient accounts receivable, estimated receivables and payables under third-party programs, grants and contracts receivable, pledges receivable, operating lease assets, accounts payable and other accrued expenses, self-insurance reserves, operating lease liabilities, long-term debt, and interest rate exchange agreements. Except for long-term debt, the carrying amount of these assets and liabilities approximates fair value.

As of June 30, 2021, the carrying value and estimated fair value of total long-term debt totaled \$1.7 billion and \$1.9 billion, respectively. As of June 30, 2020, the carrying value and estimated fair value of total long-term debt totaled \$2.0 billion and \$2.0 billion, respectively. VUMC bases estimated fair value of long-term debt on market conditions prevailing at fiscal year-end reporting dates. Besides potentially volatile market conditions, fair value estimates typically reflect limited secondary market trading. The fair values of the fixed-rate Series Debt, as defined in Note 11 Long-Term Debt, were based on a Level 2 computation using quoted prices for similar liabilities in active markets as of June 30, 2021 and 2020, as applicable. The carrying amounts related to VUMC's variable-rate Series Debt and other long-term debt obligations approximate their fair values as of June 30, 2021 and 2020. As of June 30, 2021 and 2020, the fair values of the subordinated note payable and the product financing arrangement were based on a Level 2 discounted cash flow approach applying a risk-adjusted spread for issuers of similar credit quality to U.S. Treasury yields for securities with comparable maturities.

**Vanderbilt University Medical Center**  
**Notes to Consolidated Financial Statements**  
**June 30, 2021 and 2020**

For financial instruments measured at fair value on a recurring basis, the following tables summarize valuation hierarchy levels as of June 30, 2021 and 2020, determined by the nature of the financial instrument and the least observable input significant to the fair value measurement:

<b>Fair Value Measurements as of June 30, 2021</b>				
<i>(\$ in thousands)</i>	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>	<u>Total Carrying Amount</u>
<b>Assets</b>				
Corporate bonds	\$ 38,310	\$ 298,595	\$ -	\$ 336,905
Equity mutual funds	29,174	122,026	-	151,200
Cash and cash equivalents	27,681	-	-	27,681
Beneficial interests in				
split-interest trusts	-	9,503	-	9,503
Hedged equity mutual funds	-	107,548	-	107,548
Fixed-income mutual funds	114,871	102,891	-	217,762
Certificates of deposit	-	21,162	-	21,162
Asset-backed securities	6,982	21,989	-	28,971
Mortgage-backed securities	-	6,503	-	6,503
Commercial paper	-	37,040	-	37,040
Government bonds	21,884	31,249	-	53,133
Hedged debt mutual funds	-	114,474	-	114,474
Commodities and managed				
futures mutual funds	10,759	9,043	-	19,802
Target date mutual funds	-	5,168	-	5,168
Total assets reported at fair value	<u>\$ 249,661</u>	<u>\$ 887,191</u>	<u>\$ -</u>	<u>\$ 1,136,852</u>
<b>Liabilities</b>				
Interest rate exchange agreements	\$ -	\$ 76,864	\$ -	\$ 76,864
Total liabilities reported at fair value	<u>\$ -</u>	<u>\$ 76,864</u>	<u>\$ -</u>	<u>\$ 76,864</u>

**Vanderbilt University Medical Center**  
**Notes to Consolidated Financial Statements**  
**June 30, 2021 and 2020**

(\$ in thousands)	Fair Value Measurements as of June 30, 2020			Total Carrying Amount
	Level 1	Level 2	Level 3	
<b>Assets</b>				
Corporate bonds	\$ 15,805	\$ 219,444	\$ -	\$ 235,249
Equity mutual funds	34,589	93,980	-	128,569
Cash and cash equivalents	13,147	-	-	13,147
Beneficial interests in				
split-interest trusts	-	7,124	-	7,124
Hedged equity mutual funds	-	64,986	-	64,986
Fixed-income mutual funds	120,658	69,396	-	190,054
Certificates of deposit	-	16,338	-	16,338
Asset-backed securities	-	26,448	-	26,448
Real estate mutual funds	-	20,680	-	20,680
Commercial paper	-	22,218	-	22,218
Government bonds	10,665	69,480	-	80,145
Hedged debt mutual funds	-	70,958	-	70,958
Commodities and managed				
futures mutual funds	9,121	6,781	-	15,902
Target date mutual funds	-	4,865	-	4,865
Total assets reported at fair value	<u>\$ 203,985</u>	<u>\$ 692,698</u>	<u>\$ -</u>	<u>\$ 896,683</u>
<b>Liabilities</b>				
Interest rate exchange agreements	\$ -	\$ 100,342	\$ -	\$ 100,342
Total liabilities reported at fair value	<u>\$ -</u>	<u>\$ 100,342</u>	<u>\$ -</u>	<u>\$ 100,342</u>

VUMC employs derivatives, primarily interest rate exchange agreements, to help manage interest rate risks associated with variable-rate debt. In addition to the credit risk of the counterparty owing a balance, VUMC calculates the fair value of interest rate exchange agreements based on the present value of future net cash settlements that reflect market yields as of the measurement date.

Parties to interest rate exchange agreements are subject to risk for changes in interest rates, as well as the risk of credit loss in the event of nonperformance by the counterparty. VUMC deals only with high-quality counterparties that meet rating criteria for financial stability and credit-worthiness.

**16. Retirement Plan**

VUMC's full-time employees participate in a 403(b) defined contribution retirement plan administered by a third party. For eligible employees with one year of continuous service, this plan requires employer matching of employee contributions up to 5% of eligible compensation. The employee immediately vests in these contributions.

VUMC funds the obligations under this plan through monthly transfers to the respective retirement plan administrator with the corresponding expense recognized in the year incurred. During Fiscal 2021 and 2020, VUMC recognized \$76.8 million and \$69.8 million, respectively, of expense in connection with this plan.

**Vanderbilt University Medical Center**  
**Notes to Consolidated Financial Statements**  
**June 30, 2021 and 2020**

---

**17. Functional Expense**

VUMC provides general health care services primarily to residents within its geographic location and supports research and education programs. Total operating expense by nature and function for Fiscal 2021 and 2020 were as follows:

*(\$ in thousands)*

	<b>For the year ended June 30, 2021</b>			
	<b>Healthcare Services</b>	<b>Academic Research and Education</b>	<b>Administrative and Other</b>	<b>Total</b>
Salaries, wages, and benefits	\$ 2,021,532	\$ 581,945	\$ 233,067	\$ 2,836,544
Supplies and drugs	1,134,657	56,507	25,039	1,216,203
Facilities and equipment	177,973	44,722	74,053	296,748
Services and other	599,477	107,610	88,200	795,287
Depreciation and amortization	128,181	1,582	21,691	151,454
Interest	49,351	11,163	16	60,530
Total operating expense	<u>\$ 4,111,171</u>	<u>\$ 803,529</u>	<u>\$ 442,066</u>	<u>\$ 5,356,766</u>

*(\$ in thousands)*

	<b>For the year ended June 30, 2020</b>			
	<b>Healthcare Services</b>	<b>Academic Research and Education</b>	<b>Administrative and Other</b>	<b>Total</b>
Salaries, wages, and benefits	\$ 1,773,506	\$ 542,728	\$ 179,561	\$ 2,495,795
Supplies and drugs	980,544	46,640	19,214	1,046,398
Facilities and equipment	160,705	40,556	72,144	273,405
Services and other	549,059	98,291	92,905	740,255
Depreciation and amortization	103,734	1,521	21,399	126,654
Interest	47,172	13,585	14	60,771
Total operating expense	<u>\$ 3,614,720</u>	<u>\$ 743,321</u>	<u>\$ 385,237</u>	<u>\$ 4,743,278</u>

Certain expense categories are attributable to more than one function. Therefore, these expenses require an allocation on a reasonable basis that is consistently applied. The expenses that are allocated include salaries, wages, and benefits, and services and other.



# Vanderbilt University Medical Center

## Notes to Consolidated Financial Statements

### June 30, 2021 and 2020

---

#### 18. Commitments and Contingencies

Management has policies, procedures, and an organizational structure to enforce and monitor compliance with government statutes and regulations. VUMC's compliance with such laws and regulations is subject to future government review and interpretations, as well as regulatory actions unknown or unasserted at this time.

- Litigation. VUMC is a defendant in certain lawsuits alleging medical malpractice and civil action.

In December 2019, VUMC was notified by the Internal Revenue Service (the "IRS") of its intention to conduct an examination of the 403b Plan for the year ending December 31, 2017. During that examination, the Company identified certain concerns relating to the calculation of the employer match provided by the Company under the 403b Plan, which was implemented by the Company in April 2016. Following review and discussion, in November 2020 the Company and IRS entered into a Closing Agreement, under which the IRS agreed to accept the Company's implementation of a retroactive amendment to the 403b Plan to correct the calculation of the employer match in exchange for payment by the Company of a penalty of a nominal amount. The execution and delivery of the Closing Agreement fully resolves such matters relating to the examination of the 403b Plan by the IRS.

Through the operation of its compliance program, VUMC from time to time initiates the review of billing for clinical services provided by VUMC and its affiliated providers. VUMC has established a liability reserve relating to certain matters under review as of June 30, 2021 and 2020, which is not material to VUMC's overall financial position.

- Regulations. VUMC's compliance with regulations and laws is subject to future government reviews and interpretations, as well as regulatory actions unknown at this time. VUMC believes that the liability, if any, from such reviews will not have a significant effect on VUMC's consolidated financial position.
- Medical Malpractice Self-Insurance. The consolidated balance sheets include reserves for medical malpractice, professional, and general liability coverage totaling \$72.6 million as of June 30, 2021, and \$60.3 million as of June 30, 2020. These liabilities are measured at the net present value of those cash flows using a discount rate of 2.5% at both dates and are classified as current or noncurrent based on the expected timing of cash flows. Other current assets include expected recoveries from commercial insurance carriers under excess coverage arrangements totaling \$3.8 million as of June 30, 2021, and \$2.7 million as of June 30, 2020. During Fiscal 2021 and 2020, VUMC recorded expenses for medical malpractice self-insurance of \$22.4 million and \$27.7 million, respectively.
- Employee Health and Workers' Compensation Insurance. Accrued compensation and benefits included actuarially determined liabilities for employee health and workers' compensation claims totaling \$21.8 million and \$6.7 million, respectively, as of June 30, 2021, and \$16.9 million and \$6.1 million, respectively, as of June 30, 2020. During Fiscal 2021 and 2020, VUMC recorded expenses for self-insured employee health benefit plans, net of employee premiums, totaling \$241.9 million and \$181.5 million, respectively. During Fiscal 2021 and 2020, VUMC recorded expenses for self-insured workers' compensation plans of \$4.9 million and \$2.9 million, respectively.

# Vanderbilt University Medical Center

## Notes to Consolidated Financial Statements

### June 30, 2021 and 2020

---

- Federal and State Contracts and Other Requirements. Expenditures related to federal and state grants and contracts are subject to adjustment based upon review by the granting agencies. Amounts of expenditures that granting agencies might disallow cannot be determined at this time. These amounts affect government grants and contracts revenue, as well as facilities and administrative costs recovery. VUMC does not expect these costs to impact the consolidated financial position by material amounts.
- Health Care Services. In Fiscal 2021 and 2020, 85% and 83%, respectively, of VUMC's operating revenue was generated by providing health care services, where revenue is affected by reimbursement arrangements with federal and state healthcare programs, commercial insurance, and other managed care payors. If reimbursement rates from third-party payors decrease or if contract terms become less favorable in future periods, VUMC's operating revenues may decline. See Note 4 Patient Service Revenue, Patient Accounts Receivable, and Estimated Third-Party Settlements, for further information regarding healthcare revenues and related receivables.
- HIPAA Compliance. Under the Health Insurance Portability and Accountability Act of 1996 ("HIPAA"), the federal government has authority to complete fraud and abuse investigations. HIPAA has established substantial fines and penalties for offenders. VUMC maintains policies, procedures, and organizational structures to enforce and monitor compliance with HIPAA, as well as other applicable local, state, and federal statutes and regulations.
- Construction. VUMC had contractual commitments under major construction and equipment contracts totaling \$56.8 million and \$90.2 million as of June 30, 2021 and 2020, respectively.
- Letter of Credit. As a requirement of the assignment of the 100 Oaks Lease described in Note 13 Leases, VUMC provided an irrevocable standby letter of credit of \$25.0 million to the landlord of the property dated June 10, 2016. In FY21, this letter of credit was canceled and is no longer required as a result of VUMC achieving certain financial requirements.

## 19. Other Events

### *COVID-19*

In March of Fiscal 2020, COVID-19, a disease caused by the novel strain of the coronavirus, was designated by the World Health Organization as a global pandemic. A state of emergency was subsequently announced by the State of Tennessee, quickly followed by "stay at home" orders and orders for hospitals and outpatient surgical facilities to stop non-essential procedures. This global health crisis negatively impacted many facets of the business, including lower patient volumes and related revenues, significant increases in certain supply cost (in particular personal protective equipment) as well as difficulties sourcing these supplies, and volatility in the U.S. and global financial markets impacting VUMC's investment portfolios. By the end of Fiscal 2020 and throughout Fiscal 2021, volumes rebounded, although subsequent surges of the virus in the winter of Fiscal 2021 and fall of Fiscal 2022 caused somewhat similar impacts, although to a lesser degree. Due to the evolving nature of the COVID-19 pandemic, despite positive indicators, the ultimate impact to VUMC and its financial condition is presently unknown.

Sources of pandemic relief include the federal stimulus package known as The Coronavirus Aid, Relief, and Economic Security ("CARES") Act, signed into law on March 27, 2020, the Coronavirus Response and Consolidated Appropriations Act ("CRCA") signed into law on December 27, 2020, and the American Rescue Plan ("ARP"), signed into law on March 11, 2021. These laws include a number of provisions: most importantly providing funding through the Public Health and Social

# Vanderbilt University Medical Center

## Notes to Consolidated Financial Statements

### June 30, 2021 and 2020

---

Services Emergency Fund (“Provider Relief Fund”) to reimburse eligible health care providers for health care-related expenses or lost revenues not otherwise reimbursed that are directly attributable to COVID-19. These provider relief funds included amounts distributed to providers based on their share of the Medicare fee-for-service reimbursement (“General Distributions”). The funds also included for certain targeted distributions (“Targeted Distributions”) to qualifying providers (primarily rural and high impact areas). For the period ended June 30, 2021, VUMC recognized as revenue approximately \$46.3 million in General Distributions and \$8.8 million in Targeted Distributions, for a total of \$55.1 million, under the Provider Relief Fund. For the period ended June 30, 2020, VUMC recognized as revenue approximately \$83.3 million in General Distributions and \$35.7 million in Targeted Distributions, for a total of \$119.0 million, under the Provider Relief Fund. These amounts are presented in Other operating revenue in the consolidated statement of operations.

In addition, the CARES Act provides for an expansion of the Medicare Accelerated and Advance Payment Program (“MAAPP”) whereby inpatient acute care hospitals and other eligible providers may request an advanced payment of up to 100% of their Medicare payment amount for a six-month period to be repaid through withholding of future Medicare fee-for-service payments beginning 120 days after receipt. During Fiscal 2020, VUMC received advance payments from Medicare of \$222.4 million, which is recorded as a current liability on the consolidated balance sheet as of June 30, 2020.

On October 1, 2020, the Continuing Appropriations and Other Extensions Acts amended the repayment terms for the funds received under the MAAPP. Under the revised repayment terms, the Centers for Medicare and Medicaid Services (“CMS”) began to automatically recoup the advance payments one year from the original date of issuance by offsetting the payments against newly submitted Medicare claims. Once the recoupment period began, for the first eleven (11) months, Medicare automatically recoups payments at a rate of 25% of the Medicare claims amount otherwise owed to VUMC. After the first recoupment period of eleven (11) months, and continuing for the following six (6) months, Medicare automatically recoups payments at a rate of 50% of the Medicare claims amount otherwise owed to VUMC. After this repayment term concludes, any balance that remains outstanding will be subject to interest at a rate of four percent (4%) per annum. In accordance with the repayment terms, CMS began recoupment of VUMC’s MAAPP funds in April 2021 and has recouped \$33.0M as of June 30, 2021. VUMC expects the remaining liability will be subject to recoupment within the next twelve months, and as such, VUMC has classified the remaining MAAPP liability of \$189.4M as a current liability on the consolidated balance sheet as of June 30, 2021.

The CARES Act also allows for deferred payment of the employer portion of certain payroll taxes between March 27, 2020 and December 31, 2020, with 50% due December 31, 2021 and the remaining 50% due December 31, 2022. VUMC began deferring these payroll tax payments during the fourth quarter of Fiscal 2020. As of June 30, 2021, VUMC had deferred payroll tax payments of \$75.8 million, with \$37.9 million and \$37.9 million included in Accrued compensation and benefits and Other noncurrent liabilities, respectively, in the consolidated balance sheet. As of June 30, 2020, VUMC had deferred payroll tax payments of \$27.6 million, which are included in Other noncurrent liabilities in the consolidated balance sheet.

In addition, the CARES Act suspended the sequestration payment adjustment percentage of 2% applied to all Medicare Fee-for-Service claims from May 1, 2020 through December 31, 2020, with subsequent acts extending through December 31, 2021. This positively impacted Patient Service Revenue in the consolidated statements of operations by approximately \$14 million for Fiscal 2021 and \$3 million for Fiscal 2020. Beginning, September 1, 2020, the CARES Act also provided for a 20% Medicare supplement for Medicare patients diagnosed with COVID-19 that are admitted to the

**Vanderbilt University Medical Center**  
**Notes to Consolidated Financial Statements**  
**June 30, 2021 and 2020**

---

hospital, reflecting the additional costs of treating a patient with this diagnosis. VUMC recognized an additional \$6 million in Patient service revenue in the consolidated statement of operations for Fiscal 2021 related to this supplement.

Through the Paycheck Protection Program and Health Care Enhancement Act (the “PPHCE Act”), which was enacted on April 24, 2020, VUMC recognized an additional \$11.4 million as a payroll retention credit in Other operating revenue in Fiscal 2020.

During Fiscal 2021, VUMC recognized as Other operating revenue \$3.1 million for Tennessee staffing grants, \$2.0 million of business interruption insurance payments, \$2.0 million of State of Tennessee CARES funding, and \$0.8 million of other COVID-19 grants.

*Acquisition of VBCH and VTHH*

Effective January 1, 2021, VUMC acquired from CHS: Tennova Healthcare – Shelbyville and Tennova Healthcare – Harton, now known as Vanderbilt Bedford Hospital (“VBCH”) and Vanderbilt Tullahoma-Harton Hospital (“VTHH”) for total consideration of \$15.6 million.

The following table summarizes the fair value of net assets acquired:

*(\$ in thousands)*

Inventories	\$ 2,808
Other current assets	882
Property, plant, and equipment, net	11,943
Operating lease assets	4,230
Other noncurrent assets	122
Accounts payable and other accrued expenses	(155)
Operating lease liabilities	(4,230)
Total invested capital	\$ 15,600

*Acquisition of VWCH*

Effective August 1, 2019, VUMC acquired from CHS: Tennova Healthcare – Lebanon, now known as Vanderbilt Wilson County Hospital (“VWCH”) for total consideration of \$19.3 million.

The following table summarizes the fair value of net assets acquired:

*(\$ in thousands)*

Inventories	\$ 2,966
Other current assets	865
Property, plant, and equipment, net	15,780
Accounts payable and other accrued expenses	(359)
Total invested capital	\$ 19,252

The results of operations for these acquisitions are included in the consolidated statements of operations and changes in net assets beginning on the acquisition dates. Pro forma results of operations and changes in net assets as though these acquisitions occurred on July 1, 2019 are not materially different and accordingly are not provided.

**Vanderbilt University Medical Center**  
**Notes to Consolidated Financial Statements**  
**June 30, 2021 and 2020**

---

*Acquisition of Noncontrolling Interest in VMH*

As discussed in Note 1 – Description of Organization, effective January 1, 2021, VUMC acquired a noncontrolling ownership interest of 20% in CHS's affiliated Tennova Healthcare – Clarksville for total consideration of \$36.9 million. The noncontrolling interest is accounted for as an equity method investment and is included in Other noncurrent assets on the consolidated balance sheet.

**20. Subsequent Events**

Management evaluated events after June 30, 2021 through October 1, 2021, the date on which the consolidated financial statements were issued. During this period, there were no subsequent events requiring recognition or disclosure in the consolidated financial statements that have not been recorded or disclosed.

## Supplementary Information

**VANDERBILT UNIVERSITY MEDICAL CENTER  
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS  
Fiscal Period 7/1/2020 – 6/30/2021**

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
<b>DEPARTMENT OF AGRICULTURE</b>									
AGRICULTURAL RESEARCH_BASIC AND APPLIED RESEARCH	10.001	59-0210-8-184	UNIVERSITY OF CAPE TOWN (SOUTH AFRICA)	59-0210-8-184	\$ -	\$ 50,675	\$ 154,342	RESEARCH AND DEVELOPMENT	\$ 425,311,746
AGRICULTURAL RESEARCH_BASIC AND APPLIED RESEARCH	10.001	59-0210-6-004	US CIVILIAN RESEARCH AND DEVELOPMENT FOUNDATION	59-0210-6-004		2,130	154,342	RESEARCH AND DEVELOPMENT	425,311,746
AGRICULTURAL RESEARCH_BASIC AND APPLIED RESEARCH	10.001	59-0210-6-004	US CIVILIAN RESEARCH AND DEVELOPMENT FOUNDATION	59-0210-6-004		9,132	154,342	RESEARCH AND DEVELOPMENT	425,311,746
AGRICULTURAL RESEARCH_BASIC AND APPLIED RESEARCH	10.001	59-0210-6-004	US CIVILIAN RESEARCH AND DEVELOPMENT FOUNDATION	59-0210-6-004		54,148	154,342	RESEARCH AND DEVELOPMENT	425,311,746
AGRICULTURAL RESEARCH_BASIC AND APPLIED RESEARCH	10.001	59-0210-8-184	US CIVILIAN RESEARCH AND DEVELOPMENT FOUNDATION	59-0210-8-184		36,366	154,342	RESEARCH AND DEVELOPMENT	425,311,746
AGRICULTURAL RESEARCH_BASIC AND APPLIED RESEARCH	10.001	59-0210-8-184	US CIVILIAN RESEARCH AND DEVELOPMENT FOUNDATION	59-0210-8-184		1,891	154,342	RESEARCH AND DEVELOPMENT	425,311,746
AGRICULTURE AND FOOD RESEARCH INITIATIVE (AFRI)	10.310	2017-68001-26352			29,643	41,033	129,499	RESEARCH AND DEVELOPMENT	425,311,746
AGRICULTURE AND FOOD RESEARCH INITIATIVE (AFRI)	10.310	USDA-UNIV OF KENTUCKY	UNIVERSITY OF KENTUCKY	USDA-UNIV OF KENTUCKY		88,466	129,499	RESEARCH AND DEVELOPMENT	425,311,746
DISTANCE LEARNING AND TELEMEDICINE LOANS AND GRANTS	10.855	TN 754-A17				48,069	48,069	RESEARCH AND DEVELOPMENT	425,311,746
<b>TOTAL DEPARTMENT OF AGRICULTURE</b>					29,643	331,910			
<b>DEPARTMENT OF DEFENSE</b>									
COLLABORATIVE RESEARCH AND DEVELOPMENT	12.114	W912HQ-16-C-0033	UNIVERSITY OF PITTSBURGH	W912HQ-16-C-0033		165,355	165,355	RESEARCH AND DEVELOPMENT	425,311,746
BASIC SCIENTIFIC RESEARCH – COMBATING WEAPONS OF MASS DESTRUCTION	12.351	W15QKN-16-9-1002	EMORY UNIVERSITY	W15QKN-16-9-1002		46,513	46,513	RESEARCH AND DEVELOPMENT	425,311,746
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-10-2-0133			135,475	135,475	9,365,154	RESEARCH AND DEVELOPMENT	425,311,746
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-15-1-0259			14,150	14,745	9,365,154	RESEARCH AND DEVELOPMENT	425,311,746
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-16-1-0605				32,499	9,365,154	RESEARCH AND DEVELOPMENT	425,311,746
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-16-2-0061			88,730	144,075	9,365,154	RESEARCH AND DEVELOPMENT	425,311,746
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-17-1-0257				47,806	9,365,154	RESEARCH AND DEVELOPMENT	425,311,746
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-17-1-0304				10,797	9,365,154	RESEARCH AND DEVELOPMENT	425,311,746
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-17-1-0308				13,431	9,365,154	RESEARCH AND DEVELOPMENT	425,311,746
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-17-1-0309				22,901	9,365,154	RESEARCH AND DEVELOPMENT	425,311,746
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-17-1-0345				48,171	9,365,154	RESEARCH AND DEVELOPMENT	425,311,746
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-17-1-0442				260,819	9,365,154	RESEARCH AND DEVELOPMENT	425,311,746
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-17-1-0503				233,266	9,365,154	RESEARCH AND DEVELOPMENT	425,311,746
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-17-2-0003			75,512	252,706	9,365,154	RESEARCH AND DEVELOPMENT	425,311,746
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-17-2-0055			107,408	447,645	9,365,154	RESEARCH AND DEVELOPMENT	425,311,746
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-1-0029				306,388	9,365,154	RESEARCH AND DEVELOPMENT	425,311,746
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-1-0301				193,346	9,365,154	RESEARCH AND DEVELOPMENT	425,311,746
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-1-0149			281,621	1,036,997	9,365,154	RESEARCH AND DEVELOPMENT	425,311,746
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-1-0536			9,891	227,410	9,365,154	RESEARCH AND DEVELOPMENT	425,311,746
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-1-0683				362,948	9,365,154	RESEARCH AND DEVELOPMENT	425,311,746
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-1-0810			454,434	643,649	9,365,154	RESEARCH AND DEVELOPMENT	425,311,746
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-1-0814			83,496	122,147	9,365,154	RESEARCH AND DEVELOPMENT	425,311,746
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-1-0090				104,133	9,365,154	RESEARCH AND DEVELOPMENT	425,311,746
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-1-0415				465,470	9,365,154	RESEARCH AND DEVELOPMENT	425,311,746
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-1-0446				(4,195)	9,365,154	RESEARCH AND DEVELOPMENT	425,311,746
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-1-0580				207,140	9,365,154	RESEARCH AND DEVELOPMENT	425,311,746
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-1-0640			32,555	71,515	9,365,154	RESEARCH AND DEVELOPMENT	425,311,746
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-1-0782				196,227	9,365,154	RESEARCH AND DEVELOPMENT	425,311,746
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-1-0812				386,950	9,365,154	RESEARCH AND DEVELOPMENT	425,311,746
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-PRCRP-IPA			118,632	374,104	9,365,154	RESEARCH AND DEVELOPMENT	425,311,746
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-PRMRP-EA			105,473	208,096	9,365,154	RESEARCH AND DEVELOPMENT	425,311,746
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0269			7,314	181,096	9,365,154	RESEARCH AND DEVELOPMENT	425,311,746
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0475			82,432	203,886	9,365,154	RESEARCH AND DEVELOPMENT	425,311,746
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0593				113,720	9,365,154	RESEARCH AND DEVELOPMENT	425,311,746
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0648				254,904	9,365,154	RESEARCH AND DEVELOPMENT	425,311,746
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0691				89,863	9,365,154	RESEARCH AND DEVELOPMENT	425,311,746
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0910				153,886	9,365,154	RESEARCH AND DEVELOPMENT	425,311,746
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-2-0046			27,933	138,820	9,365,154	RESEARCH AND DEVELOPMENT	425,311,746

**VANDERBILT UNIVERSITY MEDICAL CENTER**  
**SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS (CONTINUED)**  
 Fiscal Period 7/1/2020 – 6/30/2021

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
<b>COVID-19 MILITARY MEDICAL RESEARCH AND DEVELOPMENT</b>	12.420	COVID-19 W81XWH-21-1-0051			\$ -	\$ 44,010	\$ 9,365,154	RESEARCH AND DEVELOPMENT	\$ 425,311,746
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0540	EPICTRACKER, INC.	W81XWH-20-1-0540		38,636	9,365,154	RESEARCH AND DEVELOPMENT	425,311,746
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-16-2-0003	FLORIDA STATE UNIVERSITY	W81XWH-16-2-0003		123,981	9,365,154	RESEARCH AND DEVELOPMENT	425,311,746
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-1-0405	IDBIOLOGICS, LLC	W81XWH-19-1-0405		44,101	9,365,154	RESEARCH AND DEVELOPMENT	425,311,746
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0620	IOWA STATE UNIVERSITY	W81XWH-20-1-0620		2,706	9,365,154	RESEARCH AND DEVELOPMENT	425,311,746
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-10-2-0090	JOHNS HOPKINS UNIVERSITY	W81XWH-10-2-0090		1,306	9,365,154	RESEARCH AND DEVELOPMENT	425,311,746
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-15-2-0067	JOHNS HOPKINS UNIVERSITY	W81XWH-15-2-0067		36,442	9,365,154	RESEARCH AND DEVELOPMENT	425,311,746
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-15-2-0074	JOHNS HOPKINS UNIVERSITY	W81XWH-15-2-0074		316	9,365,154	RESEARCH AND DEVELOPMENT	425,311,746
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-16-2-0060	JOHNS HOPKINS UNIVERSITY	W81XWH-16-2-0060		116,076	9,365,154	RESEARCH AND DEVELOPMENT	425,311,746
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0698	MEHARRY MEDICAL COLLEGE	W81XWH-20-1-0698		5,803	9,365,154	RESEARCH AND DEVELOPMENT	425,311,746
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-1-0719	NATIONAL JEWISH HEALTH	W81XWH-18-1-0719		16,239	9,365,154	RESEARCH AND DEVELOPMENT	425,311,746
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0692	NORTHWESTERN UNIVERSITY	W81XWH-20-1-0692		8,705	9,365,154	RESEARCH AND DEVELOPMENT	425,311,746
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-1-0821	RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY	W81XWH-19-1-0821		47,234	9,365,154	RESEARCH AND DEVELOPMENT	425,311,746
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-17-1-0631	UNIVERSITY OF CALIFORNIA AT SAN FRANCISCO	W81XWH-17-1-0631		548	9,365,154	RESEARCH AND DEVELOPMENT	425,311,746
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-17-1-0631	UNIVERSITY OF CALIFORNIA AT SAN FRANCISCO	W81XWH-17-1-0631		277,755	9,365,154	RESEARCH AND DEVELOPMENT	425,311,746
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-17-1-0597	UNIVERSITY OF COLORADO	W81XWH-17-1-0597		117	9,365,154	RESEARCH AND DEVELOPMENT	425,311,746
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-2-0001	UNIVERSITY OF COLORADO	W81XWH-20-2-0001		63,682	9,365,154	RESEARCH AND DEVELOPMENT	425,311,746
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-17-1-0702	UNIVERSITY OF MARYLAND	W81XWH-17-1-0702		70,477	9,365,154	RESEARCH AND DEVELOPMENT	425,311,746
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-16-D-0024	UNIVERSITY OF PITTSBURGH	W81XWH-16-D-0024		75,583	9,365,154	RESEARCH AND DEVELOPMENT	425,311,746
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-16-D-0024	UNIVERSITY OF PITTSBURGH	W81XWH-16-D-0024		11,862	9,365,154	RESEARCH AND DEVELOPMENT	425,311,746
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-17-1-0610	UNIVERSITY OF PITTSBURGH	W81XWH-17-1-0610		49,314	9,365,154	RESEARCH AND DEVELOPMENT	425,311,746
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-1-0790	UNIVERSITY OF ROCHESTER	W81XWH-18-1-0790		622,455	9,365,154	RESEARCH AND DEVELOPMENT	425,311,746
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-1-0234	VANDERBILT UNIVERSITY	W81XWH-18-1-0234		(2,407)	9,365,154	RESEARCH AND DEVELOPMENT	425,311,746
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-1-0412	VANDERBILT UNIVERSITY	W81XWH-18-1-0412		9,364	9,365,154	RESEARCH AND DEVELOPMENT	425,311,746
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-10-2-0133				(1,987)	9,365,154	RESEARCH AND DEVELOPMENT	425,311,746
BASIC SCIENTIFIC RESEARCH	12.431	W911NF-14-2-0022	VANDERBILT UNIVERSITY	W911NF-14-2-0022		45,986	45,986	RESEARCH AND DEVELOPMENT	425,311,746
COMMUNITY INVESTMENT	12.600	W81XWH-15-9-001	UNIVERSITY OF COLORADO	W81XWH-15-9-001		63,957	63,957	RESEARCH AND DEVELOPMENT	425,311,746
RESEARCH AND TECHNOLOGY DEVELOPMENT	12.910	HR0011-18-2-0001			4,342,130	5,029,571	5,646,028	RESEARCH AND DEVELOPMENT	425,311,746
RESEARCH AND TECHNOLOGY DEVELOPMENT	12.910	D17AP00023	UNIVERSITY OF TENNESSEE	D17AP00023		30,497	5,646,028	RESEARCH AND DEVELOPMENT	425,311,746
<b>COVID-19 RESEARCH AND TECHNOLOGY DEVELOPMENT</b>	12.910	COVID-19 HR0011-18-2-0001				585,960	5,646,028	RESEARCH AND DEVELOPMENT	425,311,746
W81XWH-17-C-0252	12.RD	W81XWH-17-C-0252			17,201	17,201	9,988	RESEARCH AND DEVELOPMENT	425,311,746
W81XWH-17-C-0252	12.RD	W81XWH-17-C-0252				(7,213)	9,988	RESEARCH AND DEVELOPMENT	425,311,746
<b>TOTAL DEPARTMENT OF DEFENSE</b>					5,984,387	15,342,981			
<b>DEPARTMENT OF JUSTICE</b>									
CRIME VICTIM ASSISTANCE	16.575	63811:ST TN	TN DEPARTMENT OF CHILDREN'S SERVICES	63811:ST TN		782	207,253	RESEARCH AND DEVELOPMENT	425,311,746
CRIME VICTIM ASSISTANCE	16.575	63811:ST TN	TN DEPARTMENT OF CHILDREN'S SERVICES	63811:ST TN		206,471	207,253	RESEARCH AND DEVELOPMENT	425,311,746
HAROLD ROGERS PRESCRIPTION DRUG MONITORING PROGRAM	16.754	64793:ST TN	TN DEPARTMENT OF HEALTH	64793:ST TN		91,462	91,462	RESEARCH AND DEVELOPMENT	425,311,746
COMPREHENSIVE OPIOID ABUSE SITE-BASED PROGRAM	16.838	65987:ST TN	TN DEPARTMENT OF MENTAL HEALTH AND DEVELOPMENTAL DISABILITIES	65987:ST TN		31,275	52,185	RESEARCH AND DEVELOPMENT	425,311,746
COMPREHENSIVE OPIOID ABUSE SITE-BASED PROGRAM	16.838	66183:ST TN	TN DEPARTMENT OF MENTAL HEALTH AND DEVELOPMENTAL DISABILITIES	66183:ST TN		6,940	52,185	RESEARCH AND DEVELOPMENT	425,311,746
COMPREHENSIVE OPIOID ABUSE SITE-BASED PROGRAM	16.838	68104:ST TN	TN DEPARTMENT OF MENTAL HEALTH AND DEVELOPMENTAL DISABILITIES	68104:ST TN		13,970	52,185	RESEARCH AND DEVELOPMENT	425,311,746
15JC1V19P00000597	16.RD	15JC1V19P00000597				36,081	205,012	RESEARCH AND DEVELOPMENT	425,311,746
15JC1V20P00000511	16.RD	15JC1V20P00000511				168,931	205,012	RESEARCH AND DEVELOPMENT	425,311,746
<b>TOTAL DEPARTMENT OF JUSTICE</b>						555,912			



**VANDERBILT UNIVERSITY MEDICAL CENTER**  
**SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS (CONTINUED)**  
 Fiscal Period 7/1/2020 – 6/30/2021

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
<b>DEPARTMENT OF TREASURY</b>									
COVID-19 CORONAVIRUS RELIEF FUND	21.019	COVID-19 TN COMMUNITY CARES PROGRAM	UNITED WAY OF GREATER NASHVILLE	TN COMMUNITY CARES PROGRAM	\$ -	\$ 1,516,688	\$ 5,947,472	N/A	\$ -
COVID-19 CORONAVIRUS RELIEF FUND	21.019	COVID-19 TN CARES STAFFING GRANT	TN CARES STAFFING GRANT	TN CARES ACT		4,430,784	5,947,472	N/A	-
<b>TOTAL DEPARTMENT OF TREASURY</b>							5,947,472		
<b>NATIONAL AERONAUTICS &amp; SPACE ADMINISTRATION</b>									
EXPLORATION	43.003	80NCCS19M0161	NATIONAL COUNCIL ON RADIATION PROTECTION AND MEASUREMENTS	80NCCS19M0161		81,522	81,522	RESEARCH AND DEVELOPMENT	425,311,746
<b>TOTAL NATIONAL AERONAUTICS &amp; SPACE ADMINISTRATION</b>							81,522		
<b>INSTITUTE OF MUSEUM AND LIBRARY SERVICES OR NATIONAL ENDOWMENT FOR THE ARTS OR NATIONAL ENDOWMENT FOR THE HUMANITIES</b>									
PROMOTION OF THE ARTS GRANTS TO ORGANIZATIONS AND PROMOTION OF THE ARTS GRANTS TO ORGANIZATIONS AND INDIVIDUALS	45.024	1863278-38-20				38,649	45,505	RESEARCH AND DEVELOPMENT	425,311,746
	45.024	1884433-38-C-18				6,856	45,505	RESEARCH AND DEVELOPMENT	425,311,746
<b>TOTAL INSTITUTE OF MUSEUM AND LIBRARY SERVICES OR NATIONAL ENDOWMENT FOR THE ARTS OR NATIONAL ENDOWMENT FOR THE HUMANITIES</b>							45,505		
<b>NATIONAL SCIENCE FOUNDATION</b>									
ENGINEERING	47.041	NSF CMMI-1944386				107,922	110,597	RESEARCH AND DEVELOPMENT	425,311,746
ENGINEERING	47.041	NSF CMMI-2050252				2,675	110,597	RESEARCH AND DEVELOPMENT	425,311,746
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	NSF CNS-2050895				120,882	289,456	RESEARCH AND DEVELOPMENT	425,311,746
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	NSF CNS-1757644				52,218	289,456	RESEARCH AND DEVELOPMENT	425,311,746
COVID-19 COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	COVID-19 NSF CNS-2029651				93,133	289,456	RESEARCH AND DEVELOPMENT	425,311,746
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	NSF CNS-2129909				2,796	289,456	RESEARCH AND DEVELOPMENT	425,311,746
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	1952029	VANDERBILT UNIVERSITY	1952029		20,427	289,456	RESEARCH AND DEVELOPMENT	425,311,746
COVID-19 BIOLOGICAL SCIENCES	47.074	COVID-19 NSF MCB-2032016				176,545	464,666	RESEARCH AND DEVELOPMENT	425,311,746
BIOLOGICAL SCIENCES	47.074	NSF IOS-2011291				136,044	464,666	RESEARCH AND DEVELOPMENT	425,311,746
BIOLOGICAL SCIENCES	47.074	NSF IOS-1557634				7,111	464,666	RESEARCH AND DEVELOPMENT	425,311,746
BIOLOGICAL SCIENCES	47.074	1845634	UNIVERSITY OF MASSACHUSETTS	1845634		12,360	464,666	RESEARCH AND DEVELOPMENT	425,311,746
BIOLOGICAL SCIENCES	47.074	1814520	UNIVERSITY OF TENNESSEE	1814520		112,034	464,666	RESEARCH AND DEVELOPMENT	425,311,746
BIOLOGICAL SCIENCES	47.074	1329686	VANDERBILT UNIVERSITY	1329686		20,572	464,666	RESEARCH AND DEVELOPMENT	425,311,746
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	1840896	VANDERBILT UNIVERSITY	1840896		18,137	18,137	RESEARCH AND DEVELOPMENT	425,311,746
EDUCATION AND HUMAN RESOURCES	47.076	NSF DUE-1926794				225,473	225,473	RESEARCH AND DEVELOPMENT	425,311,746
COVID-19 OFFICE OF INTERNATIONAL SCIENCE AND ENGINEERING	47.079	COVID-19 OISE-20-66590-1	UNIVERSITY OF WISCONSIN US CIVILIAN RESEARCH AND DEVELOPMENT FOUNDATION	OISE-20-66590-1		46,203	105,789	RESEARCH AND DEVELOPMENT	425,311,746
OFFICE OF INTERNATIONAL SCIENCE AND ENGINEERING	47.079	OISE-19-66185-1	US CIVILIAN RESEARCH AND DEVELOPMENT FOUNDATION	OISE-19-66185-1		41,080	105,789	RESEARCH AND DEVELOPMENT	425,311,746
OFFICE OF INTERNATIONAL SCIENCE AND ENGINEERING	47.079	OISE-9531011	US CIVILIAN RESEARCH AND DEVELOPMENT FOUNDATION	OISE-9531011		18,506	105,789	RESEARCH AND DEVELOPMENT	425,311,746
INTEGRATIVE ACTIVITIES	47.083	2033413	VANDERBILT UNIVERSITY	2033413		87,363	107,999	RESEARCH AND DEVELOPMENT	425,311,746
INTEGRATIVE ACTIVITIES	47.083	2040462	VANDERBILT UNIVERSITY	2040462		20,636	107,999	RESEARCH AND DEVELOPMENT	425,311,746
<b>TOTAL NATIONAL SCIENCE FOUNDATION</b>							1,322,117		

**VANDERBILT UNIVERSITY MEDICAL CENTER**  
**SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS (CONTINUED)**  
 Fiscal Period 7/1/2020 – 6/30/2021

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
<b>ENVIRONMENTAL PROTECTION AGENCY</b>									
SCIENCE TO ACHIEVE RESULTS (STAR) RESEARCH PROGRAM	66.509	RD-83950101-0			\$ 76,347	\$ 230,761	\$ 270,519	RESEARCH AND DEVELOPMENT	\$ 425,311,746
SCIENCE TO ACHIEVE RESULTS (STAR) RESEARCH PROGRAM	66.509	83927501	MEHARRY MEDICAL COLLEGE	83927501		19,397	270,519	RESEARCH AND DEVELOPMENT	425,311,746
SCIENCE TO ACHIEVE RESULTS (STAR) RESEARCH PROGRAM	66.509	83950401	VANDERBILT UNIVERSITY	83950401		20,361	270,519	RESEARCH AND DEVELOPMENT	425,311,746
<b>TOTAL ENVIRONMENTAL PROTECTION AGENCY</b>					<b>76,347</b>	<b>270,519</b>			
<b>DEPARTMENT OF ENERGY</b>									
NUCLEAR ENERGY RESEARCH, DEVELOPMENT AND DEMONSTRATION	81.121	DE-NE0008664	VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY	DE-NE0008664		84,726	84,726	RESEARCH AND DEVELOPMENT	425,311,746
<b>TOTAL DEPARTMENT OF ENERGY</b>						<b>84,726</b>			
<b>DEPARTMENT OF EDUCATION</b>									
SPECIAL EDUCATION GRANTS TO STATES	84.027	45026:ST TN	TN DEPARTMENT OF EDUCATION	45026:ST TN		331,744	2,535,307	SPECIAL EDUCATION CLUSTER (IDEA)	2,741,959
SPECIAL EDUCATION GRANTS TO STATES	84.027	45237:ST TN	TN DEPARTMENT OF EDUCATION	45237:ST TN	41,661	2,151,505	2,535,307	SPECIAL EDUCATION CLUSTER (IDEA)	2,741,959
SPECIAL EDUCATION GRANTS TO STATES	84.027	33136-00718	VANDERBILT UNIVERSITY	33136-00718		4,647	2,535,307	SPECIAL EDUCATION CLUSTER (IDEA)	2,741,959
SPECIAL EDUCATION GRANTS TO STATES	84.027	H027A140052-14A	VANDERBILT UNIVERSITY	H027A140052-14A		47,411	2,535,307	SPECIAL EDUCATION CLUSTER (IDEA)	2,741,959
REHABILITATION SERVICES_VOCATIONAL REHABILITATION GRANTS TO STATES	84.126	34570-91018	VANDERBILT UNIVERSITY	34570-91018		36,880	36,880	N/A	-
SPECIAL EDUCATION PRESCHOOL GRANTS	84.173	49454:ST TN	TN DEPARTMENT OF EDUCATION	49454:ST TN		76	206,652	SPECIAL EDUCATION CLUSTER (IDEA)	2,741,959
SPECIAL EDUCATION PRESCHOOL GRANTS	84.173	49454:ST TN	TN DEPARTMENT OF EDUCATION	49454:ST TN		206,576	206,652	SPECIAL EDUCATION CLUSTER (IDEA)	2,741,959
SPECIAL EDUCATION GRANTS FOR INFANTS AND FAMILIES	84.181	62363:ST TN	TN DEPARTMENT OF EDUCATION	62363:ST TN		968,515	968,515	N/A	-
RESEARCH IN SPECIAL EDUCATION	84.324	R324 A160300				20,531	99,115	RESEARCH AND DEVELOPMENT	425,311,746
RESEARCH IN SPECIAL EDUCATION	84.324	R324 A180171-19	VANDERBILT UNIVERSITY	R324 A180171-19		78,584	99,115	RESEARCH AND DEVELOPMENT	425,311,746
SPECIAL EDUCATION - PERSONNEL DEVELOPMENT TO IMPROVE SERVICES AND RESULTS FOR CHILDREN WITH DISABILITIES	84.325	H325 K190046-20				158,353	682,422	N/A	-
SPECIAL EDUCATION - PERSONNEL DEVELOPMENT TO IMPROVE SERVICES AND RESULTS FOR CHILDREN WITH DISABILITIES	84.325	H325 K190064			48,888	253,061	682,422	N/A	-
SPECIAL EDUCATION - PERSONNEL DEVELOPMENT TO IMPROVE SERVICES AND RESULTS FOR CHILDREN WITH DISABILITIES	84.325	H325 K190068				268,897	682,422	N/A	-
SPECIAL EDUCATION - PERSONNEL DEVELOPMENT TO IMPROVE SERVICES AND RESULTS FOR CHILDREN WITH DISABILITIES	84.325	H325K200036	VANDERBILT UNIVERSITY	H325K200036		2,111	682,422	N/A	-
SPECIAL EDUCATION TECHNICAL ASSISTANCE AND DISSEMINATION TO IMPROVE SERVICES AND RESULTS FOR CHILDREN WITH DISABILITIES	84.326	H326 T180048				221,865	221,865	N/A	-
TRANSITION PROGRAMS FOR STUDENTS WITH INTELLECTUAL DISABILITIES INTO HIGHER EDUCATION	84.407	P407A150058-19	VANDERBILT UNIVERSITY	P407A150058-19		5,801	5,801	RESEARCH AND DEVELOPMENT	425,311,746
<b>TOTAL DEPARTMENT OF EDUCATION</b>					<b>90,549</b>	<b>4,756,557</b>			
<b>DEPARTMENT OF HEALTH AND HUMAN SERVICES</b>									
GLOBAL AIDS	93.067	5 NU2 GGH001943-04-00			1,122,495	7,332,726	26,141,336	N/A	-
COVID-19 GLOBAL AIDS	93.067	COVID-19 5 NU2 GGH001943-04-00				251,425	26,141,336	N/A	-
GLOBAL AIDS	93.067	5 NU2 GGH001943-05-00			1,115,376	18,350,733	26,141,336	N/A	-
GLOBAL AIDS	93.067	6 NU2GGH002071-01-03				(424)	26,141,336	N/A	-
GLOBAL AIDS	93.067	6 NU2 GGH001370-05	MAKERERE UNIVERSITY SCHOOL OF PUBLIC HEALTH	6 NU2 GGH001370-05		31,998	26,141,336	N/A	-

**VANDERBILT UNIVERSITY MEDICAL CENTER**  
**SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS (CONTINUED)**  
Fiscal Period 7/1/2020 – 6/30/2021

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
<b>COVID-19 GLOBAL AIDS</b>	93.067	COVID-19 5 NU2 GGH001943-05-00			\$ -	\$ 174,878	\$ 26,141,336	N/A	\$ -
HOSPITAL PREPAREDNESS PROGRAM (HPP) AND PUBLIC HEALTH EMERGENCY PREPAREDNESS (PHEP) ALIGNED COOPERATIVE AGREEMENTS	93.074	54788:ST TN	TN DEPARTMENT OF HEALTH	54788:ST TN		249,957	249,957	N/A	-
FAMILY SMOKING PREVENTION AND TOBACCO CONTROL ACT REGULATORY RESEARCH	93.077	1 R21 DA052026-01A1				6,873	49,165	RESEARCH AND DEVELOPMENT	425,311,746
FAMILY SMOKING PREVENTION AND TOBACCO CONTROL ACT REGULATORY RESEARCH	93.077	5 U54 HL120163-08	AMERICAN HEART ASSOCIATION-HEADQUARTERS	5 U54 HL120163-08		31,772	49,165	RESEARCH AND DEVELOPMENT	425,311,746
FAMILY SMOKING PREVENTION AND TOBACCO CONTROL ACT REGULATORY RESEARCH	93.077	3 R01 HL141851-02S1	STANFORD UNIVERSITY	3 R01 HL141851-02S1		10,520	49,165	RESEARCH AND DEVELOPMENT	425,311,746
BLOOD DISORDER PROGRAM: PREVENTION, SURVEILLANCE, AND RESEARCH	93.080	1 NU 58DD000019-01-00	UNIVERSITY OF MEMPHIS	1 NU 58DD000019-01-00		31,735	49,087	RESEARCH AND DEVELOPMENT	425,311,746
BLOOD DISORDER PROGRAM: PREVENTION, SURVEILLANCE, AND RESEARCH	93.080	1 NU27 DD000020-01-00	UNIVERSITY OF NORTH CAROLINA	1 NU27 DD000020-01-00		2,794	49,087	RESEARCH AND DEVELOPMENT	425,311,746
BLOOD DISORDER PROGRAM: PREVENTION, SURVEILLANCE, AND RESEARCH	93.080	6 NU27 DD001155-04-02	UNIVERSITY OF NORTH CAROLINA	6 NU27 DD001155-04-02		(34)	49,087	RESEARCH AND DEVELOPMENT	425,311,746
BLOOD DISORDER PROGRAM: PREVENTION, SURVEILLANCE, AND RESEARCH	93.080	6 NU27 DD001155-05-02	UNIVERSITY OF NORTH CAROLINA	6 NU27 DD001155-05-02		5,075	49,087	RESEARCH AND DEVELOPMENT	425,311,746
BLOOD DISORDER PROGRAM: PREVENTION, SURVEILLANCE, AND RESEARCH	93.080	1 NU58 DD000010-01-00	UNIVERSITY OF TENNESSEE	1 NU58 DD000010-01-00		9,517	49,087	RESEARCH AND DEVELOPMENT	425,311,746
PREVENTION OF DISEASE, DISABILITY, AND DEATH THROUGH IMMUNIZATION AND CONTROL OF RESPIRATORY AND RELATED DISEASES	93.083	5 U01 IP000979-06			46,362	781,898	1,102,097	RESEARCH AND DEVELOPMENT	425,311,746
<b>COVID-19 PREVENTION OF DISEASE, DISABILITY, AND DEATH THROUGH IMMUNIZATION AND CONTROL OF RESPIRATORY AND RELATED</b>	93.083	COVID-19 6 U01 IP000979-06-03				320,199	1,102,097	RESEARCH AND DEVELOPMENT	425,311,746
PREVENTION OF DISEASE, DISABILITY, AND DEATH BY INFECTIOUS DISEASES	93.084	1 U01 CK000512-01	UNIVERSITY OF TEXAS	1 U01 CK000512-01		(75)	(75)	RESEARCH AND DEVELOPMENT	425,311,746
FOOD AND DRUG ADMINISTRATION_RESEARCH	93.103	5 R01 FD004778-05			182,882	182,882	1,817,233	RESEARCH AND DEVELOPMENT	425,311,746
FOOD AND DRUG ADMINISTRATION_RESEARCH	93.103	1 R01 FD006649-01			56,226	458,136	1,817,233	RESEARCH AND DEVELOPMENT	425,311,746
FOOD AND DRUG ADMINISTRATION_RESEARCH	93.103	1 R01 FD006003-01	BOSTON CHILDREN'S HOSPITAL CUMBERLAND PHARMACEUTICALS, INC.	1 R01 FD006003-01		6,361	1,817,233	RESEARCH AND DEVELOPMENT	425,311,746
FOOD AND DRUG ADMINISTRATION_RESEARCH	93.103	1 R01 FD006371-01A1		1 R01 FD006371-01A1		5,054	1,817,233	RESEARCH AND DEVELOPMENT	425,311,746
FOOD AND DRUG ADMINISTRATION_RESEARCH	93.103	5 U01 FD006292-03	DUKE UNIVERSITY	5 U01 FD006292-03		10,265	1,817,233	RESEARCH AND DEVELOPMENT	425,311,746
FOOD AND DRUG ADMINISTRATION_RESEARCH	93.103	HHSF223201400020I	HARVARD PILGRIM HEALTH CARE	HHSF223201400020I		87,940	1,817,233	RESEARCH AND DEVELOPMENT	425,311,746
FOOD AND DRUG ADMINISTRATION_RESEARCH	93.103	HHSF223201400030I	HARVARD PILGRIM HEALTH CARE	HHSF223201400030I		9	1,817,233	RESEARCH AND DEVELOPMENT	425,311,746
FOOD AND DRUG ADMINISTRATION_RESEARCH	93.103	HHSF223201400030I	HARVARD PILGRIM HEALTH CARE	HHSF223201400030I		7,739	1,817,233	RESEARCH AND DEVELOPMENT	425,311,746
FOOD AND DRUG ADMINISTRATION_RESEARCH	93.103	HHSF223201710132C	HARVARD PILGRIM HEALTH CARE	HHSF223201710132C		10,008	1,817,233	RESEARCH AND DEVELOPMENT	425,311,746
FOOD AND DRUG ADMINISTRATION_RESEARCH	93.103	5 U02 FD006292-03	MEDICAL DEVICE INNOVATION CONSORTIUM	5 U02 FD006292-03	158,068	341,311	1,817,233	RESEARCH AND DEVELOPMENT	425,311,746
FOOD AND DRUG ADMINISTRATION_RESEARCH	93.103	5 U01 FD006292-03	MEDICAL DEVICE INNOVATION CONSORTIUM	5 U01 FD006292-03	45,692	133,830	1,817,233	RESEARCH AND DEVELOPMENT	425,311,746
FOOD AND DRUG ADMINISTRATION_RESEARCH	93.103	5 U01 FD006292-03	MEDICAL DEVICE INNOVATION CONSORTIUM	5 U01 FD006292-03	216,882	469,067	1,817,233	RESEARCH AND DEVELOPMENT	425,311,746
FOOD AND DRUG ADMINISTRATION_RESEARCH	93.103	5 U01 FD006292-03	WAKE FOREST UNIVERSITY	5 U01 FD006292-03		112,698	1,817,233	RESEARCH AND DEVELOPMENT	425,311,746
FOOD AND DRUG ADMINISTRATION_RESEARCH	93.103	5 R01 FD004778-05				(8,067)	1,817,233	RESEARCH AND DEVELOPMENT	425,311,746
COMPREHENSIVE COMMUNITY MENTAL HEALTH SERVICES FOR CHILDREN WITH SERIOUS EMOTIONAL DISTURBANCES (SED)	93.104	64172:ST TN	TN DEPARTMENT OF MENTAL HEALTH AND DEVELOPMENTAL DISABILITIE	64172:ST TN		191,914	195,011	N/A	-
COMPREHENSIVE COMMUNITY MENTAL HEALTH SERVICES FOR CHILDREN WITH SERIOUS EMOTIONAL DISTURBANCES (SED)	93.104	70832:ST TN	TN DEPARTMENT OF MENTAL HEALTH AND DEVELOPMENTAL DISABILITIE	70832:ST TN		3,097	195,011	N/A	-
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110	5 H6M MC33236-02-00				269,609	4,489,346	RESEARCH AND DEVELOPMENT	425,311,746
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110	1 H6M MC033236-01-00				83,675	4,489,346	RESEARCH AND DEVELOPMENT	425,311,746
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110	5 T73 MC030767-04-00			111,981	111,981	4,489,346	RESEARCH AND DEVELOPMENT	425,311,746
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110	5 T73 MC30767-05-00			111,412	674,522	4,489,346	RESEARCH AND DEVELOPMENT	425,311,746
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110	2 UC4 MC28042-05-00	AMERICAN COLLEGE OF OBSTETRICIANS AND GYNECOLOGISTS	2 UC4 MC28042-05-00		33,817	4,489,346	RESEARCH AND DEVELOPMENT	425,311,746
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110	5 H30 MC24046-04-00	HEMPHILIA OF GEORGIA, INC.	5 H30 MC24046-04-00		3,209,148	4,489,346	RESEARCH AND DEVELOPMENT	425,311,746

**VANDERBILT UNIVERSITY MEDICAL CENTER**  
**SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS (CONTINUED)**  
 Fiscal Period 7/1/2020 – 6/30/2021

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110	5 H30 MC24046-09-00	HEMPHILIA OF GEORGIA, INC.	5 H30 MC24046-09-00	\$ -	\$ 16,400	\$ 4,489,346	RESEARCH AND DEVELOPMENT	\$ 425,311,746
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110	6 UA3 MC11054-11-00	MASSACHUSETTS GENERAL HOSPITAL	6 UA3 MC11054-11-00		4,269	4,489,346	RESEARCH AND DEVELOPMENT	425,311,746
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110	5 UA3 MC11054-11-00	MASSACHUSETTS GENERAL HOSPITAL	5 UA3 MC11054-11-00		16,499	4,489,346	RESEARCH AND DEVELOPMENT	425,311,746
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110	6 UA6 MC32492-02-01	UNIVERSITY OF CALIFORNIA AT LOS ANGELES	6 UA6 MC32492-02-01		37,365	4,489,346	RESEARCH AND DEVELOPMENT	425,311,746
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110	5 UA6 MC32492-03-00	UNIVERSITY OF CALIFORNIA AT LOS ANGELES	5 UA6 MC32492-03-00		32,194	4,489,346	RESEARCH AND DEVELOPMENT	425,311,746
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110	5 T73 MC030767-04-00				(133)	4,489,346	RESEARCH AND DEVELOPMENT	425,311,746
ENVIRONMENTAL HEALTH	93.113	1 R01 ES031401-01			291,488	590,001	876,420	RESEARCH AND DEVELOPMENT	425,311,746
ENVIRONMENTAL HEALTH	93.113	5 R01 ES027845-04	COLUMBIA UNIVERSITY	5 R01 ES027845-04		21,640	876,420	RESEARCH AND DEVELOPMENT	425,311,746
ENVIRONMENTAL HEALTH	93.113	2 R01 ES010563-18	PURDUE UNIVERSITY	2 R01 ES010563-18		40,930	876,420	RESEARCH AND DEVELOPMENT	425,311,746
ENVIRONMENTAL HEALTH	93.113	5 R01 ES007331-26	PURDUE UNIVERSITY	5 R01 ES007331-26		39,426	876,420	RESEARCH AND DEVELOPMENT	425,311,746
ENVIRONMENTAL HEALTH	93.113	2 R01 ES010563-19	PURDUE UNIVERSITY	2 R01 ES010563-19		9,941	876,420	RESEARCH AND DEVELOPMENT	425,311,746
ENVIRONMENTAL HEALTH	93.113	5 R01 ES019217-08	UNIVERSITY OF LOUISVILLE	5 R01 ES019217-08		11,143	876,420	RESEARCH AND DEVELOPMENT	425,311,746
ENVIRONMENTAL HEALTH	93.113	5 R01 ES019217-09	UNIVERSITY OF LOUISVILLE	5 R01 ES019217-09		5,826	876,420	RESEARCH AND DEVELOPMENT	425,311,746
ENVIRONMENTAL HEALTH	93.113	5 R01 ES029846-04	UNIVERSITY OF LOUISVILLE	5 R01 ES029846-04		11,628	876,420	RESEARCH AND DEVELOPMENT	425,311,746
ENVIRONMENTAL HEALTH	93.113	2 T32 ES007028-45	VANDERBILT UNIVERSITY	2 T32 ES007028-45		23,194	876,420	RESEARCH AND DEVELOPMENT	425,311,746
ENVIRONMENTAL HEALTH	93.113	2 T32 ES007028-45	VANDERBILT UNIVERSITY	2 T32 ES007028-45		57,555	876,420	RESEARCH AND DEVELOPMENT	425,311,746
ENVIRONMENTAL HEALTH	93.113	2 T32 ES007028-46	VANDERBILT UNIVERSITY	2 T32 ES007028-46		39,807	876,420	RESEARCH AND DEVELOPMENT	425,311,746
ENVIRONMENTAL HEALTH	93.113	5 T32 ES007028-46	VANDERBILT UNIVERSITY	5 T32 ES007028-46		25,329	876,420	RESEARCH AND DEVELOPMENT	425,311,746
ORAL DISEASES AND DISORDERS RESEARCH	93.121	5 K23 DE028010-03				133,393	1,096,993	RESEARCH AND DEVELOPMENT	425,311,746
ORAL DISEASES AND DISORDERS RESEARCH	93.121	5 R01 DE027749-04			128,677	629,321	1,096,993	RESEARCH AND DEVELOPMENT	425,311,746
ORAL DISEASES AND DISORDERS RESEARCH	93.121	5 R21 DE029002-02				257,709	1,096,993	RESEARCH AND DEVELOPMENT	425,311,746
ORAL DISEASES AND DISORDERS RESEARCH	93.121	1 R01 DE029650-01			1,771	22,938	1,096,993	RESEARCH AND DEVELOPMENT	425,311,746
ORAL DISEASES AND DISORDERS RESEARCH	93.121	7 R01 DE029650-02	UNIVERSITY OF KENTUCKY	7 R01 DE029650-02		50,840	1,096,993	RESEARCH AND DEVELOPMENT	425,311,746
ORAL DISEASES AND DISORDERS RESEARCH	93.121	1 R03 DE027494-01	UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON	1 R03 DE027494-01		2,792	1,096,993	RESEARCH AND DEVELOPMENT	425,311,746
EMERGENCY MEDICAL SERVICES FOR CHILDREN	93.127	5 H33 MC31540-04-00				99,357	133,977	N/A	-
EMERGENCY MEDICAL SERVICES FOR CHILDREN	93.127	5 H33 MC31540-05-00				32,243	133,977	N/A	-
EMERGENCY MEDICAL SERVICES FOR CHILDREN	93.127	2 U03 MC00001-19-00	UNIVERSITY OF CALIFORNIA, DAVIS	2 U03 MC00001-19-00		2,377	133,977	N/A	-
INJURY PREVENTION AND CONTROL RESEARCH AND STATE AND COMMUNITY BASED PROGRAMS	93.136	34301-29421:ST TN	TN DEPARTMENT OF HEALTH	34301-29421:ST TN		103,549	207,841	RESEARCH AND DEVELOPMENT	425,311,746
INJURY PREVENTION AND CONTROL RESEARCH AND STATE AND COMMUNITY BASED PROGRAMS	93.136	34301-29420:ST TN	TN DEPARTMENT OF HEALTH	34301-29420:ST TN		83,559	207,841	RESEARCH AND DEVELOPMENT	425,311,746
INJURY PREVENTION AND CONTROL RESEARCH AND STATE AND COMMUNITY BASED PROGRAMS	93.136	5 R01 CE003009-03-00	UNIVERSITY OF NORTH CAROLINA	5 R01 CE003009-03-00		20,733	207,841	RESEARCH AND DEVELOPMENT	425,311,746
COVID-19 AIDS EDUCATION AND TRAINING CENTERS	93.145	COVID-19 1 H1L HA37340-01-00				113,491	398,735	RESEARCH AND DEVELOPMENT	425,311,746
AIDS EDUCATION AND TRAINING CENTERS	93.145	5 U10 HA30535-05-00			2,820,001	3,827,918	4,936,991	RESEARCH AND DEVELOPMENT	425,311,746
AIDS EDUCATION AND TRAINING CENTERS	93.145	5 U10 HA30535-03-00			(4,141)	-	4,936,991	RESEARCH AND DEVELOPMENT	425,311,746
AIDS EDUCATION AND TRAINING CENTERS	93.145	6 U10 HA030535-04-07			729,964	729,964	4,936,991	RESEARCH AND DEVELOPMENT	425,311,746
AIDS EDUCATION AND TRAINING CENTERS	93.145	6 U10 HA030535-04-07				(19,626)	4,936,991	RESEARCH AND DEVELOPMENT	425,311,746
COORDINATED SERVICES AND ACCESS TO RESEARCH FOR WOMEN, INFANTS, CHILDREN, AND YOUTH	93.153	5 H12 HA030750-04-00				36,037	603,371	N/A	-
COORDINATED SERVICES AND ACCESS TO RESEARCH FOR WOMEN, INFANTS, CHILDREN, AND YOUTH	93.153	4 H12 HA30750-04-01				541,417	603,371	N/A	-
COVID-19 COORDINATED SERVICES AND ACCESS TO RESEARCH FOR WOMEN, INFANTS, CHILDREN, AND YOUTH	93.153	COVID-19 1 H1X HA37046-01-00				25,917	603,371	N/A	-
HUMAN GENOME RESEARCH	93.172	5 U01 HG010232-02			153,632	160,642	7,458,085	RESEARCH AND DEVELOPMENT	425,311,746
HUMAN GENOME RESEARCH	93.172	5 K99 HG010904-02				137,424	7,458,085	RESEARCH AND DEVELOPMENT	425,311,746
HUMAN GENOME RESEARCH	93.172	5 R01 HG006844-09			139,094	266,117	7,458,085	RESEARCH AND DEVELOPMENT	425,311,746
HUMAN GENOME RESEARCH	93.172	5 RM1 HG009034-03			67,613	143,493	7,458,085	RESEARCH AND DEVELOPMENT	425,311,746
HUMAN GENOME RESEARCH	93.172	2 RM1 HG009034-05			128,434	575,246	7,458,085	RESEARCH AND DEVELOPMENT	425,311,746
HUMAN GENOME RESEARCH	93.172	5 R01 HG009694-04			200,194	592,162	7,458,085	RESEARCH AND DEVELOPMENT	425,311,746
HUMAN GENOME RESEARCH	93.172	5 R21 HG010652-02			11,483	209,609	7,458,085	RESEARCH AND DEVELOPMENT	425,311,746
HUMAN GENOME RESEARCH	93.172	1 R35 HG010718-01				(11,832)	7,458,085	RESEARCH AND DEVELOPMENT	425,311,746
HUMAN GENOME RESEARCH	93.172	5 R35 HG010718-02				404,957	7,458,085	RESEARCH AND DEVELOPMENT	425,311,746

**VANDERBILT UNIVERSITY MEDICAL CENTER**  
**SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS (CONTINUED)**  
 Fiscal Period 7/1/2020 – 6/30/2021

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
HUMAN GENOME RESEARCH	93.172	5 R01 HG010863-03			\$ 27,799	\$ 452,906	\$ 7,458,085	RESEARCH AND DEVELOPMENT	\$ 425,311,746
HUMAN GENOME RESEARCH	93.172	5 R01 HG011138-02			-	243,917	7,458,085	RESEARCH AND DEVELOPMENT	425,311,746
HUMAN GENOME RESEARCH	93.172	5 T32 HG008341-04				(6,745)	7,458,085	RESEARCH AND DEVELOPMENT	425,311,746
HUMAN GENOME RESEARCH	93.172	5 T32 HG008341-05				225,282	7,458,085	RESEARCH AND DEVELOPMENT	425,311,746
HUMAN GENOME RESEARCH	93.172	5 U01 HG007253-04			90,326	90,326	7,458,085	RESEARCH AND DEVELOPMENT	425,311,746
HUMAN GENOME RESEARCH	93.172	5 U01 HG008672-04			16,578	99,719	7,458,085	RESEARCH AND DEVELOPMENT	425,311,746
HUMAN GENOME RESEARCH	93.172	5 U01 HG008701-04			79,057	110,725	7,458,085	RESEARCH AND DEVELOPMENT	425,311,746
HUMAN GENOME RESEARCH	93.172	5 U01 HG010232-03			48,376	568,011	7,458,085	RESEARCH AND DEVELOPMENT	425,311,746
HUMAN GENOME RESEARCH	93.172	1 U01 HG011166-01			477,320	1,005,207	7,458,085	RESEARCH AND DEVELOPMENT	425,311,746
HUMAN GENOME RESEARCH	93.172	5 U01 HG011166-02				245,036	7,458,085	RESEARCH AND DEVELOPMENT	425,311,746
HUMAN GENOME RESEARCH	93.172	1 U01 HG011181-01				647,387	7,458,085	RESEARCH AND DEVELOPMENT	425,311,746
HUMAN GENOME RESEARCH	93.172	5 R01 HG010004-03	BOSTON CHILDREN'S HOSPITAL	5 R01 HG010004-03		43,626	7,458,085	RESEARCH AND DEVELOPMENT	425,311,746
HUMAN GENOME RESEARCH	93.172	1 U24 HG010262-02	BROAD INSTITUTE OF MIT AND HARVARD	1 U24 HG010262-02		17,718	7,458,085	RESEARCH AND DEVELOPMENT	425,311,746
HUMAN GENOME RESEARCH	93.172	5 U24 HG010262-03	BROAD INSTITUTE OF MIT AND HARVARD	5 U24 HG010262-03		364,111	7,458,085	RESEARCH AND DEVELOPMENT	425,311,746
HUMAN GENOME RESEARCH	93.172	1 R21 HG010952-01	GEORGIA STATE UNIVERSITY	1 R21 HG010952-01		132,089	7,458,085	RESEARCH AND DEVELOPMENT	425,311,746
HUMAN GENOME RESEARCH	93.172	5 R01 HG009914-03	UNIVERSITY OF LOUISVILLE	5 R01 HG009914-03		73,545	7,458,085	RESEARCH AND DEVELOPMENT	425,311,746
HUMAN GENOME RESEARCH	93.172	5 R01 HG008605-03	UNIVERSITY OF MINNESOTA	5 R01 HG008605-03		7,033	7,458,085	RESEARCH AND DEVELOPMENT	425,311,746
HUMAN GENOME RESEARCH	93.172	5 U01 HG009086-03	VANDERBILT UNIVERSITY	5 U01 HG009086-03		317,084	7,458,085	RESEARCH AND DEVELOPMENT	425,311,746
HUMAN GENOME RESEARCH	93.172	5 U01 HG007253-04				(1,394)	7,458,085	RESEARCH AND DEVELOPMENT	425,311,746
COVID-19 HUMAN GENOME RESEARCH	93.172	COVID-19 1 U01 HG011166-01				344,684	7,458,085	RESEARCH AND DEVELOPMENT	425,311,746
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5 R01 DC008408-14			304,134	376,583	6,761,516	RESEARCH AND DEVELOPMENT	425,311,746
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5 R01 DC011777-06			74,213	91,328	6,761,516	RESEARCH AND DEVELOPMENT	425,311,746
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5 R01 DC013270-04			(1,303)	(1,303)	6,761,516	RESEARCH AND DEVELOPMENT	425,311,746
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5 R01 DC013270-07			1,303	443,711	6,761,516	RESEARCH AND DEVELOPMENT	425,311,746
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5 R03 DC015075-03				31,479	6,761,516	RESEARCH AND DEVELOPMENT	425,311,746
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5 R01 DC015388-06				246,786	6,761,516	RESEARCH AND DEVELOPMENT	425,311,746
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5 R01 DC015988-04			107,583	606,388	6,761,516	RESEARCH AND DEVELOPMENT	425,311,746
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5 R21 DC016710-02:03				42,114	6,761,516	RESEARCH AND DEVELOPMENT	425,311,746
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	1 R01 DC016977-02			46,484	1,123,237	6,761,516	RESEARCH AND DEVELOPMENT	425,311,746
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5 R01 DC017175-03			120,695	495,564	6,761,516	RESEARCH AND DEVELOPMENT	425,311,746
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5 R01 DC017683-03			29,282	496,323	6,761,516	RESEARCH AND DEVELOPMENT	425,311,746
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5 R01 DC017926-02			223,123	649,268	6,761,516	RESEARCH AND DEVELOPMENT	425,311,746
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5 R01 DC009404-11			10,602	36,840	6,761,516	RESEARCH AND DEVELOPMENT	425,311,746
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5 R21 DC016723-03				113,689	6,761,516	RESEARCH AND DEVELOPMENT	425,311,746
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5 T35 DC008763-14				24,294	6,761,516	RESEARCH AND DEVELOPMENT	425,311,746
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5 U01 DC016033-02				(26)	6,761,516	RESEARCH AND DEVELOPMENT	425,311,746
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5 U01 DC016033-03				629,772	6,761,516	RESEARCH AND DEVELOPMENT	425,311,746
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5 R01 DC016643-03	BOYS TOWN NATIONAL RESEARCH HOSPITAL	5 R01 DC016643-03		(3,288)	6,761,516	RESEARCH AND DEVELOPMENT	425,311,746
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5 R01 DC016643-04	BOYS TOWN NATIONAL RESEARCH HOSPITAL	5 R01 DC016643-04		81,497	6,761,516	RESEARCH AND DEVELOPMENT	425,311,746
COVID-19 RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	COVID-19 3 R01 DC018060-02S1	COLUMBIA UNIVERSITY	3 R01 DC018060-02S1		31,985	6,761,516	RESEARCH AND DEVELOPMENT	425,311,746
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	1 R01 DC016680-01A1	CREIGHTON UNIVERSITY	1 R01 DC016680-01A1		227,060	6,761,516	RESEARCH AND DEVELOPMENT	425,311,746
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	1 R44 DC018491-01A1	INTELLIGENT HEARING SYSTEMS, INC.	1 R44 DC018491-01A1		233,198	6,761,516	RESEARCH AND DEVELOPMENT	425,311,746
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	1 P50 DC015857-03	MASSACHUSETTS EYE AND EAR INFIRMARY	1 P50 DC015857-03		664	6,761,516	RESEARCH AND DEVELOPMENT	425,311,746
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	1 P50 DC015857-04	MASSACHUSETTS EYE AND EAR INFIRMARY	1 P50 DC015857-04		16,847	6,761,516	RESEARCH AND DEVELOPMENT	425,311,746
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5 P50 DC015857-04	MASSACHUSETTS EYE AND EAR INFIRMARY	5 P50 DC015857-04		13,755	6,761,516	RESEARCH AND DEVELOPMENT	425,311,746
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5 R01 DC017078-03	MASSACHUSETTS EYE AND EAR INFIRMARY	5 R01 DC017078-03		67,061	6,761,516	RESEARCH AND DEVELOPMENT	425,311,746
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5 R01 DC017078-04	MASSACHUSETTS EYE AND EAR INFIRMARY	5 R01 DC017078-04		16,348	6,761,516	RESEARCH AND DEVELOPMENT	425,311,746

**VANDERBILT UNIVERSITY MEDICAL CENTER**  
**SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS (CONTINUED)**  
Fiscal Period 7/1/2020 – 6/30/2021

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	2 R44 DC016780-02	MIMOSA ACOUSTIC	2 R44 DC016780-02	\$ -	\$ 108,078	\$ 6,761,516	RESEARCH AND DEVELOPMENT	\$ 425,311,746
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5 R01 DC015780-04	NATHAN S. KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH (NKI)	5 R01 DC015780-04	10,772	25,699	6,761,516	RESEARCH AND DEVELOPMENT	425,311,746
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5 R01 DC015780-05	NATHAN S. KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH (NKI)	5 R01 DC015780-05	2,522	23,611	6,761,516	RESEARCH AND DEVELOPMENT	425,311,746
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5 R01 DC003937-20	NEW YORK UNIVERSITY	5 R01 DC003937-20		(114)	6,761,516	RESEARCH AND DEVELOPMENT	425,311,746
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5 R01 DC003937-21	NEW YORK UNIVERSITY	5 R01 DC003937-21		32,159	6,761,516	RESEARCH AND DEVELOPMENT	425,311,746
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	1 U01 DC018920-01	OHIO STATE UNIVERSITY	1 U01 DC018920-01		35,783	6,761,516	RESEARCH AND DEVELOPMENT	425,311,746
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	3 R01 DC015997-02S1	UNIVERSITY OF IOWA	3 R01 DC015997-02S1		69,620	6,761,516	RESEARCH AND DEVELOPMENT	425,311,746
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	3 R01 DC015997-03	UNIVERSITY OF IOWA	3 R01 DC015997-03		134,078	6,761,516	RESEARCH AND DEVELOPMENT	425,311,746
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5 U01 DC014706-02	UNIVERSITY OF UTAH	5 U01 DC014706-02		3,555	6,761,516	RESEARCH AND DEVELOPMENT	425,311,746
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5 R01 DC013767-05	VANDERBILT UNIVERSITY	5 R01 DC013767-05		317	6,761,516	RESEARCH AND DEVELOPMENT	425,311,746
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5 R01 DC014037-05	VANDERBILT UNIVERSITY	5 R01 DC014037-05		(4,728)	6,761,516	RESEARCH AND DEVELOPMENT	425,311,746
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	2 R01 DC014037-06	VANDERBILT UNIVERSITY	2 R01 DC014037-06		152,469	6,761,516	RESEARCH AND DEVELOPMENT	425,311,746
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	2 R01 DC014037-07	VANDERBILT UNIVERSITY	2 R01 DC014037-07		27,322	6,761,516	RESEARCH AND DEVELOPMENT	425,311,746
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5 R01 DC014462-03	VANDERBILT UNIVERSITY	5 R01 DC014462-03		70,571	6,761,516	RESEARCH AND DEVELOPMENT	425,311,746
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	1 R01 DC018171-01	VANDERBILT UNIVERSITY	1 R01 DC018171-01		25,316	6,761,516	RESEARCH AND DEVELOPMENT	425,311,746
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5 R01 DC013270-04				(33,394)	6,761,516	RESEARCH AND DEVELOPMENT	425,311,746
IMMUNIZATION RESEARCH, DEMONSTRATION, PUBLIC INFORMATION AND EDUCATION_TRAINING AND CLINICAL SKILLS IMPROVEMENT PROJECTS	93.185	5 U01 IP001063-04				27,669	2,432,919	RESEARCH AND DEVELOPMENT	425,311,746
COVID-19 IMMUNIZATION RESEARCH, DEMONSTRATION, PUBLIC INFORMATION AND EDUCATION_TRAINING AND CLINICAL SKILLS IMPROVEMENT PROJECTS	93.185	COVID-19 6 U01 IP001063-04-03				234,981	2,432,919	RESEARCH AND DEVELOPMENT	425,311,746
IMMUNIZATION RESEARCH, DEMONSTRATION, PUBLIC INFORMATION AND EDUCATION_TRAINING AND CLINICAL SKILLS IMPROVEMENT PROJECTS	93.185	COVID-19 5 U01 IP001063-05-00				474,170	2,432,919	RESEARCH AND DEVELOPMENT	425,311,746
IMMUNIZATION RESEARCH, DEMONSTRATION, PUBLIC INFORMATION AND EDUCATION_TRAINING AND CLINICAL SKILLS IMPROVEMENT PROJECTS	93.185	5 U01 IP001063-05-00				853,022	2,432,919	RESEARCH AND DEVELOPMENT	425,311,746
IMMUNIZATION RESEARCH, DEMONSTRATION, PUBLIC INFORMATION AND EDUCATION_TRAINING AND CLINICAL SKILLS IMPROVEMENT PROJECTS	93.185	6 U01 IP001083-03				322,091	2,432,919	RESEARCH AND DEVELOPMENT	425,311,746
COVID-19 IMMUNIZATION RESEARCH, DEMONSTRATION, PUBLIC INFORMATION AND EDUCATION_TRAINING AND CLINICAL SKILLS IMPROVEMENT PROJECTS	93.185	COVID-19 6 U01 IP001083-03				404,784	2,432,919	RESEARCH AND DEVELOPMENT	425,311,746
IMMUNIZATION RESEARCH, DEMONSTRATION, PUBLIC INFORMATION AND EDUCATION_TRAINING AND CLINICAL SKILLS IMPROVEMENT PROJECTS	93.185	COVID-19 5 U01 IP001116-02-00	JOHNS HOPKINS UNIVERSITY	5 U01 IP001116-02-00		58,416	2,432,919	RESEARCH AND DEVELOPMENT	425,311,746
IMMUNIZATION RESEARCH, DEMONSTRATION, PUBLIC INFORMATION AND EDUCATION_TRAINING AND CLINICAL SKILLS IMPROVEMENT PROJECTS	93.185	5 U01 IP001116-02-00	JOHNS HOPKINS UNIVERSITY	5 U01 IP001116-02-00		57,786	2,432,919	RESEARCH AND DEVELOPMENT	425,311,746
RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH	93.213	1 R01 AT011456-01				30,314	387,947	RESEARCH AND DEVELOPMENT	425,311,746
RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH	93.213	5 R34 AT009685-03	NORTHWESTERN UNIVERSITY RUSH UNIVERSITY MEDICAL CENTER	5 R34 AT009685-03		8,050	387,947	RESEARCH AND DEVELOPMENT	425,311,746
RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH	93.213	1 R01 AT009680-03				349,583	387,947	RESEARCH AND DEVELOPMENT	425,311,746
NATIONAL RESEARCH SERVICE AWARDS_HEALTH SERVICES RESEARCH TRAINING	93.225	5 T32 HS026122-02				6,724	474,644	RESEARCH AND DEVELOPMENT	425,311,746

**VANDERBILT UNIVERSITY MEDICAL CENTER**  
**SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS (CONTINUED)**  
 Fiscal Period 7/1/2020 – 6/30/2021

<i>Federal Awarding Agency/Program Title</i>	<i>Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
NATIONAL RESEARCH SERVICE AWARDS_HEALTH SERVICES RESEARCH TRAINING	93.225	5 T32 HS026122-03			\$ -	\$ 467,920	\$ 474,644	RESEARCH AND DEVELOPMENT	\$ 425,311,746
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	1 R18 HS025931-01A1				(1,167)	2,698,112	RESEARCH AND DEVELOPMENT	425,311,746
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	5 K12 HS022990-05			-	(2,369)	2,698,112	RESEARCH AND DEVELOPMENT	425,311,746
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	5 K12 HS026395-02			109,435	139,247	2,698,112	RESEARCH AND DEVELOPMENT	425,311,746
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	5 K12 HS026395-03				364,987	2,698,112	RESEARCH AND DEVELOPMENT	425,311,746
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	5 R18 HS025910-02			9,772	409,539	2,698,112	RESEARCH AND DEVELOPMENT	425,311,746
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	5 R18 HS025931-02			187,654	263,716	2,698,112	RESEARCH AND DEVELOPMENT	425,311,746
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	5 R18 HS025931-03			3,126	30,102	2,698,112	RESEARCH AND DEVELOPMENT	425,311,746
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	5 R01 HS025976-02			6,765	35,897	2,698,112	RESEARCH AND DEVELOPMENT	425,311,746
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	5 R01 HS025976-03			59,648	279,690	2,698,112	RESEARCH AND DEVELOPMENT	425,311,746
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	5 R03 HS026069-02				3,540	2,698,112	RESEARCH AND DEVELOPMENT	425,311,746
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	1 R18 HS026158-01				258	2,698,112	RESEARCH AND DEVELOPMENT	425,311,746
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	5 R18 HS026158-02			43,792	61,369	2,698,112	RESEARCH AND DEVELOPMENT	425,311,746
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	5 R18 HS026158-03			75,054	310,555	2,698,112	RESEARCH AND DEVELOPMENT	425,311,746
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	5 R18 HS026616-02			56,005	208,750	2,698,112	RESEARCH AND DEVELOPMENT	425,311,746
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	5 R18 HS026616-03			75,256	496,429	2,698,112	RESEARCH AND DEVELOPMENT	425,311,746
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	1 R18 HS025910-01A1			3,909	6,157	2,698,112	RESEARCH AND DEVELOPMENT	425,311,746
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	1 R01 HS025979-02	ATRIUM HEALTH	1 R01 HS025979-02		8,255	2,698,112	RESEARCH AND DEVELOPMENT	425,311,746
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	5 R01 HS025979-03	ATRIUM HEALTH	5 R01 HS025979-03		18,560	2,698,112	RESEARCH AND DEVELOPMENT	425,311,746
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	7 U18 HS025291-04	KAISER FOUNDATION	7 U18 HS025291-04		14,273	2,698,112	RESEARCH AND DEVELOPMENT	425,311,746
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	1 R01 HS027419-01A1	UNIVERSITY OF COLORADO WASHINGTON UNIVERSITY IN ST. LOUIS	1 R01 HS027419-01A1		42,314	2,698,112	RESEARCH AND DEVELOPMENT	425,311,746
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	1 R01 HS026742-01A1	WASHINGTON UNIVERSITY IN ST. LOUIS	1 R01 HS026742-01A1		65	2,698,112	RESEARCH AND DEVELOPMENT	425,311,746
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	5 R01 HS026742-02	WASHINGTON UNIVERSITY IN ST. LOUIS	5 R01 HS026742-02		7,945	2,698,112	RESEARCH AND DEVELOPMENT	425,311,746
MENTAL HEALTH RESEARCH GRANTS	93.242	5 K01 MH107255-04				12,679	13,239,316	RESEARCH AND DEVELOPMENT	425,311,746
MENTAL HEALTH RESEARCH GRANTS	93.242	5 K24 MH110598-03				1	13,239,316	RESEARCH AND DEVELOPMENT	425,311,746
MENTAL HEALTH RESEARCH GRANTS	93.242	5 K23 MH116339-05			2,590	200,500	13,239,316	RESEARCH AND DEVELOPMENT	425,311,746
MENTAL HEALTH RESEARCH GRANTS	93.242	1 K23 MH122737-01A1				62,811	13,239,316	RESEARCH AND DEVELOPMENT	425,311,746
MENTAL HEALTH RESEARCH GRANTS	93.242	1 K18 MH122755-01				140,642	13,239,316	RESEARCH AND DEVELOPMENT	425,311,746
MENTAL HEALTH RESEARCH GRANTS	93.242	1 K08 MH126166-01				46,003	13,239,316	RESEARCH AND DEVELOPMENT	425,311,746
MENTAL HEALTH RESEARCH GRANTS	93.242	1 K23 MH126313-01				32,646	13,239,316	RESEARCH AND DEVELOPMENT	425,311,746
MENTAL HEALTH RESEARCH GRANTS	93.242	2 R01 MH070560-12				6,244	13,239,316	RESEARCH AND DEVELOPMENT	425,311,746
MENTAL HEALTH RESEARCH GRANTS	93.242	5 R01 MH102246-06			9,608	242,152	13,239,316	RESEARCH AND DEVELOPMENT	425,311,746
MENTAL HEALTH RESEARCH GRANTS	93.242	5 R01 MH102266-05				(868)	13,239,316	RESEARCH AND DEVELOPMENT	425,311,746
MENTAL HEALTH RESEARCH GRANTS	93.242	2 R01 MH102272-06				411,650	13,239,316	RESEARCH AND DEVELOPMENT	425,311,746
MENTAL HEALTH RESEARCH GRANTS	93.242	5 R01 MH107435-05				468,646	13,239,316	RESEARCH AND DEVELOPMENT	425,311,746
MENTAL HEALTH RESEARCH GRANTS	93.242	2 R01 MH107435-06				38,842	13,239,316	RESEARCH AND DEVELOPMENT	425,311,746
MENTAL HEALTH RESEARCH GRANTS	93.242	5 R24 MH109105-04				1,624	13,239,316	RESEARCH AND DEVELOPMENT	425,311,746
MENTAL HEALTH RESEARCH GRANTS	93.242	5 R21 MH109225-03			(3,059)	-	13,239,316	RESEARCH AND DEVELOPMENT	425,311,746
MENTAL HEALTH RESEARCH GRANTS	93.242	5 R01 MH111599-04				566,157	13,239,316	RESEARCH AND DEVELOPMENT	425,311,746
MENTAL HEALTH RESEARCH GRANTS	93.242	5 R01 MH111776-04			41,014	304,560	13,239,316	RESEARCH AND DEVELOPMENT	425,311,746
MENTAL HEALTH RESEARCH GRANTS	93.242	5 R01 MH111877-04			21,182	170,473	13,239,316	RESEARCH AND DEVELOPMENT	425,311,746
MENTAL HEALTH RESEARCH GRANTS	93.242	5 R01 MH113362-04			96,692	646,792	13,239,316	RESEARCH AND DEVELOPMENT	425,311,746
MENTAL HEALTH RESEARCH GRANTS	93.242	5 R01 MH113438-03			49,653	194,686	13,239,316	RESEARCH AND DEVELOPMENT	425,311,746
MENTAL HEALTH RESEARCH GRANTS	93.242	5 R01 MH113478-05			117,510	532,523	13,239,316	RESEARCH AND DEVELOPMENT	425,311,746
MENTAL HEALTH RESEARCH GRANTS	93.242	5 R01 MH114906-04			344,942	573,627	13,239,316	RESEARCH AND DEVELOPMENT	425,311,746
MENTAL HEALTH RESEARCH GRANTS	93.242	5 R01 MH115000-03			180,768	378,470	13,239,316	RESEARCH AND DEVELOPMENT	425,311,746
MENTAL HEALTH RESEARCH GRANTS	93.242	5 R01 MH116058-03			207,363	520,101	13,239,316	RESEARCH AND DEVELOPMENT	425,311,746
MENTAL HEALTH RESEARCH GRANTS	93.242	5 R01 MH116269-03				211,978	13,239,316	RESEARCH AND DEVELOPMENT	425,311,746
MENTAL HEALTH RESEARCH GRANTS	93.242	5 R01 MH118273-03			122,791	922,239	13,239,316	RESEARCH AND DEVELOPMENT	425,311,746
MENTAL HEALTH RESEARCH GRANTS	93.242	1 R21 MH118539-02				173,729	13,239,316	RESEARCH AND DEVELOPMENT	425,311,746
MENTAL HEALTH RESEARCH GRANTS	93.242	5 R01 MH119817-02				565,428	13,239,316	RESEARCH AND DEVELOPMENT	425,311,746
MENTAL HEALTH RESEARCH GRANTS	93.242	5 R33 MH120149-02				190,939	13,239,316	RESEARCH AND DEVELOPMENT	425,311,746
MENTAL HEALTH RESEARCH GRANTS	93.242	5 R56 MH120736-02			107,266	655,366	13,239,316	RESEARCH AND DEVELOPMENT	425,311,746
MENTAL HEALTH RESEARCH GRANTS	93.242	5 R01 MH121438-02			201,429	386,343	13,239,316	RESEARCH AND DEVELOPMENT	425,311,746
MENTAL HEALTH RESEARCH GRANTS	93.242	5 R01 MH121455-02			77,861	536,321	13,239,316	RESEARCH AND DEVELOPMENT	425,311,746
MENTAL HEALTH RESEARCH GRANTS	93.242	5 R01 MH121620-02			40,044	730,394	13,239,316	RESEARCH AND DEVELOPMENT	425,311,746
MENTAL HEALTH RESEARCH GRANTS	93.242	5 R61 MH122464-02			36,277	434,277	13,239,316	RESEARCH AND DEVELOPMENT	425,311,746

**VANDERBILT UNIVERSITY MEDICAL CENTER**  
**SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS (CONTINUED)**  
Fiscal Period 7/1/2020 – 6/30/2021

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
MENTAL HEALTH RESEARCH GRANTS	93.242	5 R61 MH123029-02			\$ 37,812	\$ 339,331	\$ 13,239,316	RESEARCH AND DEVELOPMENT	\$ 425,311,746
MENTAL HEALTH RESEARCH GRANTS	93.242	1 R01 MH123201-01A1				14,103	13,239,316	RESEARCH AND DEVELOPMENT	425,311,746
MENTAL HEALTH RESEARCH GRANTS	93.242	5 R01 MH123563-02			36,636	322,145	13,239,316	RESEARCH AND DEVELOPMENT	425,311,746
MENTAL HEALTH RESEARCH GRANTS	93.242	5 R01 MH123662-02			16,832	463,331	13,239,316	RESEARCH AND DEVELOPMENT	425,311,746
MENTAL HEALTH RESEARCH GRANTS	93.242	1 R34 MH124496-01A1				22,581	13,239,316	RESEARCH AND DEVELOPMENT	425,311,746
MENTAL HEALTH RESEARCH GRANTS	93.242	1 R21 MH126272-01				5,900	13,239,316	RESEARCH AND DEVELOPMENT	425,311,746
MENTAL HEALTH RESEARCH GRANTS	93.242	2 R44 MH115528-02	ADAPTIVE TECHNOLOGY CONSULTING, LLC	2 R44 MH115528-02		295,350	13,239,316	RESEARCH AND DEVELOPMENT	425,311,746
MENTAL HEALTH RESEARCH GRANTS	93.242	5 UG3 MH120102-02	CALIFORNIA INSTITUTE OF TECHNOLOGY (CALTECH)	5 UG3 MH120102-02		229,501	13,239,316	RESEARCH AND DEVELOPMENT	425,311,746
MENTAL HEALTH RESEARCH GRANTS	93.242	1 UG3 MH120102-01	CALIFORNIA INSTITUTE OF TECHNOLOGY (CALTECH)	1 UG3 MH120102-01		(1,763)	13,239,316	RESEARCH AND DEVELOPMENT	425,311,746
MENTAL HEALTH RESEARCH GRANTS	93.242	5 R21 MH121165-02	CASE WESTERN RESERVE UNIVERSITY	5 R21 MH121165-02		12,537	13,239,316	RESEARCH AND DEVELOPMENT	425,311,746
MENTAL HEALTH RESEARCH GRANTS	93.242	3 R01 MH123262-01S1	CITY UNIVERSITY OF NEW YORK (CUNY)	3 R01 MH123262-01S1		7,528	13,239,316	RESEARCH AND DEVELOPMENT	425,311,746
MENTAL HEALTH RESEARCH GRANTS	93.242	1 R21 MH121165-01	CLEVELAND CLINIC FOUNDATION	1 R21 MH121165-01		(2,413)	13,239,316	RESEARCH AND DEVELOPMENT	425,311,746
MENTAL HEALTH RESEARCH GRANTS	93.242	1 R01 MH120588-01A1	INDIANA UNIVERSITY	1 R01 MH120588-01A1		75,808	13,239,316	RESEARCH AND DEVELOPMENT	425,311,746
MENTAL HEALTH RESEARCH GRANTS	93.242	5 R01 MH118233-03	MASSACHUSETTS GENERAL HOSPITAL	5 R01 MH118233-03		186,056	13,239,316	RESEARCH AND DEVELOPMENT	425,311,746
MENTAL HEALTH RESEARCH GRANTS	93.242	5 R01 MH118233-02	MASSACHUSETTS GENERAL HOSPITAL	5 R01 MH118233-02		148,451	13,239,316	RESEARCH AND DEVELOPMENT	425,311,746
MENTAL HEALTH RESEARCH GRANTS	93.242	5 U01 MH109539-05	MASSACHUSETTS GENERAL HOSPITAL	5 U01 MH109539-05		96,330	13,239,316	RESEARCH AND DEVELOPMENT	425,311,746
MENTAL HEALTH RESEARCH GRANTS	93.242	5 R01 MH121407-02	PORTLAND STATE UNIVERSITY	5 R01 MH121407-02		38,040	13,239,316	RESEARCH AND DEVELOPMENT	425,311,746
MENTAL HEALTH RESEARCH GRANTS	93.242	5 R01 MH107467-05	UNIVERSITY OF CALIFORNIA AT SAN FRANCISCO	5 R01 MH107467-05		49,990	13,239,316	RESEARCH AND DEVELOPMENT	425,311,746
MENTAL HEALTH RESEARCH GRANTS	93.242	5 R01 MH120122-02	UNIVERSITY OF COLORADO	5 R01 MH120122-02		132,299	13,239,316	RESEARCH AND DEVELOPMENT	425,311,746
MENTAL HEALTH RESEARCH GRANTS	93.242	3 R01 MH120124-02S2	UNIVERSITY OF MICHIGAN	3 R01 MH120124-02S2		28,349	13,239,316	RESEARCH AND DEVELOPMENT	425,311,746
MENTAL HEALTH RESEARCH GRANTS	93.242	1 R56 MH120826-01A1	UNIVERSITY OF NEW MEXICO	1 R56 MH120826-01A1		111,216	13,239,316	RESEARCH AND DEVELOPMENT	425,311,746
MENTAL HEALTH RESEARCH GRANTS	93.242	5 U01 MH110925-04	UNIVERSITY OF NORTH CAROLINA	5 U01 MH110925-04		427	13,239,316	RESEARCH AND DEVELOPMENT	425,311,746
MENTAL HEALTH RESEARCH GRANTS	93.242	5 U01 MH110925-04	UNIVERSITY OF NORTH CAROLINA	5 U01 MH110925-04		10,337	13,239,316	RESEARCH AND DEVELOPMENT	425,311,746
MENTAL HEALTH RESEARCH GRANTS	93.242	5 U01 MH110925-05	UNIVERSITY OF NORTH CAROLINA	5 U01 MH110925-05		8,944	13,239,316	RESEARCH AND DEVELOPMENT	425,311,746
MENTAL HEALTH RESEARCH GRANTS	93.242	5 U01 MH110925-05	UNIVERSITY OF NORTH CAROLINA	5 U01 MH110925-05		4,748	13,239,316	RESEARCH AND DEVELOPMENT	425,311,746
MENTAL HEALTH RESEARCH GRANTS	93.242	5 U01 MH112913-03	UNIVERSITY OF WISCONSIN	5 U01 MH112913-03		224,715	13,239,316	RESEARCH AND DEVELOPMENT	425,311,746
MENTAL HEALTH RESEARCH GRANTS	93.242	5 U01 MH112913-04	UNIVERSITY OF WISCONSIN	5 U01 MH112913-04		4,436	13,239,316	RESEARCH AND DEVELOPMENT	425,311,746
MENTAL HEALTH RESEARCH GRANTS	93.242	1 R01 MH118273-01A1	VANDERBILT UNIVERSITY	1 R01 MH118273-01A1		(255)	13,239,316	RESEARCH AND DEVELOPMENT	425,311,746
MENTAL HEALTH RESEARCH GRANTS	93.242	1 RF1 MH123971-01	VANDERBILT UNIVERSITY	1 RF1 MH123971-01		26,803	13,239,316	RESEARCH AND DEVELOPMENT	425,311,746
MENTAL HEALTH RESEARCH GRANTS	93.242	1 R01 MH124671-01	VANDERBILT UNIVERSITY	1 R01 MH124671-01		26,516	13,239,316	RESEARCH AND DEVELOPMENT	425,311,746
ADVANCED NURSING EDUCATION GRANT PROGRAM	93.247	1 T14 HP33119-01-00	VANDERBILT UNIVERSITY	1 T14 HP33119-01-00		251,118	251,118	RESEARCH AND DEVELOPMENT	425,311,746
EARLY HEARING DETECTION AND INTERVENTION	93.251	65942:ST TN	TN DEPARTMENT OF HEALTH	65942:ST TN		114,101	114,101	RESEARCH AND DEVELOPMENT	425,311,746
POISON CENTER SUPPORT AND ENHANCEMENT GRANT	93.253	2 H4B HS030752-04-00				70,844	491,634	N/A	-
POISON CENTER SUPPORT AND ENHANCEMENT GRANT	93.253	5 H4B HS030752-05				347,831	491,634	N/A	-
COVID-19 POISON CENTER SUPPORT AND ENHANCEMENT GRANT	93.253	COVID-19 1 H4C HS37367-01-00				72,959	491,634	N/A	-
OCCUPATIONAL SAFETY AND HEALTH PROGRAM	93.262	5 R21 OH011452-02-00	UNIVERSITY OF CALIFORNIA AT SAN FRANCISCO	5 R21 OH011452-02-00		2,708	2,708	RESEARCH AND DEVELOPMENT	425,311,746
IMMUNIZATION COOPERATIVE AGREEMENTS	93.268	200-2012-50430				8,046	8,046	RESEARCH AND DEVELOPMENT	425,311,746
ALCOHOL RESEARCH PROGRAMS	93.273	1 K01 AA029042-01				58,034	1,168,579	RESEARCH AND DEVELOPMENT	425,311,746
ALCOHOL RESEARCH PROGRAMS	93.273	5 R01 AA026186-05			15,992	374,211	1,168,579	RESEARCH AND DEVELOPMENT	425,311,746
ALCOHOL RESEARCH PROGRAMS	93.273	5 U01 AA026222-03			149,226	165,922	1,168,579	RESEARCH AND DEVELOPMENT	425,311,746
ALCOHOL RESEARCH PROGRAMS	93.273	5 U01 AA026222-04			92,851	286,061	1,168,579	RESEARCH AND DEVELOPMENT	425,311,746
ALCOHOL RESEARCH PROGRAMS	93.273	5 R01 AA025859-03	BOSTON MEDICAL CENTER	5 R01 AA025859-03		6,932	1,168,579	RESEARCH AND DEVELOPMENT	425,311,746
ALCOHOL RESEARCH PROGRAMS	93.273	5 U01 AA020780-09	BOSTON MEDICAL CENTER	5 U01 AA020780-09		15,646	1,168,579	RESEARCH AND DEVELOPMENT	425,311,746
ALCOHOL RESEARCH PROGRAMS	93.273	5 U01 AA020780-10	BOSTON MEDICAL CENTER	5 U01 AA020780-10		83,253	1,168,579	RESEARCH AND DEVELOPMENT	425,311,746
ALCOHOL RESEARCH PROGRAMS	93.273	7 R03 AA026099-03	OCHSNER CLINIC FOUNDATION RESEARCH FOUNDATION FOR	7 R03 AA026099-03		46,755	1,168,579	RESEARCH AND DEVELOPMENT	425,311,746
ALCOHOL RESEARCH PROGRAMS	93.273	5 R01 AA025947-02	MENTAL HYGIENE, INC.	5 R01 AA025947-02		11,073	1,168,579	RESEARCH AND DEVELOPMENT	425,311,746
ALCOHOL RESEARCH PROGRAMS	93.273	5 R01 AA025337-02	UNIVERSITY OF FLORIDA	5 R01 AA025337-02		60,998	1,168,579	RESEARCH AND DEVELOPMENT	425,311,746
ALCOHOL RESEARCH PROGRAMS	93.273	1 R01 AA027654-02	UNIVERSITY OF IOWA	1 R01 AA027654-02		23,054	1,168,579	RESEARCH AND DEVELOPMENT	425,311,746



**VANDERBILT UNIVERSITY MEDICAL CENTER**  
**SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS (CONTINUED)**  
 Fiscal Period 7/1/2020 – 6/30/2021

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
ALCOHOL RESEARCH PROGRAMS	93.273	5 U01 AA026224-03	YALE UNIVERSITY	5 U01 AA026224-03	\$ -	\$ 7,665	\$ 1,168,579	RESEARCH AND DEVELOPMENT	\$ 425,311,746
ALCOHOL RESEARCH PROGRAMS	93.273	5 U01 AA026224-04	YALE UNIVERSITY	5 U01 AA026224-04		28,975	1,168,579	RESEARCH AND DEVELOPMENT	425,311,746
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	5 K23 DA047476-03				159,844	1,621,773	RESEARCH AND DEVELOPMENT	425,311,746
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	5 K01 DA050740-02				180,964	1,621,773	RESEARCH AND DEVELOPMENT	425,311,746
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	5 R01 DA040630-05				333,586	1,621,773	RESEARCH AND DEVELOPMENT	425,311,746
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	1 R01 DA045729-04			8,868	297,419	1,621,773	RESEARCH AND DEVELOPMENT	425,311,746
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	1 R01 DA050334-01A1				22,438	1,621,773	RESEARCH AND DEVELOPMENT	425,311,746
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	3 UG1 DA040317-05S2	DUKE UNIVERSITY	3 UG1 DA040317-05S2	4,639	103,805	1,621,773	RESEARCH AND DEVELOPMENT	425,311,746
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	3 UG1 DA015831-18S9	THE MCLEAN HOSPITAL CORPORATION	3 UG1 DA015831-18S9		(9,947)	1,621,773	RESEARCH AND DEVELOPMENT	425,311,746
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	3 UG1 DA015831-19S1	THE MCLEAN HOSPITAL CORPORATION	3 UG1 DA015831-19S1		251,027	1,621,773	RESEARCH AND DEVELOPMENT	425,311,746
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	5 R21 DA043960-02	UNIVERSITY OF ALABAMA AT BIRMINGHAM	5 R21 DA043960-02		2,402	1,621,773	RESEARCH AND DEVELOPMENT	425,311,746
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	2 UG1 DA013732-21S1	UNIVERSITY OF CINCINNATI	2 UG1 DA013732-21S1	3,711	146,857	1,621,773	RESEARCH AND DEVELOPMENT	425,311,746
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	2 UG1 DA013732-22S1	UNIVERSITY OF CINCINNATI	2 UG1 DA013732-22S1	928	133,378	1,621,773	RESEARCH AND DEVELOPMENT	425,311,746
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	5 T32 EB001628-17				3,958	3,367,766	RESEARCH AND DEVELOPMENT	425,311,746
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	5 K01 EB030039-02				145,496	3,367,766	RESEARCH AND DEVELOPMENT	425,311,746
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	5 R01 EB018992-04			4,648	4,648	3,367,766	RESEARCH AND DEVELOPMENT	425,311,746
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	2 R01 EB018992-05				34,506	3,367,766	RESEARCH AND DEVELOPMENT	425,311,746
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	5 R21 EB021012-02			6,143	10,472	3,367,766	RESEARCH AND DEVELOPMENT	425,311,746
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	5 R01 EB024525-04				452,777	3,367,766	RESEARCH AND DEVELOPMENT	425,311,746
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	5 R21 EB025258-03			32,263	161,802	3,367,766	RESEARCH AND DEVELOPMENT	425,311,746
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	5 R01 EB026991-02			105,128	195,171	3,367,766	RESEARCH AND DEVELOPMENT	425,311,746
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	5 R03 EB029078-02				73,725	3,367,766	RESEARCH AND DEVELOPMENT	425,311,746
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	1 R01 EB029443-01A1				38,072	3,367,766	RESEARCH AND DEVELOPMENT	425,311,746
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	5 R21 EB029639-02			50,814	206,758	3,367,766	RESEARCH AND DEVELOPMENT	425,311,746
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	5 T32 EB001628-18				414,263	3,367,766	RESEARCH AND DEVELOPMENT	425,311,746
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	1 U18 EB029351-01			429,416	1,100,707	3,367,766	RESEARCH AND DEVELOPMENT	425,311,746
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	5 U01 EB021214-04	UNIVERSITY OF CALIFORNIA AT SAN FRANCISCO	5 U01 EB021214-04		6,064	3,367,766	RESEARCH AND DEVELOPMENT	425,311,746
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	5 R01 EB014308-04	VANDERBILT UNIVERSITY	5 R01 EB014308-04		163,597	3,367,766	RESEARCH AND DEVELOPMENT	425,311,746
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	5 R01 EB016695-07	VANDERBILT UNIVERSITY	5 R01 EB016695-07		78,036	3,367,766	RESEARCH AND DEVELOPMENT	425,311,746
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	5 R01 EB023717-02	VANDERBILT UNIVERSITY	5 R01 EB023717-02		79,217	3,367,766	RESEARCH AND DEVELOPMENT	425,311,746
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	5 R21 EB024311-02	VANDERBILT UNIVERSITY	5 R21 EB024311-02		26,307	3,367,766	RESEARCH AND DEVELOPMENT	425,311,746
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	1 R01 EB024864-01	VANDERBILT UNIVERSITY	1 R01 EB024864-01		17,063	3,367,766	RESEARCH AND DEVELOPMENT	425,311,746
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	1 R01 EB026901-01A1	VANDERBILT UNIVERSITY	1 R01 EB026901-01A1		74,781	3,367,766	RESEARCH AND DEVELOPMENT	425,311,746
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	5 R01 EB027498-02	VANDERBILT UNIVERSITY	5 R01 EB027498-02		55,493	3,367,766	RESEARCH AND DEVELOPMENT	425,311,746
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	1 R01 EB028615-01	VANDERBILT UNIVERSITY	1 R01 EB028615-01		28,738	3,367,766	RESEARCH AND DEVELOPMENT	425,311,746

**VANDERBILT UNIVERSITY MEDICAL CENTER**  
**SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS (CONTINUED)**  
Fiscal Period 7/1/2020 – 6/30/2021

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total	
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	5 R01 EB018992-04			\$ -	\$ (3,885)	\$ 3,367,766	RESEARCH AND DEVELOPMENT	\$ 425,311,746	
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	5 U54 MD010722-04				4,746	2,147,026	RESEARCH AND DEVELOPMENT	425,311,746	
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	5 U54 MD010722-05			1,123,246	1,942,549	2,147,026	RESEARCH AND DEVELOPMENT	425,311,746	
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	5 R01 MD013493-03	DUKE UNIVERSITY	5 R01 MD013493-03		23,917	2,147,026	RESEARCH AND DEVELOPMENT	425,311,746	
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	5 R01 MD013493-04	DUKE UNIVERSITY	5 R01 MD013493-04		9,268	2,147,026	RESEARCH AND DEVELOPMENT	425,311,746	
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	5 U54 MD007586-34	MEHARRY MEDICAL COLLEGE	5 U54 MD007586-34		24,092	2,147,026	RESEARCH AND DEVELOPMENT	425,311,746	
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	5 U54 MD007586-34	MEHARRY MEDICAL COLLEGE	5 U54 MD007586-34		18,487	2,147,026	RESEARCH AND DEVELOPMENT	425,311,746	
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	5 U54 MD007586-34	MEHARRY MEDICAL COLLEGE	5 U54 MD007586-34		7,702	2,147,026	RESEARCH AND DEVELOPMENT	425,311,746	
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	5 U54 MD012397-03	SAN DIEGO STATE UNIVERSITY	5 U54 MD012397-03		18,558	2,147,026	RESEARCH AND DEVELOPMENT	425,311,746	
		COVID-19 5 U54 MD010722-05S1					97,707	RESEARCH AND DEVELOPMENT	425,311,746	
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	5 U54 MD010722-05S1					97,707	RESEARCH AND DEVELOPMENT	425,311,746	
TRANS-NIH RESEARCH SUPPORT	93.310	1 DP2 HD098859-01			115,386	619,058	35,428,916	RESEARCH AND DEVELOPMENT	425,311,746	
TRANS-NIH RESEARCH SUPPORT	93.310	1 DP5 OD029586-01				314,825	35,428,916	RESEARCH AND DEVELOPMENT	425,311,746	
TRANS-NIH RESEARCH SUPPORT	93.310	3 DP5 OD029586-01S1				7,116	35,428,916	RESEARCH AND DEVELOPMENT	425,311,746	
TRANS-NIH RESEARCH SUPPORT	93.310	5 U01 HG007674-07			4,503	4,503	35,428,916	RESEARCH AND DEVELOPMENT	425,311,746	
TRANS-NIH RESEARCH SUPPORT	93.310	3 OT2 OD023850-01				(1,104)	35,428,916	RESEARCH AND DEVELOPMENT	425,311,746	
TRANS-NIH RESEARCH SUPPORT	93.310	5 U01 HG007674-08			24,817	1,122,545	35,428,916	RESEARCH AND DEVELOPMENT	425,311,746	
TRANS-NIH RESEARCH SUPPORT	93.310	3 U01 HG007674-08S1				92,394	35,428,916	RESEARCH AND DEVELOPMENT	425,311,746	
TRANS-NIH RESEARCH SUPPORT	93.310	5 U2C OD23196-02			(7,112)	-	35,428,916	RESEARCH AND DEVELOPMENT	425,311,746	
TRANS-NIH RESEARCH SUPPORT	93.310	5 U2C OD023196-03			8,750,205	18,172,039	35,428,916	RESEARCH AND DEVELOPMENT	425,311,746	
TRANS-NIH RESEARCH SUPPORT	93.310	5 U2C OD023196-04			1,577,840	11,865,551	35,428,916	RESEARCH AND DEVELOPMENT	425,311,746	
TRANS-NIH RESEARCH SUPPORT	93.310	1 U01 GM132769-02	ALABAMA STATE UNIVERSITY	1 U01 GM132769-02		66,562	35,428,916	RESEARCH AND DEVELOPMENT	425,311,746	
TRANS-NIH RESEARCH SUPPORT	93.310	5 UH3 OD023320-05	ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY	5 UH3 OD023320-05			35,809	35,428,916	RESEARCH AND DEVELOPMENT	425,311,746
TRANS-NIH RESEARCH SUPPORT	93.310	5 UH3 OD023320-06	MEDICINE OF YESHIVA UNIVERSITY	5 UH3 OD023320-06		196,376	35,428,916	RESEARCH AND DEVELOPMENT	425,311,746	
TRANS-NIH RESEARCH SUPPORT	93.310	5 UH3 OD023268-05	BRIGHAM AND WOMEN'S HOSPITAL	5 UH3 OD023268-05		3,217	35,428,916	RESEARCH AND DEVELOPMENT	425,311,746	
TRANS-NIH RESEARCH SUPPORT	93.310	5 U2C OD023375-05	DUKE UNIVERSITY	5 U2C OD023375-05		34,541	35,428,916	RESEARCH AND DEVELOPMENT	425,311,746	
TRANS-NIH RESEARCH SUPPORT	93.310	5 U2C OD023375-05	DUKE UNIVERSITY	5 U2C OD023375-05		18,289	35,428,916	RESEARCH AND DEVELOPMENT	425,311,746	
TRANS-NIH RESEARCH SUPPORT	93.310	4 U24 OD023319-04	NORTHWESTERN UNIVERSITY	4 U24 OD023319-04		15,901	35,428,916	RESEARCH AND DEVELOPMENT	425,311,746	
TRANS-NIH RESEARCH SUPPORT	93.310	4 U24 OD023319-05	NORTHWESTERN UNIVERSITY	4 U24 OD023319-05		60,344	35,428,916	RESEARCH AND DEVELOPMENT	425,311,746	
TRANS-NIH RESEARCH SUPPORT	93.310	1 U24 GM132217-01	UNIVERSITY OF NORTH TEXAS	1 U24 GM132217-01		2,003	35,428,916	RESEARCH AND DEVELOPMENT	425,311,746	
TRANS-NIH RESEARCH SUPPORT	93.310	5 U24 GM132217-02	UNIVERSITY OF NORTH TEXAS	5 U24 GM132217-02		528,242	35,428,916	RESEARCH AND DEVELOPMENT	425,311,746	
TRANS-NIH RESEARCH SUPPORT	93.310	5 U01 GM132133-02	UNIVERSITY OF PITTSBURGH	5 U01 GM132133-02		21,613	35,428,916	RESEARCH AND DEVELOPMENT	425,311,746	
TRANS-NIH RESEARCH SUPPORT	93.310	4 UH3 OD023271-04	UNIVERSITY OF WASHINGTON	4 UH3 OD023271-04		25,359	35,428,916	RESEARCH AND DEVELOPMENT	425,311,746	
TRANS-NIH RESEARCH SUPPORT	93.310	5 UH3 OD023271-05	UNIVERSITY OF WASHINGTON	5 UH3 OD023271-05		128,154	35,428,916	RESEARCH AND DEVELOPMENT	425,311,746	
TRANS-NIH RESEARCH SUPPORT	93.310	5 UH3 OD023282-04	UNIVERSITY OF WISCONSIN	5 UH3 OD023282-04		286,593	35,428,916	RESEARCH AND DEVELOPMENT	425,311,746	
TRANS-NIH RESEARCH SUPPORT	93.310	5 UH3 OD023282-05	UNIVERSITY OF WISCONSIN	5 UH3 OD023282-05		1,569,222	35,428,916	RESEARCH AND DEVELOPMENT	425,311,746	
TRANS-NIH RESEARCH SUPPORT	93.310	1 U54 DK120058-01	VANDERBILT UNIVERSITY	1 U54 DK120058-01		25	35,428,916	RESEARCH AND DEVELOPMENT	425,311,746	
TRANS-NIH RESEARCH SUPPORT	93.310	1 U54 DK120058-02	VANDERBILT UNIVERSITY	1 U54 DK120058-02		235,690	35,428,916	RESEARCH AND DEVELOPMENT	425,311,746	
TRANS-NIH RESEARCH SUPPORT	93.310	5 U54 DK120058-02	VANDERBILT UNIVERSITY	5 U54 DK120058-02		91	35,428,916	RESEARCH AND DEVELOPMENT	425,311,746	
TRANS-NIH RESEARCH SUPPORT	93.310	5 U54 DK120058-03	VANDERBILT UNIVERSITY	5 U54 DK120058-03		7,158	35,428,916	RESEARCH AND DEVELOPMENT	425,311,746	
TRANS-NIH RESEARCH SUPPORT	93.310	5 U01 HG007674-07				(3,200)	35,428,916	RESEARCH AND DEVELOPMENT	425,311,746	
RARE DISORDERS: RESEARCH, SURVEILLANCE, HEALTH PROMOTION, AND EDUCATION	93.315	1 U01 DD001234-01-00				3,267	107,233	RESEARCH AND DEVELOPMENT	425,311,746	
RARE DISORDERS: RESEARCH, SURVEILLANCE, HEALTH PROMOTION, AND EDUCATION	93.315	5 U01 DD001234-02-00				15,384	107,233	RESEARCH AND DEVELOPMENT	425,311,746	
RARE DISORDERS: RESEARCH, SURVEILLANCE, HEALTH PROMOTION, AND EDUCATION	93.315	1 U01 DD001235-01-00				36,617	107,233	RESEARCH AND DEVELOPMENT	425,311,746	
RARE DISORDERS: RESEARCH, SURVEILLANCE, HEALTH PROMOTION, AND EDUCATION	93.315	5 U01 DD001235-02-00				51,965	107,233	RESEARCH AND DEVELOPMENT	425,311,746	
EMERGING INFECTIONS PROGRAMS	93.317	59293:ST TN	TN DEPARTMENT OF HEALTH	59293:ST TN		1,016,521	2,871,886	RESEARCH AND DEVELOPMENT	425,311,746	
EMERGING INFECTIONS PROGRAMS	93.317	59293:ST TN	TN DEPARTMENT OF HEALTH	59293:ST TN		938,134	2,871,886	RESEARCH AND DEVELOPMENT	425,311,746	
COVID-19 EMERGING INFECTIONS PROGRAMS	93.317	COVID-19 59293:ST TN	TN DEPARTMENT OF HEALTH	59293:ST TN		430,825	2,871,886	RESEARCH AND DEVELOPMENT	425,311,746	
COVID-19 EMERGING INFECTIONS PROGRAMS	93.317	COVID-19 59293:ST TN	TN DEPARTMENT OF HEALTH	59293:ST TN		486,406	2,871,886	RESEARCH AND DEVELOPMENT	425,311,746	
EPIDEMIOLOGY AND LABORATORY CAPACITY FOR INFECTIOUS DISEASES (ELC)	93.323	61814:ST TN	TN DEPARTMENT OF HEALTH	61814:ST TN	42,572	42,572	339,499	RESEARCH AND DEVELOPMENT	425,311,746	
COVID-19 EPIDEMIOLOGY AND LABORATORY CAPACITY FOR INFECTIOUS DISEASES (ELC)	93.323	COVID-19 67997:ST TN	TN DEPARTMENT OF HEALTH	67997:ST TN		296,927	339,499	RESEARCH AND DEVELOPMENT	425,311,746	

**VANDERBILT UNIVERSITY MEDICAL CENTER**  
**SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS (CONTINUED)**  
 Fiscal Period 7/1/2020 – 6/30/2021

<i>Federal Awarding Agency/Program Title</i>	<i>Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	5 KL2 TR002245-04			\$ 84,941	\$ 490,656	\$ 31,044,738	RESEARCH AND DEVELOPMENT	\$ 425,311,746
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	5 KL2 TR002245-05				179,673	31,044,738	RESEARCH AND DEVELOPMENT	425,311,746
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	5 R21 TR001723-02				212	31,044,738	RESEARCH AND DEVELOPMENT	425,311,746
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	5 KL2 TR002245-03				(3,848)	31,044,738	RESEARCH AND DEVELOPMENT	425,311,746
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	5 TL1 TR002244-03				(828)	31,044,738	RESEARCH AND DEVELOPMENT	425,311,746
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	5 TL1 TR002244-04				246,793	31,044,738	RESEARCH AND DEVELOPMENT	425,311,746
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	5 TL1 TR002244-05				74,562	31,044,738	RESEARCH AND DEVELOPMENT	425,311,746
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	5 U24 TR001579-04			135,381	178,095	31,044,738	RESEARCH AND DEVELOPMENT	425,311,746
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	5 U24 TR001579-05			176,556	3,608,409	31,044,738	RESEARCH AND DEVELOPMENT	425,311,746
<b>COVID-19 NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES</b>		COVID-19 3 U24 TR001579-05S1							
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	5 UL1 TR002243-03				738,846	31,044,738	RESEARCH AND DEVELOPMENT	425,311,746
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	5 UL1 TR002243-04			581,208	6,048,063	31,044,738	RESEARCH AND DEVELOPMENT	425,311,746
<b>COVID-19 NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES</b>		COVID-19 3 UL1 TR002243-04S2							
<b>COVID-19 NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES</b>	93.350	COVID-19 3 UL1 TR002243-04S3				93,787	31,044,738	RESEARCH AND DEVELOPMENT	425,311,746
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	5 UL1 TR002243-05			5,836,009	12,633,555	31,044,738	RESEARCH AND DEVELOPMENT	425,311,746
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	5 U01 TR002398-02				2,335,812	31,044,738	RESEARCH AND DEVELOPMENT	425,311,746
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	1 U34 TR003298-01			228,624	739,615	31,044,738	RESEARCH AND DEVELOPMENT	425,311,746
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	5 U24 TR001608-04	DUKE UNIVERSITY	5 U24 TR001608-04		21,690	31,044,738	RESEARCH AND DEVELOPMENT	425,311,746
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	5 U24 TR001608-05	DUKE UNIVERSITY	5 U24 TR001608-05		1,173,170	31,044,738	RESEARCH AND DEVELOPMENT	425,311,746
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	5 U24 TR001608-05S1	DUKE UNIVERSITY	5 U24 TR001608-05S1		260,672	31,044,738	RESEARCH AND DEVELOPMENT	425,311,746
<b>COVID-19 NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES</b>		COVID-19 3 U24 TR001608-05S4							
<b>COVID-19 NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES</b>	93.350	COVID-19 3 U24 TR001608-05S4	DUKE UNIVERSITY	3 U24 TR001608-05S4		315,297	31,044,738	RESEARCH AND DEVELOPMENT	425,311,746
<b>COVID-19 NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES</b>		COVID-19 3 U24 TR001608-05S4							
<b>COVID-19 NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES</b>	93.350	COVID-19 3 U24 TR001608-06S4	DUKE UNIVERSITY	3 U24 TR001608-06S4		4,854	31,044,738	RESEARCH AND DEVELOPMENT	425,311,746
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	5 U01 TR001803-02	DUKE UNIVERSITY	5 U01 TR001803-02		44,447	31,044,738	RESEARCH AND DEVELOPMENT	425,311,746
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	5 U01 TR001803-04	DUKE UNIVERSITY	5 U01 TR001803-04		1,397	31,044,738	RESEARCH AND DEVELOPMENT	425,311,746
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	5 U01 TR001803-05	DUKE UNIVERSITY	5 U01 TR001803-05		162,042	31,044,738	RESEARCH AND DEVELOPMENT	425,311,746
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	3 UL1 TR002553-02S1	DUKE UNIVERSITY	3 UL1 TR002553-02S1		(26,384)	31,044,738	RESEARCH AND DEVELOPMENT	425,311,746
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	1 U01 TR003206-01	ROCKEFELLER UNIVERSITY	1 U01 TR003206-01		106,064	31,044,738	RESEARCH AND DEVELOPMENT	425,311,746
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	1 U01 TR003206-02	ROCKEFELLER UNIVERSITY	1 U01 TR003206-02		29,348	31,044,738	RESEARCH AND DEVELOPMENT	425,311,746
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	5 UL1 TR001881-04	UNIVERSITY OF CALIFORNIA AT LOS ANGELES	5 UL1 TR001881-04		(16,800)	31,044,738	RESEARCH AND DEVELOPMENT	425,311,746
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	3 UL1 TR001881-04S2	UNIVERSITY OF CALIFORNIA AT LOS ANGELES	3 UL1 TR001881-04S2		326,703	31,044,738	RESEARCH AND DEVELOPMENT	425,311,746
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	5 U01 TR001812-04	UNIVERSITY OF MASSACHUSETTS	5 U01 TR001812-04	4,879	11,878	31,044,738	RESEARCH AND DEVELOPMENT	425,311,746
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	5 U01 TR001812-05	UNIVERSITY OF MASSACHUSETTS	5 U01 TR001812-05		61,501	31,044,738	RESEARCH AND DEVELOPMENT	425,311,746
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	5 KL2 TR002490-03	UNIVERSITY OF NORTH CAROLINA	5 KL2 TR002490-03		3,923	31,044,738	RESEARCH AND DEVELOPMENT	425,311,746
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	4 UH3 TR002097-03	VANDERBILT UNIVERSITY	4 UH3 TR002097-03		8,910	31,044,738	RESEARCH AND DEVELOPMENT	425,311,746
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	4 UH3 TR002097-04	VANDERBILT UNIVERSITY	4 UH3 TR002097-04		295,319	31,044,738	RESEARCH AND DEVELOPMENT	425,311,746
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	5 U01 TR002383-02	VANDERBILT UNIVERSITY	5 U01 TR002383-02		13,006	31,044,738	RESEARCH AND DEVELOPMENT	425,311,746
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	5 U01 TR002383-03	VANDERBILT UNIVERSITY	5 U01 TR002383-03		100,576	31,044,738	RESEARCH AND DEVELOPMENT	425,311,746
<b>COVID-19 NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES</b>		COVID-19 3 UL1 TR002243-04S4							
RESEARCH INFRASTRUCTURE PROGRAMS	93.351	1 S10 OD025092-01A1				456,268	31,044,738	RESEARCH AND DEVELOPMENT	425,311,746
21ST CENTURY CURES ACT – BEAU BIDEN CANCER MOONSHOT	93.353	5 U01 CA232829-01A1			257,893	1,534,981	1,534,981	RESEARCH AND DEVELOPMENT	425,311,746
21ST CENTURY CURES ACT – BEAU BIDEN CANCER MOONSHOT	93.353	1 U2C CA233291-01			771,980	2,028,641	3,018,645	RESEARCH AND DEVELOPMENT	425,311,746
21ST CENTURY CURES ACT – BEAU BIDEN CANCER MOONSHOT	93.353	1 U01 CA254832-01			15,935	345,181	3,018,645	RESEARCH AND DEVELOPMENT	425,311,746
<b>PUBLIC HEALTH EMERGENCY RESPONSE: COOPERATIVE AGREEMENT FOR EMERGENCY RESPONSE: PUBLIC HEALTH CRISIS RESPONSE</b>		61319:ST TN	TN DEPARTMENT OF HEALTH	61319:ST TN		279	279	RESEARCH AND DEVELOPMENT	425,311,746
<b>NURSE EDUCATION, PRACTICE QUALITY AND RETENTION GRANTS</b>	93.359	4 UD7 HP030932-02-03	VANDERBILT UNIVERSITY	4 UD7 HP030932-02-03		138,475	138,475	RESEARCH AND DEVELOPMENT	425,311,746
NURSING RESEARCH	93.361	3 R01 NR015079-06S1				72,079	574,766	RESEARCH AND DEVELOPMENT	425,311,746
NURSING RESEARCH	93.361	5 R01 NR015079-08				437,243	574,766	RESEARCH AND DEVELOPMENT	425,311,746

**VANDERBILT UNIVERSITY MEDICAL CENTER**  
**SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS (CONTINUED)**  
 Fiscal Period 7/1/2020 – 6/30/2021

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
<i>NURSING RESEARCH</i>	93.361	1 R01 NR017622-01A1	UNIVERSITY OF CALIFORNIA AT SAN FRANCISCO	1 R01 NR017622-01A1	\$ -	\$ 65,444	\$ 574,766	RESEARCH AND DEVELOPMENT	\$ 425,311,746
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5 U01 CA202979-04			22,307	133,179	16,633,917	RESEARCH AND DEVELOPMENT	425,311,746
CANCER CAUSE AND PREVENTION RESEARCH	93.393	1 R01 CA240093-01			56,569	846,560	16,633,917	RESEARCH AND DEVELOPMENT	425,311,746
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5 P01 CA028842-34			173,075	457,449	16,633,917	RESEARCH AND DEVELOPMENT	425,311,746
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5 P01 CA116087-13			120,390	864,016	16,633,917	RESEARCH AND DEVELOPMENT	425,311,746
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5 P01 CA116087-14				576,895	16,633,917	RESEARCH AND DEVELOPMENT	425,311,746
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5 R01 CA077955-25				468,294	16,633,917	RESEARCH AND DEVELOPMENT	425,311,746
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5 R01 CA188214-06				275,216	16,633,917	RESEARCH AND DEVELOPMENT	425,311,746
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5 R01 CA189152-06			191,429	329,823	16,633,917	RESEARCH AND DEVELOPMENT	425,311,746
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5 R01 CA190612-06			101,436	308,591	16,633,917	RESEARCH AND DEVELOPMENT	425,311,746
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5 R01 CA198482-06			85,765	154,519	16,633,917	RESEARCH AND DEVELOPMENT	425,311,746
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5 R01 CA200999-05			21,286	149,242	16,633,917	RESEARCH AND DEVELOPMENT	425,311,746
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5 R01 CA202936-05			204,305	401,373	16,633,917	RESEARCH AND DEVELOPMENT	425,311,746
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5 R01 CA202981-05			730,121	2,006,786	16,633,917	RESEARCH AND DEVELOPMENT	425,311,746
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5 R01 CA203012-05			242,997	322,722	16,633,917	RESEARCH AND DEVELOPMENT	425,311,746
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5 R01 CA204819-04			31,520	257,195	16,633,917	RESEARCH AND DEVELOPMENT	425,311,746
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5 R01 CA207401-04			2,395	2,395	16,633,917	RESEARCH AND DEVELOPMENT	425,311,746
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5 R01 CA207466-04			22,421	175,792	16,633,917	RESEARCH AND DEVELOPMENT	425,311,746
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5 R01 CA225005-03			284,525	541,071	16,633,917	RESEARCH AND DEVELOPMENT	425,311,746
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5 R37 CA227130-03			15,083	397,908	16,633,917	RESEARCH AND DEVELOPMENT	425,311,746
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5 R01 CA230352-03			336,323	657,211	16,633,917	RESEARCH AND DEVELOPMENT	425,311,746
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5 R01 CA232516-02			22,120	717,219	16,633,917	RESEARCH AND DEVELOPMENT	425,311,746
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5 R01 CA235553-03				596,275	16,633,917	RESEARCH AND DEVELOPMENT	425,311,746
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5 R37 CA237452-02			28,119	445,741	16,633,917	RESEARCH AND DEVELOPMENT	425,311,746
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5 R01 CA237895-02				353,380	16,633,917	RESEARCH AND DEVELOPMENT	425,311,746
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5 R21 CA243036-02				133,767	16,633,917	RESEARCH AND DEVELOPMENT	425,311,746
CANCER CAUSE AND PREVENTION RESEARCH	93.393	1 R01 CA247987-01A1				46,693	16,633,917	RESEARCH AND DEVELOPMENT	425,311,746
CANCER CAUSE AND PREVENTION RESEARCH	93.393	1 R01 CA249863-01A1				113,356	16,633,917	RESEARCH AND DEVELOPMENT	425,311,746
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5 UM1 CA173640-06				115,521	16,633,917	RESEARCH AND DEVELOPMENT	425,311,746
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5 UM1 CA182910-06				466,590	16,633,917	RESEARCH AND DEVELOPMENT	425,311,746
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5 U01 CA202979-05			48,947	2,449,431	16,633,917	RESEARCH AND DEVELOPMENT	425,311,746
CANCER CAUSE AND PREVENTION RESEARCH	93.393	1 U01 CA242740-01A1	ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY BAPTIST HOSPITAL SYSTEM DBA	1 U01 CA242740-01A1		27,951	16,633,917	RESEARCH AND DEVELOPMENT	425,311,746
CANCER CAUSE AND PREVENTION RESEARCH	93.393	2 R01 CA172253-08	BH1	2 R01 CA172253-08		14,231	16,633,917	RESEARCH AND DEVELOPMENT	425,311,746
CANCER CAUSE AND PREVENTION RESEARCH	93.393	1 UG3 CA243120-01	BOSTON CHILDREN'S HOSPITAL	1 UG3 CA243120-01		14,572	16,633,917	RESEARCH AND DEVELOPMENT	425,311,746
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5 UG3 CA243120-02	BOSTON CHILDREN'S HOSPITAL	5 UG3 CA243120-02		18,954	16,633,917	RESEARCH AND DEVELOPMENT	425,311,746
CANCER CAUSE AND PREVENTION RESEARCH	93.393	1 U24 CA248010-01A1	BOSTON CHILDREN'S HOSPITAL	1 U24 CA248010-01A1		68,252	16,633,917	RESEARCH AND DEVELOPMENT	425,311,746
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5 U01 CA187508-04	BOSTON MEDICAL CENTER	5 U01 CA187508-04		2,691	16,633,917	RESEARCH AND DEVELOPMENT	425,311,746
CANCER CAUSE AND PREVENTION RESEARCH	93.393	1 U01 CA250476-01A1	BRIGHAM AND WOMEN'S HOSPITAL	1 U01 CA250476-01A1		14,421	16,633,917	RESEARCH AND DEVELOPMENT	425,311,746
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5 R01 CA220581-03	CASE WESTERN RESERVE UNIVERSITY	5 R01 CA220581-03		19,405	16,633,917	RESEARCH AND DEVELOPMENT	425,311,746
CANCER CAUSE AND PREVENTION RESEARCH	93.393	2 R01 CA157823-07A1	INDIANA UNIVERSITY	2 R01 CA157823-07A1		80,458	16,633,917	RESEARCH AND DEVELOPMENT	425,311,746
CANCER CAUSE AND PREVENTION RESEARCH	93.393	7 U19 CA203654-04	INTERNATIONAL AGENCY FOR RESEARCH ON CANCER (FRANCE)	7 U19 CA203654-04		58,220	16,633,917	RESEARCH AND DEVELOPMENT	425,311,746
CANCER CAUSE AND PREVENTION RESEARCH	93.393	7 U19 CA203654-04	INTERNATIONAL AGENCY FOR RESEARCH ON CANCER (FRANCE)	7 U19 CA203654-04		57,416	16,633,917	RESEARCH AND DEVELOPMENT	425,311,746
CANCER CAUSE AND PREVENTION RESEARCH	93.393	1 U01 CA247283-01	JOHNS HOPKINS UNIVERSITY MEDICAL UNIVERSITY OF SOUTH CAROLINA	1 U01 CA247283-01		80,781	16,633,917	RESEARCH AND DEVELOPMENT	425,311,746
CANCER CAUSE AND PREVENTION RESEARCH	93.393	7 R01 CA226086-03	MEMORIAL SLOAN-KETTERING CANCER CENTER	7 R01 CA226086-03		34,040	16,633,917	RESEARCH AND DEVELOPMENT	425,311,746
CANCER CAUSE AND PREVENTION RESEARCH	93.393	4 R00 CA230205-03	CANCER CENTER	4 R00 CA230205-03		36,722	16,633,917	RESEARCH AND DEVELOPMENT	425,311,746
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5 R01 CA204113-05	NEW YORK UNIVERSITY	5 R01 CA204113-05		107,637	16,633,917	RESEARCH AND DEVELOPMENT	425,311,746
CANCER CAUSE AND PREVENTION RESEARCH	93.393	HHSN261201200035I	NORTHWESTERN UNIVERSITY	HHSN261201200035I		23,523	16,633,917	RESEARCH AND DEVELOPMENT	425,311,746
CANCER CAUSE AND PREVENTION RESEARCH	93.393	HHSN261201200035I	NORTHWESTERN UNIVERSITY	HHSN261201200035I		165,202	16,633,917	RESEARCH AND DEVELOPMENT	425,311,746
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5 R01 CA228156-03	ROSWELL PARK CANCER INSTITUTE	5 R01 CA228156-03		283,298	16,633,917	RESEARCH AND DEVELOPMENT	425,311,746
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5 R01 CA215520-02	THOMAS JEFFERSON UNIVERSITY	5 R01 CA215520-02		19,251	16,633,917	RESEARCH AND DEVELOPMENT	425,311,746
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5 R01 CA192156-05	UNIVERSITY OF CALIFORNIA AT SAN FRANCISCO	5 R01 CA192156-05		2,974	16,633,917	RESEARCH AND DEVELOPMENT	425,311,746

**VANDERBILT UNIVERSITY MEDICAL CENTER**  
**SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS (CONTINUED)**  
 Fiscal Period 7/1/2020 – 6/30/2021

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5 R01 CA197422-05	UNIVERSITY OF CALIFORNIA, SYSTEMWIDE	5 R01 CA197422-05	\$ -	\$ 12,413	\$ 16,633,917	RESEARCH AND DEVELOPMENT	\$ 425,311,746
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5 P01 CA138336-10	UNIVERSITY OF HAWAII	5 P01 CA138336-10		6,067	16,633,917	RESEARCH AND DEVELOPMENT	425,311,746
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5 R01 CA207401-04	UNIVERSITY OF KENTUCKY	5 R01 CA207401-04		137,460	16,633,917	RESEARCH AND DEVELOPMENT	425,311,746
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5 P01 CA138338-07	UNIVERSITY OF SOUTHERN CALIFORNIA	5 P01 CA138338-07		2,245	16,633,917	RESEARCH AND DEVELOPMENT	425,311,746
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5 R01 CA209798-03	UNIVERSITY OF SOUTHERN CALIFORNIA	5 R01 CA209798-03		(948)	16,633,917	RESEARCH AND DEVELOPMENT	425,311,746
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5 R01 CA209798-04	UNIVERSITY OF SOUTHERN CALIFORNIA	5 R01 CA209798-04		35,535	16,633,917	RESEARCH AND DEVELOPMENT	425,311,746
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5 R00 CA207848-05	UNIVERSITY OF WISCONSIN	5 R00 CA207848-05		71,008	16,633,917	RESEARCH AND DEVELOPMENT	425,311,746
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5 R01 CA164605-08	VANDERBILT UNIVERSITY	5 R01 CA164605-08		31,710	16,633,917	RESEARCH AND DEVELOPMENT	425,311,746
CANCER CAUSE AND PREVENTION RESEARCH	93.393	1 R01 CA200709-01	VANDERBILT UNIVERSITY	1 R01 CA200709-01		43,067	16,633,917	RESEARCH AND DEVELOPMENT	425,311,746
CANCER CAUSE AND PREVENTION RESEARCH	93.393	1 R01 CA247833-01	VANDERBILT UNIVERSITY	1 R01 CA247833-01		93,254	16,633,917	RESEARCH AND DEVELOPMENT	425,311,746
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5 U01 CA224276-02	VANDERBILT UNIVERSITY	5 U01 CA224276-02		35,747	16,633,917	RESEARCH AND DEVELOPMENT	425,311,746
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5 U01 CA224276-03	VANDERBILT UNIVERSITY	5 U01 CA224276-03		107,129	16,633,917	RESEARCH AND DEVELOPMENT	425,311,746
CANCER CAUSE AND PREVENTION RESEARCH	93.393	1 R37 CA246175-01A1	WASHINGTON UNIVERSITY IN ST. LOUIS	1 R37 CA246175-01A1		19,404	16,633,917	RESEARCH AND DEVELOPMENT	425,311,746
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5 R01 CA207401-04				(2,764)	16,633,917	RESEARCH AND DEVELOPMENT	425,311,746
CANCER CAUSE AND PREVENTION RESEARCH	93.393	COVID-19 5 U01 CA202979-05S1				148,381	16,633,917	RESEARCH AND DEVELOPMENT	425,311,746
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5 R01 CA109106-15				237,633	4,628,119	RESEARCH AND DEVELOPMENT	425,311,746
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5 R01 CA184693-06			2,447	131,970	4,628,119	RESEARCH AND DEVELOPMENT	425,311,746
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	7 R01 CA194024-05			166,025	303,514	4,628,119	RESEARCH AND DEVELOPMENT	425,311,746
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5 R01 CA214494-03				133,110	4,628,119	RESEARCH AND DEVELOPMENT	425,311,746
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5 R01 CA227133-03			48,956	557,155	4,628,119	RESEARCH AND DEVELOPMENT	425,311,746
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	1 R01 CA250506-01				247,267	4,628,119	RESEARCH AND DEVELOPMENT	425,311,746
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	1 R21 CA252629-01A1				12,644	4,628,119	RESEARCH AND DEVELOPMENT	425,311,746
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	1 R01 CA253923-01				147,578	4,628,119	RESEARCH AND DEVELOPMENT	425,311,746
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5 U01 CA152662-09				5,155	4,628,119	RESEARCH AND DEVELOPMENT	425,311,746
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5 U01 CA152662-10			25,459	691,946	4,628,119	RESEARCH AND DEVELOPMENT	425,311,746
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5 U01 CA182364-06			15,724	19,868	4,628,119	RESEARCH AND DEVELOPMENT	425,311,746
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	2 UM1 CA183727-07				(1,682)	4,628,119	RESEARCH AND DEVELOPMENT	425,311,746
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5 UM1 CA183727-08				738,443	4,628,119	RESEARCH AND DEVELOPMENT	425,311,746
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5 UM1 CA183727-09				265,788	4,628,119	RESEARCH AND DEVELOPMENT	425,311,746
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5 U01 CA186145-06			68,988	136,987	4,628,119	RESEARCH AND DEVELOPMENT	425,311,746
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5 U24 CA220325-02			27,610	105,045	4,628,119	RESEARCH AND DEVELOPMENT	425,311,746
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5 U01 CA231840-02			160,607	198,627	4,628,119	RESEARCH AND DEVELOPMENT	425,311,746
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5 U01 CA231840-03			63,424	176,040	4,628,119	RESEARCH AND DEVELOPMENT	425,311,746
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5 U01 CA214182-03	BOSTON UNIVERSITY	5 U01 CA214182-03		1,349	4,628,119	RESEARCH AND DEVELOPMENT	425,311,746
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5 U01 CA214182-04	BOSTON UNIVERSITY	5 U01 CA214182-04		29,641	4,628,119	RESEARCH AND DEVELOPMENT	425,311,746
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5 R01 CA218526-03	CEDARS-SINAI MEDICAL CENTER	5 R01 CA218526-03		71	4,628,119	RESEARCH AND DEVELOPMENT	425,311,746
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5 R01 CA218526-04	CEDARS-SINAI MEDICAL CENTER	5 R01 CA218526-04		32,365	4,628,119	RESEARCH AND DEVELOPMENT	425,311,746
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5 R01 CA193478-04	CHILDREN'S HOSPITAL OF PHILADELPHIA	5 R01 CA193478-04		2,826	4,628,119	RESEARCH AND DEVELOPMENT	425,311,746
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5 U24 CA086368-20	FRED HUTCHINSON CANCER RESEARCH CENTER	5 U24 CA086368-20	25,120	69,958	4,628,119	RESEARCH AND DEVELOPMENT	425,311,746
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5 U24 CA0866368-19	FRED HUTCHINSON CANCER RESEARCH CENTER	5 U24 CA0866368-19	907	907	4,628,119	RESEARCH AND DEVELOPMENT	425,311,746
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	4 R44 CA228897-02	FRONTIER DIAGNOSTICS, LLC	4 R44 CA228897-02		10,408	4,628,119	RESEARCH AND DEVELOPMENT	425,311,746
COVID-19 CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	COVID-19 1 U54 CA260560-01	MOUNT SINAI SCHOOL OF MEDICINE	1 U54 CA260560-01		117,755	4,628,119	RESEARCH AND DEVELOPMENT	425,311,746
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	2 R01 CA159036-05A1	NEW YORK UNIVERSITY	2 R01 CA159036-05A1		16,672	4,628,119	RESEARCH AND DEVELOPMENT	425,311,746
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	1 UG3 CA232820-01A1	UNIVERSITY OF ALABAMA AT BIRMINGHAM	1 UG3 CA232820-01A1		8,931	4,628,119	RESEARCH AND DEVELOPMENT	425,311,746
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5 UG3 CA232820-02	UNIVERSITY OF ALABAMA AT BIRMINGHAM	5 UG3 CA232820-02		49,693	4,628,119	RESEARCH AND DEVELOPMENT	425,311,746
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	1 R01 CA227466-01	UNIVERSITY OF CALIFORNIA AT SAN FRANCISCO	1 R01 CA227466-01		(21)	4,628,119	RESEARCH AND DEVELOPMENT	425,311,746
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5 R01 CA227466-03	UNIVERSITY OF CALIFORNIA AT SAN FRANCISCO	5 R01 CA227466-03		59,087	4,628,119	RESEARCH AND DEVELOPMENT	425,311,746

**VANDERBILT UNIVERSITY MEDICAL CENTER**  
**SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS (CONTINUED)**  
Fiscal Period 7/1/2020 – 6/30/2021

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	1 R01 CA200987-03	UNIVERSITY OF MIAMI	1 R01 CA200987-03	\$ -	\$ (1,940)	\$ 4,628,119	RESEARCH AND DEVELOPMENT	\$ 425,311,746
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5 R01 CA200987-05	UNIVERSITY OF MIAMI	5 R01 CA200987-05		89,381	4,628,119	RESEARCH AND DEVELOPMENT	425,311,746
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5 U24 CA086368-18	UNIVERSITY OF MICHIGAN	5 U24 CA086368-18		3,644	4,628,119	RESEARCH AND DEVELOPMENT	425,311,746
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	1 R01 CA212147-01A1	VANDERBILT UNIVERSITY	1 R01 CA212147-01A1		21,900	4,628,119	RESEARCH AND DEVELOPMENT	425,311,746
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	1 R01 CA245134-01A1	VANDERBILT UNIVERSITY	1 R01 CA245134-01A1		14,069	4,628,119	RESEARCH AND DEVELOPMENT	425,311,746
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5 U24 CA0866368-19				(5,665)	4,628,119	RESEARCH AND DEVELOPMENT	425,311,746
CANCER TREATMENT RESEARCH	93.395	5 R01 CA213201-03			116,453	281,373	3,056,259	RESEARCH AND DEVELOPMENT	425,311,746
CANCER TREATMENT RESEARCH	93.395	5 R21 CA226562-02			9,423	173,067	3,056,259	RESEARCH AND DEVELOPMENT	425,311,746
CANCER TREATMENT RESEARCH	93.395	5 R01 CA227481-03			49,932	391,796	3,056,259	RESEARCH AND DEVELOPMENT	425,311,746
CANCER TREATMENT RESEARCH	93.395	1 R01 CA248505-01A1				36,743	3,056,259	RESEARCH AND DEVELOPMENT	425,311,746
CANCER TREATMENT RESEARCH	93.395	1 R03 CA252807-01				47,834	3,056,259	RESEARCH AND DEVELOPMENT	425,311,746
CANCER TREATMENT RESEARCH	93.395	5 UG1 CA233270-02				330,623	3,056,259	RESEARCH AND DEVELOPMENT	425,311,746
CANCER TREATMENT RESEARCH	93.395	5 UG1 CA233270-03				108,880	3,056,259	RESEARCH AND DEVELOPMENT	425,311,746
CANCER TREATMENT RESEARCH	93.395	1 U01 CA253560-01			154,469	553,538	3,056,259	RESEARCH AND DEVELOPMENT	425,311,746
CANCER TREATMENT RESEARCH	93.395	5 U01 CA253560-02				128,771	3,056,259	RESEARCH AND DEVELOPMENT	425,311,746
CANCER TREATMENT RESEARCH	93.395	5 R01 CA181050-02	CHILDREN'S HOSPITAL LOS ANGELES	5 R01 CA181050-02		(4,047)	3,056,259	RESEARCH AND DEVELOPMENT	425,311,746
CANCER TREATMENT RESEARCH	93.395	5 R01 CA196854-04	CHILDREN'S HOSPITAL OF PHILADELPHIA	5 R01 CA196854-04		300	3,056,259	RESEARCH AND DEVELOPMENT	425,311,746
CANCER TREATMENT RESEARCH	93.395	5 R01 CA201788-04	CHILDREN'S HOSPITAL OF PHILADELPHIA	5 R01 CA201788-04		327	3,056,259	RESEARCH AND DEVELOPMENT	425,311,746
CANCER TREATMENT RESEARCH	93.395	2 U10 CA180886-06	CHILDREN'S HOSPITAL OF PHILADELPHIA	2 U10 CA180886-06		127,310	3,056,259	RESEARCH AND DEVELOPMENT	425,311,746
CANCER TREATMENT RESEARCH	93.395	2 U10 CA180886-06	CHILDREN'S HOSPITAL OF PHILADELPHIA	2 U10 CA180886-06		17,810	3,056,259	RESEARCH AND DEVELOPMENT	425,311,746
CANCER TREATMENT RESEARCH	93.395	2 U10 CA180886-07	CHILDREN'S HOSPITAL OF PHILADELPHIA	2 U10 CA180886-07		13,339	3,056,259	RESEARCH AND DEVELOPMENT	425,311,746
CANCER TREATMENT RESEARCH	93.395	5 U10 CA180886-07	CHILDREN'S HOSPITAL OF PHILADELPHIA	5 U10 CA180886-07		12,228	3,056,259	RESEARCH AND DEVELOPMENT	425,311,746
CANCER TREATMENT RESEARCH	93.395	5 U10 CA180886-07	CHILDREN'S HOSPITAL OF PHILADELPHIA	5 U10 CA180886-07		12,164	3,056,259	RESEARCH AND DEVELOPMENT	425,311,746
CANCER TREATMENT RESEARCH	93.395	9 R44 CA228756-02	CUMBERLAND PHARMACEUTICALS, INC.	9 R44 CA228756-02		94,518	3,056,259	RESEARCH AND DEVELOPMENT	425,311,746
CANCER TREATMENT RESEARCH	93.395	ECOG/NCTN: BRE R1304	EASTERN COOPERATIVE ONCOLOGY GROUP	ECOG/NCTN: BRE R1304		(97)	3,056,259	RESEARCH AND DEVELOPMENT	425,311,746
CANCER TREATMENT RESEARCH	93.395	ECOG/NCTN: BRE EA1141	EASTERN COOPERATIVE ONCOLOGY GROUP	ECOG/NCTN: BRE EA1141		(8,078)	3,056,259	RESEARCH AND DEVELOPMENT	425,311,746
CANCER TREATMENT RESEARCH	93.395	ECOG/NCTN: BRE S1418	EASTERN COOPERATIVE ONCOLOGY GROUP	ECOG/NCTN: BRE S1418		(2,638)	3,056,259	RESEARCH AND DEVELOPMENT	425,311,746
CANCER TREATMENT RESEARCH	93.395	ECOG/NCTN GI A021501	EASTERN COOPERATIVE ONCOLOGY GROUP	ECOG/NCTN GI A021501		(522)	3,056,259	RESEARCH AND DEVELOPMENT	425,311,746
CANCER TREATMENT RESEARCH	93.395	ECOG/NCTN NEU A221208	EASTERN COOPERATIVE ONCOLOGY GROUP	ECOG/NCTN NEU A221208		(5,858)	3,056,259	RESEARCH AND DEVELOPMENT	425,311,746
CANCER TREATMENT RESEARCH	93.395	ECOG/NCTN NRG NEUR0631	EASTERN COOPERATIVE ONCOLOGY GROUP	ECOG/NCTN NRG NEUR0631		(936)	3,056,259	RESEARCH AND DEVELOPMENT	425,311,746
CANCER TREATMENT RESEARCH	93.395	ECOG/NCTN: NRG-GI002	EASTERN COOPERATIVE ONCOLOGY GROUP	ECOG/NCTN: NRG-GI002		(16,208)	3,056,259	RESEARCH AND DEVELOPMENT	425,311,746
CANCER TREATMENT RESEARCH	93.395	ECOG/NCTN: THO EA5142	EASTERN COOPERATIVE ONCOLOGY GROUP	ECOG/NCTN: THO EA5142		(5,329)	3,056,259	RESEARCH AND DEVELOPMENT	425,311,746
CANCER TREATMENT RESEARCH	93.395	ECOG/NCTN: BRE EA1131	EASTERN COOPERATIVE ONCOLOGY GROUP	ECOG/NCTN: BRE EA1131		(1,911)	3,056,259	RESEARCH AND DEVELOPMENT	425,311,746
CANCER TREATMENT RESEARCH	93.395	ECOG/NCTN: GI S1505	EASTERN COOPERATIVE ONCOLOGY GROUP	ECOG/NCTN: GI S1505		(716)	3,056,259	RESEARCH AND DEVELOPMENT	425,311,746
CANCER TREATMENT RESEARCH	93.395	ECOG/NCTN: THO S1403	EASTERN COOPERATIVE ONCOLOGY GROUP	ECOG/NCTN: THO S1403		(11,000)	3,056,259	RESEARCH AND DEVELOPMENT	425,311,746
CANCER TREATMENT RESEARCH	93.395	ECOG/NCTN: URO EA8141	EASTERN COOPERATIVE ONCOLOGY GROUP	ECOG/NCTN: URO EA8141		(2,579)	3,056,259	RESEARCH AND DEVELOPMENT	425,311,746
CANCER TREATMENT RESEARCH	93.395	ECOG/NCTN: BRE E4112	EASTERN COOPERATIVE ONCOLOGY GROUP	ECOG/NCTN: BRE E4112		(4,273)	3,056,259	RESEARCH AND DEVELOPMENT	425,311,746

**VANDERBILT UNIVERSITY MEDICAL CENTER**  
**SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS (CONTINUED)**  
Fiscal Period 7/1/2020 – 6/30/2021

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
CANCER TREATMENT RESEARCH	93.395	ECOG/NCTN:GI EA2131	EASTERN COOPERATIVE ONCOLOGY GROUP	ECOG/NCTN:GI EA2131	\$ -	\$ (3,736)	\$ 3,056,259	RESEARCH AND DEVELOPMENT	\$ 425,311,746
CANCER TREATMENT RESEARCH	93.395	ECOG/NCTN:GI S1513	EASTERN COOPERATIVE ONCOLOGY GROUP	ECOG/NCTN:GI S1513		2,342	3,056,259	RESEARCH AND DEVELOPMENT	425,311,746
CANCER TREATMENT RESEARCH	93.395	ECOG/NCTN:GYN GY005	EASTERN COOPERATIVE ONCOLOGY GROUP	ECOG/NCTN:GYN GY005		(15,433)	3,056,259	RESEARCH AND DEVELOPMENT	425,311,746
CANCER TREATMENT RESEARCH	93.395	ECOG/NCTN:HEM E4412	EASTERN COOPERATIVE ONCOLOGY GROUP	ECOG/NCTN:HEM E4412		(15,486)	3,056,259	RESEARCH AND DEVELOPMENT	425,311,746
CANCER TREATMENT RESEARCH	93.395	ECOG/NCTN:MD EAY131	EASTERN COOPERATIVE ONCOLOGY GROUP	ECOG/NCTN:MD EAY131		(42,420)	3,056,259	RESEARCH AND DEVELOPMENT	425,311,746
CANCER TREATMENT RESEARCH	93.395	ECOG/NCTN:MEL EA6141	EASTERN COOPERATIVE ONCOLOGY GROUP	ECOG/NCTN:MEL EA6141		(13,072)	3,056,259	RESEARCH AND DEVELOPMENT	425,311,746
CANCER TREATMENT RESEARCH	93.395	ECOG/NCTN:MEL S1404	EASTERN COOPERATIVE ONCOLOGY GROUP	ECOG/NCTN:MEL S1404		(35,215)	3,056,259	RESEARCH AND DEVELOPMENT	425,311,746
CANCER TREATMENT RESEARCH	93.395	ECOG/NCTN:NEU A071102	EASTERN COOPERATIVE ONCOLOGY GROUP	ECOG/NCTN:NEU A071102		(387)	3,056,259	RESEARCH AND DEVELOPMENT	425,311,746
CANCER TREATMENT RESEARCH	93.395	ECOG/NCTN:THO E4512	EASTERN COOPERATIVE ONCOLOGY GROUP	ECOG/NCTN:THO E4512		(9,460)	3,056,259	RESEARCH AND DEVELOPMENT	425,311,746
CANCER TREATMENT RESEARCH	93.395	ECOG/NCTN:THO A081105	EASTERN COOPERATIVE ONCOLOGY GROUP	ECOG/NCTN:THO A081105		(5,516)	3,056,259	RESEARCH AND DEVELOPMENT	425,311,746
CANCER TREATMENT RESEARCH	93.395	ECOG/NCTN:URO EA8143	EASTERN COOPERATIVE ONCOLOGY GROUP	ECOG/NCTN:URO EA8143		(2,903)	3,056,259	RESEARCH AND DEVELOPMENT	425,311,746
CANCER TREATMENT RESEARCH	93.395	ECOG/NCTN:URO S1314	EASTERN COOPERATIVE ONCOLOGY GROUP	ECOG/NCTN:URO S1314		(2,577)	3,056,259	RESEARCH AND DEVELOPMENT	425,311,746
CANCER TREATMENT RESEARCH	93.395	ECOG: BRE S1007	EASTERN COOPERATIVE ONCOLOGY GROUP	ECOG: BRE S1007		315	3,056,259	RESEARCH AND DEVELOPMENT	425,311,746
CANCER TREATMENT RESEARCH	93.395	ECOG/NCTN:MEL E1697	EASTERN COOPERATIVE ONCOLOGY GROUP	ECOG/NCTN:MEL E1697		(10)	3,056,259	RESEARCH AND DEVELOPMENT	425,311,746
CANCER TREATMENT RESEARCH	93.395	ECOG/NCTN:URO S0931	EASTERN COOPERATIVE ONCOLOGY GROUP	ECOG/NCTN:URO S0931		(8,446)	3,056,259	RESEARCH AND DEVELOPMENT	425,311,746
CANCER TREATMENT RESEARCH	93.395	5 U10 CA180820-05	EASTERN COOPERATIVE ONCOLOGY GROUP	5 U10 CA180820-05		(15,162)	3,056,259	RESEARCH AND DEVELOPMENT	425,311,746
CANCER TREATMENT RESEARCH	93.395	5 U10 CA018082-05	EASTERN COOPERATIVE ONCOLOGY GROUP	5 U10 CA018082-05		(2,757)	3,056,259	RESEARCH AND DEVELOPMENT	425,311,746
CANCER TREATMENT RESEARCH	93.395	ECOGRADN107C	EASTERN COOPERATIVE ONCOLOGY GROUP	ECOGRADN107C		(924)	3,056,259	RESEARCH AND DEVELOPMENT	425,311,746
CANCER TREATMENT RESEARCH	93.395	ECOG/NCTN:HEM EAI141	EASTERN COOPERATIVE ONCOLOGY GROUP	ECOG/NCTN:HEM EAI141		(60,317)	3,056,259	RESEARCH AND DEVELOPMENT	425,311,746
CANCER TREATMENT RESEARCH	93.395	5 U10 CA180820-05	EASTERN COOPERATIVE ONCOLOGY GROUP	5 U10 CA180820-05		(2,301)	3,056,259	RESEARCH AND DEVELOPMENT	425,311,746
CANCER TREATMENT RESEARCH	93.395	5 U10 CA180820-05	EASTERN COOPERATIVE ONCOLOGY GROUP	5 U10 CA180820-05		(5,557)	3,056,259	RESEARCH AND DEVELOPMENT	425,311,746
CANCER TREATMENT RESEARCH	93.395	5 U10 CA180820-05	EASTERN COOPERATIVE ONCOLOGY GROUP	5 U10 CA180820-05		(12,992)	3,056,259	RESEARCH AND DEVELOPMENT	425,311,746
CANCER TREATMENT RESEARCH	93.395	5 U10 CA180820-05	EASTERN COOPERATIVE ONCOLOGY GROUP	5 U10 CA180820-05		(13,863)	3,056,259	RESEARCH AND DEVELOPMENT	425,311,746
CANCER TREATMENT RESEARCH	93.395	5 U10 CA180820-05	EASTERN COOPERATIVE ONCOLOGY GROUP	5 U10 CA180820-05		(7,291)	3,056,259	RESEARCH AND DEVELOPMENT	425,311,746
CANCER TREATMENT RESEARCH	93.395	5 U10 CA180820-05	EASTERN COOPERATIVE ONCOLOGY GROUP	5 U10 CA180820-05		(278)	3,056,259	RESEARCH AND DEVELOPMENT	425,311,746
CANCER TREATMENT RESEARCH	93.395	5 U10 CA180820-05	EASTERN COOPERATIVE ONCOLOGY GROUP	5 U10 CA180820-05		(5,141)	3,056,259	RESEARCH AND DEVELOPMENT	425,311,746
CANCER TREATMENT RESEARCH	93.395	5 U10 CA180820-05	EASTERN COOPERATIVE ONCOLOGY GROUP	5 U10 CA180820-05		(13,295)	3,056,259	RESEARCH AND DEVELOPMENT	425,311,746
CANCER TREATMENT RESEARCH	93.395	5 U10 CA180820-05	EASTERN COOPERATIVE ONCOLOGY GROUP	5 U10 CA180820-05		(16,625)	3,056,259	RESEARCH AND DEVELOPMENT	425,311,746
CANCER TREATMENT RESEARCH	93.395	5 U10 CA180820-05	EASTERN COOPERATIVE ONCOLOGY GROUP	5 U10 CA180820-05		(7,242)	3,056,259	RESEARCH AND DEVELOPMENT	425,311,746
CANCER TREATMENT RESEARCH	93.395	5 U10 CA180820-05	EASTERN COOPERATIVE ONCOLOGY GROUP	5 U10 CA180820-05		(1,226)	3,056,259	RESEARCH AND DEVELOPMENT	425,311,746

**VANDERBILT UNIVERSITY MEDICAL CENTER**  
**SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS (CONTINUED)**  
Fiscal Period 7/1/2020 – 6/30/2021

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
CANCER TREATMENT RESEARCH	93.395	5 U10 CA180820-07	EASTERN COOPERATIVE ONCOLOGY GROUP	5 U10 CA180820-07	\$ -	\$ 17,269	\$ 3,056,259	RESEARCH AND DEVELOPMENT	\$ 425,311,746
CANCER TREATMENT RESEARCH	93.395	2 U10 CA180820-07	EASTERN COOPERATIVE ONCOLOGY GROUP	2 U10 CA180820-07		12,116	3,056,259	RESEARCH AND DEVELOPMENT	425,311,746
CANCER TREATMENT RESEARCH	93.395	2 U10 CA180820-08	EASTERN COOPERATIVE ONCOLOGY GROUP	2 U10 CA180820-08		6,618	3,056,259	RESEARCH AND DEVELOPMENT	425,311,746
CANCER TREATMENT RESEARCH	93.395	5 U10 CA180820-08	EASTERN COOPERATIVE ONCOLOGY GROUP	5 U10 CA180820-08		6,475	3,056,259	RESEARCH AND DEVELOPMENT	425,311,746
CANCER TREATMENT RESEARCH	93.395	2 U10 CA180886-07	EASTERN COOPERATIVE ONCOLOGY GROUP	2 U10 CA180886-07		14,324	3,056,259	RESEARCH AND DEVELOPMENT	425,311,746
CANCER TREATMENT RESEARCH	93.395	2 UG1 CA189828-06	EASTERN COOPERATIVE ONCOLOGY GROUP	2 UG1 CA189828-06		4,458	3,056,259	RESEARCH AND DEVELOPMENT	425,311,746
CANCER TREATMENT RESEARCH	93.395	2 UG1 CA189828-06	EASTERN COOPERATIVE ONCOLOGY GROUP	2 UG1 CA189828-06		4,425	3,056,259	RESEARCH AND DEVELOPMENT	425,311,746
CANCER TREATMENT RESEARCH	93.395	2 UG1 CA189828-06	EASTERN COOPERATIVE ONCOLOGY GROUP	2 UG1 CA189828-06		9,460	3,056,259	RESEARCH AND DEVELOPMENT	425,311,746
CANCER TREATMENT RESEARCH	93.395	2 UG1 CA189828-06	EASTERN COOPERATIVE ONCOLOGY GROUP	2 UG1 CA189828-06		547	3,056,259	RESEARCH AND DEVELOPMENT	425,311,746
CANCER TREATMENT RESEARCH	93.395	2 UG1 CA189828-06	EASTERN COOPERATIVE ONCOLOGY GROUP	2 UG1 CA189828-06		703	3,056,259	RESEARCH AND DEVELOPMENT	425,311,746
CANCER TREATMENT RESEARCH	93.395	2 UG1 CA189828-06	EASTERN COOPERATIVE ONCOLOGY GROUP	2 UG1 CA189828-06		2,671	3,056,259	RESEARCH AND DEVELOPMENT	425,311,746
CANCER TREATMENT RESEARCH	93.395	ECOG/NCTN:URO R0924	EASTERN COOPERATIVE ONCOLOGY GROUP	ECOG/NCTN:URO R0924		(1,180)	3,056,259	RESEARCH AND DEVELOPMENT	425,311,746
CANCER TREATMENT RESEARCH	93.395	5 U10 CA180820-05	EASTERN COOPERATIVE ONCOLOGY GROUP	5 U10 CA180820-05		4,774	3,056,259	RESEARCH AND DEVELOPMENT	425,311,746
CANCER TREATMENT RESEARCH	93.395	1 UG1 CA233259-01	EMORY UNIVERSITY	1 UG1 CA233259-01		(35)	3,056,259	RESEARCH AND DEVELOPMENT	425,311,746
CANCER TREATMENT RESEARCH	93.395	5 UG1 CA233259-02	EMORY UNIVERSITY	5 UG1 CA233259-02		71,179	3,056,259	RESEARCH AND DEVELOPMENT	425,311,746
CANCER TREATMENT RESEARCH	93.395	5 UG1 CA233259-03	EMORY UNIVERSITY	5 UG1 CA233259-03		23,609	3,056,259	RESEARCH AND DEVELOPMENT	425,311,746
CANCER TREATMENT RESEARCH	93.395	2 R01 CA118953-11	FRED HUTCHINSON CANCER RESEARCH CENTER	2 R01 CA118953-11		8,830	3,056,259	RESEARCH AND DEVELOPMENT	425,311,746
CANCER TREATMENT RESEARCH	93.395	5 U01 CA236229-02	FRED HUTCHINSON CANCER RESEARCH CENTER	5 U01 CA236229-02		10,339	3,056,259	RESEARCH AND DEVELOPMENT	425,311,746
CANCER TREATMENT RESEARCH	93.395	1 U01 CA253166-01	FRED HUTCHINSON CANCER RESEARCH CENTER	1 U01 CA253166-01		35,717	3,056,259	RESEARCH AND DEVELOPMENT	425,311,746
CANCER TREATMENT RESEARCH	93.395	5 P01 CA129243-12	MEMORIAL SLOAN-KETTERING CANCER CENTER	5 P01 CA129243-12		13,068	3,056,259	RESEARCH AND DEVELOPMENT	425,311,746
CANCER TREATMENT RESEARCH	93.395	5 P01 CA129243-13	MEMORIAL SLOAN-KETTERING CANCER CENTER	5 P01 CA129243-13		115,471	3,056,259	RESEARCH AND DEVELOPMENT	425,311,746
CANCER TREATMENT RESEARCH	93.395	5 U10 CA180868-08	NRG ONCOLOGY FOUNDATION	5 U10 CA180868-08		9,548	3,056,259	RESEARCH AND DEVELOPMENT	425,311,746
CANCER TREATMENT RESEARCH	93.395	2 UG1 CA189867-06	NRG ONCOLOGY FOUNDATION	2 UG1 CA189867-06		2,853	3,056,259	RESEARCH AND DEVELOPMENT	425,311,746
CANCER TREATMENT RESEARCH	93.395	5 U10 CA180888-07	SOUTHWEST ONCOLOGY GROUP	5 U10 CA180888-07		18,269	3,056,259	RESEARCH AND DEVELOPMENT	425,311,746
CANCER TREATMENT RESEARCH	93.395	5 U10 CA180888-08	SOUTHWEST ONCOLOGY GROUP	5 U10 CA180888-08		6,363	3,056,259	RESEARCH AND DEVELOPMENT	425,311,746
CANCER TREATMENT RESEARCH	93.395	4 R00 CA218892-02	UNIVERSITY OF HAWAII	4 R00 CA218892-02		17,050	3,056,259	RESEARCH AND DEVELOPMENT	425,311,746
CANCER TREATMENT RESEARCH	93.395	5 R01 CA218892-02	UNIVERSITY OF HAWAII	5 R01 CA218892-02		15,343	3,056,259	RESEARCH AND DEVELOPMENT	425,311,746
CANCER TREATMENT RESEARCH	93.395	5 R01 CA243511-03	UNIVERSITY OF WASHINGTON	5 R01 CA243511-03		37,575	3,056,259	RESEARCH AND DEVELOPMENT	425,311,746
CANCER TREATMENT RESEARCH	93.395	2 R01 CA116021-17	VANDERBILT UNIVERSITY	2 R01 CA116021-17		51,988	3,056,259	RESEARCH AND DEVELOPMENT	425,311,746
CANCER TREATMENT RESEARCH	93.395	5 R01 CA214043-05	VANDERBILT UNIVERSITY	5 R01 CA214043-05		51,417	3,056,259	RESEARCH AND DEVELOPMENT	425,311,746
CANCER TREATMENT RESEARCH	93.395	1 R01 CA224241-01A1	VANDERBILT UNIVERSITY	1 R01 CA224241-01A1		147,575	3,056,259	RESEARCH AND DEVELOPMENT	425,311,746
CANCER TREATMENT RESEARCH	93.395	1 R01 CA243326-01A1	VANDERBILT UNIVERSITY	1 R01 CA243326-01A1		48,637	3,056,259	RESEARCH AND DEVELOPMENT	425,311,746
CANCER TREATMENT RESEARCH	93.395	5 UM1 CA186689-05	YALE UNIVERSITY	5 UM1 CA186689-05		7,124	3,056,259	RESEARCH AND DEVELOPMENT	425,311,746
CANCER TREATMENT RESEARCH	93.395	2 UM1 CA186689-06	YALE UNIVERSITY	2 UM1 CA186689-06		263,487	3,056,259	RESEARCH AND DEVELOPMENT	425,311,746
CANCER TREATMENT RESEARCH	93.395	2 UM1 CA186689-07	YALE UNIVERSITY	2 UM1 CA186689-07		68,738	3,056,259	RESEARCH AND DEVELOPMENT	425,311,746
CANCER BIOLOGY RESEARCH	93.396	5 R01 CA095004-15				153,056	7,504,900	RESEARCH AND DEVELOPMENT	425,311,746
CANCER BIOLOGY RESEARCH	93.396	5 R01 CA177681-06				(1,549)	7,504,900	RESEARCH AND DEVELOPMENT	425,311,746
CANCER BIOLOGY RESEARCH	93.396	5 R01 CA193219-07				259,962	7,504,900	RESEARCH AND DEVELOPMENT	425,311,746
CANCER BIOLOGY RESEARCH	93.396	5 R00 CA194198-04				16	7,504,900	RESEARCH AND DEVELOPMENT	425,311,746
CANCER BIOLOGY RESEARCH	93.396	5 R35 CA197570-03				1	7,504,900	RESEARCH AND DEVELOPMENT	425,311,746
CANCER BIOLOGY RESEARCH	93.396	5 R35 CA197570-04				651,596	7,504,900	RESEARCH AND DEVELOPMENT	425,311,746
CANCER BIOLOGY RESEARCH	93.396	5 R35 CA197570-05				253,837	7,504,900	RESEARCH AND DEVELOPMENT	425,311,746



**VANDERBILT UNIVERSITY MEDICAL CENTER**  
**SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS (CONTINUED)**  
Fiscal Period 7/1/2020 – 6/30/2021

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
CANCER BIOLOGY RESEARCH	93.396	5 R01 CA200681-05			\$ -	\$ 314,739	\$ 7,504,900	RESEARCH AND DEVELOPMENT	\$ 425,311,746
CANCER BIOLOGY RESEARCH	93.396	5 R01 CA211695-05				360,009	7,504,900	RESEARCH AND DEVELOPMENT	425,311,746
CANCER BIOLOGY RESEARCH	93.396	5 R01 CA217987-04			52,163	518,549	7,504,900	RESEARCH AND DEVELOPMENT	425,311,746
CANCER BIOLOGY RESEARCH	93.396	5 R01 CA222594-03				90,698	7,504,900	RESEARCH AND DEVELOPMENT	425,311,746
CANCER BIOLOGY RESEARCH	93.396	5 R01 CA227833-03			193,001	420,874	7,504,900	RESEARCH AND DEVELOPMENT	425,311,746
CANCER BIOLOGY RESEARCH	93.396	5 R01 CA235016-02			11,755	493,220	7,504,900	RESEARCH AND DEVELOPMENT	425,311,746
CANCER BIOLOGY RESEARCH	93.396	1 R37 CA244970-01A1				243,062	7,504,900	RESEARCH AND DEVELOPMENT	425,311,746
CANCER BIOLOGY RESEARCH	93.396	5 R01 CA249424-02			121,682	288,421	7,504,900	RESEARCH AND DEVELOPMENT	425,311,746
CANCER BIOLOGY RESEARCH	93.396	5 R01 CA250051-02				334,549	7,504,900	RESEARCH AND DEVELOPMENT	425,311,746
CANCER BIOLOGY RESEARCH	93.396	5 U24 CA163056-10				221,302	7,504,900	RESEARCH AND DEVELOPMENT	425,311,746
CANCER BIOLOGY RESEARCH	93.396	5 U24 CA163056-11				74,737	7,504,900	RESEARCH AND DEVELOPMENT	425,311,746
CANCER BIOLOGY RESEARCH	93.396	5 U01 CA196405-06			158,126	922,073	7,504,900	RESEARCH AND DEVELOPMENT	425,311,746
CANCER BIOLOGY RESEARCH	93.396	1 UG3 CA241685-01			64,256	74,180	7,504,900	RESEARCH AND DEVELOPMENT	425,311,746
CANCER BIOLOGY RESEARCH	93.396	5 UG3 CA241685-02			220,733	512,504	7,504,900	RESEARCH AND DEVELOPMENT	425,311,746
CANCER BIOLOGY RESEARCH	93.396	1 R01 CA234557-01A1	CEDARS-SINAI MEDICAL CENTER	1 R01 CA234557-01A1		(1,984)	7,504,900	RESEARCH AND DEVELOPMENT	425,311,746
CANCER BIOLOGY RESEARCH	93.396	HHSN261200800001E	LEIDOS BIOMEDICAL RESEARCH, INC.(FORMERLY SAIC-FREDERICK)	HHSN261200800001E		(720)	7,504,900	RESEARCH AND DEVELOPMENT	425,311,746
CANCER BIOLOGY RESEARCH	93.396	5 U24 CA213274-04	MEMORIAL SLOAN-KETTERING CANCER CENTER	5 U24 CA213274-04		31,661	7,504,900	RESEARCH AND DEVELOPMENT	425,311,746
CANCER BIOLOGY RESEARCH	93.396	5 U24 CA213274-04	MEMORIAL SLOAN-KETTERING CANCER CENTER	5 U24 CA213274-04		29,503	7,504,900	RESEARCH AND DEVELOPMENT	425,311,746
CANCER BIOLOGY RESEARCH	93.396	5 U24 CA213274-05	MEMORIAL SLOAN-KETTERING CANCER CENTER	5 U24 CA213274-05		17,413	7,504,900	RESEARCH AND DEVELOPMENT	425,311,746
CANCER BIOLOGY RESEARCH	93.396	5 U01 CA233581-02	UNIVERSITY OF ALABAMA AT BIRMINGHAM	5 U01 CA233581-02		10,592	7,504,900	RESEARCH AND DEVELOPMENT	425,311,746
CANCER BIOLOGY RESEARCH	93.396	5 U01 CA233581-03	UNIVERSITY OF ALABAMA AT BIRMINGHAM	5 U01 CA233581-03		40,826	7,504,900	RESEARCH AND DEVELOPMENT	425,311,746
CANCER BIOLOGY RESEARCH	93.396	7 R01 CA222594-04	UNIVERSITY OF MIAMI	7 R01 CA222594-04		70,681	7,504,900	RESEARCH AND DEVELOPMENT	425,311,746
CANCER BIOLOGY RESEARCH	93.396	5 U24 CA194215-04	UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON	5 U24 CA194215-04		51,654	7,504,900	RESEARCH AND DEVELOPMENT	425,311,746
CANCER BIOLOGY RESEARCH	93.396	5 U24 CA194215-05	UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON	5 U24 CA194215-05		192,932	7,504,900	RESEARCH AND DEVELOPMENT	425,311,746
CANCER BIOLOGY RESEARCH	93.396	1 P01 CA229123-01A1	VANDERBILT UNIVERSITY	1 P01 CA229123-01A1		835,852	7,504,900	RESEARCH AND DEVELOPMENT	425,311,746
CANCER BIOLOGY RESEARCH	93.396	5 R01 CA226833-02	VANDERBILT UNIVERSITY	5 R01 CA226833-02		16,756	7,504,900	RESEARCH AND DEVELOPMENT	425,311,746
CANCER BIOLOGY RESEARCH	93.396	5 R01 CA226833-03	VANDERBILT UNIVERSITY	5 R01 CA226833-03		23,898	7,504,900	RESEARCH AND DEVELOPMENT	425,311,746
CANCER CENTERS SUPPORT GRANTS	93.397	1 P50 CA236733-01			416,236	416,236	12,412,138	RESEARCH AND DEVELOPMENT	425,311,746
CANCER CENTERS SUPPORT GRANTS	93.397	5 P30 CA068485-23				(141)	12,412,138	RESEARCH AND DEVELOPMENT	425,311,746
CANCER CENTERS SUPPORT GRANTS	93.397	5 P30 CA068485-24			526,412	1,142,480	12,412,138	RESEARCH AND DEVELOPMENT	425,311,746
CANCER CENTERS SUPPORT GRANTS	93.397	2 P30 CA068485-25				5,267,485	12,412,138	RESEARCH AND DEVELOPMENT	425,311,746
CANCER CENTERS SUPPORT GRANTS	93.397	2 P50 CA098131-17A1			120,902	330,103	12,412,138	RESEARCH AND DEVELOPMENT	425,311,746
CANCER CENTERS SUPPORT GRANTS	93.397	5 P50 CA098131-18			255,256	2,005,240	12,412,138	RESEARCH AND DEVELOPMENT	425,311,746
CANCER CENTERS SUPPORT GRANTS	93.397	5 P50 CA236733-02			423,875	1,746,463	12,412,138	RESEARCH AND DEVELOPMENT	425,311,746
CANCER CENTERS SUPPORT GRANTS	93.397	5 P50 CA236733-03				107,186	12,412,138	RESEARCH AND DEVELOPMENT	425,311,746
CANCER CENTERS SUPPORT GRANTS	93.397	5 U54 CA163072-10			138,668	215,536	12,412,138	RESEARCH AND DEVELOPMENT	425,311,746
CANCER CENTERS SUPPORT GRANTS	93.397	5 U54 CA163072-11			127,080	759,546	12,412,138	RESEARCH AND DEVELOPMENT	425,311,746
CANCER CENTERS SUPPORT GRANTS	93.397	3 P30 CA016086-43S3	UNIVERSITY OF NORTH CAROLINA	3 P30 CA016086-43S3		25,515	12,412,138	RESEARCH AND DEVELOPMENT	425,311,746
CANCER CENTERS SUPPORT GRANTS	93.397	5 U54 CA217450-02	VANDERBILT UNIVERSITY	5 U54 CA217450-02		(58)	12,412,138	RESEARCH AND DEVELOPMENT	425,311,746
CANCER CENTERS SUPPORT GRANTS	93.397	5 U54 CA217450-03	VANDERBILT UNIVERSITY	5 U54 CA217450-03		267,176	12,412,138	RESEARCH AND DEVELOPMENT	425,311,746
CANCER CENTERS SUPPORT GRANTS	93.397	5 U54 CA217450-04	VANDERBILT UNIVERSITY	5 U54 CA217450-04		84,348	12,412,138	RESEARCH AND DEVELOPMENT	425,311,746
CANCER CENTERS SUPPORT GRANTS	93.397	1 P50 CA236733-01				(1,104)	12,412,138	RESEARCH AND DEVELOPMENT	425,311,746
CANCER CENTERS SUPPORT GRANTS	93.397	COVID-19 5 P30 CA068485-24S4				46,127	12,412,138	RESEARCH AND DEVELOPMENT	425,311,746
CANCER RESEARCH MANPOWER	93.398	5 T32 CA106183-16				(462)	3,096,990	RESEARCH AND DEVELOPMENT	425,311,746
CANCER RESEARCH MANPOWER	93.398	5 F32 CA224962-02				(24)	3,096,990	RESEARCH AND DEVELOPMENT	425,311,746
CANCER RESEARCH MANPOWER	93.398	5 F32 CA236309-02				3,151	3,096,990	RESEARCH AND DEVELOPMENT	425,311,746
CANCER RESEARCH MANPOWER	93.398	1 F32 CA254070-01				45,510	3,096,990	RESEARCH AND DEVELOPMENT	425,311,746
CANCER RESEARCH MANPOWER	93.398	5 K12 CA090625-20				(20,379)	3,096,990	RESEARCH AND DEVELOPMENT	425,311,746
CANCER RESEARCH MANPOWER	93.398	5 K12 CA090625-21				868,814	3,096,990	RESEARCH AND DEVELOPMENT	425,311,746
CANCER RESEARCH MANPOWER	93.398	5 K25 CA176219-06				60,634	3,096,990	RESEARCH AND DEVELOPMENT	425,311,746
CANCER RESEARCH MANPOWER	93.398	5 K23 CA204726-05				156,418	3,096,990	RESEARCH AND DEVELOPMENT	425,311,746

**VANDERBILT UNIVERSITY MEDICAL CENTER**  
**SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS (CONTINUED)**  
 Fiscal Period 7/1/2020 – 6/30/2021

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
CANCER RESEARCH MANPOWER	93.398	5 K07 CA218247-03			\$ -	\$ 12,413	\$ 3,096,990	RESEARCH AND DEVELOPMENT	\$ 425,311,746
CANCER RESEARCH MANPOWER	93.398	5 K07 CA225404-04				141,426	3,096,990	RESEARCH AND DEVELOPMENT	425,311,746
CANCER RESEARCH MANPOWER	93.398	1 K99 CA230205-01A1				16,842	3,096,990	RESEARCH AND DEVELOPMENT	425,311,746
CANCER RESEARCH MANPOWER	93.398	4 K00 CA234920-03				87,046	3,096,990	RESEARCH AND DEVELOPMENT	425,311,746
CANCER RESEARCH MANPOWER	93.398	1 K08 CA240901-01A1				192,510	3,096,990	RESEARCH AND DEVELOPMENT	425,311,746
CANCER RESEARCH MANPOWER	93.398	5 K08 CA241351-02				170,537	3,096,990	RESEARCH AND DEVELOPMENT	425,311,746
CANCER RESEARCH MANPOWER	93.398	5 K01 CA245231-02				113,564	3,096,990	RESEARCH AND DEVELOPMENT	425,311,746
CANCER RESEARCH MANPOWER	93.398	1 K99 CA248822-01A1				43,817	3,096,990	RESEARCH AND DEVELOPMENT	425,311,746
CANCER RESEARCH MANPOWER	93.398	4 R00 CA215360-03				28,543	3,096,990	RESEARCH AND DEVELOPMENT	425,311,746
CANCER RESEARCH MANPOWER	93.398	2 T32 CA106183-17				235,909	3,096,990	RESEARCH AND DEVELOPMENT	425,311,746
CANCER RESEARCH MANPOWER	93.398	5 T32 CA160056-08				(1,627)	3,096,990	RESEARCH AND DEVELOPMENT	425,311,746
CANCER RESEARCH MANPOWER	93.398	5 T32 CA160056-09				72,763	3,096,990	RESEARCH AND DEVELOPMENT	425,311,746
CANCER RESEARCH MANPOWER	93.398	5 T32 CA160056-10				349,068	3,096,990	RESEARCH AND DEVELOPMENT	425,311,746
CANCER RESEARCH MANPOWER	93.398	5 T32 CA217834-02				2,550	3,096,990	RESEARCH AND DEVELOPMENT	425,311,746
CANCER RESEARCH MANPOWER	93.398	5 T32 CA217834-03				257,798	3,096,990	RESEARCH AND DEVELOPMENT	425,311,746
CANCER RESEARCH MANPOWER	93.398	2 T32 CA009582-31	VANDERBILT UNIVERSITY	2 T32 CA009582-31		(6,055)	3,096,990	RESEARCH AND DEVELOPMENT	425,311,746
CANCER RESEARCH MANPOWER	93.398	5 T32 CA009582-32	VANDERBILT UNIVERSITY	5 T32 CA009582-32		60,633	3,096,990	RESEARCH AND DEVELOPMENT	425,311,746
CANCER RESEARCH MANPOWER	93.398	5 T32 CA009582-33	VANDERBILT UNIVERSITY	5 T32 CA009582-33		3,747	3,096,990	RESEARCH AND DEVELOPMENT	425,311,746
CANCER RESEARCH MANPOWER	93.398	5 T32 CA009582-34	VANDERBILT UNIVERSITY	5 T32 CA009582-34		388	3,096,990	RESEARCH AND DEVELOPMENT	425,311,746
CANCER RESEARCH MANPOWER	93.398	2 T32 CA009592-31A1	VANDERBILT UNIVERSITY	2 T32 CA009592-31A1		(924)	3,096,990	RESEARCH AND DEVELOPMENT	425,311,746
CANCER RESEARCH MANPOWER	93.398	5 T32 CA009592-32	VANDERBILT UNIVERSITY	5 T32 CA009592-32		11,248	3,096,990	RESEARCH AND DEVELOPMENT	425,311,746
CANCER RESEARCH MANPOWER	93.398	5 T32 CA009592-32	VANDERBILT UNIVERSITY	5 T32 CA009592-32		52,355	3,096,990	RESEARCH AND DEVELOPMENT	425,311,746
CANCER RESEARCH MANPOWER	93.398	5 T32 CA009592-33	VANDERBILT UNIVERSITY	5 T32 CA009592-33		954	3,096,990	RESEARCH AND DEVELOPMENT	425,311,746
CANCER RESEARCH MANPOWER	93.398	2 T32 CA119925-11	VANDERBILT UNIVERSITY	2 T32 CA119925-11		3,845	3,096,990	RESEARCH AND DEVELOPMENT	425,311,746
CANCER RESEARCH MANPOWER	93.398	5 T32 CA119925-12	VANDERBILT UNIVERSITY	5 T32 CA119925-12		25,123	3,096,990	RESEARCH AND DEVELOPMENT	425,311,746
CANCER RESEARCH MANPOWER	93.398	5 T32 CA119925-12	VANDERBILT UNIVERSITY	5 T32 CA119925-12		37,535	3,096,990	RESEARCH AND DEVELOPMENT	425,311,746
CANCER RESEARCH MANPOWER	93.398	5 T32 CA119925-12	VANDERBILT UNIVERSITY	5 T32 CA119925-12		19,239	3,096,990	RESEARCH AND DEVELOPMENT	425,311,746
CANCER RESEARCH MANPOWER	93.398	5 T32 CA119925-13	VANDERBILT UNIVERSITY	5 T32 CA119925-13		26,752	3,096,990	RESEARCH AND DEVELOPMENT	425,311,746
CANCER RESEARCH MANPOWER	93.398	5 T32 CA119925-13	VANDERBILT UNIVERSITY	5 T32 CA119925-13		25,329	3,096,990	RESEARCH AND DEVELOPMENT	425,311,746
CANCER CONTROL	93.399	2 UG1 CA189955-06	CHILDREN'S HOSPITAL OF PHILADELPHIA	2 UG1 CA189955-06		2,223	118,787	RESEARCH AND DEVELOPMENT	425,311,746
CANCER CONTROL	93.399	2 UG1 CA189955-06	CHILDREN'S HOSPITAL OF PHILADELPHIA	2 UG1 CA189955-06		13,580	118,787	RESEARCH AND DEVELOPMENT	425,311,746
CANCER CONTROL	93.399	2 UG1 CA189955-07	CHILDREN'S HOSPITAL OF PHILADELPHIA	2 UG1 CA189955-07		24,458	118,787	RESEARCH AND DEVELOPMENT	425,311,746
CANCER CONTROL	93.399	5 UG1 CA189828-07	EASTERN COOPERATIVE ONCOLOGY GROUP	5 UG1 CA189828-07		41,563	118,787	RESEARCH AND DEVELOPMENT	425,311,746
CANCER CONTROL	93.399	5 UG1 CA189824-07	WAKE FOREST UNIVERSITY	5 UG1 CA189824-07		36,963	118,787	RESEARCH AND DEVELOPMENT	425,311,746
STRENGTHENING PUBLIC HEALTH SYSTEMS AND SERVICES THROUGH NATIONAL PARTNERSHIPS TO IMPROVE AND PROTECT THE NATIONS HEALTH	93.421	775 2020 007	ACADEMYHEALTH	775 2020 007		35,107	81,176	RESEARCH AND DEVELOPMENT	425,311,746
COVID-19 STRENGTHENING PUBLIC HEALTH SYSTEMS AND SERVICES THROUGH NATIONAL PARTNERSHIPS TO IMPROVE AND PROTECT THE NATIONS HEALTH	93.421	COVID-19 NU38OT000316	THE TASK FORCE FOR GLOBAL HEALTH	NU38OT000316		46,069	81,176	RESEARCH AND DEVELOPMENT	425,311,746
ACL NATIONAL INSTITUTE ON DISABILITY, INDEPENDENT LIVING, AND REHABILITATION RESEARCH	93.433	90IFRE0001-03-00	VANDERBILT UNIVERSITY	90IFRE0001-03-00		6,534	9,484	RESEARCH AND DEVELOPMENT	425,311,746
ACL NATIONAL INSTITUTE ON DISABILITY, INDEPENDENT LIVING, AND REHABILITATION RESEARCH	93.433	90RTEM0002-02-00	VANDERBILT UNIVERSITY	90RTEM0002-02-00		1,770	9,484	RESEARCH AND DEVELOPMENT	425,311,746
ACL NATIONAL INSTITUTE ON DISABILITY, INDEPENDENT LIVING, AND REHABILITATION RESEARCH	93.433	90RTEM0002-02-00	VANDERBILT UNIVERSITY	90RTEM0002-02-00		1,180	9,484	RESEARCH AND DEVELOPMENT	425,311,746
COVID-19 HRSA COVID-19 Claims Reimbursement for the Uninsured Program and the COVID-19 Coverage Assistance Fund	93.461	COVID-19				2,990,137	2,990,137	N/A	-
ALZHEIMER'S DISEASE PROGRAM INITIATIVE (ADPI)	93.470	65462:ST TN	STATE TENNESSEE COMMISSION ON AGING AND DISABILITY	65462:ST TN		81,455	81,455	RESEARCH AND DEVELOPMENT	425,311,746
PREVENTING MATERNAL DEATHS: SUPPORTING MATERNAL MORTALITY REVIEW COMMITTEES (B)	93.478	65663:ST TN	TN DEPARTMENT OF HEALTH	65663:ST TN		22,726	23,437	N/A	-
PREVENTING MATERNAL DEATHS: SUPPORTING MATERNAL MORTALITY REVIEW COMMITTEES (B)	93.478	68711:ST TN	TN DEPARTMENT OF HEALTH	68711:ST TN		711	23,437	N/A	-
COVID-19 Provider Relief Fund and American Rescue Plan (ARP) Rural Distribution	93.498	COVID-19				115,447,363	115,447,363	N/A	-

**VANDERBILT UNIVERSITY MEDICAL CENTER**  
**SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS (CONTINUED)**  
 Fiscal Period 7/1/2020 – 6/30/2021

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
ACA – STATE INNOVATION MODELS: FUNDING FOR MODEL DESIGN AND MODEL TESTING ASSISTANCE	93.624	60138:ST TN	TN DEPARTMENT OF HEALTH	60138:ST TN	\$ –	\$ (558)	\$ (558)	RESEARCH AND DEVELOPMENT	\$ 425,311,746
DEVELOPMENTAL DISABILITIES BASIC SUPPORT AND ADVOCACY GRANTS	93.630	58369:ST TN	TN DEPARTMENT OF ECONOMIC AND COMMUNITY DEVELOPMENT	58369:ST TN		(397)	294,954	N/A	–
DEVELOPMENTAL DISABILITIES BASIC SUPPORT AND ADVOCACY GRANTS	93.630	62942:ST TN	TN DEPARTMENT OF MENTAL HEALTH AND DEVELOPMENTAL DISABILITIE	62942:ST TN		4,070	294,954	N/A	–
DEVELOPMENTAL DISABILITIES BASIC SUPPORT AND ADVOCACY GRANTS	93.630	67852:ST TN	TN DEPARTMENT OF MENTAL HEALTH AND DEVELOPMENTAL DISABILITIE	67852:ST TN		276,026	294,954	N/A	–
DEVELOPMENTAL DISABILITIES BASIC SUPPORT AND ADVOCACY GRANTS	93.630	69637:ST TN	TN DEPARTMENT OF MENTAL HEALTH AND DEVELOPMENTAL DISABILITIE	69637:ST TN		15,255	294,954	N/A	–
DEVELOPMENTAL DISABILITIES PROJECTS OF NATIONAL SIGNIFICANCE	93.631	90D NHC0001-01-00	CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER	90D NHC0001-01-00		24,657	31,513	N/A	–
DEVELOPMENTAL DISABILITIES PROJECTS OF NATIONAL SIGNIFICANCE	93.631	90DNHC0001-01-00	CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER	90DNHC0001-01-00		6,856	31,513	N/A	–
UNIVERSITY CENTERS FOR EXCELLENCE IN DEVELOPMENTAL DISABILITIES EDUCATION, RESEARCH, AND SERVICE	93.632	90 DD000825-04-00			83,558	111,838	526,486	N/A	–
UNIVERSITY CENTERS FOR EXCELLENCE IN DEVELOPMENTAL DISABILITIES EDUCATION, RESEARCH, AND SERVICE	93.632	90DDUC0077-01-00				385,742	526,486	N/A	–
UNIVERSITY CENTERS FOR EXCELLENCE IN DEVELOPMENTAL DISABILITIES EDUCATION, RESEARCH, AND SERVICE	93.632	90DDUC0080-01-00				28,906	526,486	N/A	–
ACA-TRANSFORMING CLINICAL PRACTICE INITIATIVE: PRACTICE TRANSFORMATION NETWORKS (PTNS)	93.638	1 L1 CMS331549-03-00				(282)	(282)	RESEARCH AND DEVELOPMENT	425,311,746
FOSTER CARE_TITLE IV-E	93.658	56787:ST TN	TN DEPARTMENT OF CHILDREN'S SERVICES	56787:ST TN		1,417	123,836	N/A	–
FOSTER CARE_TITLE IV-E	93.658	56787:ST TN	TN DEPARTMENT OF CHILDREN'S SERVICES	56787:ST TN		122,437	123,836	N/A	–
FOSTER CARE_TITLE IV-E	93.658	64269:ST TN	TN DEPARTMENT OF MENTAL HEALTH AND DEVELOPMENTAL DISABILITIE	64269:ST TN		(18)	123,836	N/A	–
MATERNAL OPIOID MISUSE MODEL (A)	93.687	65326:ST TN	TN BUREAU OF TENNCARE	65326:ST TN		225,694	499,954	RESEARCH AND DEVELOPMENT	425,311,746
MATERNAL OPIOID MISUSE MODEL (A)	93.687	65326:ST TN	TN BUREAU OF TENNCARE	65326:ST TN		274,260	499,954	RESEARCH AND DEVELOPMENT	425,311,746
MEDICAL ASSISTANCE PROGRAM	93.778	CDC-BCBS	BLUECROSS BLUESHIELD OF TENNESSEE HEALTH FOUNDATION, INC.	CDC-BCBS		772,838	5,211,971	MEDICAID CLUSTER	5,211,971
MEDICAL ASSISTANCE PROGRAM	93.778	46264:ST TN	TN BUREAU OF TENNCARE	46264:ST TN		341,710	5,211,971	MEDICAID CLUSTER	5,211,971
MEDICAL ASSISTANCE PROGRAM	93.778	61290:ST TN	TN BUREAU OF TENNCARE	61290:ST TN		10,690	5,211,971	MEDICAID CLUSTER	5,211,971
MEDICAL ASSISTANCE PROGRAM	93.778	46264:ST TN	TN DEPARTMENT OF HEALTH	46264:ST TN		795,225	5,211,971	MEDICAID CLUSTER	5,211,971
MEDICAL ASSISTANCE PROGRAM	93.778	54867:ST TN	TN DEPARTMENT OF HEALTH	54867:ST TN	1,980	19,020	5,211,971	MEDICAID CLUSTER	5,211,971
MEDICAL ASSISTANCE PROGRAM	93.778	65729:ST TN	TN DEPARTMENT OF HEALTH	65729:ST TN	9,902	533,203	5,211,971	MEDICAID CLUSTER	5,211,971
MEDICAL ASSISTANCE PROGRAM	93.778	52379:ST TN	TN DEPARTMENT OF MENTAL HEALTH AND DEVELOPMENTAL DISABILITIE	52379:ST TN		(2,681)	5,211,971	MEDICAID CLUSTER	5,211,971
MEDICAL ASSISTANCE PROGRAM	93.778	53068:ST TN	TN DEPARTMENT OF MENTAL HEALTH AND DEVELOPMENTAL DISABILITIE	53068:ST TN	46,662	2,741,966	5,211,971	MEDICAID CLUSTER	5,211,971
OPIOID STR	93.788	65038:ST TN	TN DEPARTMENT OF MENTAL HEALTH AND DEVELOPMENTAL DISABILITIE	65038:ST TN		617,817	972,101	N/A	–
OPIOID STR	93.788	65428:ST TN	TN DEPARTMENT OF MENTAL HEALTH AND DEVELOPMENTAL DISABILITIE	65428:ST TN		69,424	972,101	N/A	–
OPIOID STR	93.788	70172:ST TN	TN DEPARTMENT OF MENTAL HEALTH AND DEVELOPMENTAL DISABILITIE	70172:ST TN		284,860	972,101	N/A	–
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 DP2 HL137166-01			15,248	610,013	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 DP2 HL152426-01				331,158	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 F32 HL143927-01A1				583	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746

**VANDERBILT UNIVERSITY MEDICAL CENTER**  
**SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS (CONTINUED)**  
 Fiscal Period 7/1/2020 – 6/30/2021

<i>Federal Awarding Agency/Program Title</i>	<i>Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 F32 HL143927-02			\$ -	\$ 46,114	\$ 27,529,500	RESEARCH AND DEVELOPMENT	\$ 425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 F32 HL144048-02				2,090	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 F32 HL144050-01A1				1,572	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 F32 HL144081-02				6,935	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 F32 HL144081-03				19,629	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL094786-08			149,500	329,910	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 T32 HL105334-09				9,014	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 P01 HL129941-04			658,729	804,018	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL144846-03			17,714	666,279	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 K23 HL127104-04				77,512	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 K23 HL127130-04				24,442	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 K23 HL127704-05				38,905	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 K23 HL128928-04				27,485	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 K01 HL130497-06				123,021	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 K12 HL133117-05				237,389	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 K01 HL135461-05				161,080	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 K01 HL140278-04				133,174	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 K08 HL145075-02				124,925	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	7 K01 HL145345-02				78,710	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 K23 HL148640-02				184,806	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 K23 HL151871-01A1				68,145	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 K08 HL153786-01				149,211	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 K08 HL153789-01				123,097	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 P01 HL116263-04				(128)	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 P01 HL116263-05				9,482	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	2 P01 HL116263-06A1				1,027,534	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 P01 HL128203-04			412,937	412,937	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 P01 HL128203-05			1,260,543	1,860,156	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 P01 HL129941-05			711,167	1,805,842	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 R01 HL140074-04				308,805	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL148661-01			31,858	50,958	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 R01 HL146654-01A1			17,532	549,367	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL070715-17				535,806	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	2 R56 HL081707-12A1				137,448	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R25 HL096223-11				6,382	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL121139-05				(504)	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL124116-04				(124)	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL124935-06			15,811	227,526	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL125426-06				25,553	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL127173-05				6,045	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL128386-04				23,933	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL128983-04			10,117	82,647	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL128996-05				43,925	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL131977-04			28,730	28,730	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL131977-05			94,424	459,338	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL133127-02			21,257	260,420	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL133786-04				339,939	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL133860-04			73,591	247,185	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL134895-04				308,307	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL135011-05			32,757	530,988	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R00 HL135442-05			11,379	242,364	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL138519-04				351,120	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R35 HL140016-03			30,623	299,341	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R35 HL140016-04				313,003	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL140145-03			12,609	162,212	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL140145-04				143,588	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R21 HL140375-02				47,091	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R21 HL140382-02			21,944	108,119	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 R56 HL141248-01			13,500	98,394	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL141466-02				618,850	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746

**VANDERBILT UNIVERSITY MEDICAL CENTER**  
**SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS (CONTINUED)**  
Fiscal Period 7/1/2020 – 6/30/2021

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 R01 HL142583-01A1			\$ -	\$ 387,980	\$ 27,529,500	RESEARCH AND DEVELOPMENT	\$ 425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL142856-03				472,799	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL144568-02				417,693	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 R01 HL144941-01A1				2,796	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL144943-03			34,144	444,904	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R35 HL144980-02				425,048	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R35 HL144980-03				254,197	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 R01 HL145293-01A1			37,564	703,133	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL146524-03				517,471	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL148244-02				508,197	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL148661-02			150,069	239,335	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 R01 HL149386-01				(333)	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL149386-02				426,439	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL149386-03				40,109	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 R01 HL149779-01A1			10,238	794,624	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL149826-02				691,556	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL149948-02			81,159	277,588	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 R56 HL150186-01A1			46,133	151,155	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL151523-02				487,795	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 R01 HL153607-01A1				9,314	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 R03 HL154243-01				75,968	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 R03 HL155041-01				16,170	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 R01 HL155523-01				118,796	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 R01 HL155990-01				57,387	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 R01 HL156021-01A1				72,702	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 R01 HL157378-01				23,595	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 R01 HL157583-01				44,688	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 U01 HL131911-05				201,015	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 T32 HL105334-10				489,437	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 R21 HL140443-02	BOSTON CHILDREN'S HOSPITAL	1 R21 HL140443-02		8,266	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL146134-02	BOSTON CHILDREN'S HOSPITAL	5 R01 HL146134-02		16,848	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL146134-03	BOSTON CHILDREN'S HOSPITAL	5 R01 HL146134-03		17,509	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 U01 HL130163-04	BRIGHAM AND WOMEN'S HOSPITAL	5 U01 HL130163-04		3,754	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 P50 HL112349-05	BRIGHAM AND WOMEN'S HOSPITAL	5 P50 HL112349-05		(48,375)	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 R21 HL145420-01	BRIGHAM AND WOMEN'S HOSPITAL	1 R21 HL145420-01		(251)	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R21 HL145420-02	BRIGHAM AND WOMEN'S HOSPITAL	5 R21 HL145420-02		11,020	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 R01 HL148439-01A1	BRIGHAM AND WOMEN'S HOSPITAL	1 R01 HL148439-01A1		159,514	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 U01 HL123336-01	BRIGHAM AND WOMEN'S HOSPITAL	1 U01 HL123336-01		9,400	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 U01 HL130163-02	BRIGHAM AND WOMEN'S HOSPITAL	5 U01 HL130163-02		(6,452)	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 U2C HL156291-01	CHILDREN'S HOSPITAL OF PHILADELPHIA	1 U2C HL156291-01		40,737	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 R01 HL151604-01	CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER	1 R01 HL151604-01		115,871	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL130828-04	DARTMOUTH COLLEGE	5 R01 HL130828-04		25,678	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 U10 HL084904-12	DUKE UNIVERSITY	5 U10 HL084904-12		1,545	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 U01 HL105462-07	DUKE UNIVERSITY	5 U01 HL105462-07		3,282	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 R01 HL151152-01A1	FRED HUTCHINSON CANCER RESEARCH CENTER	1 R01 HL151152-01A1		59,879	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 R01 HL148137-02	HARVARD UNIVERSITY	1 R01 HL148137-02		127,977	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL111821-09	MASSACHUSETTS GENERAL HOSPITAL	5 R01 HL111821-09		111,969	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL111821-10	MASSACHUSETTS GENERAL HOSPITAL	5 R01 HL111821-10		13,371	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 R01 HL151838-01	MASSACHUSETTS GENERAL HOSPITAL	1 R01 HL151838-01		91,399	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	4 U10 HL068270-15	NEW ENGLAND RESEARCH INSTITUTES	4 U10 HL068270-15		(2,069)	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R25 HL105444-11	NEW YORK UNIVERSITY	5 R25 HL105444-11		4,319	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL130502-04	NORTHWESTERN UNIVERSITY	5 R01 HL130502-04		(12)	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL130502-05	NORTHWESTERN UNIVERSITY	5 R01 HL130502-05		6,530	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746

**VANDERBILT UNIVERSITY MEDICAL CENTER**  
**SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS (CONTINUED)**  
 Fiscal Period 7/1/2020 – 6/30/2021

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL123968-07	STANFORD UNIVERSITY	5 R01 HL123968-07	\$ -	\$ 5,667	\$ 27,529,500	RESEARCH AND DEVELOPMENT	\$ 425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	2 R25 HL105446-09	STATE UNIVERSITY OF NEW YORK (SUNY)	2 R25 HL105446-09		1,334	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL139968-03	STATE UNIVERSITY OF NEW YORK (SUNY)	5 R01 HL139968-03		39,771	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 R44 HL132746-01A1	THERMEDICAL, INC.	1 R44 HL132746-01A1		66,379	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL133790-04	TULANE UNIVERSITY	5 R01 HL133790-04		197	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 U01 HL120338-06	UNIVERSITY OF ALABAMA AT BIRMINGHAM	5 U01 HL120338-06		1,946	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 K01 HL142848-03	UNIVERSITY OF ARIZONA	5 K01 HL142848-03		2,683	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	2 K24 HL112827-07	UNIVERSITY OF CALIFORNIA AT SAN FRANCISCO	2 K24 HL112827-07		45,839	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 OT3 HL142481-01	UNIVERSITY OF CALIFORNIA, SANTA CRUZ	1 OT3 HL142481-01		38,263	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	3 OT3 HL142481-03	UNIVERSITY OF CALIFORNIA, SANTA CRUZ	3 OT3 HL142481-03		83,209	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 R01 HL147171-01A1	UNIVERSITY OF CINCINNATI	1 R01 HL147171-01A1		18,328	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 R01 HL153118-01	UNIVERSITY OF CINCINNATI	1 R01 HL153118-01		41,905	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL134731-04	UNIVERSITY OF KENTUCKY	5 R01 HL134731-04		58,249	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 R01 HL152081-01	UNIVERSITY OF KENTUCKY	1 R01 HL152081-01		31,641	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 U10 HL069330-15	UNIVERSITY OF MICHIGAN	5 U10 HL069330-15		(1,992)	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL136679-02	UNIVERSITY OF MINNESOTA	5 R01 HL136679-02		2,816	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 R01 HL150053-01A1	UNIVERSITY OF MINNESOTA	1 R01 HL150053-01A1		8,409	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 OT3 HL147154-01	UNIVERSITY OF NORTH CAROLINA	1 OT3 HL147154-01		42,323	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL142302-03	UNIVERSITY OF NORTH CAROLINA	5 R01 HL142302-03		224,803	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL134905-04	UNIVERSITY OF PENNSYLVANIA	5 R01 HL134905-04		29,294	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL134905-05	UNIVERSITY OF PENNSYLVANIA	5 R01 HL134905-05		31,541	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	7 R01 HL136824-03	UNIVERSITY OF PITTSBURGH	7 R01 HL136824-03		11,615	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL147818-22	UNIVERSITY OF PITTSBURGH	5 R01 HL147818-22		465,511	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 R01 HL151223-01	VANDERBILT UNIVERSITY	1 R01 HL151223-01		403,607	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	2 T32 HL007411-39	VANDERBILT UNIVERSITY	2 T32 HL007411-39		19,148	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 T32 HL007411-39	VANDERBILT UNIVERSITY	5 T32 HL007411-39		9,850	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 T32 HL007411-39	VANDERBILT UNIVERSITY	5 T32 HL007411-39		5,859	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 T32 HL007411-40	VANDERBILT UNIVERSITY	5 T32 HL007411-40		53,340	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 T32 HL007411-40	VANDERBILT UNIVERSITY	5 T32 HL007411-40		57,579	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 T32 HL007411-40	VANDERBILT UNIVERSITY	5 T32 HL007411-40		65,455	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 T32 HL007411-40	VANDERBILT UNIVERSITY	5 T32 HL007411-40		59,580	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 T32 HL007411-40	VANDERBILT UNIVERSITY	5 T32 HL007411-40		59,580	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 T32 HL144446-01	VANDERBILT UNIVERSITY	1 T32 HL144446-01		569	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 T32 HL144446-02	VANDERBILT UNIVERSITY	5 T32 HL144446-02		61,014	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 T32 HL144446-02	VANDERBILT UNIVERSITY	5 T32 HL144446-02		65,192	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 T32 HL144446-02	VANDERBILT UNIVERSITY	1 T32 HL144446-02		2,800	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 T32 HL144446-02	VANDERBILT UNIVERSITY	5 T32 HL144446-02		72,830	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 T32 HL144446-03	VANDERBILT UNIVERSITY	5 T32 HL144446-03		2,006	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	4 R44 HL140669-02	VOLUMETRIX LLC	4 R44 HL140669-02		190,556	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 UG3 HL145269-01A1	WAYNE STATE UNIVERSITY	1 UG3 HL145269-01A1		112	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	R01 HL125918	YALE UNIVERSITY	R01 HL125918		1,147	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 P01 HL128203-04				(25)	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL131977-04				(25,493)	27,529,500	RESEARCH AND DEVELOPMENT	425,311,746
LUNG DISEASES RESEARCH	93.838	5 P01 HL108800-09			89,788	95,415	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
LUNG DISEASES RESEARCH	93.838	5 R38 HL143619-02				727	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
LUNG DISEASES RESEARCH	93.838	5 K12 HL143956-02				4,665	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
LUNG DISEASES RESEARCH	93.838	2 K24 HL103836-06				93,870	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
LUNG DISEASES RESEARCH	93.838	5 K08 HL127102-05				2,795	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
LUNG DISEASES RESEARCH	93.838	5 K24 HL127301-06				71,674	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
LUNG DISEASES RESEARCH	93.838	5 K08 HL130595-06				17,574	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
LUNG DISEASES RESEARCH	93.838	5 K08 HL133484-04				136,287	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
LUNG DISEASES RESEARCH	93.838	5 K08 HL136888-05				176,835	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
LUNG DISEASES RESEARCH	93.838	5 K23 HL141539-04				215,989	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
LUNG DISEASES RESEARCH	93.838	5 K08 HL143051-02				152,200	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746

**VANDERBILT UNIVERSITY MEDICAL CENTER**  
**SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS (CONTINUED)**  
Fiscal Period 7/1/2020 – 6/30/2021

<i>Federal Awarding Agency/Program Title</i>	<i>Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
LUNG DISEASES RESEARCH	93.838	5 K23 HL143053-04			\$ -	\$ 187,807	\$ 18,199,332	RESEARCH AND DEVELOPMENT	\$ 425,311,746
LUNG DISEASES RESEARCH	93.838	5 K99 HL143441-02				54,877	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
LUNG DISEASES RESEARCH	93.838	5 K12 HL143956-03				257,309	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
LUNG DISEASES RESEARCH	93.838	5 K01 HL145338-02				10,455	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
LUNG DISEASES RESEARCH	93.838	5 K23 HL148638-02				158,518	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
LUNG DISEASES RESEARCH	93.838	1 K01 HL149989-01A1				113,499	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
LUNG DISEASES RESEARCH	93.838	5 K24 HL150312-02				77,215	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
LUNG DISEASES RESEARCH	93.838	1 K23 HL153584-01				166,241	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
LUNG DISEASES RESEARCH	93.838	1 K01 HL157755-01				21,475	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
LUNG DISEASES RESEARCH	93.838	5 P01 HL092870-09			81,503	81,503	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
LUNG DISEASES RESEARCH	93.838	5 P01 HL092870-10			600,947	1,564,999	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
LUNG DISEASES RESEARCH	93.838	5 P01 HL108800-10			78,237	1,740,843	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
LUNG DISEASES RESEARCH	93.838	5 R01 HL095797-12				730,536	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
LUNG DISEASES RESEARCH	93.838	2 R01 HL122554-07A1				101,122	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
LUNG DISEASES RESEARCH	93.838	5 R01 HL126176-06			135,842	304,970	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
LUNG DISEASES RESEARCH	93.838	5 R01 HL131906-04				24,740	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
LUNG DISEASES RESEARCH	93.838	5 R01 HL132338-05			403,447	848,402	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
LUNG DISEASES RESEARCH	93.838	5 R01 HL134802-03				346,857	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
LUNG DISEASES RESEARCH	93.838	5 R01 HL134802-04				300,185	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
LUNG DISEASES RESEARCH	93.838	5 R01 HL135849-04			21,451	403,010	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
LUNG DISEASES RESEARCH	93.838	5 R01 HL136664-04			35,527	264,123	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
LUNG DISEASES RESEARCH	93.838	2 R01 HL136664-05A1				105,102	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
LUNG DISEASES RESEARCH	93.838	5 R01 HL136748-04				483,094	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
LUNG DISEASES RESEARCH	93.838	5 R34 HL136989-03			719	1,120	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
LUNG DISEASES RESEARCH	93.838	5 R01 HL140231-03			171,212	849,804	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
LUNG DISEASES RESEARCH	93.838	1 R56 HL141567-01A1				65,319	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
LUNG DISEASES RESEARCH	93.838	5R01 HL142720-03				655,251	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
LUNG DISEASES RESEARCH	93.838	5 R38 HL143619-03				296,228	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
LUNG DISEASES RESEARCH	93.838	5 R01 HL146401-03				338,057	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
LUNG DISEASES RESEARCH	93.838	5 R01 HL146588-02			438,636	1,032,016	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
LUNG DISEASES RESEARCH	93.838	1 R56 HL149129-01A1				235,355	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
LUNG DISEASES RESEARCH	93.838	1 R35 HL150783-01			9,636	417,956	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
LUNG DISEASES RESEARCH	93.838	5 R35 HL150783-02				191,494	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
LUNG DISEASES RESEARCH	93.838	5 R01 HL151016-02				382,521	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
LUNG DISEASES RESEARCH	93.838	1 R61 HL151951-01				365,576	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
LUNG DISEASES RESEARCH	93.838	5 R01 HL152210-02				598,446	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
LUNG DISEASES RESEARCH	93.838	5 R01 HL153246-02			31,855	694,710	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
LUNG DISEASES RESEARCH	93.838	1 R03 HL154287-01				74,681	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
LUNG DISEASES RESEARCH	93.838	1 R01 HL157373-01				104,472	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
LUNG DISEASES RESEARCH	93.838	5 T32 HL087738-13				(4,925)	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
LUNG DISEASES RESEARCH	93.838	5 T32 HL087738-14				2,924	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
LUNG DISEASES RESEARCH	93.838	5 T32 HL087738-15				328,172	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
LUNG DISEASES RESEARCH	93.838	5 T32 HL087738-16				38,927	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
LUNG DISEASES RESEARCH	93.838	5 T32 HL094296-12				(8,065)	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
LUNG DISEASES RESEARCH	93.838	5 T32 HL094296-13				445,207	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
LUNG DISEASES RESEARCH	93.838	5 U01 HL123033-06			19,790	19,790	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
LUNG DISEASES RESEARCH	93.838	5 U01 HL123033-07				284,563	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
LUNG DISEASES RESEARCH	93.838	5 U01 HL125212-06				3,460	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
LUNG DISEASES RESEARCH	93.838	1 U01 HL152976-01	BOSTON UNIVERSITY	1 U01 HL152976-01		6,476	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
LUNG DISEASES RESEARCH	93.838	5 R01 HL116473-08	BRIGHAM AND WOMEN'S HOSPITAL	5 R01 HL116473-08		19,298	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
LUNG DISEASES RESEARCH	93.838	5 R21 HL145246-02	BRIGHAM AND WOMEN'S HOSPITAL	5 R21 HL145246-02		944	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
LUNG DISEASES RESEARCH	93.838	5 U01 HL125177-05	CLEVELAND CLINIC FOUNDATION	5 U01 HL125177-05		(7,882)	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
LUNG DISEASES RESEARCH	93.838	5 U01 HL125177-06	CLEVELAND CLINIC FOUNDATION	5 U01 HL125177-06		44,338	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
LUNG DISEASES RESEARCH	93.838	5 U01 HL145561-02	CORNELL UNIVERSITY	5 U01 HL145561-02		11,372	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
LUNG DISEASES RESEARCH	93.838	5 U01 HL145561-03	CORNELL UNIVERSITY	5 U01 HL145561-03		6,889	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
LUNG DISEASES RESEARCH	93.838	5 R61 HL147833-02	DUKE UNIVERSITY	5 R61 HL147833-02		3,546	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
LUNG DISEASES RESEARCH	93.838	1 UG3 HL147011-01A1	FRED HUTCHINSON CANCER RESEARCH CENTER	1 UG3 HL147011-01A1		1,295	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
LUNG DISEASES RESEARCH	93.838	5 R01 HL149422-02	HARVARD UNIVERSITY	5 R01 HL149422-02		19,873	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
LUNG DISEASES RESEARCH	93.838	1 R01 HL144624-01	INTERMOUNTAIN MEDICAL	1 R01 HL144624-01		5,278	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746

**VANDERBILT UNIVERSITY MEDICAL CENTER**  
**SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS (CONTINUED)**  
 Fiscal Period 7/1/2020 – 6/30/2021

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
LUNG DISEASES RESEARCH	93.838	5 R01 HL132153-04	JOHNS HOPKINS UNIVERSITY	5 R01 HL132153-04	\$ -	\$ 3,849	\$ 18,199,332	RESEARCH AND DEVELOPMENT	\$ 425,311,746
LUNG DISEASES RESEARCH	93.838	5 R01 HL135114-04	JOHNS HOPKINS UNIVERSITY	5 R01 HL135114-04		25,127	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
LUNG DISEASES RESEARCH	93.838	1 R01 HL150070-01A1	JOHNS HOPKINS UNIVERSITY	1 R01 HL150070-01A1		22,776	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
<b>COVID-19 LUNG DISEASES RESEARCH</b>	93.838	COVID-19 1 OT2 HL156812-01	MASSACHUSETTS GENERAL HOSPITAL	1 OT2 HL156812-01		196,006	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
LUNG DISEASES RESEARCH	93.838	5 U01 HL123009-06	MASSACHUSETTS GENERAL HOSPITAL	5 U01 HL123009-06		95,038	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
LUNG DISEASES RESEARCH	93.838	5 U01HL123009-06	MASSACHUSETTS GENERAL HOSPITAL	5 U01HL123009-06		(37)	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
<b>COVID-19 LUNG DISEASES RESEARCH</b>	93.838	COVID-19 3 U01 HL123009-06S1	MASSACHUSETTS GENERAL HOSPITAL	3 U01 HL123009-06S1		39,009	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
<b>COVID-19 LUNG DISEASES RESEARCH</b>	93.838	COVID-19 3 U01 HL 123009-06S1	MASSACHUSETTS GENERAL HOSPITAL	3 U01 HL 123009-06S1	17,750	41,363	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
<b>COVID-19 LUNG DISEASES RESEARCH</b>	93.838	COVID-19 3 U01 HL123009-06S2	MASSACHUSETTS GENERAL HOSPITAL	3 U01 HL123009-06S2		7,422	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
<b>COVID-19 LUNG DISEASES RESEARCH</b>	93.838	COVID-19 3 U01 HL123009-06S2	MASSACHUSETTS GENERAL HOSPITAL	3 U01 HL123009-06S2		3,935	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
<b>COVID-19 LUNG DISEASES RESEARCH</b>	93.838	COVID-19 3 U01 HL123009-06S2	MASSACHUSETTS GENERAL HOSPITAL	3 U01 HL123009-06S2		22,575	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
LUNG DISEASES RESEARCH	93.838	5 U01 HL123009-07	MASSACHUSETTS GENERAL HOSPITAL	5 U01 HL123009-07		14,365	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
LUNG DISEASES RESEARCH	93.838	5 U01 HL123009-07	MASSACHUSETTS GENERAL HOSPITAL	5 U01 HL123009-07		86,063	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
LUNG DISEASES RESEARCH	93.838	5 R01 HL113326-08	OKLAHOMA MEDICAL RESEARCH FOUNDATION	5 R01 HL113326-08		25,694	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
LUNG DISEASES RESEARCH	93.838	1 R01 HL152083-01	STANFORD UNIVERSITY TRANSLATIONAL GENOMICS RESEARCH INSTITUTE	1 R01 HL152083-01		27,463	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
LUNG DISEASES RESEARCH	93.838	5 R01 HL145372-02	UNIVERSITY OF CALIFORNIA AT SAN FRANCISCO	5 R01 HL145372-02		204,367	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
LUNG DISEASES RESEARCH	93.838	5 R35 HL140026-03	UNIVERSITY OF CALIFORNIA AT SAN FRANCISCO	5 R35 HL140026-03		60,691	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
LUNG DISEASES RESEARCH	93.838	5 R35 HL140026-04	UNIVERSITY OF CALIFORNIA AT SAN FRANCISCO	5 R35 HL140026-04		25,524	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
LUNG DISEASES RESEARCH	93.838	5 UG1 HL139119-05	UNIVERSITY OF KANSAS	5 UG1 HL139119-05		35,423	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
LUNG DISEASES RESEARCH	93.838	5 U24 HL138998-04	UNIVERSITY OF NORTH CAROLINA	5 U24 HL138998-04		425	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
LUNG DISEASES RESEARCH	93.838	1 R01 HL134015-01	UNIVERSITY OF PENNSYLVANIA	1 R01 HL134015-01		(137)	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
LUNG DISEASES RESEARCH	93.838	1 R01 HL135144-02	UNIVERSITY OF PITTSBURGH	1 R01 HL135144-02		112,683	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
LUNG DISEASES RESEARCH	93.838	5 U01 HL128954-04	UNIVERSITY OF PITTSBURGH	5 U01 HL128954-04		221	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
LUNG DISEASES RESEARCH	93.838	15FED1511233-0006	VETERANS AFFAIRS	15FED1511233-0006	131,321	180,458	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
LUNG DISEASES RESEARCH	93.838	20FED20000031PSE	VETERANS AFFAIRS	20FED20000031PSE		54,255	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
LUNG DISEASES RESEARCH	93.838	2 R44 HL140709-02	VIRTUOSO SURGICAL	2 R44 HL140709-02		43,312	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
LUNG DISEASES RESEARCH	93.838	5 R01 HL130876-05	WASHINGTON UNIVERSITY IN ST. LOUIS	5 R01 HL130876-05		18,694	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
LUNG DISEASES RESEARCH	93.838	5 U01 HL130045-05	WASHINGTON UNIVERSITY IN ST. LOUIS	5 U01 HL130045-05		14,425	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
LUNG DISEASES RESEARCH	93.838	5 P01 HL092870-09				(793)	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
LUNG DISEASES RESEARCH	93.838	5 U01 HL123033-06				(263)	18,199,332	RESEARCH AND DEVELOPMENT	425,311,746
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	5 K23 HL138291-04				141,072	3,489,035	RESEARCH AND DEVELOPMENT	425,311,746
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	5 K23 HL141447-03				48,686	3,489,035	RESEARCH AND DEVELOPMENT	425,311,746
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	5 K24 HL147017-02				96,915	3,489,035	RESEARCH AND DEVELOPMENT	425,311,746
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	5 K08 HL150282-03				104,870	3,489,035	RESEARCH AND DEVELOPMENT	425,311,746
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	1 OT3 HL147810-01			21,963	482,170	3,489,035	RESEARCH AND DEVELOPMENT	425,311,746
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	5 R01 HL124159-08				430,620	3,489,035	RESEARCH AND DEVELOPMENT	425,311,746
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	5 R01 HL130018-04			32,129	265,793	3,489,035	RESEARCH AND DEVELOPMENT	425,311,746
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	5 R01 HL133559-04				339,990	3,489,035	RESEARCH AND DEVELOPMENT	425,311,746
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	5 R35 HL140025-03				384,936	3,489,035	RESEARCH AND DEVELOPMENT	425,311,746
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	5 R35 HL140025-04				552,984	3,489,035	RESEARCH AND DEVELOPMENT	425,311,746
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	5 R01 HL141943-04				329,458	3,489,035	RESEARCH AND DEVELOPMENT	425,311,746
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	1 U01 HL156620-01				59,859	3,489,035	RESEARCH AND DEVELOPMENT	425,311,746
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	5 R01 HL089456-08	CORNELL UNIVERSITY	5 R01 HL089456-08		(60)	3,489,035	RESEARCH AND DEVELOPMENT	425,311,746



**VANDERBILT UNIVERSITY MEDICAL CENTER**  
**SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS (CONTINUED)**  
Fiscal Period 7/1/2020 – 6/30/2021

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
			EASTERN COOPERATIVE ONCOLOGY GROUP						
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	5 U10 CA180820-05		5 U10 CA180820-05	\$ -	\$ (9,044)	\$ 3,489,035	RESEARCH AND DEVELOPMENT	\$ 425,311,746
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	5 U01 HL128566-05	EMORY UNIVERSITY	5 U01 HL128566-05		17,147	3,489,035	RESEARCH AND DEVELOPMENT	425,311,746
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	5 U01 HL128568-05	EMORY UNIVERSITY	5 U01 HL128568-05		1,575	3,489,035	RESEARCH AND DEVELOPMENT	425,311,746
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	5 UG1 HL138645-04	MOUNT SINAI SCHOOL OF MEDICINE NATIONAL MARROW DONOR PROGRAM	5 UG1 HL138645-04		18,966	3,489,035	RESEARCH AND DEVELOPMENT	425,311,746
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	1 U24 HL138660-01		1 U24 HL138660-01		(3,477)	3,489,035	RESEARCH AND DEVELOPMENT	425,311,746
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	7 K23 HL141447-04	OHIO STATE UNIVERSITY OREGON HEALTH & SCIENCE UNIVERSITY	7 K23 HL141447-04		10,333	3,489,035	RESEARCH AND DEVELOPMENT	425,311,746
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	2 R01 HL101972-11	OHIO STATE UNIVERSITY OREGON HEALTH & SCIENCE UNIVERSITY	2 R01 HL101972-11		46,237	3,489,035	RESEARCH AND DEVELOPMENT	425,311,746
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	5 R01 HL144113-03	OHIO STATE UNIVERSITY	5 R01 HL144113-03		69,703	3,489,035	RESEARCH AND DEVELOPMENT	425,311,746
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	5 U01 HL133817-05	RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY	5 U01 HL133817-05		34,554	3,489,035	RESEARCH AND DEVELOPMENT	425,311,746
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	5 U01 HL133996-04	ST. JUDE HOSPITAL UNIVERSITY OF ALABAMA AT BIRMINGHAM	5 U01 HL133996-04		3,466	3,489,035	RESEARCH AND DEVELOPMENT	425,311,746
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	7 R01 HL133896-04	UNIVERSITY OF ALABAMA AT BIRMINGHAM	7 R01 HL133896-04		28,703	3,489,035	RESEARCH AND DEVELOPMENT	425,311,746
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	2 R01 HL118979-05	UNIVERSITY OF MINNESOTA	2 R01 HL118979-05		32,093	3,489,035	RESEARCH AND DEVELOPMENT	425,311,746
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	5 U01 HL133815-02	UNIVERSITY OF PITTSBURGH	5 U01 HL133815-02		1,486	3,489,035	RESEARCH AND DEVELOPMENT	425,311,746
TRANSLATION AND IMPLEMENTATION SCIENCE RESEARCH FOR HEART, LUNG, BLOOD DISEASES, AND SLEEP DISORDERS	93.840	5 K12 HL137943-04			166,661	854,199	3,392,815	RESEARCH AND DEVELOPMENT	425,311,746
TRANSLATION AND IMPLEMENTATION SCIENCE RESEARCH FOR HEART, LUNG, BLOOD DISEASES, AND SLEEP DISORDERS	93.840	1 UG3 HL154297-01	NORTHWESTERN UNIVERSITY	1 UG3 HL154297-01		16,811	3,392,815	RESEARCH AND DEVELOPMENT	425,311,746
TRANSLATION AND IMPLEMENTATION SCIENCE RESEARCH FOR HEART, LUNG, BLOOD DISEASES, AND SLEEP DISORDERS	93.840	1 R01 HL146781-01	OHIO STATE UNIVERSITY	1 R01 HL146781-01		25,251	3,392,815	RESEARCH AND DEVELOPMENT	425,311,746
COVID-19 TRANSLATION AND IMPLEMENTATION SCIENCE RESEARCH FOR HEART, LUNG, BLOOD DISEASES, AND SLEEP DISORDERS	93.840	COVID-19 1 OT2 HL156812-01	RESEARCH TRIANGLE INSTITUTE	1 OT2 HL156812-01		662,700	3,392,815	RESEARCH AND DEVELOPMENT	425,311,746
COVID-19 TRANSLATION AND IMPLEMENTATION SCIENCE RESEARCH FOR HEART, LUNG, BLOOD DISEASES, AND SLEEP DISORDERS	93.840	COVID-19 1 OT2 HL156812-01	RESEARCH TRIANGLE INSTITUTE	1 OT2 HL156812-01		1,762,783	3,392,815	RESEARCH AND DEVELOPMENT	425,311,746
TRANSLATION AND IMPLEMENTATION SCIENCE RESEARCH FOR HEART, LUNG, BLOOD DISEASES, AND SLEEP DISORDERS	93.840	5 U01 HL142103-03	SEATTLE INSTITUTE FOR BIOMEDICAL AND CLINICAL RESEARCH	5 U01 HL142103-03		8,708	3,392,815	RESEARCH AND DEVELOPMENT	425,311,746
TRANSLATION AND IMPLEMENTATION SCIENCE RESEARCH FOR HEART, LUNG, BLOOD DISEASES, AND SLEEP DISORDERS	93.840	1 R01 HL154153-01	UNIVERSITY OF PITTSBURGH	1 R01 HL154153-01		62,363	3,392,815	RESEARCH AND DEVELOPMENT	425,311,746
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	5 K01 AR072123-05				97,106	3,011,419	RESEARCH AND DEVELOPMENT	425,311,746
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	5 K08 AR072757-04				183,827	3,011,419	RESEARCH AND DEVELOPMENT	425,311,746
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	5 R01 AR060846-08			244,010	484,173	3,011,419	RESEARCH AND DEVELOPMENT	425,311,746
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	5 R21 AR067871-02			(6,565)	-	3,011,419	RESEARCH AND DEVELOPMENT	425,311,746
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1 R21 AR072483-01A1				14,704	3,011,419	RESEARCH AND DEVELOPMENT	425,311,746
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	5 R01 AR073001-03				120,525	3,011,419	RESEARCH AND DEVELOPMENT	425,311,746
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	5 R21 AR073133-02			3,395	8,413	3,011,419	RESEARCH AND DEVELOPMENT	425,311,746
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	5 R01 AR073764-03				402,975	3,011,419	RESEARCH AND DEVELOPMENT	425,311,746
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	5 R01 AR073831-02			(12,244)	217,320	3,011,419	RESEARCH AND DEVELOPMENT	425,311,746
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	5 R21 AR074261-02				62,268	3,011,419	RESEARCH AND DEVELOPMENT	425,311,746
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	5 R01 AR076516-02				286,321	3,011,419	RESEARCH AND DEVELOPMENT	425,311,746
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	2 R01 AR055557-11A1	BRIGHAM AND WOMEN'S HOSPITAL	2 R01 AR055557-11A1		18,253	3,011,419	RESEARCH AND DEVELOPMENT	425,311,746
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	5 R01 AR074131-02	CASE WESTERN RESERVE UNIVERSITY	5 R01 AR074131-02		62,683	3,011,419	RESEARCH AND DEVELOPMENT	425,311,746
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	5 R01 AR075422-02	CASE WESTERN RESERVE UNIVERSITY	5 R01 AR075422-02		112,841	3,011,419	RESEARCH AND DEVELOPMENT	425,311,746
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	2 R01 AR053684-10	CLEVELAND CLINIC FOUNDATION	2 R01 AR053684-10		351,325	3,011,419	RESEARCH AND DEVELOPMENT	425,311,746
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	5 R01 AR073874-04	EMORY UNIVERSITY	5 R01 AR073874-04		67,315	3,011,419	RESEARCH AND DEVELOPMENT	425,311,746
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1 R01 AR073773-01A1	STANFORD UNIVERSITY	1 R01 AR073773-01A1		23,951	3,011,419	RESEARCH AND DEVELOPMENT	425,311,746
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	3 P50 AR060772-08S1	UNIVERSITY OF ALABAMA AT BIRMINGHAM	3 P50 AR060772-08S1		88,453	3,011,419	RESEARCH AND DEVELOPMENT	425,311,746
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1 UG3 AR076387-01	UNIVERSITY OF IOWA	1 UG3 AR076387-01		20,312	3,011,419	RESEARCH AND DEVELOPMENT	425,311,746
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	4 UH3 AR076387-02	UNIVERSITY OF IOWA	4 UH3 AR076387-02		86,166	3,011,419	RESEARCH AND DEVELOPMENT	425,311,746

**VANDERBILT UNIVERSITY MEDICAL CENTER  
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS (CONTINUED)  
Fiscal Period 7/1/2020 – 6/30/2021**

<i>Federal Awarding Agency/Program Title</i>	<i>Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	5 R01 AR073486-02	UNIVERSITY OF SOUTHERN CALIFORNIA	5 R01 AR073486-02	\$ -	\$ 8,787	\$ 3,011,419	RESEARCH AND DEVELOPMENT	\$ 425,311,746
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1 R01 AR074989-01A1	UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER AT DALLAS	1 R01 AR074989-01A1		71,712	3,011,419	RESEARCH AND DEVELOPMENT	425,311,746
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	5 R01 AR064772-05	VANDERBILT UNIVERSITY	5 R01 AR064772-05		103	3,011,419	RESEARCH AND DEVELOPMENT	425,311,746
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1 R21 AR074589-02	VANDERBILT UNIVERSITY	1 R21 AR074589-02		1,425	3,011,419	RESEARCH AND DEVELOPMENT	425,311,746
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	5 T32 AR059039-08	VANDERBILT UNIVERSITY	5 T32 AR059039-08		51,444	3,011,419	RESEARCH AND DEVELOPMENT	425,311,746
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	5 T32 AR059039-09	VANDERBILT UNIVERSITY	5 T32 AR059039-09		19,215	3,011,419	RESEARCH AND DEVELOPMENT	425,311,746
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	5 T32 AR059039-09	VANDERBILT UNIVERSITY	5 T32 AR059039-09		59,546	3,011,419	RESEARCH AND DEVELOPMENT	425,311,746
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	5 T32 AR059039-09	VANDERBILT UNIVERSITY	5 T32 AR059039-09		8,651	3,011,419	RESEARCH AND DEVELOPMENT	425,311,746
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	5 T32 AR059039-10	VANDERBILT UNIVERSITY	5 T32 AR059039-10		63,427	3,011,419	RESEARCH AND DEVELOPMENT	425,311,746
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	5 T32 AR059039-10	VANDERBILT UNIVERSITY	5 T32 AR059039-10		11,879	3,011,419	RESEARCH AND DEVELOPMENT	425,311,746
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	5 T32 AR059039-10	VANDERBILT UNIVERSITY	5 T32 AR059039-10		5,219	3,011,419	RESEARCH AND DEVELOPMENT	425,311,746
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	5 T32 AR059039-11	VANDERBILT UNIVERSITY	5 T32 AR059039-11		1,080	3,011,419	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 T32 DK007061-46				5,354	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2 T32 DK007673-27				3,914	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK056942-16				195,167	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 P30 DK058404-18			124,934	124,934	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK093660-09				325,808	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	7 U01 DK105556-05				365,889	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 U01 DK110804-05			24,989	24,989	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 P30 DK114809-03			24,014	24,014	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 F32 DK116520-03				4,355	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 F32 DK116520-04				63,437	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1 F32 DK127679-01A1				11,024	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 K23 DK103910-06				77,937	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 K01 DK106311-04				21,415	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 K23 DK106511-05				72,360	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 K01 DK109019-03				731	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 K23 DK114566-03				202,025	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 K01 DK117969-03				131,559	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 K23 DK118118-03				199,598	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 K23 DK118192-03				157,965	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 K01 DK120631-02				125,078	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 K01 DK121869-03				79,352	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1 K23 DK123392-01A1				133,145	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 K01 DK123495-02				137,460	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 K08 DK124686-02				111,231	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 P30 DK020593-42S1			15,729	68,868	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 P30 DK020593-43			606,547	2,056,605	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 P30 DK020593-44			15,806	410,280	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 P30 DK058404-19			119,241	1,123,012	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 P30 DK058404-20				62,284	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 P30 DK092986-10			17,748	76,161	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 P30 DK092986-11			79,570	561,205	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 P30 DK114809-04				1,052,122	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1 P20 DK123967-01				(93)	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 P20 DK123967-02				358,302	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK113423-03				269,013	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2 R01 DK018381-49				1,065,888	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK048370-25				415,504	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK051265-24				173,743	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2 R01 DK051265-25A1				195,234	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	7 R01 DK051610-25				284,736	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK058587-19				8,385	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK058587-21				384,634	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK062794-18				480,535	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2 R01 DK065138-18				262,149	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK066358-13			61,830	231,758	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746

**VANDERBILT UNIVERSITY MEDICAL CENTER**  
**SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS (CONTINUED)**  
 Fiscal Period 7/1/2020 – 6/30/2021

<i>Federal Awarding Agency/Program Title</i>	<i>Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1 R01 DK069921-16A1			\$ -	\$ 349,568	\$ 42,739,599	RESEARCH AND DEVELOPMENT	\$ 425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK081134-11			29,492	282,574	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK081646-13				397,986	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK093501-10			305,590	625,164	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2 R01 DK093501-11				20,364	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK095785-09				601,902	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK099467-08				529,799	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK100431-04				(160)	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	6 R01 DK100694-05				51,058	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK101332-08			10,283	652,259	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK101791-05				118	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R24 DK103067-06			18,126	292,795	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK103935-06			30,338	107,106	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK104817-05				182,252	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK105371-06				156,537	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK105550-09			9,533	620,108	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK105847-05				12,040	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R24 DK106755-06			678,915	822,094	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK108159-05			(1,523)	(1,523)	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK108968-05			1,437	119,720	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK109102-06			22,352	290,406	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2 R01 DK109102-07				44,093	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK110166-05			44,160	313,707	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK111554-05			35,836	412,096	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK111671-04				386,621	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK112262-06				454,213	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK112688-04				283,124	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK115545-02			4,577	393,777	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1 R01 DK116625-01			86,400	624,253	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK116957-03			609,729	705,330	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK116964-04				411,149	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK117144-04			17,856	533,598	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK117875-03			14,127	696,379	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1 R01 DK118407-01A1				120,494	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK119212-03				328,740	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK119282-03			26,415	738,862	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1 R03 DK119733-01				44,217	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R03 DK119735-02				97,435	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK120025-03				389,130	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK120626-2				571,532	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK120814-02			26,575	475,165	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK120821-02			106,585	246,174	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK121101-03				344,895	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK121316-03			347,990	665,079	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1 R01 DK122075-02				241,427	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK122147-02			80,650	617,171	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R18 DK123373-03				668,671	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R03 DK123489-02				210,165	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1 R01 DK124845-01A1				161,446	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK125895-02			40,216	475,960	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1 R01 DK126721-01				109,665	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1 R56 DK126890-01				194,562	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1 R21 DK127075-01				25,729	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1 R01 DK128200-01				85,539	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1 R56 DK128337-01				49,124	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R25 DK096999-10				82,307	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 T32 DK007061-47				312,442	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 T35 DK007383-40				(4,600)	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 T35 DK007383-41				23,625	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 T35 DK007383-42				51,351	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746

**VANDERBILT UNIVERSITY MEDICAL CENTER**  
**SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS (CONTINUED)**  
Fiscal Period 7/1/2020 – 6/30/2021

<i>Federal Awarding Agency/Program Title</i>	<i>Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 T32 DK007569-31			\$ -	\$ (2,534)	\$ 42,739,599	RESEARCH AND DEVELOPMENT	\$ 425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2 T32 DK007569-32				297,887	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 T32 DK007673-28				442,849	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 U01 DK082192-11				28,385	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 U01 DK085465-10				91,150	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 U01 DK099923-06				7,712	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 U01 DK110804-06				361,207	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1 UC4 DK112232-01			1,788,456	2,473,227	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 U01 DK112271-03			31,016	111,105	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 U01 DK112271-04			139,197	496,463	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 U01 DK116093-03			8,750	13,829	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 U01 DK116093-04				290,403	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1 U01 DK123716-01			787,258	943,234	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 U01 DK123716-02			623,545	1,022,575	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1 U01 DK123821-01			140,399	259,286	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1 U34 DK123895-01			37,065	86,385	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 U34 DK123895-02				173,185	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R18 DK118471-03	ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY	5 R18 DK118471-03		8,106	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R18 DK118471-04	ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY	5 R18 DK118471-04		131,269	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 U24 DK076169-12	AUGUSTA UNIVERSITY	5 U24 DK076169-12		(8)	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 U24 DK076169-13	AUGUSTA UNIVERSITY	5 U24 DK076169-13		52,207	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 U24 DK115255-03	AUGUSTA UNIVERSITY	5 U24 DK115255-03		24,387	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK115392-03	BRIGHAM AND WOMEN'S HOSPITAL	5 R01 DK115392-03		74,224	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK115392-04	BRIGHAM AND WOMEN'S HOSPITAL	5 R01 DK115392-04		4,811	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK116898-03	BRIGHAM AND WOMEN'S HOSPITAL	5 R01 DK116898-03		2,651	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK116898-03	BRIGHAM AND WOMEN'S HOSPITAL	5 R01 DK116898-03		29,477	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1 DP3 DK114812-01	CASE WESTERN RESERVE UNIVERSITY	1 DP3 DK114812-01		(7)	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 U01 DK094157-09	CASE WESTERN RESERVE UNIVERSITY	5 U01 DK094157-09		(144)	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 U01 DK094157-10	CASE WESTERN RESERVE UNIVERSITY	5 U01 DK094157-10		163,670	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2 UC4 DK098085-02	CITY OF HOPE	2 UC4 DK098085-02		3	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2 UC4 DK098085-03	CITY OF HOPE	2 UC4 DK098085-03		249,998	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK113201-02	DARTMOUTH COLLEGE	5 R01 DK113201-02	9,725	15,366	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK113201-03	DARTMOUTH COLLEGE	5 R01 DK113201-03		89,946	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 U24 DK065176-18	DUKE UNIVERSITY	5 U24 DK065176-18		37,853	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 U01 DK098246-08	GEORGE WASHINGTON UNIVERSITY	5 U01 DK098246-08		44,782	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 U01 DK098246-09	GEORGE WASHINGTON UNIVERSITY	5 U01 DK098246-09		426,579	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1 R01 DK120598-01A1	HARVARD PILGRIM HEALTH CARE	1 R01 DK120598-01A1		55,591	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK110375-05	JOHNS HOPKINS UNIVERSITY	5 R01 DK110375-05		214,616	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746

**VANDERBILT UNIVERSITY MEDICAL CENTER**  
**SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS (CONTINUED)**  
Fiscal Period 7/1/2020 – 6/30/2021

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	3 U01 DK104833-06S1	MEDICAL UNIVERSITY OF SOUTH CAROLINA	3 U01 DK104833-06S1	\$ -	\$ 5,257	\$ 42,739,599	RESEARCH AND DEVELOPMENT	\$ 425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2 U01 DK100866-07	NATIONWIDE CHILDREN'S HOSPITAL	2 U01 DK100866-07		1,579	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2 R01 DK092217-05A1	NORTHWESTERN UNIVERSITY	2 R01 DK092217-05A1		(3)	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1 U01 DK123743-02	STANFORD UNIVERSITY	1 U01 DK123743-02		145,356	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1 R01 DK114485-01A1	STATE UNIVERSITY OF NEW YORK (SUNY)	1 R01 DK114485-01A1		7,053	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	3 P30 DK079337-12S1	UNIVERSITY OF ALABAMA AT BIRMINGHAM	3 P30 DK079337-12S1		64,951	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 P30 DK079337-13S1	UNIVERSITY OF ALABAMA AT BIRMINGHAM	5 P30 DK079337-13S1		49,320	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK113980-03	UNIVERSITY OF ALABAMA AT BIRMINGHAM	5 R01 DK113980-03	17,504	53,394	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK113980-04	UNIVERSITY OF ALABAMA AT BIRMINGHAM	5 R01 DK113980-04		47,520	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK108438-05	UNIVERSITY OF CALIFORNIA AT LOS ANGELES	5 R01 DK108438-05		1,577	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1 RC2 DK118640-01A1	UNIVERSITY OF CALIFORNIA AT LOS ANGELES	1 RC2 DK118640-01A1	20,089	399,729	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1 R01 DK122797-01	UNIVERSITY OF CALIFORNIA AT SAN FRANCISCO	1 R01 DK122797-01		134,221	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2 U01 DK120429-02	UNIVERSITY OF CALIFORNIA, SAN DIEGO	2 U01 DK120429-02		2,780	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 U01 DK120429-02	UNIVERSITY OF CALIFORNIA, SAN DIEGO	5 U01 DK120429-02		30,022	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1 U54 DK118612-02	UNIVERSITY OF CHICAGO	1 U54 DK118612-02		(11,665)	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 U54 DK118612-03	UNIVERSITY OF CHICAGO	5 U54 DK118612-03		91,322	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1 R01 DK123330-01A1	UNIVERSITY OF CINCINNATI	1 R01 DK123330-01A1		12,630	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1 R01 DK110375-02	UNIVERSITY OF MARYLAND	1 R01 DK110375-02		2,307	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 U01 DK120456-02	UNIVERSITY OF MIAMI	5 U01 DK120456-02	24,343	66,787	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 U01 DK120456-03	UNIVERSITY OF MIAMI	5 U01 DK120456-03	46,994	301,104	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1 R01 DK121709-01A1	UNIVERSITY OF MICHIGAN	1 R01 DK121709-01A1		23,670	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2 U01 DK100867-07	UNIVERSITY OF NORTH CAROLINA	2 U01 DK100867-07		2,710	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2 U01 DK100867-08	UNIVERSITY OF NORTH CAROLINA	2 U01 DK100867-08		31,666	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2 U01 DK100867-09	UNIVERSITY OF NORTH CAROLINA	2 U01 DK100867-09		130	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R24 DK090964-10	UNIVERSITY OF OKLAHOMA	5 R24 DK090964-10		69,035	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2 R01 DK087635-11A1	UNIVERSITY OF PENNSYLVANIA	2 R01 DK087635-11A1		12,573	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2 R01 DK087635-11A1	UNIVERSITY OF PENNSYLVANIA	2 R01 DK087635-11A1		6,479	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK087635-12	UNIVERSITY OF PENNSYLVANIA	5 R01 DK087635-12		8,549	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R18 DK118460-02	UNIVERSITY OF PITTSBURGH	5 R18 DK118460-02		9,135	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1 UC2 DK126122-01	UNIVERSITY OF PITTSBURGH	1 UC2 DK126122-01		206,168	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746

**VANDERBILT UNIVERSITY MEDICAL CENTER**  
**SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS (CONTINUED)**  
Fiscal Period 7/1/2020 – 6/30/2021

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1 UC2 DK126122-02	UNIVERSITY OF PITTSBURGH	1 UC2 DK126122-02	\$ -	\$ 25,813	\$ 42,739,599	RESEARCH AND DEVELOPMENT	\$ 425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 U01 DK085465-07	UNIVERSITY OF SOUTH FLORIDA	5 U01 DK085465-07		83,595	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2 U01 DK106993-02	UNIVERSITY OF SOUTH FLORIDA	2 U01 DK106993-02		(25,670)	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 U01 DK106993-03	UNIVERSITY OF SOUTH FLORIDA	5 U01 DK106993-03		266,503	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK038217-25	UNIVERSITY OF TEXAS UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER AT DALLAS	5 R01 DK038217-25		1,338	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	7 R01 DK108159-06	UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER AT DALLAS	7 R01 DK108159-06		7,191	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1 R01 DK127589-01	UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER AT DALLAS	1 R01 DK127589-01		6,805	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1 R01 DK124063-01	UNIVERSITY OF WASHINGTON	1 R01 DK124063-01		192,288	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2 R01 DK050277-24	VANDERBILT UNIVERSITY	2 R01 DK050277-24		29,603	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK059402-20	VANDERBILT UNIVERSITY	5 R01 DK059402-20		27,876	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2 R01 DK103831-06	VANDERBILT UNIVERSITY	2 R01 DK103831-06		15,990	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK106228-04	VANDERBILT UNIVERSITY	5 R01 DK106228-04		3,018	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK111949-03	VANDERBILT UNIVERSITY	5 R01 DK111949-03		(17,836)	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1 R01 DK117147-01A1	VANDERBILT UNIVERSITY	1 R01 DK117147-01A1		352,135	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1 R01 DK119508-02	VANDERBILT UNIVERSITY	1 R01 DK119508-02		14,467	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1 R01 DK121520-01A1	VANDERBILT UNIVERSITY	1 R01 DK121520-01A1		1,882	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 T32 DK007563-33	VANDERBILT UNIVERSITY	5 T32 DK007563-33		53,067	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 T32 DK101003-07	VANDERBILT UNIVERSITY	5 T32 DK101003-07		53,979	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 T32 DK101003-08	VANDERBILT UNIVERSITY	5 T32 DK101003-08		24,769	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 U2C DK059637-19	VANDERBILT UNIVERSITY	5 U2C DK059637-19		3,758	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 U2C DK059637-20	VANDERBILT UNIVERSITY	5 U2C DK059637-20		257,017	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	3 U2C DK059637-20S1	VANDERBILT UNIVERSITY	3 U2C DK059637-20S1		103,645	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1 UC4 DK108120-01	VANDERBILT UNIVERSITY	1 UC4 DK108120-01		11,958	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK111175-04	WASHINGTON UNIVERSITY IN ST. LOUIS	5 R01 DK111175-04		538	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 P30 DK058404-18				(25,916)	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 U01 DK110804-05				(31,989)	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 P30 DK114809-03				(13,321)	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK108159-05				(15,865)	42,739,599	RESEARCH AND DEVELOPMENT	425,311,746
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 K23 NS113858-02				202,855	10,918,376	RESEARCH AND DEVELOPMENT	425,311,746
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 T32 NS007491-19			19,139	19,139	10,918,376	RESEARCH AND DEVELOPMENT	425,311,746
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 R01 NS094041-05			160,639	280,695	10,918,376	RESEARCH AND DEVELOPMENT	425,311,746

**VANDERBILT UNIVERSITY MEDICAL CENTER**  
**SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS (CONTINUED)**  
 Fiscal Period 7/1/2020 – 6/30/2021

<i>Federal Awarding Agency/Program Title</i>	<i>Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 U24 NS107128-02			\$ -	\$ 9,155	\$ 10,918,376	RESEARCH AND DEVELOPMENT	\$ 425,311,746
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 R01 NS078680-10			11,684	605,435	10,918,376	RESEARCH AND DEVELOPMENT	425,311,746
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 R01 NS092961-06			6,423	514,229	10,918,376	RESEARCH AND DEVELOPMENT	425,311,746
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	2 R01 NS092961-07			789	142,522	10,918,376	RESEARCH AND DEVELOPMENT	425,311,746
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 R01 NS093669-06			393,764	520,836	10,918,376	RESEARCH AND DEVELOPMENT	425,311,746
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 R01 NS096127-06				243,840	10,918,376	RESEARCH AND DEVELOPMENT	425,311,746
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 R00 NS097618-05				90,260	10,918,376	RESEARCH AND DEVELOPMENT	425,311,746
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 R01 NS097763-05				237,798	10,918,376	RESEARCH AND DEVELOPMENT	425,311,746
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 R01 NS097783-05			2,664	350,331	10,918,376	RESEARCH AND DEVELOPMENT	425,311,746
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	3 R01 NS100980-01				464,951	10,918,376	RESEARCH AND DEVELOPMENT	425,311,746
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 R01 NS104149-04				302,967	10,918,376	RESEARCH AND DEVELOPMENT	425,311,746
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1 R01 NS107424-01				492,881	10,918,376	RESEARCH AND DEVELOPMENT	425,311,746
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 R01 NS107424-03				4,435	10,918,376	RESEARCH AND DEVELOPMENT	425,311,746
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 R21 NS107877-02			5,717	86,051	10,918,376	RESEARCH AND DEVELOPMENT	425,311,746
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 R01 NS108445-02			63,288	428,894	10,918,376	RESEARCH AND DEVELOPMENT	425,311,746
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 R01 NS109114-04			17,487	433,633	10,918,376	RESEARCH AND DEVELOPMENT	425,311,746
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 R01 NS110130-03			78,522	396,067	10,918,376	RESEARCH AND DEVELOPMENT	425,311,746
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 R01 NS110661-02			203,819	400,832	10,918,376	RESEARCH AND DEVELOPMENT	425,311,746
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1 R03 NS111486-01				216,270	10,918,376	RESEARCH AND DEVELOPMENT	425,311,746
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 R01 NS112252-03			261,240	613,747	10,918,376	RESEARCH AND DEVELOPMENT	425,311,746
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1 R01 NS113171-01				(47,415)	10,918,376	RESEARCH AND DEVELOPMENT	425,311,746
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 R01 NS113171-02			539,386	1,184,130	10,918,376	RESEARCH AND DEVELOPMENT	425,311,746
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 R01 NS113171-03				8,583	10,918,376	RESEARCH AND DEVELOPMENT	425,311,746
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 R01 NS113832-02			66,506	289,798	10,918,376	RESEARCH AND DEVELOPMENT	425,311,746
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1 R01 NS117816-01A1				81,940	10,918,376	RESEARCH AND DEVELOPMENT	425,311,746
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1 R01 NS118483-01			79,516	224,902	10,918,376	RESEARCH AND DEVELOPMENT	425,311,746
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 R01 NS118483-02				41,542	10,918,376	RESEARCH AND DEVELOPMENT	425,311,746
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 T32 NS007491-20				9,671	10,918,376	RESEARCH AND DEVELOPMENT	425,311,746
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 T32 NS007491-20			16,780	128,970	10,918,376	RESEARCH AND DEVELOPMENT	425,311,746
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 U54 NS065736-10			136,091	136,091	10,918,376	RESEARCH AND DEVELOPMENT	425,311,746

**VANDERBILT UNIVERSITY MEDICAL CENTER**  
**SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS (CONTINUED)**  
 Fiscal Period 7/1/2020 – 6/30/2021

<i>Federal Awarding Agency/Program Title</i>	<i>Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 U24 NS107128-03			\$ -	\$ 311,920	\$ 10,918,376	RESEARCH AND DEVELOPMENT	\$ 425,311,746
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1 UF1 NS107666-01			191,765	448,583	10,918,376	RESEARCH AND DEVELOPMENT	425,311,746
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 K12 NS080223-09	ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY	5 K12 NS080223-09		60,885	10,918,376	RESEARCH AND DEVELOPMENT	425,311,746
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1 R01 NS116148-01A1	CHILDREN'S NATIONAL MEDICAL CENTER	1 R01 NS116148-01A1		19,939	10,918,376	RESEARCH AND DEVELOPMENT	425,311,746
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1 U24 NS114416-01	DUKE UNIVERSITY	1 U24 NS114416-01		13,619	10,918,376	RESEARCH AND DEVELOPMENT	425,311,746
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 R01 NS105746-02	MASSACHUSETTS GENERAL HOSPITAL	5 R01 NS105746-02		43,843	10,918,376	RESEARCH AND DEVELOPMENT	425,311,746
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 R01 NS102371-03	MASSACHUSETTS GENERAL HOSPITAL	5 R01 NS102371-03		22,094	10,918,376	RESEARCH AND DEVELOPMENT	425,311,746
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1 U01 NS088312-01	MASSACHUSETTS GENERAL HOSPITAL	1 U01 NS088312-01		128	10,918,376	RESEARCH AND DEVELOPMENT	425,311,746
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1 U01 NS088312-01	MASSACHUSETTS GENERAL HOSPITAL	1 U01 NS088312-01		43,162	10,918,376	RESEARCH AND DEVELOPMENT	425,311,746
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1 U01 NS096767-01	MASSACHUSETTS GENERAL HOSPITAL	1 U01 NS096767-01		(9,606)	10,918,376	RESEARCH AND DEVELOPMENT	425,311,746
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 U01 NS080168-05	MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH	5 U01 NS080168-05		25,100	10,918,376	RESEARCH AND DEVELOPMENT	425,311,746
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 R01 NS097512-05	THE MCLEAN HOSPITAL CORPORATION	5 R01 NS097512-05		63,768	10,918,376	RESEARCH AND DEVELOPMENT	425,311,746
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 R01 NS104339-03	UNIVERSITY OF ALABAMA AT BIRMINGHAM	5 R01 NS104339-03		8,370	10,918,376	RESEARCH AND DEVELOPMENT	425,311,746
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 R01 NS104339-04	UNIVERSITY OF ALABAMA AT BIRMINGHAM	5 R01 NS104339-04		13,331	10,918,376	RESEARCH AND DEVELOPMENT	425,311,746
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1 R01 NS112171-02	UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCE	1 R01 NS112171-02		8,819	10,918,376	RESEARCH AND DEVELOPMENT	425,311,746
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1 R01 NS104094-01	UNIVERSITY OF CALIFORNIA AT SAN FRANCISCO	1 R01 NS104094-01		4,779	10,918,376	RESEARCH AND DEVELOPMENT	425,311,746
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1 R01 NS096173-01A1	UNIVERSITY OF CALIFORNIA AT SAN FRANCISCO	1 R01 NS096173-01A1		51,593	10,918,376	RESEARCH AND DEVELOPMENT	425,311,746
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1 U01 NS092764-01A1	UNIVERSITY OF CALIFORNIA AT SAN FRANCISCO	1 U01 NS092764-01A1		2,056	10,918,376	RESEARCH AND DEVELOPMENT	425,311,746
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 U01 NS092764-04	UNIVERSITY OF CALIFORNIA AT SAN FRANCISCO	5 U01 NS092764-04		459	10,918,376	RESEARCH AND DEVELOPMENT	425,311,746
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 U01 NS092764-05	UNIVERSITY OF CALIFORNIA AT SAN FRANCISCO	5 U01 NS092764-05		23,617	10,918,376	RESEARCH AND DEVELOPMENT	425,311,746
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 U01 NS095869-02	UNIVERSITY OF CINCINNATI	5 U01 NS095869-02		10,372	10,918,376	RESEARCH AND DEVELOPMENT	425,311,746
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1 U01 NS100699-01A1	UNIVERSITY OF CINCINNATI	1 U01 NS100699-01A1		13,510	10,918,376	RESEARCH AND DEVELOPMENT	425,311,746
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1 U01 NS110728-01	UNIVERSITY OF CINCINNATI	1 U01 NS110728-01		1,294	10,918,376	RESEARCH AND DEVELOPMENT	425,311,746
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1 R01 NS100996-02	UNIVERSITY OF LOUISVILLE	1 R01 NS100996-02		57,707	10,918,376	RESEARCH AND DEVELOPMENT	425,311,746
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1 RF1 NS113285-01	UNIVERSITY OF NORTH CAROLINA	1 RF1 NS113285-01		167,127	10,918,376	RESEARCH AND DEVELOPMENT	425,311,746
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	2 U01 NS061799-07	UNIVERSITY OF ROCHESTER	2 U01 NS061799-07		1,432	10,918,376	RESEARCH AND DEVELOPMENT	425,311,746
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1 U01 NS107486-01A1	UNIVERSITY OF UTAH	1 U01 NS107486-01A1		3,271	10,918,376	RESEARCH AND DEVELOPMENT	425,311,746
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1 U01 NS107486-02	UNIVERSITY OF UTAH	1 U01 NS107486-02		17,453	10,918,376	RESEARCH AND DEVELOPMENT	425,311,746
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 R01 NS096238-04	VANDERBILT UNIVERSITY	5 R01 NS096238-04		12,066	10,918,376	RESEARCH AND DEVELOPMENT	425,311,746
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1 R01 NS104497-01	VANDERBILT UNIVERSITY	1 R01 NS104497-01		9,306	10,918,376	RESEARCH AND DEVELOPMENT	425,311,746



**VANDERBILT UNIVERSITY MEDICAL CENTER**  
**SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS (CONTINUED)**  
 Fiscal Period 7/1/2020 – 6/30/2021

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	4 R33 NS109521-02	VANDERBILT UNIVERSITY	4 R33 NS109521-02	\$ -	\$ 43,295	\$ 10,918,376	RESEARCH AND DEVELOPMENT	\$ 425,311,746
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1 R01 NS110665-01A1	VANDERBILT UNIVERSITY	1 R01 NS110665-01A1		8,561	10,918,376	RESEARCH AND DEVELOPMENT	425,311,746
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1 R01 NS118580-01	VANDERBILT UNIVERSITY	1 R01 NS118580-01		113,142	10,918,376	RESEARCH AND DEVELOPMENT	425,311,746
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1 R01 NS120518-01	VANDERBILT UNIVERSITY	1 R01 NS120518-01		15,507	10,918,376	RESEARCH AND DEVELOPMENT	425,311,746
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1 R01 NS107281-01A1	WASHINGTON UNIVERSITY IN ST. LOUIS	1 R01 NS107281-01A1		171,943	10,918,376	RESEARCH AND DEVELOPMENT	425,311,746
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 T32 NS007491-19				(104)	10,918,376	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 T32 AI007474-26				45,975	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	2 R56 AI076121-10A1			18,600	284,087	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 U19 AI095227-10			48,290	167,451	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
<b>COVID-19 ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH</b>	93.855	COVID-19 5 U19 AI095227-10				567,927	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI131722-05			94,375	623,019	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI147765-03			368,358	526,749	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 U01 AI069923-15			285,129	301,512	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 F32 AI143005-02				7	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 F32 AI157215-01				50,238	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 K08 AI106420-06			6,459	20,769	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 K23 AI113150-06				2,310	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 K23 AI118804-06				16,115	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 K23 AI120875-06				127,517	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 K01 AI131895-05				104,856	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 K23 AI141621-03			12,782	178,352	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 K24 AI148459-02				187,195	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 K08 AI151100-02				173,400	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 K99 AI154672-01				82,049	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 K23 AI156132-01				90,847	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 P30 AI110527-05				(2,279)	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	2 P30 AI110527-06			465,675	1,675,635	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 P30 AI110527-07				179,443	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI039657-24			33,994	277,221	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI044924-19				12,153	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI051448-19				403,625	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	6 R01 AI069233-12				427,942	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI073843-11				47,776	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	2 R01 AI073843-12A1				14,305	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI077505-11			312,659	546,102	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	2 R01 AI077505-12				45,828	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	2 R01 AI093234-07:08			194,055	415,713	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI095755-11			33,854	258,807	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	2 R01 AI095755-12				130,892	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI101171-10			265,799	593,820	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
<b>COVID-19 ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH</b>	93.855	COVID-19 3 R01 AI108197-			129,008	271,032	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
<b>COVID-19 ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH</b>	93.855	COVID-19 5 R01 AI108197-09			144,026	510,782	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI113292-06				(2,935)	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI114816-06			(477)	(477)	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI118932-06			103,922	554,893	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	2 R01 AI118932-07			12,794	240,784	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI120790-04			71,212	483,770	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI124456-05				287,403	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R24 AI124872-06			80,635	678,144	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	2 R24 AI124872-07				12,580	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI125642-05			242,603	820,127	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R21 AI127129-02				12,879	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI127828-05			359,796	662,442	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 R21 AI128281-02			(100)	8,963	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746

**VANDERBILT UNIVERSITY MEDICAL CENTER**  
**SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS (CONTINUED)**  
Fiscal Period 7/1/2020 – 6/30/2021

<i>Federal Awarding Agency/Program Title</i>	<i>Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R21 AI129950-02			\$ -	\$ 1,076	\$ 56,074,347	RESEARCH AND DEVELOPMENT	\$ 425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI130459-05				153,291	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
<b>COVID-19 ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH</b>	93.855	COVID-19 3 R01 AI131722-			31,099	534,813	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI131771-04			245,523	519,970	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI132560-05				408,754	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI134036-04			129,069	525,025	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI136526-03			585,179	706,459	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 R34 AI136815-01			1,351	1,836	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI137082-02			122,754	658,507	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI138581-02			472,589	673,159	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R21 AI139012-01:02			38,611	62,142	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R21 AI139021-02				28,143	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI139046-02				409,002	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI139172-03			7,175	635,347	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 R01 AI141448-01A1				334,276	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R21 AI142042-02			3,926	209,730	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI142095-03				611,821	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
<b>COVID-19 ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH</b>	93.855	COVID-19 3 R21 AI142321-01A1S1				204,171	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R21 AI142321-02				246,756	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
<b>COVID-19 ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH</b>	93.855	COVID-19 3 R21 AI142321-				134,755	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI143710-03			18,026	347,629	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 R21 AI144193-01:02				273,493	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI145265-03				377,731	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R21 AI145397-02				129,893	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R21 AI145686-02			16,309	99,739	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI145992-02			106,779	504,451	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R21 AI146698-02				200,518	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 R13 AI147694-01				636	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R21 AI147768-02				225,166	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R21 AI149207-02				204,194	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R21 AI149262-02				163,426	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R21 AI149303-02				277,593	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI149722-02			38,725	416,574	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R21 AI150302-02				31,947	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R21 AI150384-02				172,623	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 R34 AI150532-01			42,539	201,412	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI150701-02				401,953	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI151210-02				558,655	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 R01 AI152693-01A1			36,159	499,663	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI153167-02				460,126	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R21 AI153769-02				163,570	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R21 AI154016-02				225,502	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R21 AI154064-02			28,426	203,129	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 R01 AI155668-01				137,033	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 R21 AI156292-01				34,348	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 R01 AI158605-01				20,436	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 T32 AI095202-10				19,953	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 T32 AI095202-11				200,891	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 UM1 AI069439-15			934,197	1,624,288	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
<b>COVID-19 ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH</b>	93.855	COVID-19 3 UM1 AI069439-15S1			210,525	247,751	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	2 UM1 AI069439-16			205,160	1,090,393	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 U01 AI069923-16			338,043	1,032,805	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 U19 AI095227-11			39,051	1,261,005	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
<b>COVID-19 ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH</b>	93.855	COVID-19 3 U19 AI095227-				9,182	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 U19 AI117905-04			(472)	-	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 U19 AI117905-05			140,617	316,195	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 U01 AI125135-03			147,809	175,333	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 U01 AI132004-02				16,560	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746

**VANDERBILT UNIVERSITY MEDICAL CENTER**  
**SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS (CONTINUED)**  
 Fiscal Period 7/1/2020 – 6/30/2021

<i>Federal Awarding Agency/Program Title</i>	<i>Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 U01 AI132004-03			\$ 58,260	\$ 201,981	\$ 56,074,347	RESEARCH AND DEVELOPMENT	\$ 425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 UM1 AI148452-01			115,755	268,442	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
<b>COVID-19 ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH</b>	93.855	COVID-19 3 UM1 AI148452-01S2			3,587,972	4,576,237	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 UM1 AI148452-02			31,593	226,423	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
<b>COVID-19 ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH</b>	93.855	COVID-19 5 UM1 AI148452-02S1				28,568	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
<b>COVID-19 ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH</b>	93.855	COVID-19 5 UM1 AI148452-02S2			362,202	1,484,249	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
<b>COVID-19 ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH</b>	93.855	COVID-19 3 UM1 AI148452-01S1				82,667	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 U01 AI150739-01			598,340	1,221,526	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 U01 AI150739-02			52,407	184,250	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 U01 AI152967-01			36,566	700,580	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 U01 AI154659-01			29,033	809,666	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 U01 AI154659-02			6,917	220,608	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 U01 AI155299-01				78,936	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 U01 AI096299-12	ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY	5 U01 AI096299-12		77,258	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 UM1 AI109565-07	BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON	5 UM1 AI109565-07		39,160	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 UM1 AI109565-07	BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON	5 UM1 AI109565-07		28,051	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
<b>COVID-19 ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH</b>	93.855	COVID-19 5 UM1 AI109565-07S1	BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON	5 UM1 AI109565-07S1		584,050	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
<b>COVID-19 ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH</b>	93.855	COVID-19 5 UM1 AI109565-08	BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON	5 UM1 AI109565-08		60,500	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 UM1 AI109565-08	BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON	5 UM1 AI109565-08		10,673	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
<b>COVID-19 ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH</b>	93.855	COVID-19 5 UM1 AI109565-08S1	BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON	5 UM1 AI109565-08S1		826,630	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI134430-02	BOSTON UNIVERSITY	5 R01 AI134430-02		69,236	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI150295-02	BRIGHAM AND WOMEN'S HOSPITAL CHILDREN'S HOSPITAL LOS ANGELES	5 R01 AI150295-02		43,026	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 U01 AI126612-01A1	CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER	1 U01 AI126612-01A1		2,708	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	2 U54 AI117804-06	CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER	2 U54 AI117804-06		14,005	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 U54 AI117804-07	CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER	5 U54 AI117804-07		11,139	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI143370-03	DUKE UNIVERSITY	5 R01 AI143370-03		18,610	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	2 UM1 AI104681-08	DUKE UNIVERSITY	2 UM1 AI104681-08		14,688	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	2 UM1 AI104681-08	DUKE UNIVERSITY	2 UM1 AI104681-08		14,688	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 UM1 AI104681-09	DUKE UNIVERSITY	5 UM1 AI104681-09		21,286	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 UM1 AI104815-09	DUKE UNIVERSITY	5 UM1 AI104815-09		21,286	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI139406-03	EMORY UNIVERSITY	5 R01 AI139406-03		17,992	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 UM1 AI148684-01	EMORY UNIVERSITY	1 UM1 AI148684-01		24,095	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
<b>COVID-19 ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH</b>	93.855	COVID-19 3 UM1 AI148684-01S1	EMORY UNIVERSITY	3 UM1 AI148684-01S1		61,456	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 UM1 AI148684-02	EMORY UNIVERSITY	1 UM1 AI148684-02		23,032	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 UM1 AI068619-12	FAMILY HEALTH INTERNATIONAL	5 UM1 AI068619-12	221,158	221,158	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
<b>COVID-19 ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH</b>	93.855	COVID-19 5 UM1 AI068619-14	FAMILY HEALTH INTERNATIONAL	5 UM1 AI068619-14	27,287	45,537	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
<b>COVID-19 ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH</b>	93.855	COVID-19 3 UM1 AI068619-14S1	FAMILY HEALTH INTERNATIONAL	3 UM1 AI068619-14S1	341,120	358,620	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
<b>COVID-19 ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH</b>	93.855	COVID-19 5 UM1 AI068614-14	FRED HUTCHINSON CANCER RESEARCH CENTER	5 UM1 AI068614-14		351,187	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
<b>COVID-19 ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH</b>	93.855	COVID-19 5 UM1 AI068614-14	FRED HUTCHINSON CANCER RESEARCH CENTER	5 UM1 AI068614-14		3,945	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
<b>COVID-19 ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH</b>	93.855	COVID-19 5 UM1 AI068614-14	FRED HUTCHINSON CANCER RESEARCH CENTER	5 UM1 AI068614-14		47,147	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746

**VANDERBILT UNIVERSITY MEDICAL CENTER**  
**SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS (CONTINUED)**  
 Fiscal Period 7/1/2020 – 6/30/2021

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 UM1 AI068614-14	FRED HUTCHINSON CANCER RESEARCH CENTER	5 UM1 AI068614-14	\$ -	\$ 28,345	\$ 56,074,347	RESEARCH AND DEVELOPMENT	\$ 425,311,746
COVID-19 ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	COVID-19 3 UM1 AI068614-14S1	FRED HUTCHINSON CANCER RESEARCH CENTER	3 UM1 AI068614-14S1		42,359	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
COVID-19 ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	COVID-19 3 UM1 AI068614-14S1	FRED HUTCHINSON CANCER RESEARCH CENTER	3 UM1 AI068614-14S1		1,250,475	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 UM1 AI068614-15	FRED HUTCHINSON CANCER RESEARCH CENTER	5 UM1 AI068614-15		90,760	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 U19 AI142764-03	HENRY M. JACKSON FOUNDATION	5 U19 AI142764-03	4,346	174,109	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 U19 AI142764-02	HENRY M. JACKSON FOUNDATION	1 U19 AI142764-02	48,926	610,954	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 R41 AI140945-01A1	IDBIOLOGICS, LLC	1 R41 AI140945-01A1		114,830	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 R41 AI148019-01	IDBIOLOGICS, LLC	1 R41 AI148019-01		103,325	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI077653-11	INDOOR BIOTECHNOLOGIES, INC.	5 R01 AI077653-11		85,042	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI127469-05	JOHNS HOPKINS UNIVERSITY	5 R01 AI127469-05		34,170	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 UM1 AI068632-14	JOHNS HOPKINS UNIVERSITY	5 UM1 AI068632-14		2,204	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	2 UMI AI068632-15	JOHNS HOPKINS UNIVERSITY	2 UMI AI068632-15		5,566	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 U01 AI069918-15	JOHNS HOPKINS UNIVERSITY	5 U01 AI069918-15		95,832	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
COVID-19 ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	COVID-19 3 U01 AI069918-15S1	JOHNS HOPKINS UNIVERSITY	3 U01 AI069918-15S1		61,987	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 U19 AI142790-01	LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY	1 U19 AI142790-01		(1,238)	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 U19 AI142790-02	LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY	1 U19 AI142790-02		893,945	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 U19 AI142790-03	LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY	1 U19 AI142790-03		9,427	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 U19 AI142790-03	LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY	1 U19 AI142790-03		9,246	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 U19 AI142790-03	LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY	1 U19 AI142790-03		45,972	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 U01 AI136816-02	MASSACHUSETTS GENERAL HOSPITAL	1 U01 AI136816-02		5,730	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 R01 AL136740-01A1	MEHARRY MEDICAL COLLEGE	1 R01 AL136740-01A1		65,110	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 R21 AI128418-01A1	OHIO STATE UNIVERSITY	1 R21 AI128418-01A1		2,094	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 R01 AI157037-01	UNIVERSITY OF CALIFORNIA AT LOS ANGELES	1 R01 AI157037-01		31,816	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 R01 AI137523-01	STANFORD UNIVERSITY	1 R01 AI137523-01		243,040	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
COVID-19 ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	COVID-19 3 U01 AI135950-03S1	STANFORD UNIVERSITY	3 U01 AI135950-03S1		574,825	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI134648-05	UNIVERSITY OF ALABAMA AT BIRMINGHAM	5 R01 AI134648-05		89,824	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 U19 AI142759-02	UNIVERSITY OF ALABAMA AT BIRMINGHAM	5 U19 AI142759-02		282,575	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 U19 AI142759-03	UNIVERSITY OF ALABAMA AT BIRMINGHAM	5 U19 AI142759-03		114,968	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	7 UM1 AI068636-14	UNIVERSITY OF CALIFORNIA AT LOS ANGELES	7 UM1 AI068636-14		5,985	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 UM1 AI068636-14	UNIVERSITY OF CALIFORNIA AT LOS ANGELES	5 UM1 AI068636-14		4,390	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 UM1 AI068636-14	UNIVERSITY OF CALIFORNIA AT LOS ANGELES	5 UM1 AI068636-14		10,256	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	7 UM1 AI068636-14	UNIVERSITY OF CALIFORNIA AT LOS ANGELES	7 UM1 AI068636-14		75,734	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	7 UM1 AI068636-15	UNIVERSITY OF CALIFORNIA AT LOS ANGELES	7 UM1 AI068636-15		8,620	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 UM1 AI068636-15	UNIVERSITY OF CALIFORNIA AT LOS ANGELES	5 UM1 AI068636-15		6,651	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 UM1 AI068636-15	UNIVERSITY OF CALIFORNIA AT LOS ANGELES	5 UM1 AI068636-15		7,788	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	7 UM1 AI068636-15	UNIVERSITY OF CALIFORNIA AT LOS ANGELES	7 UM1 AI068636-15		134,940	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746

**VANDERBILT UNIVERSITY MEDICAL CENTER**  
**SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS (CONTINUED)**  
Fiscal Period 7/1/2020 – 6/30/2021

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 UM1 AI106701-07	UNIVERSITY OF CALIFORNIA AT LOS ANGELES	5 UM1 AI106701-07	\$ -	\$ 277,389	\$ 56,074,347	RESEARCH AND DEVELOPMENT	\$ 425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 UM1 AI106701-08	UNIVERSITY OF CALIFORNIA AT LOS ANGELES	5 UM1 AI106701-08		29,086	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 P01 AI106695-05	UNIVERSITY OF CALIFORNIA, BERKELEY	5 P01 AI106695-05		369	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	2 P01 AI106695-06	UNIVERSITY OF CALIFORNIA, BERKELEY	2 P01 AI106695-06		295,582	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 R21 AI149255-01	UNIVERSITY OF CALIFORNIA, IRVINE	1 R21 AI149255-01		15,548	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 U19 AI070535-15	UNIVERSITY OF CALIFORNIA, SAN DIEGO	5 U19 AI070535-15		34,100	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 R01 AI152183-01	UNIVERSITY OF CAPE TOWN (SOUTH AFRICA)	1 R01 AI152183-01		21,562	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 R01 AI152183-02	UNIVERSITY OF CAPE TOWN (SOUTH AFRICA)	1 R01 AI152183-02		21,238	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI112295-05	UNIVERSITY OF EDUARDO MONDLANE	5 R01 AI112295-05		7,463	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI089999-08	UNIVERSITY OF HAWAII	5 R01 AI089999-08		(35)	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AG046116-05	UNIVERSITY OF KENTUCKY	5 R01 AG046116-05		149,307	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI132178-02	UNIVERSITY OF NORTH CAROLINA	5 R01 AI132178-02		221,624	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
COVID-19 ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	COVID-19 3 R01 AI132178-04S1	UNIVERSITY OF NORTH CAROLINA	3 R01 AI132178-03S1		296,308	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	2 R01 AI108884-07	UNIVERSITY OF NOTRE DAME	2 R01 AI108884-07		23,067	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	2 R01 AI085062-07A1	UNIVERSITY OF PITTSBURGH	2 R01 AI085062-07A1		(393)	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 P01 AI139449-01A1	UNIVERSITY OF TEXAS	1 P01 AI139449-01A1		80,383	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI141661-02	UNIVERSITY OF TEXAS	5 R01 AI141661-02		312,959	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 U19 AI142785-01	UNIVERSITY OF TEXAS	1 U19 AI142785-01		519	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 U19 AI142785-02	UNIVERSITY OF TEXAS	1 U19 AI142785-02		845,089	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 U19 AI142785-03	UNIVERSITY OF TEXAS	5 U19 AI142785-03		180,556	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 R34 AI134569-01A1	UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER AT DALLAS	1 R34 AI134569-01A1		14,459	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI148707-02	UNIVERSITY OF WISCONSIN	5 R01 AI148707-02		293,885	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 UM1 AI114271-07	UNIVERSITY OF WISCONSIN	5 UM1 AI114271-07		35,423	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 R56 AI46096-01A1	VANDERBILT UNIVERSITY	1 R56 AI46096-01A1		974	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 T32 AI112541-05	VANDERBILT UNIVERSITY	5 T32 AI112541-05		(540)	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 T32 AI112541-06	VANDERBILT UNIVERSITY	5 T32 AI112541-06		5,604	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 T32 AI138932-01A1	VANDERBILT UNIVERSITY	1 T32 AI138932-01A1		61,053	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 T32 AI138932-02	VANDERBILT UNIVERSITY	5 T32 AI138932-02		681	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 T32 AI138932-02	VANDERBILT UNIVERSITY	5 T32 AI138932-02		81,389	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
COVID-19 ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	COVID-19 1 R01 AI157827-01	VANDERBILT UNIVERSITY	1 R01 AI157827-01		34,998	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R43 AI149906-02	VIRTICI,LLC.	5 R43 AI149906-02		23	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI073755-11	WASHINGTON UNIVERSITY IN ST. LOUIS	5 R01 AI073755-11		157,033	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
COVID-19 ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	COVID-19 1 R01 AI157155-02	WASHINGTON UNIVERSITY IN ST. LOUIS	1 R01 AI157155-01		115,600	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
COVID-19 ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	COVID-19 7 UM1 AI068636-15				117,366	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
COVID-19 ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	COVID-19 5 U19 AI095227-02S4				965,525	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
COVID-19 ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	COVID-19 5 UM1 AI148452-02S4				289,549	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
COVID-19 ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	COVID-19 7 UM1 AI068636-14	UNIVERSITY OF CALIFORNIA AT LOS ANGELES	7 UM1 AI068636-14		170,078	56,074,347	RESEARCH AND DEVELOPMENT	425,311,746
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1 F32 GM139303-01				62,868	8,716,102	RESEARCH AND DEVELOPMENT	425,311,746
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5 T32 GM007569-44				804	8,716,102	RESEARCH AND DEVELOPMENT	425,311,746
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5 R01 GM120523-05				336,893	8,716,102	RESEARCH AND DEVELOPMENT	425,311,746
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5 R01 GM130791-02			63,328	510,814	8,716,102	RESEARCH AND DEVELOPMENT	425,311,746
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5 K08 GM117367-05				3,427	8,716,102	RESEARCH AND DEVELOPMENT	425,311,746
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5 K23 GM117395-05				176,708	8,716,102	RESEARCH AND DEVELOPMENT	425,311,746
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5 K08 GM123445-04				205,501	8,716,102	RESEARCH AND DEVELOPMENT	425,311,746

**VANDERBILT UNIVERSITY MEDICAL CENTER**  
**SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS (CONTINUED)**  
 Fiscal Period 7/1/2020 – 6/30/2021

<i>Federal Awarding Agency/Program Title</i>	<i>Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5 K23 GM129662-03			\$ -	\$ 159,536	\$ 8,716,102	RESEARCH AND DEVELOPMENT	\$ 425,311,746
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5 K23 GM134482-02				149,151	8,716,102	RESEARCH AND DEVELOPMENT	425,311,746
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5 P50 GM115305-06			17,477	1,027,223	8,716,102	RESEARCH AND DEVELOPMENT	425,311,746
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5 R01 GM112871-06			9,578	147,126	8,716,102	RESEARCH AND DEVELOPMENT	425,311,746
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5 R01 GM115353-04				121,218	8,716,102	RESEARCH AND DEVELOPMENT	425,311,746
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5 R01 GM118300-04				37,893	8,716,102	RESEARCH AND DEVELOPMENT	425,311,746
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5 R01 GM120484-05			14,555	500,519	8,716,102	RESEARCH AND DEVELOPMENT	425,311,746
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5 R01 GM121711-05				244,630	8,716,102	RESEARCH AND DEVELOPMENT	425,311,746
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5 R01 GM124109-05				444,068	8,716,102	RESEARCH AND DEVELOPMENT	425,311,746
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5 R35 GM124685-04			5,165	455,704	8,716,102	RESEARCH AND DEVELOPMENT	425,311,746
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5 R01 GM126062-03			16,340	466,330	8,716,102	RESEARCH AND DEVELOPMENT	425,311,746
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5 R01 GM126535-03				284,181	8,716,102	RESEARCH AND DEVELOPMENT	425,311,746
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5 R35 GM131770-03				351,132	8,716,102	RESEARCH AND DEVELOPMENT	425,311,746
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5 R01 GM132204-03				566,179	8,716,102	RESEARCH AND DEVELOPMENT	425,311,746
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5 R01 GM132592-02				121,474	8,716,102	RESEARCH AND DEVELOPMENT	425,311,746
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5 R01 GM133169-02			278,452	724,496	8,716,102	RESEARCH AND DEVELOPMENT	425,311,746
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5 R35 GM138191-02				292,751	8,716,102	RESEARCH AND DEVELOPMENT	425,311,746
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1 R01 GM138873-01				68,024	8,716,102	RESEARCH AND DEVELOPMENT	425,311,746
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1 R01 GM139891-01				93,632	8,716,102	RESEARCH AND DEVELOPMENT	425,311,746
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1 R35 GM141927-01				23,313	8,716,102	RESEARCH AND DEVELOPMENT	425,311,746
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5 T32 GM007569-45			21,742	407,612	8,716,102	RESEARCH AND DEVELOPMENT	425,311,746
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2 T32 GM108554-07				(11,704)	8,716,102	RESEARCH AND DEVELOPMENT	425,311,746
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5 T32 GM108554-08				206,187	8,716,102	RESEARCH AND DEVELOPMENT	425,311,746
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5 R01 GM129783-03	CHILDREN'S MERCY HOSPITAL CINCINNATI CHILDREN'S HOSPITAL	5 R01 GM129783-03		17,636	8,716,102	RESEARCH AND DEVELOPMENT	425,311,746
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5 R35 GM126943-03	MEDICAL CENTER	5 R35 GM126943-03		9,203	8,716,102	RESEARCH AND DEVELOPMENT	425,311,746
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5 R01 GM117473-03	DUKE UNIVERSITY	5 R01 GM117473-03		7,571	8,716,102	RESEARCH AND DEVELOPMENT	425,311,746
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5 R01 GM117473-04	DUKE UNIVERSITY	5 R01 GM117473-04		52,001	8,716,102	RESEARCH AND DEVELOPMENT	425,311,746
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1 R01 GM119197-01	EAST TENNESSEE STATE UNIVERSITY	1 R01 GM119197-01		26,695	8,716,102	RESEARCH AND DEVELOPMENT	425,311,746
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1 R01 GM140287-01	SCRIPPS RESEARCH INSTITUTE	1 R01 GM140287-01		11,598	8,716,102	RESEARCH AND DEVELOPMENT	425,311,746
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	8 P50 AI150481-13	UNIVERSITY OF PITTSBURGH	8 P50 AI150481-13		17,727	8,716,102	RESEARCH AND DEVELOPMENT	425,311,746
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5 P50 AI150481-14	UNIVERSITY OF PITTSBURGH	5 P50 AI150481-14		286,375	8,716,102	RESEARCH AND DEVELOPMENT	425,311,746
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1 R01 GM140464-01	UNIVERSITY OF WISCONSIN	1 R01 GM140464-01		17,328	8,716,102	RESEARCH AND DEVELOPMENT	425,311,746
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5 R01 GM118412-03	VANDERBILT UNIVERSITY	5 R01 GM118412-03		(2,308)	8,716,102	RESEARCH AND DEVELOPMENT	425,311,746
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5 R01 GM118412-04	VANDERBILT UNIVERSITY	5 R01 GM118412-04		29,519	8,716,102	RESEARCH AND DEVELOPMENT	425,311,746
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5 R01 GM076592-12	VANDERBILT UNIVERSITY	5 R01 GM076592-12		25,731	8,716,102	RESEARCH AND DEVELOPMENT	425,311,746
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5 R01 GM076592-13	VANDERBILT UNIVERSITY	5 R01 GM076592-13		2,415	8,716,102	RESEARCH AND DEVELOPMENT	425,311,746
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1 R35 GM125028-01	VANDERBILT UNIVERSITY	1 R35 GM125028-01		4,080	8,716,102	RESEARCH AND DEVELOPMENT	425,311,746
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1 R01 GM137595-01	VANDERBILT UNIVERSITY	1 R01 GM137595-01		22,977	8,716,102	RESEARCH AND DEVELOPMENT	425,311,746
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	3 T32 GM007628-43S1	VANDERBILT UNIVERSITY	3 T32 GM007628-43S1		9,864	8,716,102	RESEARCH AND DEVELOPMENT	425,311,746
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1 F32 HD100087-01A1				60,666	9,299,583	RESEARCH AND DEVELOPMENT	425,311,746
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 R21 HD097992-02			10,483	29,275	9,299,583	RESEARCH AND DEVELOPMENT	425,311,746
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 K12 HD043483-20				396,068	9,299,583	RESEARCH AND DEVELOPMENT	425,311,746
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 K12 HD087023-06				155,045	9,299,583	RESEARCH AND DEVELOPMENT	425,311,746
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	2 K12 HD087023-07				64,165	9,299,583	RESEARCH AND DEVELOPMENT	425,311,746
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1 K23 HD104183-01A1				16,926	9,299,583	RESEARCH AND DEVELOPMENT	425,311,746
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 K12 HD043483-19				30,057	9,299,583	RESEARCH AND DEVELOPMENT	425,311,746
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1 P50 HD103537-01				848,287	9,299,583	RESEARCH AND DEVELOPMENT	425,311,746
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 P50 HD103537-02				72,987	9,299,583	RESEARCH AND DEVELOPMENT	425,311,746
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 R01 HD071089-08			116,059	286,361	9,299,583	RESEARCH AND DEVELOPMENT	425,311,746
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 R01 HD076983-06			25,711	105,691	9,299,583	RESEARCH AND DEVELOPMENT	425,311,746
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 R01 HD081121-06			(19,588)	(11,652)	9,299,583	RESEARCH AND DEVELOPMENT	425,311,746
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 R01 HD084461-06				461,337	9,299,583	RESEARCH AND DEVELOPMENT	425,311,746
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 R01 HD084500-06			17,708	228,303	9,299,583	RESEARCH AND DEVELOPMENT	425,311,746
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 R01 HD086792-05				39,846	9,299,583	RESEARCH AND DEVELOPMENT	425,311,746
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 R01 HD088662-04			38,894	271,213	9,299,583	RESEARCH AND DEVELOPMENT	425,311,746
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 R21 HD088830-02				61,987	9,299,583	RESEARCH AND DEVELOPMENT	425,311,746
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 R01 HD090061-05			120,681	630,361	9,299,583	RESEARCH AND DEVELOPMENT	425,311,746
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 R01 HD093671-04			11,563	849,820	9,299,583	RESEARCH AND DEVELOPMENT	425,311,746

**VANDERBILT UNIVERSITY MEDICAL CENTER**  
**SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS (CONTINUED)**  
Fiscal Period 7/1/2020 – 6/30/2021

<i>Federal Awarding Agency/Program Title</i>	<i>Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 R01 HD094946-03			\$ -	\$ 601,285	\$ 9,299,583	RESEARCH AND DEVELOPMENT	\$ 425,311,746
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 R01 HD097344-03				664,476	9,299,583	RESEARCH AND DEVELOPMENT	425,311,746
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 R01 HD098213-03				476,934	9,299,583	RESEARCH AND DEVELOPMENT	425,311,746
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 R01 HD098719-02				582,674	9,299,583	RESEARCH AND DEVELOPMENT	425,311,746
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1 R01 HD099777-01A1			19,111	329,298	9,299,583	RESEARCH AND DEVELOPMENT	425,311,746
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1 R01 HD100458-01A1				439,368	9,299,583	RESEARCH AND DEVELOPMENT	425,311,746
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1 R21 HD103348-01			15,064	128,652	9,299,583	RESEARCH AND DEVELOPMENT	425,311,746
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1 R21 HD105304-01				13,171	9,299,583	RESEARCH AND DEVELOPMENT	425,311,746
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 T32 HD060554-10				7,205	9,299,583	RESEARCH AND DEVELOPMENT	425,311,746
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 U01 HD076733-06			69,572	212,510	9,299,583	RESEARCH AND DEVELOPMENT	425,311,746
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 U54 HD083211-06			96,082	96,082	9,299,583	RESEARCH AND DEVELOPMENT	425,311,746
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 R01 HD083181-02	BAYLOR COLLEGE	5 R01 HD083181-02		180,078	9,299,583	RESEARCH AND DEVELOPMENT	425,311,746
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	7 K12 HD000850-37	CORNELL UNIVERSITY	7 K12 HD000850-37		77,733	9,299,583	RESEARCH AND DEVELOPMENT	425,311,746
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HHSN275201000003I	DUKE UNIVERSITY	HHSN275201000003I		6,815	9,299,583	RESEARCH AND DEVELOPMENT	425,311,746
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 K12 HD000850-34	DUKE UNIVERSITY	5 K12 HD000850-34		(728)	9,299,583	RESEARCH AND DEVELOPMENT	425,311,746
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 K12 HD000850-35	DUKE UNIVERSITY GEORGIA REGENTS UNIVERSITY/MEDICAL COLLEGE OF GA	5 K12 HD000850-35		43,971	9,299,583	RESEARCH AND DEVELOPMENT	425,311,746
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1 R01 HD092505-01A1		1 R01 HD092505-01A1		15,861	9,299,583	RESEARCH AND DEVELOPMENT	425,311,746
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1 R21 HD100685-01	IOWA STATE UNIVERSITY	1 R21 HD100685-01		7,050	9,299,583	RESEARCH AND DEVELOPMENT	425,311,746
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 R01 HD096147-02	JOHNS HOPKINS UNIVERSITY	5 R01 HD096147-02		91,630	9,299,583	RESEARCH AND DEVELOPMENT	425,311,746
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	2 R44 HD084151-04A1	MIYAZAKI ENTERPRISES,LLC	2 R44 HD084151-04A1		8,907	9,299,583	RESEARCH AND DEVELOPMENT	425,311,746
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 R01 HD081120-05	NATIONWIDE CHILDREN'S HOSPITAL NORTHSHORE UNIVERSITY HEALTHSYSTEM	5 R01 HD081120-05		69	9,299,583	RESEARCH AND DEVELOPMENT	425,311,746
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 R01 HD096332-02		5 R01 HD096332-02		11,064	9,299,583	RESEARCH AND DEVELOPMENT	425,311,746
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	3 UG3 HD096920-02S1	NORTHWESTERN UNIVERSITY	3 UG3 HD096920-02S1		14,681	9,299,583	RESEARCH AND DEVELOPMENT	425,311,746
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	4 UH3 HD096920-03	NORTHWESTERN UNIVERSITY	4 UH3 HD096920-03		24,098	9,299,583	RESEARCH AND DEVELOPMENT	425,311,746
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 R01 HD079625-05	TEXAS A & M UNIVERSITY	5 R01 HD079625-05		(3)	9,299,583	RESEARCH AND DEVELOPMENT	425,311,746
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 R01 HD093665-03	TULANE UNIVERSITY	5 R01 HD093665-03		17,697	9,299,583	RESEARCH AND DEVELOPMENT	425,311,746
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 U54 HD061222-13	UNIVERSITY OF ALABAMA AT BIRMINGHAM	5 U54 HD061222-13		30,150	9,299,583	RESEARCH AND DEVELOPMENT	425,311,746
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 U54 HD061222-15	UNIVERSITY OF ALABAMA AT BIRMINGHAM	5 U54 HD061222-15		38,700	9,299,583	RESEARCH AND DEVELOPMENT	425,311,746
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 U54 HD061222-15	UNIVERSITY OF ALABAMA AT BIRMINGHAM	5 U54 HD061222-15		69,435	9,299,583	RESEARCH AND DEVELOPMENT	425,311,746
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	2 R01 HD024356-25	UNIVERSITY OF CALIFORNIA, DAVIS	2 R01 HD024356-25		(13,242)	9,299,583	RESEARCH AND DEVELOPMENT	425,311,746
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	2 R01 HD024356-26	UNIVERSITY OF CALIFORNIA, DAVIS	2 R01 HD024356-26		102,490	9,299,583	RESEARCH AND DEVELOPMENT	425,311,746
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 R01 HD024356-26	UNIVERSITY OF CALIFORNIA, DAVIS	5 R01 HD024356-26		8,422	9,299,583	RESEARCH AND DEVELOPMENT	425,311,746
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	7 R01 HD082127-05	UNIVERSITY OF KANSAS	7 R01 HD082127-05		52,060	9,299,583	RESEARCH AND DEVELOPMENT	425,311,746
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1 R01 HD098867-01A1	UNIVERSITY OF PENNSYLVANIA	1 R01 HD098867-01A1		11,436	9,299,583	RESEARCH AND DEVELOPMENT	425,311,746
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1 R01 HD102318-01	UNIVERSITY OF PENNSYLVANIA	1 R01 HD102318-01		11,436	9,299,583	RESEARCH AND DEVELOPMENT	425,311,746

**VANDERBILT UNIVERSITY MEDICAL CENTER**  
**SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS (CONTINUED)**  
Fiscal Period 7/1/2020 – 6/30/2021

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	2 K12 HD047349-17	UNIVERSITY OF UTAH	2 K12 HD047349-17	\$ -	\$ 11,958	\$ 9,299,583	RESEARCH AND DEVELOPMENT	\$ 425,311,746
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 R01 HD064727-10	VANDERBILT UNIVERSITY	5 R01 HD064727-10		4,468	9,299,583	RESEARCH AND DEVELOPMENT	425,311,746
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1 R21 HD097757-01A1	VANDERBILT UNIVERSITY	1 R21 HD097757-01A1		7,563	9,299,583	RESEARCH AND DEVELOPMENT	425,311,746
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1 R21 HD098454-01A1	VANDERBILT UNIVERSITY	1 R21 HD098454-01A1		22,604	9,299,583	RESEARCH AND DEVELOPMENT	425,311,746
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1 R01 HD102752-01	VANDERBILT UNIVERSITY	1 R01 HD102752-01		92,007	9,299,583	RESEARCH AND DEVELOPMENT	425,311,746
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1 R61 HD099742-01	WASHINGTON UNIVERSITY IN ST. LOUIS	1 R61 HD099742-01		229,240	9,299,583	RESEARCH AND DEVELOPMENT	425,311,746
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 U54 HD083211-06				(26,465)	9,299,583	RESEARCH AND DEVELOPMENT	425,311,746
AGING RESEARCH	93.866	5 K76 AG060001-03				278,672	18,865,940	RESEARCH AND DEVELOPMENT	425,311,746
AGING RESEARCH	93.866	5 R01 AG061518-03			415,500	695,106	18,865,940	RESEARCH AND DEVELOPMENT	425,311,746
AGING RESEARCH	93.866	1 F32 AG062045-01A1				7,827	18,865,940	RESEARCH AND DEVELOPMENT	425,311,746
AGING RESEARCH	93.866	5 F32 AG062045-02				63,245	18,865,940	RESEARCH AND DEVELOPMENT	425,311,746
AGING RESEARCH	93.866	5 K23 AG045966-06				115,878	18,865,940	RESEARCH AND DEVELOPMENT	425,311,746
AGING RESEARCH	93.866	2 K24 AG046373-09				149,613	18,865,940	RESEARCH AND DEVELOPMENT	425,311,746
AGING RESEARCH	93.866	5 K01 AG049164-04				89,462	18,865,940	RESEARCH AND DEVELOPMENT	425,311,746
AGING RESEARCH	93.866	5 K76 AG054864-04				(338)	18,865,940	RESEARCH AND DEVELOPMENT	425,311,746
AGING RESEARCH	93.866	5 K01 AG058700-04				130,614	18,865,940	RESEARCH AND DEVELOPMENT	425,311,746
AGING RESEARCH	93.866	1 K24 AG064114-01A1				112,279	18,865,940	RESEARCH AND DEVELOPMENT	425,311,746
AGING RESEARCH	93.866	5 K76 AG068436-02				228,138	18,865,940	RESEARCH AND DEVELOPMENT	425,311,746
AGING RESEARCH	93.866	1 K23 AG070320-01A1				14,254	18,865,940	RESEARCH AND DEVELOPMENT	425,311,746
AGING RESEARCH	93.866	1 P20 AG068082-01				264,321	18,865,940	RESEARCH AND DEVELOPMENT	425,311,746
AGING RESEARCH	93.866	6 R01 AG034962-07				(42,951)	18,865,940	RESEARCH AND DEVELOPMENT	425,311,746
AGING RESEARCH	93.866	5 R01 AG034962-08				1,131,302	18,865,940	RESEARCH AND DEVELOPMENT	425,311,746
AGING RESEARCH	93.866	5 R01 AG034962-09				222,143	18,865,940	RESEARCH AND DEVELOPMENT	425,311,746
AGING RESEARCH	93.866	6 R01 AG035117-06				(1,241)	18,865,940	RESEARCH AND DEVELOPMENT	425,311,746
AGING RESEARCH	93.866	5 R01 AG047992-06			2,089,166	2,733,344	18,865,940	RESEARCH AND DEVELOPMENT	425,311,746
AGING RESEARCH	93.866	5 R01 AG048915-04				455,658	18,865,940	RESEARCH AND DEVELOPMENT	425,311,746
AGING RESEARCH	93.866	7 R21 AG049332-03				1,187	18,865,940	RESEARCH AND DEVELOPMENT	425,311,746
AGING RESEARCH	93.866	5 R01 AG053264-06				27,495	18,865,940	RESEARCH AND DEVELOPMENT	425,311,746
AGING RESEARCH	93.866	5 R01 AG056534-04				13,142	18,865,940	RESEARCH AND DEVELOPMENT	425,311,746
AGING RESEARCH	93.866	1 R01 AG058639-01A1				(4,401)	18,865,940	RESEARCH AND DEVELOPMENT	425,311,746
AGING RESEARCH	93.866	5 R01 AG058639-02			134,156	1,088,348	18,865,940	RESEARCH AND DEVELOPMENT	425,311,746
AGING RESEARCH	93.866	5 R01 AG058639-03				1,080,442	18,865,940	RESEARCH AND DEVELOPMENT	425,311,746
AGING RESEARCH	93.866	5 R01 AG058856-04				377,741	18,865,940	RESEARCH AND DEVELOPMENT	425,311,746
AGING RESEARCH	93.866	5 R01 AG059716-04			410,285	845,234	18,865,940	RESEARCH AND DEVELOPMENT	425,311,746
AGING RESEARCH	93.866	1 R21 AG059941-01				56,113	18,865,940	RESEARCH AND DEVELOPMENT	425,311,746
AGING RESEARCH	93.866	1 R03 AG060085-01				20,195	18,865,940	RESEARCH AND DEVELOPMENT	425,311,746
AGING RESEARCH	93.866	5 R01 AG061138-03			107,162	771,333	18,865,940	RESEARCH AND DEVELOPMENT	425,311,746
AGING RESEARCH	93.866	5 R01 AG061161-02				19,100	18,865,940	RESEARCH AND DEVELOPMENT	425,311,746
AGING RESEARCH	93.866	5 R01 AG061325-02				28,864	18,865,940	RESEARCH AND DEVELOPMENT	425,311,746
AGING RESEARCH	93.866	1 R01 AG061351-01				380,266	18,865,940	RESEARCH AND DEVELOPMENT	425,311,746
AGING RESEARCH	93.866	5 R01 AG062499-03				62,382	18,865,940	RESEARCH AND DEVELOPMENT	425,311,746
AGING RESEARCH	93.866	5 R01 AG062574-02				347,542	18,865,940	RESEARCH AND DEVELOPMENT	425,311,746
AGING RESEARCH	93.866	5 R01 AG062826				578,334	18,865,940	RESEARCH AND DEVELOPMENT	425,311,746
AGING RESEARCH	93.866	5 R21 AG063126-02				94,700	18,865,940	RESEARCH AND DEVELOPMENT	425,311,746
AGING RESEARCH	93.866	5 R01 AG065249-02				167,691	18,865,940	RESEARCH AND DEVELOPMENT	425,311,746
AGING RESEARCH	93.866	1 R01 AG065550-01A1				238,953	18,865,940	RESEARCH AND DEVELOPMENT	425,311,746
AGING RESEARCH	93.866	1 R03 AG065643-01A1				55,130	18,865,940	RESEARCH AND DEVELOPMENT	425,311,746
AGING RESEARCH	93.866	1 R21 AG065859-01				227,881	18,865,940	RESEARCH AND DEVELOPMENT	425,311,746
AGING RESEARCH	93.866	1 R01 AG068606-01				8,600	18,865,940	RESEARCH AND DEVELOPMENT	425,311,746
AGING RESEARCH	93.866	5 R01 AG069795-02			63,772	264,653	18,865,940	RESEARCH AND DEVELOPMENT	425,311,746
AGING RESEARCH	93.866	1 R21 AG070859-01				31,780	18,865,940	RESEARCH AND DEVELOPMENT	425,311,746
AGING RESEARCH	93.866	9 R44 AG059371-02	AVATAR MEDICAL LLC	9 R44 AG059371-02		7,648	18,865,940	RESEARCH AND DEVELOPMENT	425,311,746
AGING RESEARCH	93.866	5 R01 AG056368-02	BRIGHAM AND WOMEN'S HOSPITAL	5 R01 AG056368-02		14,900	18,865,940	RESEARCH AND DEVELOPMENT	425,311,746
AGING RESEARCH	93.866	2 P01 AG027296-11	BROWN UNIVERSITY	2 P01 AG027296-11		56,805	18,865,940	RESEARCH AND DEVELOPMENT	425,311,746



**VANDERBILT UNIVERSITY MEDICAL CENTER**  
**SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS (CONTINUED)**  
Fiscal Period 7/1/2020 – 6/30/2021

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
AGING RESEARCH	93.866	5 R01 AG059417-02	CALIFORNIA PACIFIC MEDICAL CENTER	5 R01 AG059417-02	\$ -	\$ 82	\$ 18,865,940	RESEARCH AND DEVELOPMENT	\$ 425,311,746
AGING RESEARCH	93.866	1 R56 AG061522-01A1	DARTMOUTH COLLEGE	1 R56 AG061522-01A1		119,114	18,865,940	RESEARCH AND DEVELOPMENT	425,311,746
AGING RESEARCH	93.866	1 U19 AG065188-01	DUKE UNIVERSITY	1 U19 AG065188-01		6,526	18,865,940	RESEARCH AND DEVELOPMENT	425,311,746
AGING RESEARCH	93.866	1 U19 AG065188-01	DUKE UNIVERSITY	1 U19 AG065188-01		14,636	18,865,940	RESEARCH AND DEVELOPMENT	425,311,746
AGING RESEARCH	93.866	1 U19 AG065188-01	DUKE UNIVERSITY	1 U19 AG065188-01		42,362	18,865,940	RESEARCH AND DEVELOPMENT	425,311,746
AGING RESEARCH	93.866	5 U19 AG065188-02	DUKE UNIVERSITY	5 U19 AG065188-02		58,698	18,865,940	RESEARCH AND DEVELOPMENT	425,311,746
AGING RESEARCH	93.866	1 R24 AG054259-02	HARVARD UNIVERSITY	1 R24 AG054259-02		(378)	18,865,940	RESEARCH AND DEVELOPMENT	425,311,746
AGING RESEARCH	93.866	5 R24 AG052459-03	HARVARD UNIVERSITY	5 R24 AG052459-03		7	18,865,940	RESEARCH AND DEVELOPMENT	425,311,746
AGING RESEARCH	93.866	5 R24 AG054259-05	HARVARD UNIVERSITY	5 R24 AG054259-05		8,230	18,865,940	RESEARCH AND DEVELOPMENT	425,311,746
AGING RESEARCH	93.866	5 R24 AG054259-05	HARVARD UNIVERSITY	5 R24 AG054259-05		8,681	18,865,940	RESEARCH AND DEVELOPMENT	425,311,746
AGING RESEARCH	93.866	1 RF1 AG059869-01	JOHNS HOPKINS UNIVERSITY	1 RF1 AG059869-01		74,415	18,865,940	RESEARCH AND DEVELOPMENT	425,311,746
<b>COVID-19 AGING RESEARCH</b>	93.866	COVID-19 3 R01 AG053582-05S1	MASSACHUSETTS GENERAL HOSPITAL	3 R01 AG053582-05S1		130,008	18,865,940	RESEARCH AND DEVELOPMENT	425,311,746
AGING RESEARCH	93.866	1 R44 AG055184-01	METABOLIC TECHNOLOGIES, INC.	1 R44 AG055184-01		76,042	18,865,940	RESEARCH AND DEVELOPMENT	425,311,746
AGING RESEARCH	93.866	1 U19 AG065188-01	NATIONAL ASSOCIATION OF VETERANS' RESEARCH & EDUCATION FDNS	1 U19 AG065188-01		10,817	18,865,940	RESEARCH AND DEVELOPMENT	425,311,746
AGING RESEARCH	93.866	1 R24 AG064025-02	NORTHERN CALIFORNIA INSTITUTE FOR RESEARCH AND EDUCATION	1 R24 AG064025-02		55,030	18,865,940	RESEARCH AND DEVELOPMENT	425,311,746
AGING RESEARCH	93.866	5 R01 AG059861-02	OHIO STATE UNIVERSITY	5 R01 AG059861-02		1,228	18,865,940	RESEARCH AND DEVELOPMENT	425,311,746
AGING RESEARCH	93.866	5 R01 AG059861-03	OHIO STATE UNIVERSITY	5 R01 AG059861-03		32,282	18,865,940	RESEARCH AND DEVELOPMENT	425,311,746
AGING RESEARCH	93.866	1 RF1 AG063755-01	THE JACKSON LABOR UNIVERSITY OF CALIFORNIA AT LOS ANGELES	1 RF1 AG063755-01		212,326	18,865,940	RESEARCH AND DEVELOPMENT	425,311,746
AGING RESEARCH	93.866	5 R01 AG054366-03	UNIVERSITY OF CALIFORNIA AT LOS ANGELES	5 R01 AG054366-03		3,009	18,865,940	RESEARCH AND DEVELOPMENT	425,311,746
AGING RESEARCH	93.866	5 R01 AG062563-02	UNIVERSITY OF CALIFORNIA AT SAN FRANCISCO	5 R01 AG062563-02		6,885	18,865,940	RESEARCH AND DEVELOPMENT	425,311,746
AGING RESEARCH	93.866	1 R24 AG064025-01	UNIVERSITY OF CALIFORNIA AT SAN FRANCISCO	1 R24 AG064025-01		7,597	18,865,940	RESEARCH AND DEVELOPMENT	425,311,746
AGING RESEARCH	93.866	5 R01 AG059329-03	UNIVERSITY OF CALIFORNIA, SAN DIEGO	5 R01 AG059329-03		16,095	18,865,940	RESEARCH AND DEVELOPMENT	425,311,746
AGING RESEARCH	93.866	6 R01 AG047992-02	UNIVERSITY OF SOUTHERN CALIFORNIA	6 R01 AG047992-02		3,154	18,865,940	RESEARCH AND DEVELOPMENT	425,311,746
AGING RESEARCH	93.866	5 R01 AG054029-02	UNIVERSITY OF SOUTHERN CALIFORNIA	5 R01 AG054029-02		10,206	18,865,940	RESEARCH AND DEVELOPMENT	425,311,746
AGING RESEARCH	93.866	1 R01 AG061848-01	UNIVERSITY OF SOUTHERN CALIFORNIA	1 R01 AG061848-01		1,701	18,865,940	RESEARCH AND DEVELOPMENT	425,311,746
AGING RESEARCH	93.866	1 R61 AG066543-01	UNIVERSITY OF SOUTHERN CALIFORNIA	1 R61 AG066543-01		1,260	18,865,940	RESEARCH AND DEVELOPMENT	425,311,746
AGING RESEARCH	93.866	1 R61 AG066543-01	UNIVERSITY OF SOUTHERN CALIFORNIA	1 R61 AG066543-01		27,494	18,865,940	RESEARCH AND DEVELOPMENT	425,311,746
AGING RESEARCH	93.866	5 R61 AG066543-02	UNIVERSITY OF SOUTHERN CALIFORNIA	5 R61 AG066543-02		17,673	18,865,940	RESEARCH AND DEVELOPMENT	425,311,746
AGING RESEARCH	93.866	2 U19 AG024904-11	UNIVERSITY OF SOUTHERN CALIFORNIA	2 U19 AG024904-11		130,404	18,865,940	RESEARCH AND DEVELOPMENT	425,311,746
AGING RESEARCH	93.866	1 U01 AG068057-01	UNIVERSITY OF SOUTHERN CALIFORNIA	1 U01 AG068057-01		12,717	18,865,940	RESEARCH AND DEVELOPMENT	425,311,746
AGING RESEARCH	93.866	5 R01 AG061325-02	UNIVERSITY OF TENNESSEE	5 R01 AG061325-02		103,276	18,865,940	RESEARCH AND DEVELOPMENT	425,311,746
AGING RESEARCH	93.866	1 R01 AG050716-04	UNIVERSITY OF VERMONT	1 R01 AG050716-04		8,939	18,865,940	RESEARCH AND DEVELOPMENT	425,311,746
AGING RESEARCH	93.866	1 R01 AG006159-01	UNIVERSITY OF VERMONT	1 R01 AG006159-01		802,680	18,865,940	RESEARCH AND DEVELOPMENT	425,311,746
AGING RESEARCH	93.866	1 R01 AG064800-01	UNIVERSITY OF WASHINGTON	1 R01 AG064800-01		104,447	18,865,940	RESEARCH AND DEVELOPMENT	425,311,746
AGING RESEARCH	93.866	5 R01 AG060754-01	VANDERBILT UNIVERSITY	5 R01 AG060754-01		6,475	18,865,940	RESEARCH AND DEVELOPMENT	425,311,746
AGING RESEARCH	93.866	1 R01 AG062685-01A1	VANDERBILT UNIVERSITY	1 R01 AG062685-01A1		18,978	18,865,940	RESEARCH AND DEVELOPMENT	425,311,746
AGING RESEARCH	93.866	1 R01 AG064950-01	VANDERBILT UNIVERSITY	1 R01 AG064950-01		120,056	18,865,940	RESEARCH AND DEVELOPMENT	425,311,746
AGING RESEARCH	93.866	1 R01 AG064950-01	VANDERBILT UNIVERSITY	1 R01 AG064950-01		6,822	18,865,940	RESEARCH AND DEVELOPMENT	425,311,746
AGING RESEARCH	93.866	5 R01 AG064950-02	VANDERBILT UNIVERSITY	5 R01 AG064950-02		10,237	18,865,940	RESEARCH AND DEVELOPMENT	425,311,746
AGING RESEARCH	93.866	5 T32 AG058024-03	VANDERBILT UNIVERSITY	5 T32 AG058024-03		35,460	18,865,940	RESEARCH AND DEVELOPMENT	425,311,746
AGING RESEARCH	93.866	5 T32 AG058524-02	VANDERBILT UNIVERSITY	5 T32 AG058524-02		11,313	18,865,940	RESEARCH AND DEVELOPMENT	425,311,746
AGING RESEARCH	93.866	3 T32 AG058524-02	VANDERBILT UNIVERSITY	3 T32 AG058524-02		14,237	18,865,940	RESEARCH AND DEVELOPMENT	425,311,746
AGING RESEARCH	93.866	5 T32 AG058524-03	VANDERBILT UNIVERSITY	5 T32 AG058524-03		10,331	18,865,940	RESEARCH AND DEVELOPMENT	425,311,746

**VANDERBILT UNIVERSITY MEDICAL CENTER**  
**SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS (CONTINUED)**  
Fiscal Period 7/1/2020 – 6/30/2021

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
AGING RESEARCH	93.866	5 T32 AG058524-03	VANDERBILT UNIVERSITY	5 T32 AG058524-03	\$ -	\$ 27,956	\$ 18,865,940	RESEARCH AND DEVELOPMENT	\$ 425,311,746
AGING RESEARCH	93.866	5 T32 AG058524-03	VANDERBILT UNIVERSITY	5 T32 AG058524-03		9,083	18,865,940	RESEARCH AND DEVELOPMENT	425,311,746
AGING RESEARCH	93.866	5 R44 AG058268-03	XYKEN, LLC	5 R44 AG058268-03		33,405	18,865,940	RESEARCH AND DEVELOPMENT	425,311,746
AGING RESEARCH	93.866	5 R01 AG061325-02				(41)	18,865,940	RESEARCH AND DEVELOPMENT	425,311,746
<b>COVID-19 AGING RESEARCH</b>	93.866	COVID-19 5 R01 AG058639-02S2				237,638	18,865,940	RESEARCH AND DEVELOPMENT	425,311,746
VISION RESEARCH	93.867	5 K08 EY027464-05				185,220	7,325,275	RESEARCH AND DEVELOPMENT	425,311,746
VISION RESEARCH	93.867	5 K08 EY029006-03				205,322	7,325,275	RESEARCH AND DEVELOPMENT	425,311,746
VISION RESEARCH	93.867	2 P30 EY008126-32			365,394	418,798	7,325,275	RESEARCH AND DEVELOPMENT	425,311,746
VISION RESEARCH	93.867	5 P30 EY008126-33			249,086	578,849	7,325,275	RESEARCH AND DEVELOPMENT	425,311,746
VISION RESEARCH	93.867	5 R01 EY007533-30				10,300	7,325,275	RESEARCH AND DEVELOPMENT	425,311,746
VISION RESEARCH	93.867	5 R01 EY017427-12				369,734	7,325,275	RESEARCH AND DEVELOPMENT	425,311,746
VISION RESEARCH	93.867	5 R01 EY020894-09				3,503	7,325,275	RESEARCH AND DEVELOPMENT	425,311,746
VISION RESEARCH	93.867	5 R01 EY022349-10			16,640	520,087	7,325,275	RESEARCH AND DEVELOPMENT	425,311,746
VISION RESEARCH	93.867	5 R01 EY023240-05				(159)	7,325,275	RESEARCH AND DEVELOPMENT	425,311,746
VISION RESEARCH	93.867	5 R01 EY023397-09				369,748	7,325,275	RESEARCH AND DEVELOPMENT	425,311,746
VISION RESEARCH	93.867	7 R01 EY024063-04				51,341	7,325,275	RESEARCH AND DEVELOPMENT	425,311,746
VISION RESEARCH	93.867	5 R01 EY024373-05				95,214	7,325,275	RESEARCH AND DEVELOPMENT	425,311,746
VISION RESEARCH	93.867	5 R01 EY024997-06				23,380	7,325,275	RESEARCH AND DEVELOPMENT	425,311,746
VISION RESEARCH	93.867	5 R01 EY027746-05			4,036	314,180	7,325,275	RESEARCH AND DEVELOPMENT	425,311,746
VISION RESEARCH	93.867	5 R01 EY028133-02			177,453	340,394	7,325,275	RESEARCH AND DEVELOPMENT	425,311,746
VISION RESEARCH	93.867	5 R01 EY029693-03			54,716	373,963	7,325,275	RESEARCH AND DEVELOPMENT	425,311,746
VISION RESEARCH	93.867	1 R01 EY031315-01				213,646	7,325,275	RESEARCH AND DEVELOPMENT	425,311,746
VISION RESEARCH	93.867	1 R21 EY032592-01				12,308	7,325,275	RESEARCH AND DEVELOPMENT	425,311,746
VISION RESEARCH	93.867	1 R21 EY032724-01				27,597	7,325,275	RESEARCH AND DEVELOPMENT	425,311,746
VISION RESEARCH	93.867	5 U01 EY027265-03			106,652	144,843	7,325,275	RESEARCH AND DEVELOPMENT	425,311,746
VISION RESEARCH	93.867	5 U24 EY029893-02			799,088	881,392	7,325,275	RESEARCH AND DEVELOPMENT	425,311,746
VISION RESEARCH	93.867	5 U24 EY029893-03			833,183	1,292,467	7,325,275	RESEARCH AND DEVELOPMENT	425,311,746
VISION RESEARCH	93.867	5 U10 EY011751-22	JAEB CENTER FOR HEALTH RESEARCH	5 U10 EY011751-22		90,104	7,325,275	RESEARCH AND DEVELOPMENT	425,311,746
VISION RESEARCH	93.867	2 UG1 EY011751-23	JAEB CENTER FOR HEALTH RESEARCH	2 UG1 EY011751-23		2,988	7,325,275	RESEARCH AND DEVELOPMENT	425,311,746
VISION RESEARCH	93.867	2 UG1 EY011751-23	JAEB CENTER FOR HEALTH RESEARCH	2 UG1 EY011751-23		692	7,325,275	RESEARCH AND DEVELOPMENT	425,311,746
VISION RESEARCH	93.867	2 UG1 EY011751-23	JAEB CENTER FOR HEALTH RESEARCH	2 UG1 EY011751-23		18,979	7,325,275	RESEARCH AND DEVELOPMENT	425,311,746
VISION RESEARCH	93.867	5 U10 EY024527-04	JOHNS HOPKINS UNIVERSITY	5 U10 EY024527-04		8,098	7,325,275	RESEARCH AND DEVELOPMENT	425,311,746
VISION RESEARCH	93.867	1 UG1 EY028091-01A1	JOHNS HOPKINS UNIVERSITY	1 UG1 EY028091-01A1		(625)	7,325,275	RESEARCH AND DEVELOPMENT	425,311,746
VISION RESEARCH	93.867	5 UG1 EY028091-02	JOHNS HOPKINS UNIVERSITY	5 UG1 EY028091-02		(5,648)	7,325,275	RESEARCH AND DEVELOPMENT	425,311,746
VISION RESEARCH	93.867	5 UG1 EY028091-03	JOHNS HOPKINS UNIVERSITY	5 UG1 EY028091-03		15,184	7,325,275	RESEARCH AND DEVELOPMENT	425,311,746
VISION RESEARCH	93.867	1 U10 EY026869-01	NEW YORK UNIVERSITY	1 U10 EY026869-01		983	7,325,275	RESEARCH AND DEVELOPMENT	425,311,746
VISION RESEARCH	93.867	2 UG1 EY023533-06	PENNSYLVANIA STATE UNIVERSITY	2 UG1 EY023533-06		(1,117)	7,325,275	RESEARCH AND DEVELOPMENT	425,311,746
VISION RESEARCH	93.867	5 U24 EY029903-02	STANFORD UNIVERSITY	5 U24 EY029903-02		55,946	7,325,275	RESEARCH AND DEVELOPMENT	425,311,746
VISION RESEARCH	93.867	5 U24 EY029903-03	STANFORD UNIVERSITY	5 U24 EY029903-03		405,541	7,325,275	RESEARCH AND DEVELOPMENT	425,311,746
VISION RESEARCH	93.867	2 R01 EY002686-42	VANDERBILT UNIVERSITY	2 R01 EY002686-42		10,252	7,325,275	RESEARCH AND DEVELOPMENT	425,311,746
VISION RESEARCH	93.867	5 R01 EY002686-43	VANDERBILT UNIVERSITY	5 R01 EY002686-43		7,448	7,325,275	RESEARCH AND DEVELOPMENT	425,311,746
VISION RESEARCH	93.867	1 R01 EY013769-01	VANDERBILT UNIVERSITY	1 R01 EY013769-01		2,450	7,325,275	RESEARCH AND DEVELOPMENT	425,311,746
VISION RESEARCH	93.867	5 R01 EY027729-03	VANDERBILT UNIVERSITY	5 R01 EY027729-03		21,269	7,325,275	RESEARCH AND DEVELOPMENT	425,311,746
VISION RESEARCH	93.867	5 R01 EY027729-04	VANDERBILT UNIVERSITY	5 R01 EY027729-04		109,369	7,325,275	RESEARCH AND DEVELOPMENT	425,311,746
VISION RESEARCH	93.867	1 R01 EY030490-01	VANDERBILT UNIVERSITY	1 R01 EY030490-01		9,182	7,325,275	RESEARCH AND DEVELOPMENT	425,311,746
VISION RESEARCH	93.867	5 T32 EY007135-25	VANDERBILT UNIVERSITY	5 T32 EY007135-25		2,482	7,325,275	RESEARCH AND DEVELOPMENT	425,311,746
VISION RESEARCH	93.867	5 T32 EY021453-09	VANDERBILT UNIVERSITY	5 T32 EY021453-09		55,476	7,325,275	RESEARCH AND DEVELOPMENT	425,311,746
VISION RESEARCH	93.867	5 T32 EY021453-10	VANDERBILT UNIVERSITY	5 T32 EY021453-10		53,406	7,325,275	RESEARCH AND DEVELOPMENT	425,311,746
VISION RESEARCH	93.867	1 U54 EY032442-01	VANDERBILT UNIVERSITY	1 U54 EY032442-01		30,689	7,325,275	RESEARCH AND DEVELOPMENT	425,311,746
MEDICAL LIBRARY ASSISTANCE	93.879	5 R01 LM010207-09				96,048	1,279,018	RESEARCH AND DEVELOPMENT	425,311,746
MEDICAL LIBRARY ASSISTANCE	93.879	5 R01 LM010685-11				474,773	1,279,018	RESEARCH AND DEVELOPMENT	425,311,746
MEDICAL LIBRARY ASSISTANCE	93.879	3 R01 LM010685-11S1				124,365	1,279,018	RESEARCH AND DEVELOPMENT	425,311,746
MEDICAL LIBRARY ASSISTANCE	93.879	7 R01 LM011966-05				62,170	1,279,018	RESEARCH AND DEVELOPMENT	425,311,746
MEDICAL LIBRARY ASSISTANCE	93.879	5 R01 LM012854-02				296,511	1,279,018	RESEARCH AND DEVELOPMENT	425,311,746

**VANDERBILT UNIVERSITY MEDICAL CENTER**  
**SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS (CONTINUED)**  
 Fiscal Period 7/1/2020 – 6/30/2021

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
MEDICAL LIBRARY ASSISTANCE	93.879	5 R01 LM012806-03	UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON	5 R01 LM012806-03	\$ -	\$ (52,476)	\$ 1,279,018	RESEARCH AND DEVELOPMENT	\$ 425,311,746
MEDICAL LIBRARY ASSISTANCE	93.879	5 T15 LM007450-18	VANDERBILT UNIVERSITY	5 T15 LM007450-18		4,977	1,279,018	RESEARCH AND DEVELOPMENT	425,311,746
MEDICAL LIBRARY ASSISTANCE	93.879	5 T15 LM007450-18	VANDERBILT UNIVERSITY	5 T15 LM007450-18		84,349	1,279,018	RESEARCH AND DEVELOPMENT	425,311,746
MEDICAL LIBRARY ASSISTANCE	93.879	5 T15 LM007450-19	VANDERBILT UNIVERSITY	5 T15 LM007450-19		109,386	1,279,018	RESEARCH AND DEVELOPMENT	425,311,746
MEDICAL LIBRARY ASSISTANCE	93.879	5 T15 LM007450-19	VANDERBILT UNIVERSITY	5 T15 LM007450-19		30,067	1,279,018	RESEARCH AND DEVELOPMENT	425,311,746
MEDICAL LIBRARY ASSISTANCE	93.879	5 T15 LM007450-19	VANDERBILT UNIVERSITY	5 T15 LM007450-19		48,848	1,279,018	RESEARCH AND DEVELOPMENT	425,311,746
GRANTS FOR PRIMARY CARE TRAINING AND ENHANCEMENT CANCER PREVENTION AND CONTROL PROGRAMS FOR STATE, TERRITORIAL AND TRIBAL ORGANIZATIONS	93.884	5 TOBHP33102-02-00	MEHARRY MEDICAL COLLEGE	5 TOBHP33102-02-00		12,007	12,007	RESEARCH AND DEVELOPMENT	425,311,746
COVID-19 ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSE	93.898	65897:ST TN COVID-19 U3 REP 200654-01-00	TN DEPARTMENT OF HEALTH TENNESSEE HOSPITAL ASSOCIATION	65897:ST TN U3 REP 200654-01-00		88,034	88,034	RESEARCH AND DEVELOPMENT	425,311,746
COVID-19 HIV EMERGENCY RELIEF PROJECT GRANTS	93.899	COVID-19 42015:METRO	METRO-NASH. AND DAVIDSON COUNTY, TENNESSEE	42015:METRO		50,304	50,304	N/A	-
HIV EMERGENCY RELIEF PROJECT GRANTS	93.914	COVID-19 42015:METRO	METRO-NASH. AND DAVIDSON COUNTY, TENNESSEE	42015:METRO		119,964	845,886	N/A	-
HIV EMERGENCY RELIEF PROJECT GRANTS	93.914	42015:METRO	METRO-NASH. AND DAVIDSON COUNTY, TENNESSEE	42015:METRO		82,211	845,886	N/A	-
HIV EMERGENCY RELIEF PROJECT GRANTS	93.914	42015:METRO	METRO-NASH. AND DAVIDSON COUNTY, TENNESSEE	42015:METRO		643,711	845,886	N/A	-
HIV CARE FORMULA GRANTS	93.917	65998:ST TN	TN DEPARTMENT OF HEALTH	65998:ST TN		1,007,215	1,007,215	N/A	-
GRANTS TO PROVIDE OUTPATIENT EARLY INTERVENTION SERVICES WITH RESPECT TO HIV DISEASE	93.918	5 H76 HA30761-05-00				660,872	889,289	N/A	-
GRANTS TO PROVIDE OUTPATIENT EARLY INTERVENTION SERVICES WITH RESPECT TO HIV DISEASE	93.918	4 H76 HA30761-05				118,949	889,289	N/A	-
COVID-19 GRANTS TO PROVIDE OUTPATIENT EARLY INTERVENTION SERVICES WITH RESPECT TO HIV DISEASE	93.918	COVID-19 1 H7C HA37168-01-00				111,647	889,289	N/A	-
GRANTS TO PROVIDE OUTPATIENT EARLY INTERVENTION SERVICES WITH RESPECT TO HIV DISEASE	93.918	5 H76 HA30761-04-00				(2,179)	889,289	N/A	-
BLOCK GRANTS FOR COMMUNITY MENTAL HEALTH SERVICES	93.958	66987:ST TN	TN DEPARTMENT OF MENTAL HEALTH AND DEVELOPMENTAL DISABILITIE	66987:ST TN		92,123	102,848	N/A	-
BLOCK GRANTS FOR COMMUNITY MENTAL HEALTH SERVICES	93.958	SAMSHA-UNIV OF PENN COVID-19 1 T1M HP39068-01-00	UNIVERSITY OF PENNSYLVANIA	SAMSHA-UNIV OF PENN		10,725	102,848	N/A	-
COVID-19 PPHF GERIATRIC EDUCATION CENTERS	93.969	6 U1Q HP33085-02-01			51,374	86,682	652,611	RESEARCH AND DEVELOPMENT	425,311,746
PPHF GERIATRIC EDUCATION CENTERS	93.969	1 U1Q HP033085-01-00			309,760	463,581	652,611	RESEARCH AND DEVELOPMENT	425,311,746
PPHF GERIATRIC EDUCATION CENTERS	93.969	1 U1Q HP033085-01-00			102,849	102,849	652,611	RESEARCH AND DEVELOPMENT	425,311,746
PPHF GERIATRIC EDUCATION CENTERS	93.969	1 U1Q HP033085-01-00				(501)	652,611	RESEARCH AND DEVELOPMENT	425,311,746
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	5 D43 TW009337-09			385,605	391,458	2,445,461	RESEARCH AND DEVELOPMENT	425,311,746
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	5 D43 TW009337-10			527,626	794,401	2,445,461	RESEARCH AND DEVELOPMENT	425,311,746
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	5 D43 TW009745-06				(11,897)	2,445,461	RESEARCH AND DEVELOPMENT	425,311,746
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	2 D43 TW009745-07			59,714	158,522	2,445,461	RESEARCH AND DEVELOPMENT	425,311,746
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	5 D43 TW009745-08			79,860	131,447	2,445,461	RESEARCH AND DEVELOPMENT	425,311,746
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	1 D43 TW011544-01			22,036	73,687	2,445,461	RESEARCH AND DEVELOPMENT	425,311,746
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	5 D43 TW011544-02			18,602	65,025	2,445,461	RESEARCH AND DEVELOPMENT	425,311,746
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	1 G11 TW011529-01			32,084	59,096	2,445,461	RESEARCH AND DEVELOPMENT	425,311,746
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	5 G11 TW011529-02				2,444	2,445,461	RESEARCH AND DEVELOPMENT	425,311,746
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	1 G11 TW011819-01				4,165	2,445,461	RESEARCH AND DEVELOPMENT	425,311,746
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	5 R25 TW009722-08			59,302	88,955	2,445,461	RESEARCH AND DEVELOPMENT	425,311,746
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	5 R25 TW009722-09			78,061	127,829	2,445,461	RESEARCH AND DEVELOPMENT	425,311,746
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	5 R21 TW010899-02				(366)	2,445,461	RESEARCH AND DEVELOPMENT	425,311,746
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	5 R21 TW011327-02				89,597	2,445,461	RESEARCH AND DEVELOPMENT	425,311,746
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	5 D43 TW009744-06			54,120	134,979	2,445,461	RESEARCH AND DEVELOPMENT	425,311,746
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	1 U2R TW011248-01			2,350	2,350	2,445,461	RESEARCH AND DEVELOPMENT	425,311,746
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	5 U2R TW011248-02			80,638	236,418	2,445,461	RESEARCH AND DEVELOPMENT	425,311,746
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	5 U2R TW011248-03				22,643	2,445,461	RESEARCH AND DEVELOPMENT	425,311,746
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	3 R21 TW010620-02S1	PURDUE UNIVERSITY	3 R21 TW010620-02S1		(4,230)	2,445,461	RESEARCH AND DEVELOPMENT	425,311,746
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	59823:ST TN	TN DEPARTMENT OF HEALTH UNIVERSITY OF CAPE TOWN (SOUTH AFRICA)	59823:ST TN		1	2,445,461	RESEARCH AND DEVELOPMENT	425,311,746
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	5 D43 TW010559-04				58,475	2,445,461	RESEARCH AND DEVELOPMENT	425,311,746
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	1 R25 TW011219-01A1	UNIVERSITY OF ZAMBIA	1 R25 TW011219-01A1		5,414	2,445,461	RESEARCH AND DEVELOPMENT	425,311,746
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	1 R25 TW011219-02	UNIVERSITY OF ZAMBIA	1 R25 TW011219-02		17,742	2,445,461	RESEARCH AND DEVELOPMENT	425,311,746

**VANDERBILT UNIVERSITY MEDICAL CENTER**  
**SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS (CONTINUED)**  
 Fiscal Period 7/1/2020 – 6/30/2021

<i>Federal Awarding Agency/Program Title</i>	<i>Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	1 U2R TW011248-01			\$ -	\$ (2,694)	\$ 2,445,461	RESEARCH AND DEVELOPMENT	\$ 425,311,746
MATERNAL AND CHILD HEALTH SERVICES BLOCK GRANT TO THE STATES	93.994	57826:ST TN	TN DEPARTMENT OF HEALTH	57826:ST TN		(191)	655,382	RESEARCH AND DEVELOPMENT	425,311,746
MATERNAL AND CHILD HEALTH SERVICES BLOCK GRANT TO THE STATES	93.994	57826:ST TN	TN DEPARTMENT OF HEALTH	57826:ST TN		38,935	655,382	RESEARCH AND DEVELOPMENT	425,311,746
MATERNAL AND CHILD HEALTH SERVICES BLOCK GRANT TO THE STATES	93.994	65891:ST TN	TN DEPARTMENT OF HEALTH	65891:ST TN		236,923	655,382	RESEARCH AND DEVELOPMENT	425,311,746
MATERNAL AND CHILD HEALTH SERVICES BLOCK GRANT TO THE STATES	93.994	67188:ST TN	TN DEPARTMENT OF HEALTH	67188:ST TN		379,715	655,382	N/A	-
AUTISM AND OTHER DEVELOPMENTAL DISABILITIES, SURVEILLANCE, RESEARCH, AND PREVENTION	93.998	1 NU53 DD000010-02-00				503,342	503,342	N/A	-
200-2012-50430	93.RD	200-2012-50430				86,115	12,917,006	RESEARCH AND DEVELOPMENT	425,311,746
200-2012-50430	93.RD	200-2012-50430				248,411	12,917,006	RESEARCH AND DEVELOPMENT	425,311,746
COVID-19 200-2012-50430	93.RD	COVID-19 200-2012-50430				699,361	12,917,006	RESEARCH AND DEVELOPMENT	425,311,746
200-2012-50430	93.RD	200-2012-50430				14,992	12,917,006	RESEARCH AND DEVELOPMENT	425,311,746
200-2015-63553	93.RD	200-2015-63553				104,458	12,917,006	RESEARCH AND DEVELOPMENT	425,311,746
COVID-19 200-2016-91801	93.RD	COVID-19 200-2016-91801			795,000	1,171,218	12,917,006	RESEARCH AND DEVELOPMENT	425,311,746
200-2016-91801	93.RD	200-2016-91801				278,651	12,917,006	RESEARCH AND DEVELOPMENT	425,311,746
75D301-19-C-05670	93.RD	75D301-19-C-05670			(184,112)	(106,818)	12,917,006	RESEARCH AND DEVELOPMENT	425,311,746
COVID-19 75D30120C07637	93.RD	COVID-19 75D30120C07637			2,250,675	2,956,152	12,917,006	RESEARCH AND DEVELOPMENT	425,311,746
COVID-19 75D30121C10094	93.RD	COVID-19 75D30121C10094				441,388	12,917,006	RESEARCH AND DEVELOPMENT	425,311,746
75N91020P00593	93.RD	75N91020P00593				89,728	12,917,006	RESEARCH AND DEVELOPMENT	425,311,746
75N93019C00074	93.RD	75N93019C00074			37,454	204,340	12,917,006	RESEARCH AND DEVELOPMENT	425,311,746
COVID-19 75N93019C00074	93.RD	COVID-19 75N93019C00074			453,720	1,045,634	12,917,006	RESEARCH AND DEVELOPMENT	425,311,746
75N93019C00074	93.RD	75N93019C00074			29,170	333,829	12,917,006	RESEARCH AND DEVELOPMENT	425,311,746
COVID-19 75N93019C00074	93.RD	COVID-19 75N93019C00074				1,061,860	12,917,006	RESEARCH AND DEVELOPMENT	425,311,746
75N95D19P00178	93.RD	75N95D19P00178				7,338	12,917,006	RESEARCH AND DEVELOPMENT	425,311,746
75N95D19P00178	93.RD	75N95D19P00178				2,217	12,917,006	RESEARCH AND DEVELOPMENT	425,311,746
75N97019P00279	93.RD	75N97019P00279				414,111	12,917,006	RESEARCH AND DEVELOPMENT	425,311,746
HHSN2612016000271	93.RD	HHSN2612016000271				(3,187)	12,917,006	RESEARCH AND DEVELOPMENT	425,311,746
HHSN2722013000231	93.RD	HHSN2722013000231				119,575	12,917,006	RESEARCH AND DEVELOPMENT	425,311,746
HHSN2722013000231	93.RD	HHSN2722013000231				76,769	12,917,006	RESEARCH AND DEVELOPMENT	425,311,746
HHSN2722013000231	93.RD	HHSN2722013000231				1,421	12,917,006	RESEARCH AND DEVELOPMENT	425,311,746
HHSN2722013000231	93.RD	HHSN2722013000231				42,157	12,917,006	RESEARCH AND DEVELOPMENT	425,311,746
HHSN2722013000231	93.RD	HHSN2722013000231			44,000	60,583	12,917,006	RESEARCH AND DEVELOPMENT	425,311,746
HHSN2722013000231	93.RD	HHSN2722013000231				3,727	12,917,006	RESEARCH AND DEVELOPMENT	425,311,746
HHSN2722013000231	93.RD	HHSN2722013000231				2,282	12,917,006	RESEARCH AND DEVELOPMENT	425,311,746
HHSN2722013000231	93.RD	HHSN2722013000231				21,369	12,917,006	RESEARCH AND DEVELOPMENT	425,311,746
HHSN2722013000231	93.RD	HHSN2722013000231				23,973	12,917,006	RESEARCH AND DEVELOPMENT	425,311,746
HHSN2722013000231	93.RD	HHSN2722013000231				83,419	12,917,006	RESEARCH AND DEVELOPMENT	425,311,746
HHSN2722013000231	93.RD	HHSN2722013000231				48,286	12,917,006	RESEARCH AND DEVELOPMENT	425,311,746
HHSN2722013000231	93.RD	HHSN2722013000231			401,293	513,575	12,917,006	RESEARCH AND DEVELOPMENT	425,311,746
HHSN2722013000231	93.RD	HHSN2722013000231				65,063	12,917,006	RESEARCH AND DEVELOPMENT	425,311,746
HHSP223201700050C	93.RD	HHSP223201700050C			132,637	142,092	12,917,006	RESEARCH AND DEVELOPMENT	425,311,746
HHSD20002013M53890B	93.RD	HHSD20002013M53890B	ABT ASSOCIATES, INC.	HHSD20002013M53890B		561	12,917,006	RESEARCH AND DEVELOPMENT	425,311,746
75D301-19-C-05584	93.RD	75D301-19-C-05584	BOSTON CHILDREN'S HOSPITAL	75D301-19-C-05584		67,598	12,917,006	RESEARCH AND DEVELOPMENT	425,311,746
COVID-19 75D30120C07725	93.RD	COVID-19 75D30120C07725	BOSTON CHILDREN'S HOSPITAL	75D30120C07725		119,473	12,917,006	RESEARCH AND DEVELOPMENT	425,311,746
75D301-19-C-05584	93.RD	75D301-19-C-05584	BOSTON CHILDREN'S HOSPITAL	75D301-19-C-05584		70,825	12,917,006	RESEARCH AND DEVELOPMENT	425,311,746
200-2011-41276	93.RD	200-2011-41276	DUKE UNIVERSITY	200-2011-41276	15,181	39,457	12,917,006	RESEARCH AND DEVELOPMENT	425,311,746
200-211-41276	93.RD	200-211-41276	DUKE UNIVERSITY	200-211-41276		45,541	12,917,006	RESEARCH AND DEVELOPMENT	425,311,746
75F40119D10037	93.RD	75F40119D10037	HARVARD PILGRIM HEALTH CARE	75F40119D10037		82,448	12,917,006	RESEARCH AND DEVELOPMENT	425,311,746
75F40119D10037	93.RD	75F40119D10037	HARVARD PILGRIM HEALTH CARE	75F40119D10037		61,680	12,917,006	RESEARCH AND DEVELOPMENT	425,311,746
75F40119D10037	93.RD	75F40119D10037	HARVARD PILGRIM HEALTH CARE	75F40119D10037		42,878	12,917,006	RESEARCH AND DEVELOPMENT	425,311,746
75F40119D10037	93.RD	75F40119D10037	HARVARD PILGRIM HEALTH CARE	75F40119D10037		19,962	12,917,006	RESEARCH AND DEVELOPMENT	425,311,746
HHSF223201400030I	93.RD	HHSF223201400030I	HARVARD PILGRIM HEALTH CARE	HHSF223201400030I		34,598	12,917,006	RESEARCH AND DEVELOPMENT	425,311,746
HHSF223201400030I	93.RD	HHSF223201400030I	HARVARD PILGRIM HEALTH CARE	HHSF223201400030I		86,659	12,917,006	RESEARCH AND DEVELOPMENT	425,311,746
HHSF223201400042I	93.RD	HHSF223201400042I	HARVARD PILGRIM HEALTH CARE	HHSF223201400042I		4,349	12,917,006	RESEARCH AND DEVELOPMENT	425,311,746
75N93020C00027	93.RD	75N93020C00027	IDBIOLOGICS, LLC	75N93020C00027		20,418	12,917,006	RESEARCH AND DEVELOPMENT	425,311,746
75N93019C00073	93.RD	75N93019C00073	INTEGRAL MOLECULAR	75N93019C00073		158,008	12,917,006	RESEARCH AND DEVELOPMENT	425,311,746
75N93019C00073	93.RD	75N93019C00073	INTEGRAL MOLECULAR	75N93019C00073		53,948	12,917,006	RESEARCH AND DEVELOPMENT	425,311,746

**VANDERBILT UNIVERSITY MEDICAL CENTER**  
**SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS (CONTINUED)**  
 Fiscal Period 7/1/2020 – 6/30/2021

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
<i>75N93019D00031</i>	93.RD	<i>75N93019D00031</i>	JOHNS HOPKINS UNIVERSITY LEIDOS BIOMEDICAL RESEARCH, INC. (FORMERLY SAIC-FREDERICK)	<i>75N93019D00031</i>	\$ -	\$ 206,388	\$ 12,917,006	RESEARCH AND DEVELOPMENT	\$ 425,311,746
<i>75N91019D00024</i>	93.RD	<i>75N91019D00024</i>	LEIDOS BIOMEDICAL RESEARCH, INC. (FORMERLY SAIC-FREDERICK)	<i>75N91019D00024</i>		10,105	12,917,006	RESEARCH AND DEVELOPMENT	425,311,746
<i>75N91019D00024</i>	93.RD	<i>75N91019D00024</i>	LEIDOS BIOMEDICAL RESEARCH, INC. (FORMERLY SAIC-FREDERICK)	<i>75N91019D00024</i>		243,769	12,917,006	RESEARCH AND DEVELOPMENT	425,311,746
<i>75N91020C00046</i>	93.RD	<i>75N91020C00046</i>	OUTCOMES4ME	<i>75N91020C00046</i>		114,941	12,917,006	RESEARCH AND DEVELOPMENT	425,311,746
<i>HHSP233201500024I</i>	93.RD	<i>HHSP233201500024I</i>	RESEARCH TRIANGLE INSTITUTE UNIVERSITY OF ALABAMA AT BIRMINGHAM	<i>HHSP233201500024I</i>		481,144	12,917,006	RESEARCH AND DEVELOPMENT	425,311,746
<i>HHSN272201600018C</i>	93.RD	<i>HHSN272201600018C</i>	BIRMINGHAM	<i>HHSN272201600018C</i>		17,723	12,917,006	RESEARCH AND DEVELOPMENT	425,311,746
<i>75N93019C00052</i>	93.RD	<i>75N93019C00052</i>	UNIVERSITY OF GEORGIA	<i>75N93019C00052</i>		113,462	12,917,006	RESEARCH AND DEVELOPMENT	425,311,746
<i>75N3019C00055</i>	93.RD	<i>75N3019C00055</i>	UNIVERSITY OF MARYLAND	<i>75N3019C00055</i>		29,573	12,917,006	RESEARCH AND DEVELOPMENT	425,311,746
<i>75N93019C00055</i>	93.RD	<i>75N93019C00055</i>	UNIVERSITY OF MARYLAND	<i>75N93019C00055</i>		6,198	12,917,006	RESEARCH AND DEVELOPMENT	425,311,746
<i>4I-WDR5-MLL1</i>	93.RD	<i>4I-WDR5-MLL1</i>	VANDERBILT UNIVERSITY	<i>4I-WDR5-MLL1</i>		18,538	12,917,006	RESEARCH AND DEVELOPMENT	425,311,746
<i>4I-WDR5-MLL1</i>	93.RD	<i>4I-WDR5-MLL1</i>	VANDERBILT UNIVERSITY	<i>4I-WDR5-MLL1</i>		18,730	12,917,006	RESEARCH AND DEVELOPMENT	425,311,746
<i>4I-WDR5-MLL1</i>	93.RD	<i>4I-WDR5-MLL1</i>	VANDERBILT UNIVERSITY	<i>4I-WDR5-MLL1</i>		5,066	12,917,006	RESEARCH AND DEVELOPMENT	425,311,746
<i>4I-WDR5-MLL1</i>	93.RD	<i>4I-WDR5-MLL1</i>	VANDERBILT UNIVERSITY	<i>4I-WDR5-MLL1</i>		3,689	12,917,006	RESEARCH AND DEVELOPMENT	425,311,746
<i>4I-WDR5-MLL1</i>	93.RD	<i>4I-WDR5-MLL1</i>	VANDERBILT UNIVERSITY	<i>4I-WDR5-MLL1</i>		21,768	12,917,006	RESEARCH AND DEVELOPMENT	425,311,746
<i>75N93019C00062</i>	93.RD	<i>75N93019C00062</i>	WASHINGTON UNIVERSITY IN ST. LOUIS	<i>75N93019C00062</i>		463,420	12,917,006	RESEARCH AND DEVELOPMENT	425,311,746
<b>TOTAL DEPARTMENT OF HEALTH AND HUMAN SERVICES</b>						<b>81,453,457</b>	<b>564,387,321</b>		
<b>U.S. AGENCY FOR INTERNATIONAL DEVELOPMENT</b>									
<i>USAID FOREIGN ASSISTANCE FOR PROGRAMS OVERSEAS</i>	98.001	<i>720-656-18-C-00001</i>	CHEMONICS INTERNATIONAL INC. THE NATIONAL ACADEMIES OF SCIENCE/ENGINEERING/AND MEDICINE	<i>720-656-18-C-00001</i>		304,627	412,361	N/A	-
<i>USAID FOREIGN ASSISTANCE FOR PROGRAMS OVERSEAS</i>	98.001	<i>AID-OAA-A-11-00012</i>		<i>AID-OAA-A-11-00012</i>	1,700	107,734	412,361	N/A	-
<i>USAID DEVELOPMENT PARTNERSHIPS FOR UNIVERSITY COOPERATION AND DEVELOPMENT</i>	98.012	<i>720-0AA-18-CA-00019</i>			70,230	253,566	253,566	N/A	-
<b>TOTAL U.S. AGENCY FOR INTERNATIONAL DEVELOPMENT</b>						<b>71,930</b>	<b>665,927</b>		
<b>TOTAL EXPENDITURE OF FEDERAL AWARDS</b>						<b>\$ 87,706,313</b>	<b>\$ 593,792,469</b>		

Please Note:  
*Italicized award lines indicate pass-through funding*

The accompanying Notes to the Schedule of Expenditures of Federal Awards are an integral part of the schedule.

**Vanderbilt University Medical Center**  
**Notes to the Schedule of Expenditures of Federal Awards**  
**and State Financial Assistance**  
**For the Year Ended June 30, 2021**

---

**1. Significant Accounting Policies Used in Preparing the SEFA**

The accompanying Schedule of Expenditures of Federal Awards and State Financial Assistance (the Schedule) includes the activity of Vanderbilt University Medical Center (VUMC) under programs of the federal government and of the state of Tennessee for the year ended June 30, 2021. The information in the Schedule is presented in accordance with the requirements of Title 2 U.S. Code of Federal Regulations Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance) and the State of Tennessee Audit Manual. For purposes of the Schedule, federal and state awards include all grants, contracts, and similar agreements entered into directly between VUMC and agencies and departments of the federal government and all subawards to VUMC by organizations pursuant to federal grants, contracts, and similar agreements, and agencies and departments of the Tennessee state government, including federal awards passed through by the state of Tennessee.

**2. 10% De Minimis Cost Rate**

VUMC did not use the de minimis cost rate.

**3. Summary of Significant Accounting Policies for the Schedule**

For purposes of the Schedule, expenditures for federal and state programs are recognized on the accrual basis, which is consistent with accounting principles generally accepted in the United States. Expenditures for federal and state awards of VUMC are determined using the cost accounting principles and procedures set forth in the Uniform Guidance and the State of Tennessee Audit Manual. Under these cost principles, certain expenditures are not allowable or are limited as to reimbursement. Negative amounts represent adjustments or credits made in the normal course of business to amounts reported as expenditures in prior years.

**4. COVID-19 Provider Relief Fund and American Rescue Plan (ARP) Rural Distribution (Assistance Listing No. 93.498)**

The Schedule includes \$115.4 million received from the Department of Health and Human Services (HHS) between April 10, 2020 through June 30, 2020 under the Provider Relief Fund (PRF) program of Assistance Listing No. 93.498. In accordance with guidance from HHS, these amounts are presented as Period 1 in the HHS PRF Reporting Portal. Such amounts were recognized as other operating revenue in VUMC's consolidated financial statements in the accompanying consolidated statement of operations and changes in net assets for the years ended June 30, 2021 and 2020. Due to the PRF Reporting Portal requirements, this amount is not the total PRF received and/or recognized by VUMC as other operating revenue in VUMC's consolidated financial statements for the years ended June 30, 2021 and 2020.

The amount presented on the Schedule for PRF is for the fiscal year ending June 30, 2021. The amount presented reconciles to the PRF information reported to HHS as follows:

Name of Reporting Entity for HHS Reporting Period 1 Provider Relief Fund Report	Reporting Entity Tax Identification Number (TIN)	Type of Distribution	Total Other Provider Relief Fund Expenses Reported	Total Lost Revenues Reported	Total
Vanderbilt University Medical Center	352528741	General	\$ 41,027,046	\$ 38,759,254	\$ 79,786,300
Vanderbilt University Medical Center	352528741	Targeted	-	24,752,283	24,752,283
Vanderbilt Wilson County Hospital	352528741	Targeted	-	10,908,780	10,908,780
<b>Total</b>			<b>\$ 41,027,046</b>	<b>\$ 74,420,317</b>	<b>\$ 115,447,363</b>

# Uniform Guidance Reports and Schedule



Ernst & Young LLP  
Suite 2100  
222 2nd Avenue South  
Nashville, TN 37201

Tel: +1 615 252 2000  
ey.com

## Report of Independent Auditors on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance With *Government Auditing Standards*

Senior Management and the Board of Directors  
Vanderbilt University Medical Center

We have audited, in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States, the financial statements of Vanderbilt University Medical Center, which comprise the consolidated balance sheet as of June 30, 2021, and the related consolidated statements of operations and changes in net assets, and cash flows for the year then ended, and the related notes to the consolidated financial statements, and have issued our report thereon dated October 1, 2021.

### **Internal Control Over Financial Reporting**

In planning and performing our audit of the financial statements, we considered Vanderbilt University Medical Center's internal control over financial reporting (internal control) as a basis for designing audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the financial statements, but not for the purpose of expressing an opinion on the effectiveness of Vanderbilt University Medical Center's internal control. Accordingly, we do not express an opinion on the effectiveness of Vanderbilt University Medical Center's internal control.

*A deficiency in internal control* exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct misstatements on a timely basis. A *material weakness* is a deficiency, or combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of the entity's financial statements will not be prevented or detected and corrected on a timely basis. A *significant deficiency* is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.

### **Compliance and Other Matters**

As part of obtaining reasonable assurance about whether Vanderbilt University Medical Center's financial statements are free of material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements, noncompliance with which could have a direct and material effect on the financial statements. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.





### **Purpose of This Report**

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the entity's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the entity's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

*Ernst + Young LLP*

October 1, 2021



Ernst & Young LLP  
Suite 2100  
222 2nd Avenue South  
Nashville, TN 37201

Tel: +1 615 252 2000  
ey.com

## Report of Independent Auditors on Compliance With Requirements for Each Major Federal Program and Report on Internal Control Over Compliance Required by the Uniform Guidance

The Board of Directors, Chief Executive Officer, and Chief Financial Officer  
Vanderbilt University Medical Center

### **Report on Compliance for Each Major Federal Program**

We have audited Vanderbilt University Medical Center's compliance with the types of compliance requirements described in the U.S. Office of Management and Budget (OMB) *Compliance Supplement* that could have a direct and material effect on each of Vanderbilt University Medical Center's major federal programs for the year ended June 30, 2021. Vanderbilt University Medical Center's major federal programs are identified in the summary of auditor's results section of the accompanying schedule of findings and questioned costs.

### **Management's Responsibility**

Management is responsible for compliance with federal statutes, regulations and the terms and conditions of its federal awards applicable to its federal programs.

### **Auditor's Responsibility**

Our responsibility is to express an opinion on compliance for each of Vanderbilt University Medical Center's major federal programs based on our audit of the types of compliance requirements referred to above. We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America; the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States; and the audit requirements of Title 2 U.S. Code of Federal Regulations Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Those standards and the Uniform Guidance require that we plan and perform the audit to obtain reasonable assurance about whether noncompliance with the types of compliance requirements referred to above that could have a direct and material effect on a major federal program occurred. An audit includes examining, on a test basis, evidence about Vanderbilt University Medical Center's compliance with those requirements and performing such other procedures as we considered necessary in the circumstances.

We believe that our audit provides a reasonable basis for our qualified and unmodified opinions on compliance for major federal programs. However, our audit does not provide a legal determination of Vanderbilt University Medical Center's compliance.

### **Basis for Qualified Opinion on COVID-19 HRSA COVID-19 Claims Reimbursement for the Uninsured Program and the COVID-19 Coverage Assistance Fund**

As described in the accompanying schedule of findings and questioned costs, Vanderbilt University Medical Center did not comply with requirements regarding Assistance Listing 93.461, *COVID-19 HRSA COVID-19 Claims Reimbursement for the Uninsured Program and the COVID-19 Coverage Assistance Fund*, as described in finding 2021-001 for A. Activities Allowed or Unallowed, E. Eligibility and N. Special Tests and Provisions. Compliance with such requirements is necessary, in our opinion, for Vanderbilt University Medical Center to comply with requirements applicable to that program.

**Qualified Opinion on COVID-19 HRSA COVID-19 Claims Reimbursement for the Uninsured Program and the COVID-19 Coverage Assistance Fund**

In our opinion, except for the noncompliance described in the Basis for Qualified Opinion paragraph, Vanderbilt University Medical Center complied, in all material respects, with the types of compliance requirements referred to above that could have a direct and material effect on *COVID-19 HRSA COVID-19 Claims Reimbursement for the Uninsured Program and the COVID-19 Coverage Assistance Fund* for the year ended June 30, 2021.

**Unmodified Opinion on Each of the Other Major Federal Programs**

In our opinion, Vanderbilt University Medical Center complied, in all material respects, with the types of compliance requirements referred to above that could have a direct and material effect on each of its other major federal programs for the year ended June 30, 2021.

**Other Matters**

Our audit of the major federal program identified as Assistance Listing No. 93.461 included certain audit procedures for the compliance requirement associated with activities allowed or unallowed that were limited to tests of compliance that reimbursements received, or expected to be received, related to health services allowed under this federal program. Our audit of compliance was not designed to test or provide assurance on the determination of whether a service was medically necessary, obtained through a legally appropriate referral, properly performed, rendered in a quality manner from a clinical perspective, adequately supervised, accurately documented and classified (i.e., that the correct medical bill code assigned represents the health service performed), or rendered and billed by non-sanctioned individuals. Performing procedures related to these matters is not within our professional expertise. Additional information on the nature of our procedures is available in the AICPA Audit and Accounting Guide, *Health Care Entities*. Our audit procedures for the compliance requirement associated with eligibility were limited to tests of compliance that services reimbursed, or expected to be reimbursed, were for individuals who received a temporary member identification number from the third-party service provider used by HRSA to identify a lack of active health care coverage.

The results of our auditing procedures disclosed another instance of noncompliance which is required to be reported in accordance with the Uniform Guidance, and which is described in the accompanying schedule of findings and questioned costs as follows:

<b>Finding No.</b>	<b>Assistance Listing No.</b>	<b>Program Name</b>	<b>Compliance Requirement</b>
2021-002	93.067	Global AIDS	L. Reporting

Our opinion on each major federal program is not modified with respect to these matters.

Vanderbilt University Medical Center's response to the noncompliance findings identified in our audit is described in the accompanying schedule of findings and questioned costs. Vanderbilt University Medical Center's response was not subjected to the auditing procedures applied in the audit of compliance and, accordingly, we express no opinion on the response.

## Report on Internal Control Over Compliance

Management of Vanderbilt University Medical Center is responsible for establishing and maintaining effective internal control over compliance with the types of compliance requirements referred to above. In planning and performing our audit of compliance, we considered Vanderbilt University Medical Center's internal control over compliance with the types of requirements that could have a direct and material effect on each major federal program to determine the auditing procedures that are appropriate in the circumstances for the purpose of expressing an opinion on compliance for each major federal program and to test and report on internal control over compliance in accordance with the Uniform Guidance, but not for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, we do not express an opinion on the effectiveness of Vanderbilt University Medical Center's internal control over compliance.

*A deficiency in internal control over compliance* exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. *A material weakness in internal control over compliance* is a deficiency, or a combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. *A significant deficiency in internal control over compliance* is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program that is less severe than a material weakness in internal control over compliance yet important enough to merit attention by those charged with governance.

Our consideration of internal control over compliance was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control over compliance that might be, material weaknesses or significant deficiencies and therefore, material weaknesses or significant deficiencies may exist that have not been identified. We did identify certain deficiencies in internal control over compliance, as described in the accompanying schedule of findings and questioned costs, that we consider to be material weaknesses.

Finding No.	Assistance Listing No.	Program Name	Compliance Requirement
2021-001	93.461	COVID-19 HRSA COVID-19 Claims Reimbursement for the Uninsured Program and the COVID-19 Coverage Assistance Fund	A. Activities Allowed or Unallowed E. Eligibility N. Special Tests and Provisions
2021-002	93.067	Global AIDS	L. Reporting
2021-003	93.498	COVID-19 Provider Relief Fund and American Rescue Plan (ARP) Rural Distribution	A. Activities Allowed or Unallowed L. Reporting

Vanderbilt University Medical Center's response to the internal control over compliance findings identified in our audit is described in the accompanying schedule of findings and questioned costs. Vanderbilt University Medical Center's response was not subjected to the auditing procedures applied in the audit of compliance and, accordingly, we express no opinion on the response.



Building a better  
working world

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance. Accordingly, this report is not suitable for any other purpose.

*Ernst + Young LLP*

September 29, 2022

**Vanderbilt University Medical Center  
Schedule of Findings and Questioned Costs  
For the Year Ended June 30, 2021**

---

**Section I—Summary of Auditor’s Results**

**Financial Statements**

Type of report the auditor issued on whether the financial statements audited were prepared in accordance with GAAP:

Unmodified

---

Internal control over financial reporting:

Material weakness(es) identified?

\_\_\_\_\_ Yes        X   No

Significant deficiency(ies) identified?

\_\_\_\_\_ Yes        X   None reported

Noncompliance material to financial statements noted?

\_\_\_\_\_ Yes        X   No

**Federal Awards**

Internal control over major federal programs:

Material weakness(es) identified?

  X   Yes      \_\_\_\_\_ No

Significant deficiency(ies) identified?

\_\_\_\_\_ Yes        X   None reported

Type of auditor’s report issued on compliance for major federal programs:

Unmodified

---

Any audit findings disclosed that are required to be reported in accordance with 2 CFR 200.516(a)?

  X   Yes      \_\_\_\_\_ No

Identification of major federal programs:

Assistance Listing No.	Name of Federal Program or Cluster
Various	Research & Development Cluster
93.067	Global AIDS
93.461	COVID-19 HRSA COVID-19 Claims Reimbursement for the Uninsured Program and the COVID-19 Coverage Assistance Fund
93.498	COVID-19 Provider Relief Fund and American Rescue Plan (ARP) Rural Distribution
21.019	COVID-19 Coronavirus Relief Fund

Dollar threshold used to distinguish between Type A and Type B programs:

\$3,000,000

---

Auditee qualified as low-risk auditee?

\_\_\_\_\_ Yes        X   No

**Vanderbilt University Medical Center**  
**Schedule of Findings and Questioned Costs (continued)**  
**For the Year Ended June 30, 2021**

---

**Section II—Financial Statement Findings**

No findings reported.

**Vanderbilt University Medical Center  
Schedule of Findings and Questioned Costs (continued)  
For the Year Ended June 30, 2021**

---

**Section III—Federal Award Findings and Questioned Costs**

**Finding 2021-001**

***Identification of the federal program:***

**Federal Grantor:** United States Department of Health and Human Services, Health Resources and Services Administration (HRSA)

**Assistance Listing No.:** 93.461, COVID-19 HRSA COVID-19 Claims Reimbursement for the Uninsured Program and the COVID-19 Coverage Assistance Fund

**Pass-Through Award Period of Performance:** 07/01/2020–06/30/2021

***Criteria or specific requirement:***

Section 200.303 of the Uniform Guidance states the following regarding internal control: “The non-Federal entity must: (a) Establish and maintain effective internal control over the Federal award that provides reasonable assurance that the non-Federal entity is managing the Federal award in compliance with Federal statutes, regulations, and the terms and conditions of the Federal award. These internal controls should be in compliance with guidance in “Standards for Internal Control in the Federal Government” issued by the Comptroller General of the United States or the “Internal Control Integrated Framework,” issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).”

Health and Human Services (HHS) – Health Resources and Services and Administrative (HRSA) issued Terms and Conditions for Participation in the HRSA COVID-19 Claims Reimbursement to Health Care Providers and Facilities for Testing, Treatment, and Vaccine Administration for the Uninsured Program (T&Cs) outlining requirements that recipients of funding from the HRSA COVID-19 Uninsured Program must comply with, including the following sections: Testing Services, Treatment Services and Vaccine Administration, and General Provisions in FY2020 Consolidated Appropriations.

Per the HRSA T&Cs and further clarified in the HRSA FAQs for COVID-19 Claims Reimbursement to Health Care Providers and Facilities for Testing, Treatment and Vaccine Administration, the FAQ states the following:

“If a provider tests for COVID-19 as part of pre-operative or other medical treatment unrelated to COVID-19, is the test eligible for reimbursement? For the HRSA COVID-19 Uninsured Program, COVID-19 testing is eligible for reimbursement if one of the following diagnoses codes is included in any position on the claim:

- Z03.818 – Encounter for observation for suspected exposure to other biological agents ruled out (possible exposure to COVID-19)
- Z11.59 – Encounter for screening for other viral diseases (asymptomatic)
- Z20.828 – Contact with and (suspected) exposure to other viral communicable (confirmed exposure to COVID-19)
- Z11.52 – Encounter for screening for COVID-19 (asymptomatic)
- Z20.822 – Contact with and (suspected) exposure to COVID-19
- Z86.16 – Personal history of COVID-19



## Vanderbilt University Medical Center Schedule of Findings and Questioned Costs (continued) For the Year Ended June 30, 2021

---

Related treatment visits and services are not eligible for reimbursement given the primary reason for treatment is not COVID-19.”

### **Condition:**

Vanderbilt University Medical Center (VUMC) did not retain audit evidence to support the report logic that was developed to extract patients from the patient billing systems that were identified as having an allowable COVID-19 testing and treatment diagnosis code with uninsured eligibility determination and eligible for reimbursement under this federal program. In addition, supporting documentation was not retained to validate who had access to modify and run the script, what changes were made to the script and how any changes to the script were tested and implemented during the fiscal year based on changes to HRSA guidance and how management validated the completeness and accuracy of the data extracted by the script.

For certain emergency department, physician office visits and inpatient claims that included COVID-19 testing, but COVID-19 was not the primary reason for the related treatment visit and services, VUMC erroneously billed the HRSA COVID-19 Uninsured Program for the entire encounter, which was not in compliance with the HRSA COVID-19 Uninsured Program regulations.

### **Cause:**

Management did not develop and maintain effective internal control over report writing, program changes and user access.

Additionally, refunds required to be made to the HRSA COVID-19 Uninsured Program were not identified.

### **Effect or potential effect:**

The key report used to identify eligible federal program participants could be inaccurate or incomplete.

VUMC did not have internal controls in place to formally document its compliance with the HRSA COVID-19 Uninsured Program’s allowability requirements. Outpatient encounters that included a COVID-19 testing diagnosis code, where the primary treatment diagnosis code was not COVID-19 related, were not reviewed prior to submission to HRSA to verify treatment costs were allowable under the HRSA COVID-19 Uninsured Program.

### **Questioned costs:**

\$727,235

### **Context:**

Management performed a full analysis over claims submitted to HRSA related to services with dates of service from January 1, 2021 through December 31, 2021, indicating that 3,840 patient accounts totaling \$727,235 related to certain claims that were inappropriately billed to HRSA. The \$727,235 was refunded to HRSA during 2022.

We sampled 60 claims (totaling \$119,773 in federal expenditures) for patient services occurring from January 1, 2021 through December 31, 2021, that were billed to the HRSA COVID-19 Uninsured Program. We noted 13 emergency, physician office, and inpatient claims that were inappropriately billed to HRSA (totaling \$5,396 in federal expenditures); these claims were included in the refund to HRSA noted above.

**Vanderbilt University Medical Center**  
**Schedule of Findings and Questioned Costs (continued)**  
**For the Year Ended June 30, 2021**

---

Total federal expenditures for Assistance Listing 93.461 totaled \$2,990,137 for the year ended June 30, 2021.

***Identification as a repeat finding, if applicable:***

Not applicable.

***Recommendation:***

VUMC should implement sufficiently precise internal controls to review changes to the HRSA COVID-19 Uninsured Program to ensure it is administering the program in compliance with the HRSA COVID-19 Uninsured Program regulations. In addition, internal controls should be implemented to ensure claims submitted to the HRSA COVID-19 Uninsured Program meet the allowability criteria established by the HRSA COVID-19 Uninsured Program regulations before claims are submitted to HRSA for reimbursement.

VUMC should retain evidence of internal controls related to access and change management over the report. Management should implement a quality review process of eligible claims identified on a monthly basis to ensure that patients identified meet the required eligibility requirements.

The Uninsured Program ended in 2022; therefore, developing internal controls is not required. Management should review the accounts billed in fiscal 2022 to ensure that the patient accounts billed meet the eligibility requirements of the program.

***Views of responsible officials:***

Management agrees with this finding and performed a review of claims submitted to the HRSA COVID-19 Uninsured Program identifying payments for ineligible services and refunded the entire overpayment amount. In March 2022, HRSA announced the discontinuance of the HRSA COVID-19 Uninsured Program and therefore remediation of internal controls is no longer applicable.

**Vanderbilt University Medical Center  
Schedule of Findings and Questioned Costs (continued)  
For the Year Ended June 30, 2021**

---

**Finding 2021-002**

***Identification of the federal program:***

**Federal Agency:** U.S. Department of Health and Human Services

**Assistance Listing No.:** 93.067, Global AIDS

**Award Number:** 5 NU2 GGH001943-04-00 and 5 NU2 GGH001943-05-00

**Award Year:** 2020-2021

***Criteria or specific requirement:***

2 CFR 200.303 requires that a non-federal entity must (a) establish and maintain effective internal control over the Federal award that provides reasonable assurance that the non-Federal entity is managing the Federal award in compliance with Federal statutes, regulations, and the terms and conditions of the Federal award. These internal controls should be in compliance with guidance in "Standards for Internal Control in the Federal Government" issued by the Comptroller General of the United States and the "Internal Control Integrated Framework," issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).

Under the requirements of the Federal Funding Accountability and Transparency Act (Pub. L. No. 109-282) (Transparency Act) that are codified in 2 CFR Part 170, recipients (i.e., direct recipients) of grants or cooperative agreements who make first tier subawards of \$30,000 or more are required to register in the Federal Funding Accountability and Transparency Act Subaward Reporting System (FSRS) and report subaward data through FSRS.

***Condition:***

VUMC is a prime recipient of funding from the Centers for Disease Control and Prevention related to the Global AIDS grant and made first tier subawards of greater than \$30,000. VUMC filed a single report in the FSRS for the total of all its subawards instead of filing a separate report for each subaward.

***Cause:***

Policies and procedures and internal controls were not in place to ensure compliance with the Transparency Act.

***Effect or potential effect:***

VUMC did not comply with the Transparency Act and report all required information in the FSRS.

***Questioned costs:***

\$0

***Context:***

VUMC made first tier subawards to 20 subrecipients totaling \$3,077,439 in federal expenditures. Total Global AIDS expenditures totaled \$26,141,335. Subaward reports were not independently reported in the FSRS.

**Vanderbilt University Medical Center**  
**Schedule of Findings and Questioned Costs (continued)**  
**For the Year Ended June 30, 2021**

---

***Identification as a repeat finding, if applicable:***

Not applicable

***Recommendation:***

We recommend that VUMC implement a review process and internal controls to ensure that subrecipients are appropriately entered into the FSRS website.

VUMC should make the required reporting for its subrecipient in the FSRS website to be compliant with the Transparency Act.

***Views of responsible officials:***

VUMC is a prime recipient of funding from The Centers for Disease Control and Prevention related to the Global Aids grant and made first tier subawards of greater than \$30,000. VUMC reported the subaward from VUMC, the prime, to Friends in Global Health, the subrecipient as a single report in the Federal Funding Accountability and Transparency Act Subaward Reporting System (FSRS) instead of filing a separate report for each subaward. Procedures and internal controls were in place for first tier subawards.

VUMC has changed procedures and internal controls to report each Global Aid subaward separately in FSRS. All subawards have been reported in FY23 in compliance with the Transparency Act.

**Vanderbilt University Medical Center  
Schedule of Findings and Questioned Costs (continued)  
For the Year Ended June 30, 2021**

---

**Finding 2021-003**

***Identification of the federal program:***

**Federal Agency:** U.S. Department of Health and Human Services (HHS) Health Resources and Services Administration (HRSA)

**Assistance Listing No.:** 93.498 COVID-19 Provider Relief Fund and American Rescue Plan (ARP) Rural Distribution

**Award Year:** 2020-2021

***Criteria or specific requirement:***

2 CFR Section 200.303 of the Uniform Guidance states the following regarding internal control:

“The non-Federal entity must:

(a) Establish and maintain effective internal control over the Federal award that provides reasonable assurance that the non-Federal entity is managing the Federal award in compliance with Federal statutes, regulations, and the terms and conditions of the Federal award. These internal controls should be in compliance with guidance in “Standards for Internal Control in the Federal Government” issued by the Comptroller General of the United States or the “Internal Control Integrated Framework,” issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).”

***Condition:***

Management did not retain supporting documentation over its review and approval of the lost revenue calculation and expenses reported in the HHS portal.

***Cause:***

Management represented they performed a review and approval of the lost revenue calculation, COVID-19 expenses and HHS portal submission of lost revenue; however, adequate supporting documentation to evidence that the internal controls were sufficiently designed and operating effectively was not maintained.

***Effect or potential effect:***

A lack of internal controls over the review of the lost revenue calculation, COVID-19 expenses, and the data submitted in the HHS portal could result in a misstatement of the amounts reported in the HHS portal.

***Questioned costs:***

\$0

***Context:***

VUMC had a single submission to HRSA during FY21, which included expenses and lost revenue. Total federal expenditures for Assistance Listing No. 93.498 totaled \$115,447,363 for the year ended June 30, 2021.

**Vanderbilt University Medical Center  
Schedule of Findings and Questioned Costs (continued)  
For the Year Ended June 30, 2021**

---

***Identification as a repeat finding, if applicable:***

Not applicable

***Recommendation:***

Management should implement internal controls over the review and approval of the data used to calculate lost revenue and expenses and the report of lost revenue on the HHS portal.

***Views of responsible officials:***

All expenditures included by VUMC Management (Management) in its submissions in the Department of Health and Human Services (HHS) portal were verified against HHS guidance to ensure allowability. Management understands that additional audit evidence must be retained at a detailed enough level to allow the auditor to meet their reperformance standard. Management believes that our control risk is mitigated by the fact that our lost revenues far exceed any provider relief funding received. However, should management need to report any future eligible expenses in the HHS portal, we will retain additional audit evidence to enable auditor reperformance of the controls regarding allowability of expenditures.

Management also established appropriate review and approval controls surrounding the performance and review of the lost revenue analytic and the subsequent reporting of lost revenue in the HHS portal. Management retained documentation to support execution of this control, however, management understands that additional audit evidence supporting the reviews was not available to the auditor to evidence execution of this control. Management will retain additional audit evidence to allow the auditor to reperform execution of this control for future HHS portal submissions.

## **EY | Building a better working world**

**EY exists to build a better working world, helping to create long-term value for clients, people and society and build trust in the capital markets.**

**Enabled by data and technology, diverse EY teams in over 150 countries provide trust through assurance and help clients grow, transform and operate.**

**Working across assurance, consulting, law, strategy, tax and transactions, EY teams ask better questions to find new answers for the complex issues facing our world today.**

EY refers to the global organization, and may refer to one or more, of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients. Information about how EY collects and uses personal data and a description of the rights individuals have under data protection legislation are available via [ey.com/privacy](https://ey.com/privacy). EY member firms do not practice law where prohibited by local laws. For more information about our organization, please visit [ey.com](https://ey.com).

Ernst & Young LLP is a client-serving member firm of Ernst & Young Global Limited operating in the US.

© 2022 Ernst & Young LLP.  
All Rights Reserved.

**[ey.com](https://ey.com)**



## Vanderbilt University Medical Center Summary Schedule of Prior Audit Findings For the Year Ended June 30, 2021

---

### 2020-001 – SUSPENSION AND DEBARMENT

<b>Federal Program Information:</b>	<b>Federal Agency and Program Name</b>	<b>Assistance Listing No.</b>
	Global Aids	93.067
	Grant Award 5 NU2 GGH001943-04-00	
	Grant Award 6 NU2 GGH001943-03-10	

**Finding:**

During our testing of 40 transactions, totaling \$337,363 for suspension and debarment of the Global Aids program, we noted that for 11 transactions, totaling \$20,269, there was a lack of supporting documentation demonstrating that management was monitoring the contractors to ensure they were not suspended or debarred when the purchase was made; this was determined to be a systemic issue. Vanderbilt University Medical Center does not have adequately designed internal controls and policies and procedures in place to ensure that contractors are being properly monitored for suspension and debarment.

**Status:**

The corrective action plan was taken.

### 2019-001 – SUSPENSION AND DEBARMENT

<b>Federal Program Information:</b>	<b>Federal Agency and Program Name</b>	<b>Assistance Listing No.</b>
	Research and Development Cluster	Various
	Special Education Cluster (IDEA)	84.027/84.173

**Finding:**

During testing of transactions for suspension and debarment of the Research and Development Cluster, one transaction, for \$41, of the 37 transactions tested for \$2,061,516, lacked supporting documentation demonstrating that management was monitoring the contractors to ensure they were not suspended or debarred when the purchase was made; this was determined to be a systemic issue. Further, management has internal controls to assess potential suspension and debarment matches it receives from its a third-party servicer who performs suspension and debarment searches for them. However, the internal controls are not precise enough to ensure a resolution has been completed for each match identified.

**Status:**

The corrective action plan was taken.





## **Vanderbilt University Medical Center Management's Corrective Action Plan For the Year Ended June 30, 2021**

---

### **Finding 2021-001**

**Federal Grantor:** United States Department of Health and Human Services, Health Resources and Services Administration (HRSA)

**Assistance Listing No.:** 93.461, COVID-19 HRSA COVID-19 Claims Reimbursement for the Uninsured Program and the COVID-19 Coverage Assistance Fund

Management agrees with this finding and performed a review of claims submitted to the HRSA COVID-19 Uninsured Program identifying payments for ineligible services and refunded the entire overpayment amount. In March 2022, HRSA announced the discontinuance of the HRSA COVID-19 Uninsured Program and therefore remediation of internal controls is no longer applicable.

Paula Yarbrough, VUMC Director – Grants and Contracts, will be responsible for implementation by fiscal year end 2023.

### **Finding 2021-002**

**Federal Agency:** U.S. Department of Health and Human Services

**Assistance Listing No.:** 93.067, Global AIDS

**Award Number:** 6 NU2GGH001943-05-09

VUMC is a prime recipient of funding from The Centers for Disease Control and Prevention related to the Global Aids grant and made first tier subawards of greater than \$30,000. VUMC reported the subaward from VUMC, the prime, to Friends in Global Health, the subrecipient as a single report in the Federal Funding Accountability and Transparency Act Subaward Reporting System (FSRS) instead of filing a separate report for each subaward. Procedures and internal controls were in place for first tier subawards.

VUMC has changed procedures and internal controls to report each Global Aid subaward separately in FSRS. All subawards have been reported in FY23 in compliance with the Transparency Act.

Paula Yarbrough, VUMC Director – Grants and Contracts, will be responsible for implementation by fiscal year end 2023.



**Vanderbilt University Medical Center  
Management's Corrective Action Plan (continued)  
For the Year Ended June 30, 2021**

---

**Finding 2021-003**

**Federal Agency:** U.S. Department of Health and Human Services (HHS) Health Resources and Services Administration (HRSA)

**Assistance Listing No.:** 93.498, COVID-19 Provider Relief Fund and American Rescue Plan (ARP) Rural Distribution

All expenditures included by VUMC Management (Management) in its submissions in the Department of Health and Human Services (HHS) portal were verified against HHS guidance to ensure allowability. Management understands that additional audit evidence must be retained at a detailed enough level to allow the auditor to meet their reperformance standard. Management believes that our control risk is mitigated by the fact that our lost revenues far exceed any provider relief funding received. However, should management need to report any future eligible expenses in the HHS portal, we will retain additional audit evidence to enable auditor reperformance of the controls regarding allowability of expenditures.

Management also established appropriate review and approval controls surrounding the performance and review of the lost revenue analytic and the subsequent reporting of lost revenue in the HHS portal. Management retained documentation to support execution of this control, however, management understands that additional audit evidence supporting the reviews was not available to the auditor to evidence execution of this control. Management will retain additional audit evidence to allow the auditor to reperform execution of this control for future HHS portal submissions.

Paula Yarbrough, VUMC Director – Grants and Contracts, will be responsible for implementation by fiscal year end 2023.